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                                                       Abstract 
Laura Twomey 
 
An Exploration of the Relationship between Cardiovascular Health, Lifestyle Factors 
and Platelet Function. 
 
Introduction 
Platelets are small, anucleate, cells which travel as resting discoid fragments in the blood 
circulation. Upon contact with an injured blood vessel, they prevent blood loss through 
processes of adhesion, activation and aggregation. Platelets play a central role in 
cardiovascular disease (CVD), both in the development of atherosclerosis and in the 
development of acute thrombotic events. CVD risk factors can be classed as modifiable or 
non-modifiable. This thesis focuses on the effect of the modifiable risk factors (physical 
inactivity, overweight/obesity and low cardiorespiratory fitness (CRF)) on platelet function. 
We investigate the role of acute exercise on platelet function, and the impact of CRF on 
platelet responses to acute exercise. We also explore the role of microRNA (miRNA), a 
subset of small non-coding RNA, in regulating platelet function in response to physical 
inactivity.  
Hypothesis 
Physical inactivity, overweight/obesity and low CRF adversely impact platelet function.  
miRNA expression could influence and modulate the platelet function response to physical 
inactivity. 
Results 
We performed a cross-sectional study to investigate the relationship between platelet 
function and lifestyle factors. High platelet counts and plateletcrit were associated with less 
favourable cardiovascular risk profiles, in particular with measures of overweight. Platelet 
adhesion was significantly increased in subjects with an overweight BMI compared to those 
with a healthy weight BMI. Acute strenuous aerobic exercise resulted in increased platelet 
adhesion and aggregation in adults and adolescents. This increase was more pronounced in 
those with a low CRF, particularly in adolescent subjects. Using a Dry Immersion (DI) 
model, we investigated the effect of acute physical inactivity on platelet function in 12 
healthy males. Three days of DI resulted in significant increases in platelet count, plateletcrit, 
platelet adhesion, aggregation, and an elevation of platelet reactivity index (PRI) and 
microvesicle concentration. We identified 15 cardiovascular and inflammatory protein 
biomarkers whose expression levels were altered after physical inactivity. We also identified 
a set of 22 ‘physical inactivity’ related miRNA, which have potential targets involved in 
pathways associated with platelet function.  
Conclusion 
Modifiable CVD risk factors of overweight/obesity and physical inactivity elicit a pro-
thrombotic platelet profile. CRF levels affect the platelet response to acute exercise, 
suggesting that habitual physical activity influences platelet function. miRNA expression 
can influence and modulate the platelet function response to physical inactivity by negative 
regulation of gene expression and could act as markers of megakaryocyte epigenetic drift. 
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Aims and major findings of the thesis 
Overall aim 
Investigate the effect of the lifestyle factors; physical inactivity, overweight/obesity and low 
CRF on platelet function.  
Main aims 
 Investigate the relationship between platelet function and i) overweight/obesity, ii) 
physical activity, in a diverse population 
 Establish the reliability of the Impact-R Cone and Plate device to measure platelet 
function  
 Determine the feasibility of platelet indices as biomarkers of early CVD risk in a 
disease-free population 
 Investigate differences in basal platelet function in males of varying 
cardiorespiratory fitness (CRF) 
 Examine the effect of acute aerobic exercise on platelet adhesion and aggregation in 
healthy males 
 Investigate the relationship between CRF and platelet function 
 Explore the effect of physical inactivity on platelet function and cardiovascular and 
inflammatory protein biomarker expression, in healthy males 
 Examine the role of microRNA in regulating the platelet function response to 
physical inactivity 
 
Major findings 
 High platelet counts and plateletcrit were associated with measures of overweight  
 Platelet adhesion was significantly increased in subjects with an overweight BMI 
 The Impact-R cone and plate analyser could detect platelet function variances in a 
diverse population 
 Varying cardiorespiratory fitness levels had no major influences on basal differences 
in platelet function  
 Acute aerobic exercise resulted in increased platelet adhesion and aggregation  
 This increase was more pronounced in those with a low CRF, particularly in 
adolescents 
 Physical inactivity resulted in significant increases in platelet count, plateletcrit and 
platelet adhesion 
 Physical inactivity resulted in a slight elevation in aggregation, platelet reactivity 
index (PRI) and microvesicle concentration in healthy males 
 Physical inactivity resulted in altered expression of 15 protein biomarkers  
 We identified a set of 22 ‘physical inactivity’ related miRNA, with potential targets 
involved in pathways associated with platelet function.
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Chapter One: Introduction 
1.1 The cardiovascular system  
In the broadest sense, the cardiovascular system consists of the heart, blood vessels and 
blood. Blood is circulated around the body through blood vessels by the pumping action of 
the heart, which is divided into left and right sides with two chambers in each side, the atrium 
and ventricle (Baeyens and Schwartz, 2016). During the average human lifespan, the heart 
beats about 3 billion times, pumping over 200 million litres of blood. Blood vessels are 
classified into three categories; arteries, veins and capillaries which form intricate vascular 
networks between tissues and cells, enabling blood perfusion (Figure 1.1). If an adult's blood 
vessels were laid out continuously, they would spread out over 100,000 km. Arteries and 
veins share a common three layered structure of a: (i) tunica adventitia; (ii) tunica media and 
(iii) tunica intima. The endothelium, a continuous dynamic monolayer of endothelial cells 
(ECs) lines the vasculature, forming a selective interface between circulating blood and the 
underlying vascular smooth muscle layer.  
 
Figure 1.1: The three types of blood vessels. From left to right, a cross-sectional view of an artery, 
capillary and vein. The main features highlighted include a thicker vessel wall in artery compared to 
the vein, presence of a valve in the lumen of the vein to prevent backflow of low pressure blood and 
the single endothelial layer of the capillary, emphasising the delicate structure of this vessel. The 
endothelium of both the artery and vein is also highlighted. (Image from 
http://legacy.owensboro.kctcs.edu/gcaplan/anat2/notes/APIINotes5%20Circulatory%20Anatomy.ht
m). 
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Oxygenated blood returning from the lungs is pumped from the left ventricle into a larger 
network of arteries and smaller arterioles, each supplying blood to an organ or body region. 
Returning blood flows through the right atrium, which in turn flows through the tricuspid 
valve into the right ventricle, and then up to the lungs via the pulmonary artery. Through 
gaseous exchange, the lungs oxygenate the blood, which then returns to the left atrium via 
the pulmonary vein (Figure 1.2). The oxygen rich blood now enters the left ventricle and is 
pumped into the aorta as the entire process begins again (Aaronson et al., 2012). There are 
two anatomically distinct vascular circuits through which blood is pumped. Circulation of 
deoxygenated blood flowing from the right ventricle of the heart to lungs and back to the 
heart is known as the pulmonary circulation. The circulation of blood from the left ventricle 
of the heart to the rest of the body is known as the systemic circulatory system.  
 
 
Figure 1.2: The cardiovascular system. The heart functions as a pump to maintain circulation. 
Oxygenated blood is delivered to tissues via the systemic circulation. Arteries branch into smaller 
arterioles and capillaries. Deoxygenated blood returns from the capillaries via venules and larger 
veins in the pulmonary circulation. (Image from http://humananatomybody.info/neck-arteries-
model-labeled/). 
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1.2 Blood and its cellular components 
The main functions of blood are to supply oxygen and nutrients to tissues and cells, removal 
of waste, and regulation of pH and body temperature (Ruggeri, 2009). An average adult has 
approximately five litres of blood, accounting for about 7% of their body weight. Blood is 
composed of approximately 55% plasma; a pale yellow fluid mainly consisting of water, 
proteins, sugars and fat particles, and 45% blood cells (Dean et al., 2005). Blood cells include 
erythrocytes, leukocytes and platelets. Each of these cells are derived from a haematopoietic 
stem cell (HSC), which reside in the bone marrow and sit at the peak of a developmental 
hierarchy, with a unique ability to self-renew and give rise to cells of all of the blood lineages 
(Woolthius and Park, 2016). In adults, nearly a trillion new blood cells are produced daily 
to sustain steady state in circulation (Huang and Cantor, 2009). In the classic model of 
haematopoiesis (the production of blood cells), an important bifurcation occurs between the 
lymphoid and myeloid branches, which then further divide into a number of progenitor cells, 
shown in Figure 1.3. While the main function of red blood cells (RBCs) and white blood 
cells (WBCs) is oxygen transport and defences, respectively, this Introduction will focus on 
platelets, the final product of one of the myeloid cell lines.  
 
Figure 1.3: Blood cell lineage and development from haematopoietic stem cells. HSCs are self-
renewing cells found in the bone marrow. While diverse in function, all blood cell components are 
derived from (HSCs). The myeloid stem cell leads to the production of megakaryoblasts, and 
subsequently megakaryocytes, the precursor to the mature platelet. (Image from Betts et al., 2013). 
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1.3 Introduction to platelets 
Gulio Bizzozero first described platelets as ‘spherules piastrine’ (little plates), small cell 
fragments that clumped together at an injured blood vessel site. He also showed that these 
blood elements did not have a nucleus (Bizzozero, 1882). Circulating anucleate platelets are 
now described as dynamic specialised cells, formed in an elaborate style from their precursor 
cell, the megakaryocyte. Normal platelet counts ranges between 150 - 450 x 103 per 
microliter of blood, constituting the second most abundant cell type in blood after red blood 
cells. Platelets travel as resting (quiescent) discoid fragments in the circulation, but an 
elaborate internal cytoskeleton allows shape changes to be made when they come in contact 
with an injured blood vessel (Figure 1.4).  
The size of a mature platelet is approximately 2-4 µm, making them the smallest cells in 
circulation, while their average thickness is 0.5 µm (Xu et al., 2016) and their volume about 
7 fl. The small size of platelets facilitates in their role as ‘guardians of the vasculature’, as 
under laminar flow environments, platelets are pushed to the periphery by larger white and 
red blood cells. Consequently, they are then in close proximity to the blood vessel wall where 
they can quickly detect any vascular damage (Zucker & Nachmias 1985; McFadyen and 
Kaplan, 2015). This enables platelets to perform their main physiological function to prevent 
blood loss in primary haemostasis by the formation of a ‘platelet plug’ (Cimmino and Golino 
2013). 
 
 
Figure 1.4: Quiescent (resting) and activated platelets. The left image shows, quiescent, 
inactivated platelets in their travelling discoid shape. The right image depicts activated platelets 
aggregating together after vascular damage. (http://www.ouhsc.edu/platelets). 
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1.3.1 Platelet production 
Platelets are formed and released into the bloodstream in an elaborate manner by rare 
precursor cells called megakaryocytes (MKs), which reside in the bone marrow, mainly of 
the ribs and thighs (Patel et al., 2005; Thon et al., 2013). Their production is arguably the 
most elegant and distinct developmental process in eukaryotes (Simon et al., 2014). While 
accounting for only 0.01% of nucleated bone marrow cells, MKs are also the largest cells, 
measuring between 50 – 100 µm (Machlus and Italiano, 2013). 
Both MK and platelet production are regulated by multiple cytokines, with thrombopoeitin 
(TPO), a hormone produced by the liver and kidneys, being the key regulator. In response 
to TPO, HSCs differentiate into MKs by differential expression of various transcription 
factors. This maturation is characterised by a growth in MK size and DNA ploidy levels due 
to a process called endomitosis (DNA replication without cell division) enabling the 
accumulation of RNA, protein and organelles in the MK for packaging into platelets. MKs 
then migrate to the sinusoidal blood vessels in the vascular niche and the bulk of their 
cytoplasm and its contents are bundled into numerous long processes called proplatelets. 
MKs can extend as many as 20 proplatelets which branch repeatedly over time. Platelets 
form at the tips of proplatelets, receiving organelles, genetic material and granule contents 
that are transported from the MK cell body.  The final point of platelet production occurs in 
circulation whereby anucleate fragments of proplatelets bud into preplatelets (Thon et al., 
2010) and barbell-shaped platelets (Schwartz et al., 2010) that are subsequently converted 
into single platelets in a microtubule-driven process (Poulter and Thomas, 2015) aided by 
the shear forces of the bloodstream (Thon et al., 2012). The process of platelet production 
from MKs is illustrated in Figure 1.5. 
After leaving the bone marrow and entering the blood stream, platelets then have an average 
lifespan of 8-10 days, after which they are cleared via phagocytic cells such as macrophages 
in the spleen. Apoptosis (programmed cell death) is also well recognised in the anucleate 
platelet (Gyulkhandanyan et al., 2013). The constant number of platelets in circulation is a 
consequence of a balance between their production and destruction/clearance.  
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Figure 1.5: Platelet production from megakaryocytes. 1: In response to thrombopoeitin, HSCs 
residing in the bone marrow differentiate into MKs. 2: MK size increases and they undergo DNA 
replication (endomitosis), generating nuclei of which can reach 128n. 3: Maturation of MKs involves 
the development of an elaborate membrane which acts as a reservoir for proplatelet formation. 4: 
MKs migrate to the vascular beds where they extend proplatelets and release them into sinusoidal 
vessels. The whole MK is transformed into pre/proplatelets and its nucleus is phagocytosed. 5: Once 
entered into the blood vessel, proplatelets convert to preplatelets. 6: A microtubule fission event 
produces two platelets from a barbell proplatelet. (Image from Machlus and Italiano, 2013). 
 
1.3.2 Platelet structure  
1.3.2.1 Internal 
Platelets are unique in their structural composition and, while anucleate, contain a large 
variety of cellular organelles, granules and distinct mitochondria (Figure 1.6). Granules are 
generally secretory vesicles that release their contents either to the platelet surface or to 
extracellular fluid by endocytosis. An excess of 300 proteins from platelet granules has been 
identified in the platelet releasate after strong activation (Coppinger et al., 2004; Wijten et 
al., 2013). There are 3 types of platelet granules: α-granules, dense granules, and lysomal 
granules all of which derive their cargo from MKs. α-granules are the largest and most 
numerous (50-80 per platelet) encompassing roughly 10% of the platelet volume (Blair, 
2009).  
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α-granule function originates from their contents. They harbour a vast assortment of sizable 
proteins important for primary haemostasis including integrins (αIIbβ3) immunoglobulin 
family receptors (e.g. GPVI, PECAM), leucine-rich repeat family receptors (e.g., GPIb-IX-
V complex), tetraspanins (e.g., CD9) and other adhesive proteins such as von Willebrand 
Factor (vWF), fibrinogen, and coagulation factors (Factors V, XI) that participate in 
secondary haemostasis. While it was previously assumed that platelet α-granules were 
homogenous populations, Italiano et al., (2008) suggested that platelets have distinct 
subpopulations of alpha granules which differentially release their cargo in a context-
dependent manner; for example, encouraging angiogenesis by releasing VEGF from one 
granule subset under one condition and inhibiting angiogenesis in other conditions by 
releasing angiostatin from a different granule subset. However, the regulation of the 
secretory processes in response to certain agonists is not fully understood. 
Dense granules are smaller in size and number (3-8 per platelet) storing high concentrations 
of non-protein molecules that potentiate platelet activation such as adenosine diphosphate 
(ADP, adenosine triphosphate (ATP), calcium, histamine and serotonin (Morell et al., 2014). 
Dense granules also contain polyphosphate which can be secreted upon platelet activation 
(Ruiz et al., 2004; Senis et al., 2013). Lysosomal granules are sparse and harbour enzymes 
such as acid hydrolases and proteases (Italiano et al., 2009). They function in the digestion 
of cytosolic components, similarly to nucleated cells. Secretion of the lysosomal content has 
key extracellular functions including receptor cleavage, fibrinolysis and degradation of 
extracellular matrix (ECM) (Heijnen and Van der Sluijs, 2015); however, they are the least 
researched of the platelet granules. A recent report has described a possible new type of 
secretory granule termed a T-granule, after their tubular morphology (Thon et al., 2012). 
These novel electron-dense granules have been proposed to function in toll-like receptor 
(TLR) organisation and signalling. Platelet granule deficiencies or defects such as the Gray 
Platelet Syndrome (α-granule deficiency) or Hermansky-Pudlack Syndrome (dense granule 
deficiency) can cause mild to severe bleeding disorders (Nurden et al., 2007). 
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Figure 1.6: Platelet structure highlighting the granules present in platelets. Platelets contain 
three types of granules: α-granules, dense granules, and lysosomes. They also contain a small number 
of functionally active mitochondria. The open canalicular system (OCS) is a tunnel of invaginations 
of the plasma membrane, allowing for trafficking of platelet granules. (Image from Tewfik and 
Flaumenhaft, 2013). 
 
Platelets also contain an important cytoskeleton complex of microtubules and actin filaments 
that is central to all of their functions (Sorrentin et al., 2016). The cytoskeleton of resting 
platelets has approximately 2,000 actin filaments (0.5 mM) accounting for approximately 
one fifth of total protein in platelets.  In resting platelets, only ~ 35% of actin molecules are 
assembled into filaments (F-actin) (Boyles et al., 1985) growing to ∼70% upon activation 
(Fox and Philips, 1981). These cytoskeletal proteins create a structural framework that 
responds to stimuli by forming dynamic morphological changes. In resting platelets, the 
cytoskeleton bears resemblance to a spoked wheel, whereas upon activation, platelets 
undergo a morphological transformation from a discoid to round to fully spread shape. The 
actin framework is completely rearranged to enable the extension of filipodia and 
lamelipodial from the platelet, increasing their area of surface contact. Shape change is 
mediated by a rapid remodelling of the resting platelet cytoskeleton and the assembly of 
filamentous actin (F-actin) induced by receptor interaction and phosphorylation of the 
platelet protein myosin (Hartwig, 1992; Zucker and Nachmias, 2013; Sorrentino et al., 
2015). 
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Platelets possess an intricate membranous system referred to as the open canalicular system 
(OCS) which acts as a connection between the cytosol and surrounding medium (Escolar 
and White, 1991). The OCS is an extravagant system of tunnelling invaginations of the cell 
membrane unique to platelets that increases their surface area by 2-4 fold when spreading is 
required. The OCS enables secretion of platelet granules by exocytosis and represents a 
pivotal means for uptake and trafficking of proteins from plasma to granules by endocytosis 
(Heijnen et al., 2015). Upon platelet activation, granules journey to the OCS or plasma 
membrane for fusion and content release. It also enables the formation of filipodia during 
platelet activation.  
Platelets also retain a dense tubular system (DTS) that originates from the rough endoplasmic 
reticulum in the MK and is dispersed through the platelet cytoplasm as thin elongated 
membranes. It acts as a storage base for Ca2+ and enzymes such as ATPases and 
cyclooxygenase (Gerard et al., 1978; Ebbeling et al., 1992) and has integral roles in platelet 
activation. Upon platelet activation, calcium is rapidly released from the DTS to increase 
Ca2+ levels required for regulation of platelet function.  
Platelets contain functional mitochondria which, despite being few in number, have higher 
rates of ATP turnover than resting mammalian muscle, suggesting they are very 
metabolically active (Zharikov and Shiva 2013). The traditional role of mitochondria in the 
platelet was considered to supply energy in the form of ATP for primary platelet functions. 
However, novel functions for mitochondria continue to emerge. Dual activation of platelets 
with collagen and thrombin results in a subtype of platelets known as collagen and thrombin 
activated (COAT) platelets. COAT platelets display striking alterations in function and 
structure to typical “activated platelets”, by exhibiting a myriad of features such as 
phosphatidylserine exposure due to cytoskeletal reorganisation, high microparticle release, 
and increased levels of fibrinogen on the platelet surface (Remenyi et al., 2005; Dale et al., 
2005; Jobe et al., 2008). Mitochondrial membrane potential (ΔΨm) is reduced in (COAT) 
platelets and decreases in parallel with elevated mitochondrial ROS levels that are necessary 
for facilitating platelet PS exposure upon activation (Choo et al., 2012). Mitochondria are 
involved in the process of platelet apoptosis (Hayashi et al., 2011; Yang et al., 2014) and 
can be released from platelets as potential inflammatory mediators (Bordreau et al., 2014).   
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1.3.2.2 Surface receptors 
Platelets express a wide variety of receptors on their membrane, which are constantly at the 
vanguard of platelet research and are fundamental to platelet function and downstream 
signalling (Cimmino and Golini, 2013). Major receptors include integrins, leucine-rich 
repeat receptors (Glycoprotein GPIb/IX/V, Toll-like receptors), C-type lectin receptors (P-
Selectin, CLEC-2), tyrosine kinase receptors (Ephrins and Eph kinases), proteins belonging 
to the immunoglobulin superfamily (GPVI, FcγRIIA) and other receptors shared with 
vascular cells (TNF receptor type, CD63, CD36, PSGL-1). C-type lectin receptor -2 (CLEC-
2), is a hemITAM receptor (Hemi- immunoreceptor tyrosine-based activation motif) 
expressed at high levels on the platelet surface. Binding of CLEC-2 to its endogenous ligand, 
Podoplanin, induces strong platelet activation and plays major roles in thrombus stability 
under flow conditions (Navarro-Nunez et al., 2013). 
Integrins are a major family of cell adhesion receptors (Hynes et al., 2000). They are a type 
I transmembrane molecule consisting of a short intracellular and larger extracellular domain. 
All integrins contain an α subunit and a β subunit. During signal transduction, they transmit 
information concerning the chemical and mechanical status of the ECM to the cell. Hence, 
they are involved in cell signaling and regulation of cell shape and motility (Cosemans et 
al., 2008; Bennet et al., 2009). Platelets express five integrins; αIIbβ3 (fibrinogen receptor), 
α2β1(collagen receptor), α5β1(fibronectin receptor), αVβ3 (vitronectin receptor) and α6β1 
(laminin receptor), all of which share related signal transduction processes (Shattil and 
Newman, 2004). On the cytoplasmic face of the plasma membrane, integrins organise and 
coordinate the assembly of cytoskeletal polymers and signaling complexes. On the 
extracellular side, integrins bind with high affinity to either ECM ligands or counter 
receptors on adjacent cell surfaces (Humphries et al., 2006). αIIbβ3 is the most abundant 
platelet integrin, with copy numbers of ~50,000 per platelet, and is present in both alpha 
granules and the platelet surface.  
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Platelets express a number of G-protein coupled receptors (GPCRs) which constitute a large 
family of receptors that can sense molecules outside the cell and initiate signal transduction 
pathways and ultimately cell function. The main GPCRs present on platelets include 
thrombin receptors called protease-activated receptors (PARs) (PAR1 and PAR4), ADP 
receptors (P2Y1, P2Y12,), of which approximately 150 P2Y1 receptors are present on the 
platelet (Ohlmann et al., 2010), thromboxane receptors (TPα and TPβ) and glycoprotein 
receptors (Rivera et al., 2009).  The main platelet integrins and GPCRs are highlighted in 
Figure 1.7. 
 
 
 
Figure 1.7: Major platelet receptor-ligand interactions. Shown in this diagram are platelet 
integrins α2β1 (yellow) and αIIbβ3 (Green) and their ligands collagen and fibrinogen/vWF 
respectively. Platelets express G-protein coupled receptors such as thrombin receptors called 
protease activated receptors (PARs) (pink) and ADP receptors (Purple). Receptors for Epinephrine 
and TxA2 are also shown. In orange is the platelet receptor CLEC-2 and its ligand podoplanin.  
(Image adapted from Rivera et al., 2009). 
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1.3.3 Platelet function in primary haemostasis 
Haemostasis is the physiological process which stops bleeding at an injured blood vessel, 
while maintaining normal blood flow elsewhere in circulation. Haemostasis can be 
subdivided into primary haemostasis, secondary haemostasis and fibrinolysis (Gale, 2013). 
The main physiological function of blood platelets is to prevent blood loss in primary 
haemostasis by the formation of a ‘platelet plug’. Therefore, platelets have been labelled as 
“Band-Aids” of the bloodstream (Thon et al., 2012). Secondary haemostasis refers to the 
deposition of insoluble fibrin that is generated by the coagulation cascade. Finally, 
fibrinolysis results in the breakdown of blood clots during wound healing involving the 
interplay between a number of enzymes (Gale et al., 2011).  
Under physiological conditions, a healthy endothelium provides a non-adhesive surface for 
platelets and therefore they do not normally interact with the surface of healthy vessels. 
However, in areas of vascular injury, the subendothelium is exposed and platelets may 
adhere quickly to different extracellular matrix components, and then form a platelet plug. 
This process is achieved through three distinct processes – platelet adhesion, platelet 
activation and secretion, and platelet aggregation (Clemetson, 2012).  
1.3.3.1 Platelet adhesion 
Depending on the matrix proteins exposed to blood and the hemodynamic conditions, 
platelet adhesion entails a collaborative effort of various platelet receptors, fundamentally 
leading to platelet activation and aggregation. The ECM elements that platelets adhere to 
include proteins such as collagen, vWF, fibronectin, laminin and fibrinogen amongst others 
(Ruggeri, 2007; Broos et al., 2011). Among these subendothelial substrates, the 
thrombogenic fibrillar collagens type I and III are the most powerful intermediaries of 
platelet adhesion due to their robust activating potential and affinity for vWF (Farndale et 
al., 2003). 
Early adhesive interactions between platelets and the ECM are dictated by local rheological 
environments. At areas of low shear (<1000s-1) in veins and large arteries, platelet adhesion 
mainly involves collagen, fibronectin and laminin. At areas of high shear rates (>1000s-1) 
such as small arteries or atherosclerotic vessels, the interaction between vWF and platelet 
receptor GPIbα is required to slow down fast flowing platelets, enabling the formation of 
additional bonds and definitive arrest of platelets. 
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Following vascular damage, initial platelet ‘tethering’ is mediated by the interaction between 
the A1 domain of vWF deposited in the subendothelial matrix of the damaged vessel wall, 
and the GPIbα in the platelet receptor GPIb-IX-V (Figure 1.8, (A)). This interaction is 
particularly important at high shear rates supporting platelet translocation (i.e. decelerating 
platelets and keeping them in close contact with the endothelium) over the subendothelium, 
but not stable adhesion (Ruggeri and Jackson, 2013). This interaction allows engagement of 
other platelet receptors. vWF/GPIb-IX interface also induces platelet activation signalling 
events, resulting in integrin activation (Li et al., 2010). 
Following platelet tethering, platelet collagen receptors, GPVI and α2β1, interact with 
exposed collagen and promote platelet adhesion and activation. GPVI is non-covalently 
coupled to the Fc Receptor chain (FcRγ) (Tsuji et al., 1997; Jarvis et al., 2002) and has been 
acknowledged as the major signalling receptor for collagen. FcRγ has an immunoreceptor 
tyrosine-based activation motif (ITAM) on its cytoplasmic sphere. After collagen binding to 
GPVI, the ITAM motif on the GPVI/FcRγ complex is phosphorylated, resulting in activation 
of the Syk kinase pathways that phosphorylate downstream targets, ultimately resulting in 
increased cytosolic Ca2+ and subsequent platelet shape change, granule secretion and 
integrin activation.  
GPVI has a low affinity for collagen, rendering it unable to mediate stable adhesion alone. 
The α2β1 integrin then maintains stable adhesion to collagen. α2β1 stimulates downstream 
steps indirectly by reinforcing GPVI-collagen interactions (Broos et al., 2011) and by direct 
signalling leading to activation of αIIbβ3. The importance of α2β1 in platelet adhesion has 
been a topic of deliberation for decades (Nieswandt et al., 2001; Mazzucato et al., 2009) as 
the predominant thought was that GPVI was solely responsible for signalling. However, 
platelet Ca2+ signalling is markedly dissimilar between GPVI and α2β1 (Mazzucato et al., 
2009) and it seems that the alliance regarding GPVI and α2β1 supports optimal platelet 
adhesion.  
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The final step of stable platelet adhesion occurs via binding of platelets to other ECM 
components such as fibronectin, laminin and immobilised vWF.  Platelets bind to fibronectin 
via the α5β1 receptor and αIIbβ3, whilst adhesion to laminin is mediated by their α6β1 
receptor. Stable binding of platelets elicits activation pathways involving tyrosine kinases 
and signal transduction GPCR receptor signalling, cumulatively resulting in elevated 
cytosolic Ca2+ levels, cytoskeletal reorganisation and integrin activation as discussed below. 
 
 
Figure 1.8: Platelet function in primary haemostasis. Vascular wall damage leads to exposure of 
collagen and subendothelial proteins. Platelet binding to immobilised von Willebrand factor (vWF) 
initiates adhesion to the ECM, thereby allowing the collagen receptors GPVI and α2β1 to interact 
with their ligands and mediate platelet activation. Platelet activation is reinforced by locally formed 
thrombin and platelet-derived ancillary mediators such as adenosine diphosphate (ADP) and 
thromboxane A2 (TxA2). These series of events encourage a shift in the β1 and β3 integrins from a 
low affinity resting state to a high affinity activated state through ‘inside out signalling’ enabling 
firm platelet adhesion and aggregation. Platelet aggregates are stabilised by fibrin formation and 
signalling events between neighbouring platelets comprising numerous platelet receptors (Image 
adapted from Nieswandt et al., 2011). 
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1.3.3.2 Platelet activation and secretion 
Once platelet adhesion has occurred at the site of vessel wall damage, and subsequent 
signaling to the platelet cytoplasm, platelet activation needs to be maintained for haemostasis 
to continue (Figure 1.8, (B)). Essential for the amplification of platelet activation is the 
production and release of soluble agonists at the site of damage (Zharikov and Shiva 2013), 
which act in an autocrine and paracrine manner to amplify platelet activation and recruit 
further circulating platelets. 
These agonists consist of TxA2, ADP, epinephrine and thrombin. ADP is secreted from 
platelet dense granules and binds to its relevant receptors, P2Y12 and P2Y1 on the platelet 
surface (Kaplan and Jackson, 2011). ADP is also released from red blood cells at the site of 
vascular damage (Rivera et al., 2009). Binding of ADP initiates a full complement of 
activation events such as elevation of intracellular platelet Ca2+, TxA2 synthesis, protein 
phosphorylation, shape change, granule release, and most importantly, activation of αIIbβ3 
(Andrews and Berntd, 2004). P2Y12 is also the target of a class of antiplatelet drugs called 
thienopyridines (ticlopidine, clopidogrel, prasugrel), widely used in the prevention of 
vascular events in patients with CVD.  
TxA2 is a potent platelet agonist synthesised from arachidonic acid through the COX 
pathway and TxA2 synthase enzymes. It subsequently binds to TPα and TPβ receptors that 
differ in their cytoplasmic tails, causing vasoconstriction, shape change, protein 
phosphorylation, secretion and platelet aggregation (Nakahata et al., 2009; Angiolillo et al., 
2010). Indeed, high levels of TxA2 has been implicated in CVD, whilst inhibition of TxA2 
synthesis through aspirin-mediated COX inhibition is a major antiplatelet target. 
The agonist thrombin rapidly accumulates at sites of vascular damage and has major 
functions in promoting and stabilizing thrombus formation. Platelets release factors that 
support the activation of prothrombin, which after a complex series of sequential events in 
the coagulation cascade, results in the generation of thrombin (Monroe et al., 2000). The 
increase in cytosolic Ca2+ after platelet activation results in platelet phosphatidylserine (PS) 
exposure on the activated platelet membrane providing a procoagulant surface for thrombin 
to interact with its PAR1 and PAR4 (G protein-coupled) receptors. 
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Unlike every other ligand involved in platelet activation that function by binding in a 
reversible mode to their individual receptors, thrombin activates its PAR-receptors by 
cleaving an N-terminal part at a consensus site. Cleavage exposes a new binding site that 
acts as a ligand to activate the receptor. Thrombin is the most powerful platelet activator, 
initiating an entire complement of platelet responses (shape change, granule secretion, 
TxA2 synthesis, aggregation etc.) (Candia, 2013). Thrombin can activate platelets at 
extremely low concentrations and within seconds, increases the cytosolic level of Ca2+, 
eliciting downstream signalling events. Unlike ADP, TxA2 or thrombin, the catecholamine 
epinephrine is a weak agonist unable to cause shape change alone. However, it works 
collectively with the other agonists increasing their activatory potential. Epinephrine’s mode 
of action is to inhibit cAMP formation by the platelet α2A-adrenergic receptor (Horn et al., 
2005). 
1.3.3.3 Platelet aggregation 
Following platelet adhesion and activation, the ultimate step in primary haemostasis is 
platelet aggregation, caused by crosslinking of αIIbβ3 on adjacent platelets by fibrinogen 
(Figure 1.8, (C)). While platelet aggregation is a complex process involving different 
receptors (αIIbβ3 and GPIbα) and ligands (fibrinogen, fibronectin, and vWF), the main 
process revolves around the integrin αIIbβ3. On resting platelets, integrin αIIbβ3 has a low 
affinity for its ligands fibrinogen and vWF, which dramatically increases upon platelet 
activation. 
Binding of the main agonists to their respective receptors described above induce 
intracellular signals that disrupt the complex between the cytoplasmic tails of αIIbβ3. This 
ultimately leads to a conformational change in its extracellular globular head domains from 
a low affinity resting state to a high affinity activated state in order to bind extracellular 
ligands such as fibrinogen and vWF. This irreversible activation of αIIbβ3 is a prerequisite 
for the development of irreversible platelet aggregates. Due to the symmetrical nature of 
fibrinogen, platelets can be ‘bridged’ and platelet aggregates are formed enabling the 
formation of a platelet plug (Ruggeri, 2007). 
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While αIIbβ3 is the major player in platelet aggregation, couplings between other platelet 
receptors and their ligands could be incorporated in aggregation (Figure 1.9). Some of these 
comprise CD40 ligand (Andre et al., 2002) interaction with αIIbβ3, the vWF–GPIb 
complex (Kulkarni et al., 2000), and an involvement of fibronectin in stabilising platelet 
aggregation (Ni et al., 2000; Cho and Mosher, 2006), yet the roles of these mechanisms (and 
others) in platelet aggregation remain to be clearly elucidated. Cadherin-6 was recently 
acknowledged as a new counter-receptor for αIIbβ3 that could be involved in platelet 
aggregation (Dunne et al., 2012). Furthermore, GPVI, has been identified as a receptor for 
fibrin (Alsheri et al., 2015) and has therefore been suggested as a central player not only in 
platelet adhesion to collagen, but also in both thrombus formation and stability. Importantly, 
multiple adhesive ligands regulate platelet aggregation, however further investigation is 
required to elucidate their contribution to haemostasis and thrombosis under different 
conditions. 
 
 
Figure 1.9: Multiple platelet receptors and ligands involved in aggregation. While αIIbβ3 and 
fibrinogen (FGN) interaction is the key to platelet aggregation, there are interactions between 
multiple adhesive receptors and their ligands such as cell surface ephrins and CD40L. The 
intercellular space between aggregating platelets facilitates a shielding environment for the 
accumulation of soluble agonists (ADP, thrombin, and TxA2) (Image from Jackson et al., 2007). 
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Bi-directional ‘inside out’ and ‘outside in’ signals are transferred by the two subunits of 
integrins that mediate integrin conformation and platelet function (Li et al., 2010). These 
important context-specific concepts are explained below. After platelet stimulation with 
ADP, the signal from the ADP receptors is conducted to the intracellular domain and the 
cytoplasmic tail of αIIbβ3 and subsequently transmitted through a series of events to the 
extracellular domain (inside-out) causing a conformational change in the extracellular 
domain that binds to its ligand (Figure 1.10). Inside-out signaling necessitates binding of 
talin and kindlins to the cytoplasmic domain of β3. After ligand binding (to fibrinogen or 
vWF, for example) a signal is sent to the cell (outside-in) to control platelet function such as 
filopodia and lamellipodia extension to dull platelet spreading (Shattil et al., 2004; Li et al., 
2010). Furthermore, αIIbβ3 outside-in signals can also act as a break to curb excessive 
platelet activation by activated SHIP-1 (Dai et al., 2016). While the early signalling 
mechanisms of copious platelet receptors differ during adhesion and aggregation, they 
ultimately congregate into common intracellular signalling events (Li et al., 2011). 
 
 
Figure 1.10: Outside-in and inside-out signalling in platelets. Bacteria-bound platelet factor four 
(PF4) is recognised by plasma IgG. This complex binds to the platelet receptor FcyRIIA, which 
causes inside-out signalling resulting in a conformational change in integrin αIIbβ3 to an activated 
state. Binding of fibrinogen to the activated αIIbβ3 induces outside-in signalling and release of 
platelet granule contents. Dense granule secreted ADP provides positive feedback by binding to the 
ADP receptors and stimulating more inside-out signalling. (Image from Naik et al., 2014). 
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1.3.3.4 Influencing factor in platelet aggregation 
A significant factor influencing platelet aggregation is the distinct shear environment 
experienced within the vascular system. Platelets are subjected to fluctuating haemodynamic 
(blood flow parameters) conditions in vivo such as shear stress and shear rate. The latter 
refers to the rate of increase of blood flow velocity, whereas the former denotes the force per 
unit area on the vessel wall (Sakariassen, 2015). Shear rates experienced by platelets range 
from slow flow environment in veins (shear rate 10 s-1 to 500 s-1) to small arteries (approx. 
2000 s-1) to diseased or pathological arteries, where extremely high shear rates (up to 40,000 
s-1) have been described (Jackson, 2007; Sakariassen, 2015). Increasing shear rate both 
activates platelets itself and promotes their relocation toward the vessel wall/thrombus  
At low shear rates (< 1000 s−1), platelet aggregation is primarily facilitated by αIIbβ3–
fibrinogen interactions. At shear rates typically over 5000 s-1 (but between 1000-10000), a 
two-step sequential process occurs. The first depends on the adhesive properties of GP1bα 
and αIIbβ3 and is facilitated by the formation of reversible platelet aggregates. The second 
relies on the generation of platelet agonists and involves the irreversible activation of αIIbβ3 
to form stable aggregates (Munnix et al., 2009). In stenotic arteries, at pathological shear 
rates (>10,000 s-1), platelet aggregation can occur autonomously of platelet activation, given 
that soluble vWF is present (Ruggeri et al., 2006). This is characterised by the construction 
of unstable platelet aggregates which roll over the vWF surface, facilitated by vWF-GP1bα 
interactions. Accordingly, substrates fibrinogen and vWF, and receptors GPIbα and αIIbβ3, 
have distinctive but complementary roles in platelet aggregation subject to the 
haemodynamic environment. 
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1.3.4 Signals during platelet function 
The role of platelets in haemostasis is reliant on the equilibrium between activatory and 
inhibitory signals (Jones et al., 2012). Inhibitory signals from the vasculature prevent platelet 
activation in healthy vessels, ensuring a resting state is maintained. Without inhibitory 
signals, platelets would become activated even in the absence of activating signals. 
Activatory signals present at an injured blood vessel initiate platelet activation and 
thrombosis, and endogenous negative signalling regulators diminish activatory signals to 
manage thrombus development. The interplay between these signals is illustrated in Figure 
1.11. 
 
 
Figure 1.11: The complex network of platelet signals. Platelet signalling is an extremely complex 
process, with multiple agonists and negative regulators at play. Central signalling molecules common 
to most pathways include phospholipase C (PLC), protein kinase C (PKC), and 
phosphatidylinositide‐3‐kinase (PI3K) acting as hubs of platelet regulation. Inhibitory signals that 
suppress platelet function are represented by the blue boxes and lines, e.g. binding of PGI2 to its IP 
receptors on the platelet surface activates guanylyl cyclase (GC) to elevate intracellular cAMP levels 
which ultimately suppress platelet adhesion and activation.  Activation signals are represented by the 
red boxes and lines, e.g. platelet adhesion to collagen through GPVI initiates a signalling cascade 
involving a number of downstream targets, resulting in αIIbβ3 activation. The green boxes and lines 
represent negative feedback and inhibitory signals which limit platelet activation. For example, 
Wnt3a binding to platelets regulates RhoA and inhibits platelet adhesion.  (Image from Bye et al., 
2016).  
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The primary platelet inhibiting signals produced by healthy ECs are nitric oxide (NO) and 
prostacyclin. Both NO and prostacyclin relax blood vessels and prevent platelet activation 
(Broos et al., 2011; Smolenski et al., 2012). NO is synthesised from several cells including 
platelets and ECs and plays vital roles in maintaining platelets in a resting state 
(Gkaliagkousi and Ferro 2011; Gambaryan et al., 2016). While ECs provide the main source 
of NO, RBCs are also implicated in NO-dependent regulation of cell function (Benz and 
Fleming, 2016). Endothelial-derived NO disperses throughout the platelet membrane where 
it’s effects are mainly mediated by a cGMP pathway. NO binds to its intracellular receptor 
soluble guanylyl cyclase (sGC), which causes an increase in intracellular cGMP levels. 
cGMP effects are primarily mediated by the cGMP-dependent protein kinase (PKG). 
Activation of PKG results in protein phosphorylation. These proteins inhibit increases in 
intracellular Ca2+ cytoskeletal reorganisation, integrin activation (Subramanian et al., 2013), 
activation of G-proteins (RAP1), eventually leading to inhibition of platelet adhesion and 
granule secretion and aggregation (Smolenski et al., 2012). 
Prostacyclin (PGI2) is a physiological anti-aggregating agent produced constitutively by ECs 
as a result of arachidonic acid metabolism by cyclooxygenase (COX) enzymes. Binding of 
PGI2 to its IP receptors on the platelet surface activates guanylyl cyclase (GC) to elevate 
intracellular cAMP levels and ultimately activation of the cAMP-dependent protein kinase 
A (PKA). Activated PKA can phosphorylate several regulatory proteins including 
vasodilator-stimulated phosphoprotein (VASP). Phosphorylated VASP inhibits the 
reorganisation of the actin cytoskeleton, which is associated with platelet spreading and 
aggregation. Furthermore, VASP is associated with focal adhesions where its 
phosphorylation prevents the inside-out activation of αIIbβ3 and therefore platelet 
aggregation. Elevation of platelet cyclic nucleotides obstructs nearly all platelet activation 
signalling pathways, efficiently preventing complex intracellular signalling cascades, 
cytoskeletal reorganisation, integrin activation, granule release and expression of pro-
inflammatory molecules (Schwarz et al., 2011). 
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Following endothelial damage, endogenous inhibitory signals are lost and platelets react 
rapidly to limit blood loss as described in section 1.3.3. The activating stimuli, such as 
collagen, vWF, ADP, TxA2 and thrombin, which induce platelet adhesion, activation and 
aggregation ultimately regulate a central set of signalling mediators that support activation. 
Three core mediator families of platelet activation are phospholipase C (PLC), protein kinase 
C (PKC) and phosphatidylinositide-3-kinase (PI3K), which are well characterised and 
underlie two crucial events in platelet activation – secretion of amplifying mediators and 
activation of integrin αIIbβ3. Evidently there are other regulators of platelet function, 
however these three represent main hubs in the multifaceted network of platelet signalling 
that in turn regulates other aspects of signalling such as calcium signalling 
After initiation of platelet activation and thrombus development, negative signalling 
mechanisms manage activation to ensure that platelet aggregation does not escalade out of 
control, thus avoiding excessive thrombus formation. Examples of such negative regulators 
and pathways include the immunoreceptor tyrosine-based inhibition motif (ITIM) 
containing receptors that are postulated to reduce activation of PLC, PI3K and integrin 
αIIbβ3 (Jones et al., 2012). Platelets contain a number of ITIM receptors such as G6b-B and 
platelet-endothelial cell adhesion molecule 1 (PECAM-1), highlighted in Figure 1.11 (Senis 
et al., 2014). The Wnt–β‐catenin pathway has recently gained attention as negative regulator 
of platelet function (Steele et al., 2009; MacCauley et al., 2013). The Wnt family is 
comprised of 19 Wnt glycoproteins. Wnt3a is one of these glycoproteins which is secreted 
from activated platelets, enabling the self-regulation of platelet activation. Wnt3a is a GP 
secreted from activated platelets permitting self-regulation of activation (Steele et al., 2009). 
Wnt3a has been suggested to activate the canonical Wnt–β‐catenin pathway as constituents 
of this pathway have been recognised in platelets. Wnt binding results in the inhibition of all 
aspects of platelet function – adhesion, shape change, granule release, integrin αIIbβ3 
activation and aggregation. The regulation of small GTPases such as Rap1, Rac1, RhoA and 
Cdc42 have been suggested as players in this inhibition of platelet function (Steele et al., 
2009). These pathways are less well characterised than the classical activation pathways 
(Bye et al., 2016).  
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1.3.5 Platelet function beyond haemostasis 
Besides their long-established roles in haemostasis, platelets are increasingly recognized as 
pivotal players in numerous other processes ranging from inflammation and atherosclerosis, 
fighting microbial infection and tumour growth and metastasis (shown in Figure 1.12). 
Platelets are equipped to influence inflammation and the innate immune response and 
infection. They express a collection of pattern recognition receptors called toll-like receptors 
(TLRs) that identify molecular motifs called pathogen associated molecular patterns 
(PAMPs) and initiate immune responses (Cognasse et al., 2015). Platelets express functional 
TLR 1-9, whilst TLR2 stimulation in platelets by bacteria through the activation of the PI3K 
signalling pathway induce a pro-inflammatory response (Blair et al., 2009). Platelet TLR9 
activation has been associated with thrombosis and oxidative stress, and is found within the 
previously mentioned novel T-granules in platelets (Thon et al., 2012). 
Platelets interact with numerous white blood cells, such as leukocytes, monocytes and 
granulocytes through different receptor-ligand interactions (P-Selectin and PSGL-1 
interaction) enabling communication between these cell types (Zago et al., 2008). The 
capacity of platelets to store and release copious inflammatory cytokines and chemokines is 
intimately associated to their role in inflammation. Platelets release microparticles linked to 
inflammatory pathways and which are associated with inflammatory diseases such as 
rheumatoid arthritis (Boilard et al., 2010). Platelets play key roles in infection, acting as 
sentinels in pathogen detection. They are the first cell type to arrive at areas of vascular 
infection and have been demonstrated to aid the immune system against bacterial and viral 
infections (Metcalf et al., 2014). Thrombocytopenia (low platelet count) is a well-established 
manifestation of sepsis and experimental work suggests that platelets play a functional role 
in the pathogenesis of sepsis and multi-organ failure (Guclu et al., 2013).  
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Platelets have significant roles in the pathogenesis of metastasis (Labelle et al., 2011). 
Tumour cells can aggregate platelets in vitro and it has been proposed that platelet adhesion 
to metastatic cells can act as a ‘cloak’ around circulating tumour cells therefore acting as a 
shield for immune clearance. This phenomenon of platelet cloaking has resulted in pro-
survival, pro-angiogenic and epithelial mesenchymal transition (EMT) in cancer cells 
(Cooke et al., 2015). Platelets also release growth factors such as VEGF and PDGF that can 
expedite tumour growth (Erpenbeck and Schon, 2010). Platelets are deeply implicated in 
wound healing and bone health, and indeed the use of platelet rich plasma (PRP) therapy 
(i.e. rich in growth factors and bioactive substances) is effective in osteoarthritis (Patel et 
al., 2013) and in muscle damage such as rotator cuff tendinopathy (Kesikburun et al., 2013).  
 
 
 
Figure 1.12: The multifunctional platelet. Besides their main functions in haemostasis and 
thrombosis, which are highlighted in pink above, platelets have a multitude of functions in other 
processes. These include roles in inflammation, immune response and fighting infection, tumour 
biology, wound healing and involvement in Neuroinflammatory disorders.  (Figure adapted from 
Harrison, 2005). 
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1.3.6 Platelet function tests (PFT)  
The different functions of platelets may be reliably detected with a wide spectrum of tests 
(Table 1.1). These can be utilised to identify inherited or acquired platelet dysfunction, 
monitor antiplatelet therapy, manage various aspects of platelet banking and transfusion, and 
to aid in the understanding of platelet physiology in basic research. PFTs are centred around 
principles of platelet function such as platelet adhesion and aggregation, platelet function 
under shear conditions, and measurement of the platelet releasate (Paniccia et al., 2014).  
Platelet function testing began with the evaluation of the bleeding time (the time taken for 
platelets to occlude an in vitrowound), using the Duke procedure (Duke et al., 1910), before 
the development of light transmission aggregometry (LTA) revolutionised the study of 
platelet function. Considered the historical gold standard, LTA is a relatively easy technique 
that involves stirring a suspension of platelet rich plasma in a cuvette in the presence of a 
platelet agonist (such as ADP or collagen). The cuvette is placed between a light source and 
photocell. Agonist addition causes in vitro platelet aggregation and changes in light 
absorbance, which is detected by the photocell (Born, 1960).  
1.3.6.1 Tests based on platelet adhesion under shear stress 
Investigation of platelet function in the environmental milieu of whole blood under 
conditions that take into account most of the physiological parameters that influence platelet 
adhesion and aggregation (red blood cells, white blood cells, plasma) is important. The PFA-
100, The Impact-R Cone and Plate analyser and the global thrombosis test are examples of 
such assays. The PFA-100 assesses platelet aggregation under high shear where platelets are 
activated in whole blood by an amalgamation of shear stress and agonists, resulting in 
closure of an aperture. In this assay, blood samples are aspirated at high shear (5000-6000s-
1) through a capillary in the instrument cartridge which is coated with agonists such as 
collagen and ADP. This causes platelet aggregation and occlusion of the cartridge (Karger 
et al., 2012). 
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The Impact-R Cone and Plate analyser is a point of care (POC) device which measures global 
platelet function by testing platelet adhesion and aggregation in whole blood under close to 
arterial shear conditions (Varon et al., 1997; Peerschke et al., 2007). In this assay, platelet 
adhesion is dependent on plasma proteins vWF, fibrinogen and RBCs and WBCs.   
The Impact-R has shown to correlate effectively with other platelet function tests. A study 
by Gremmel et al., (2009) compared five platelet function tests in in 225 patients on dual 
antiplatelet therapy. Included were the gold standard LTA, the VerifyNow aspirin assay, the 
PFA-100, Multiplate electrode and the Impact-R. They reported that only the correlation 
between results from LTA and Impact-R were statistically significant. Furthermore, results 
from a comparative study of platelet reactivity in healthy subjects and subjects with 
metabolic syndrome (metS) showed that Impact-R analysis correlated with the measurement 
of agonist induced P-selectin expression using flow cytometry. In this study, increased SC 
% (platelet adhesion) correlated with higher levels of P-selectin expression in metS subjects, 
reflecting activation dependent expression of adhesion receptors 
Furthermore, the addition of platelet agonists such as arachidonic acid (AA) and ADP in the 
system has enabled the evaluation of dual antiplatelet therapy (Savion and Varon, 2006; 
Anand et al., 2007; Koshy et al., 2014). The system is effective in the assessment of platelet 
function disorders in adults, (Goldschmidt et al, .2008) children (Revel-Vilk et al., 2007) 
and new-borns (Levy-Shraga et al., 2006), the latter of which demonstrated that the device 
is a convenient screening assay before more labour intensive diagnostic steps are engaged. 
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Table 1.1: Platelet function tests. Typical platelet function tests range from assessment of their 
primary haemostatic function including measurement of granule secretion using lumi-aggregometry 
to whole blood shear based assays, which measure platelet function under flow conditions. Platelet 
function can be tested in washed platelets, whole blood or platelet rich plasma. 
 
Method Sample Principle  Reference 
Platelet aggregation assays  
Light transmission 
aggregometry (LTA) 
Citrated PRP Measurement of light transmission 
in response to agonist-induced 
platelet activation 
Born, (1962) 
Whole blood 
aggregometry (WBA) 
Citrated WB Monitors changes in electrical 
impedance in relation to agonist-
induced platelet aggregation 
Toth et al., 
(2006) 
VerifyNow Citrated WB Turbidimetric optical detection of 
platelet aggregation in whole 
blood in response to 
agonists/inhibitors 
Smith et al., 
(1999) 
Plateletworks Citrated WB Platelet counting pre- and post-
activation 
Campbell et 
al., (2008) 
Assays measuring release reactions  
Lumi-aggregometry Citrated WB Combination of LTA/WBA with 
nucleotide release   
Cattaneo et 
al., (2009) 
Soluble platelet release 
markers (E.g. PF4, 
scD40L) 
Urine, serum, 
citrated 
plasma 
Typically measured by ligand 
binding ELISA immunoassays 
Chung et al., 
(2009) 
Shear-based assays  
PFA-100/200 Citrated WB High-shear platelet adhesion and 
aggregation during formation of a 
platelet plug 
Koessler et al., 
(2012) 
Impact R Cone and 
Plate Analyser 
Citrated WB  Shear-induced platelet adhesion–
aggregation upon specific surface 
Varon et al., 
(2008) 
Global thrombosis test Native WB High-shear platelet plug formation 
– measurement of time cessation 
of WB flow 
Saraf et al., 
(2009) 
Platelet activation based assays  
VASP phosphorylation Citrated WB Flow cytometry or ELISA 
measurement of VASP 
phosphorylation 
Aleil et al., 
(2005) 
Flow cytometry Citrated WB, 
PRP, Washed 
platelets 
Measurement of platelet 
glycoproteins, activation markers, 
platelet leukocyte aggregates, 
platelet microvesicles 
Michelson et 
al., (2007) 
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1.3.6.2 Platelet indices 
In addition to platelet function tests, platelet indices are useful as inexpensive non-invasive 
biomarkers for assessing platelet activation (Budak et al., 2016). Platelet indices are 
straightforwardly measured by semi-automated counters in complete blood counts (CBC) 
and usually include four factors; platelet count (PLT), mean platelet volume (MPV), platelet 
distribution width (PDW), plateletcrit (PCT), and depending on the analyser, platelet large 
cell ratio (PLCR). PLT is a universal indicator of haemostasis in a clinical setting and is 
utilised as a sensitive biomarker for a range of diseases. High PLT, even within the 
physiological range of 150 - 450 µl, is associated with a greater risk of thrombosis and CVD 
suggesting that enhanced PLT encourage platelet hyperactivity and a proinflammatory state 
(Thaulow et al., 1991; Khandekar, 2006). However, the consequence of high platelet 
numbers that are still within physiologic ranges remains unclear (Madjiid and Fatemi, 2013).  
The indices MPV, PDW and PLCR are quantitative measures of the variability in platelet 
size. MPV reflects the average platelet size while PDW reflects the volume variability in 
platelet size (Khandekar et al., 2006; Vagdatli et al., 2010). The volume of circulating 
platelets is heterogeneous with subsequent functional differences. Some authors suggest that 
larger platelets are metabolically more active than smaller platelets, that they have faster 
rates of aggregation and release higher quantities of prothrombotic elements such as TxA2 
and ADP (Thompson et al., 1983, Mangalpally et al, .2010). MPV and PDW levels can be 
altered in several diseases including T2DM (Jindal et al., 2011; Yilmaz 2016), CVD 
(Beckler et al., 2015) and atherosclerosis (Berger et al., 2010), and in this regard they have 
been suggested as markers of subclinical platelet activation. 
PLCR and PCT may serve as sensitive biomarkers of platelet health (Kaito et al., 2004; 
Yilmaz, 2016). PLCR indicates the percentage of large platelets present in blood (Budak et 
al., 2016). PLCR is significantly higher in subjects with dyslipidaemia compared to healthy 
subjects (Grotto and Noronha, 2004) and higher in children with T2DM compared to healthy 
children (Malachowska et al., 2015). Moreover, Rechcnski et al., (2013) believe that PLCR 
has the potential to be a prognostic biomarker, but more research into its relationship with 
platelet function is required. Importantly, thrombogenicity of large platelets may put 
individuals at higher risk of acute cardiovascular events.  
 
 29 
 
PCT is the volume of blood occupied by platelets as a percentage, similar to the erythrocyte 
measurement of haematocrit (HCT). PCT reflects total platelet mass and is calculated as PLT 
x MPV/107, providing comprehensive information about platelet activity. PCT has been 
proposed as a novel predictor of cardiovascular risk and higher PCT is associated with the 
risk of reinfarction and long-term mortality in CVD patients (Gul et al., 2016). However, the 
clinical significance, reference values and efficacy of some of these parameters are still 
under exploration.  
1.3.6.3 Measurement of other blood cell components 
Also measured by CBC analysis are RBC and WBC components of blood such as 
Haematocrit (HCT) and Haemoglobin (Hgb). In peripheral blood, there is ample interplay 
between RBCs, WBCs and platelets (Ho, 2004) and altered levels of blood cells and their 
morphology have been associated with CVD (Maajid 2013; Cetin et al., 2014). Platelet 
adhesion and aggregate size, as assessed by the Impact-R system, is influenced by platelet 
indices, RBC and WBC (Shenkman et al., 2000; Peerschke et al., 2007). RBCs are known 
to encourage platelets toward the vessel wall (Chestnut and Han, 2013), which can affect 
platelet adhesion and aggregation. In this context, it is important to investigate the 
associations between the various indices of each blood cell to interpret the multicellular 
contribution to both thrombogenesis and CVD risk. 
1.3.6.4 Novel platelet function testing  
Identification of primary platelet function changes in activation, aggregation, and secretion 
are typically measured by the aforementioned techniques. However, novel techniques 
continue to emerge and develop the knowledge surrounding the regulation of platelet 
function. The modern “omics” revolution enables simultaneous quantification of hundreds 
of molecules (e.g. protein or mRNA) from a single sample and their signatures may be 
reflective of platelet function changes. The amalgamation of transcriptomic and proteomic 
data and subsequent bioinformatic analysis will lead to a more complete characterisation of 
platelet function in response to environmental stimuli (Mc Redmond et al., 2004; Ferroni et 
al., 2012). Epigenetics and its ancillary elements, including platelet secreted microvesicles 
(MVs), microRNA (miRNA), and regulation of the platelet mitochondrial genome are new 
avenues of investigation and testing in platelet research (Bacarelli and Byun, 2015; Dahiya 
et al., 2016; Kaudevitz et al., 2016). 
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1.4 Epigenetics 
Epigenetics describes modifiable changes that occur to genes, via chemical modifications 
and/or varying states of chromatin organisation and structure, which alter gene expression 
without altering the actual DNA sequence (Pozharny et al., 2010).  Smoking habits, obesity, 
aging, and physical fitness among others are examples of environmental factors that have 
been suggested to have a long-term influence on epigenetic changes (Fraga et al., 2005). 
Epigenetics can be classed as three distinct but highly interconnected processes; DNA 
methylation, histone modification and RNA-associated silencing, shown in Figure 1.13. 
DNA methylation and histone modification alter DNA accessibility for transcriptional 
machinery and chromatin structure (Figure 1.13). These changes are heritable and can be 
passed down between generations through either mitosis or meiosis.  
1.4.1 Epigenetic mechanisms 
DNA methylation involves the addition of a methyl group to the 5-position of cytosine by 
DNA methyltransferases. This generally occurs at areas known as CpG islands – where a 
guanine is directly followed by a cytosine on the same DNA strand. Methyl groups control 
gene expression by binding to promotor sites of the gene and act like a switch if the gene is 
required to be turned off.  This changes the affinity of methylation-sensitive binding proteins, 
and is associated with transcriptional gene silencing. (Freson et al., 2012). Whilst required 
for normal development, changes in DNA methylation have been linked to CVD conditions 
such as atherosclerosis, for example, the atheroprotective estrogen receptor genes ESR1 and 
ESR2 that are usually expressed in smooth muscle cells (SMCs) are hypermethylated in 
atherosclerosis (Weinhold, 2006; Lund and Zaina, 2011).  
Unlike the platelet transcriptome and proteome, the investigation of epigenetic processes is 
almost a completely unexplored area in platelet biology, as analysis of these mechanisms 
requires DNA (Freson, Izzi and Van Geet, 2012). Platelets have functionally active 
mitochondria (Antony et al., 2012). Like nuclear DNA, mitochondrial DNA (mtDNA) can 
also be methylated, moderating control of mitochondrial gene expression.  
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Understanding epigenetic regulation of mitochondrial genes in platelets is proving crucial to 
understanding their implication in CVD development. Novel research by Baccarelli and 
Byun (2015) showed that CVD patients had significantly higher platelet mtDNA methylation 
than healthy individuals in MT-CO1, MT-CO2, MT-CO3, and MT-TL1, genes involved in 
ATP synthesis. These results suggest that DNA methylation in platelet mitochondria could 
be a potential contributor to CVD development through the regulation of platelet function.  
 
Figure 1.13: The three epigenetic mechanisms. DNA methylation involves the addition of a methyl 
group to the 5-position of cytosine. Histone modifications refer to the posttranslational alterations to 
the N-terminals of histone tails, which subsequently modify histone-DNA interactions, controlling 
gene transcription. miRNA regulate gene expression at a post-transcriptional level. Crosstalk 
between miRNA and epigenetic pathways form an epigenetic-miRNA regulatory circuit, arranging 
the whole gene expression profile.  (Figure adapted from Wade et al., 2015). 
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Histone modifications are another epigenetic mechanism (Figure 1.13). Histones are 
proteins that condense and structure DNA into units known as nucleosomes. Nucleosomes 
consist of 8 core histone proteins that contain modifiable amino-acid tails. Histone 
modifications refer to the posttranslational alterations of the N-termini of these tails that 
subsequently modify histone-DNA interactions (Webster et al., 2013). Acetylation is a major 
type of histone modification involving the addition or removal of an acetyl group. This 
process is catalysed by proteins known as histone acetyltransferases (HATs) and histone 
deacetyltransferases (HDACs). This mechanism changes chromatin structure to influence 
gene expression. Tightly wound bounded chromatin tends to reduce gene expression, 
whereas loosely wound DNA is more highly expressed (heterochromatin versus 
euchromatin) (Weinhold, 2006).  
RNA-based processes are the third type of epigenetic mechanism. Non-coding RNA 
(ncRNA) has emerged as a factor in the chromatin-based regulation of gene expression 
(Zaratiegui et al., 2007). ncRNAs can be classified as either long or short. Whilst long 
ncRNAs are a major form of RNA-based epigenetic regulation, some small ncRNAs also 
have a function in chromatin-based silencing. For example, microRNA (miRNA) are a 
subset of ncRNA that negatively regulate gene transcription by degrading or repressing 
target mRNA (Calin et al., 2007). miRNA can control the expression of important epigenetic 
regulators such as histone deactylases and DNA methyltransferases and similarly, DNA 
methylation and histone modification can control the expression of some miRNA, thereby 
forming a feedback loop (Sato et al., 2011; Osello et al., 2014). This complex crosstalk 
between miRNA and epigenetic pathways forms an epigenetic-miRNA regulatory circuit, 
arranging the whole gene expression profile. Disruption of this circuit interferes with normal 
physiological functions and can contribute to disease process. miRNA will be discussed in 
detail in Section 1.5. 
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1.4.2 Epigenetic drift 
Individuals age differently and lifestyle factors such as exercise or smoking have been shown 
to delay or accelerate the aging process, respectively (Blair et al.1989). These observations 
have resulted in the search for molecular markers to predict and monitor age-associated 
disease. DNA methylation is associated with chronological age over time (Bollati et al, 
.2009; Ailish et al., 2012). Epigenetic drift is the term given to epigenetic modifications as 
they occur as a direct consequence of age (Tan et al., 2016). This was previously observed 
when DNA methylation marks in identical twins differed increasingly as a function of age 
(Fraga et al., 2009). Monozygous twins share a common genotype and while this study found 
that the twins were epigenetically synonymous during childhood, older twins showed 
significant differences in their total content and dispersal of histone acetylation and DNA 
methylation, subsequently impacting their gene expression. Disparity in these epigenetic 
marks between twins can be as a result of lifestyle influences such as diet, physical activity 
levels and smoking. 
Epigenetic drift affects the majority of the genome. The aging effects of epigenetic drift over 
time are highlighted in Figure 1.14. Aging is a natural process associated with de-regulation 
of histone tags, senescence-associated ncRNA, a gradual deregulation of DNA methylation, 
in a potential linear fashion depicted by age-predictive linear models (Hannum et al., 2013). 
However, an individual exposed to either environmental or genetic risk factors may show 
signs of premature aging as a result of either lifestyle or environmental risk factors. This can 
be characterised by altered or increased deregulation of DNA methylation, increasing the 
susceptibility to chronic diseases like CVD. Furthermore, it has been hypothesised that a 
healthy lifestyle may reserve a more intact epigenome and longevity (Tschendorff et al., 
2013).  
DNA methylation undergoes extensive changes during differentiation of self-renewing stem 
cells (Broske et al., 2009; Oshima and Iwama, 2014; Choudry et al., 2016). Indeed, DNA 
methylation is involved in the production of MKs and their subsequent transcription 
(Georgantas et al., 2007). Lifestyle components such as physical inactivity and obesity may 
incur epigenetic changes in the production of platelets from megakaryocytes.  
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Thus, platelets could signify a marker of megakaryocyte epigenetic drift, holding substantial 
predictive potential of disease. Epigenetic changes in the megakaryocyte genome such as 
hypomethylation of genes determining PLT or changes in histone acetylation with aging 
have been suggested to play an important role in platelet function (Daly, 2011).  
 
 
 
Figure 1.14: Epigenetic drift. Epigenetic drift represents changes in DNA methylation as a function 
of time. Normal aging (white) results in de-regulation of DNA methylation amongst other features. 
Premature aging as a result of exposure to risk factors can display altered DNA methylation. By 
contrast, healthy aging as a result of physical activity can result in a different epigenetic profile. 
Epigenetic Drift over time can result in measurable differences between biological and chronological 
age. (Adapted from Teschendorf et al., 2013). 
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1.5 MicroRNA  
1.5.1 Introduction to miRNA 
miRNAs are short (18-24) nucleotide long non-coding RNAs that function in post 
transcriptional regulation of gene expression. They inhibit translation by binding with the 3′-
untranslated (UTR) regions of their target mRNA. Here, the miRNA promotes either 
translational repression or degradation of target mRNA, depending on complementarity with 
the mRNA strand, resulting in silencing of various genes (Van Rooij and Olsen, 2007). 
Genetic screening of the nematode, Caenorhabditis elegans, gave rise to the identification 
of the first miRNAs, lin-4 and let-7 (Lee et al., 1993), which functioned as regulators of 
developmental timing. However, miRNAs were not recognised as a distinct category of 
biological regulators until the early 2000’s. Since their discovery, huge progress has been 
made in the field and they are now labelled as “fine-tuners” of cellular phenotypes by 
repressing expression of proteins that are inappropriate for particular cell types. 
To date, more than 4000 miRNA sequences have been identified across a variety of species, 
of which over 2000 are encoded by the human genome (Van Dongen et al., 2008; Kozomara 
et al., 2011). They are thought to be involved in the regulation of ~ 60 percent of human 
genes and are convoluted in most physiological and pathological processes (Ple et al., 2012; 
Laffont et al., 2013). miRNA can be classed as intronic, exonic and intergenic miRNA, 
according to the location of their encoding genes (Wang et al., 2009).  Intronic miRNA 
account for approximately 70 percent of all transcribed miRNA (Bartel et al., 2004; 
Rodriguez et al., 2004). Intergenic miRNA are found between two protein-coding genes and 
employ their own promoters and regulatory molecules (Sarnow et al., 2006).  As miRNA 
target mRNA by imperfect binding, each miRNA has numerous targets, enabling miRNA to 
regulate over half of the human genome (Bartel et al., 2009; Rigoutous et al., 2009). Various 
online algorithms are available to predict miRNA binding sites such as Miranda, TargetScan 
and miRBase (Peterson et al., 2014). Importantly, a single miRNA can regulate hundreds of 
different mRNA, whilst each mRNA can be regulated by several miRNA (Edelstein and 
Bray, 2011). 
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1.5.2 miRNA biogenesis and function 
The miRNA population within a cell can be highly concentrated, with tens of thousands of 
miRNA copies per cell. They possess a long half-life (a half-life of between 28-220 hours 
has been reported) and are very stable (Van Rooij et.al., 2007; Zhang et al., 2012). miRNA 
biogenesis beings with transcription, followed by several processing steps to generate the 
mature miRNA. Each step of the miRNA biogenesis pathway is subject to regulation 
(Finnegan and Pasquinelli, 2013). Encoded by the genome of nucleated cells, miRNA are 
transcribed by RNA polymerase II from miRNA coding genes into long, hairpin stem-looped 
primary miRNAs (pri-miRNAs) of approximately 70 nucleotides. They are 5'7-
methylguanosine capped and poly-adenylated at the 3'end, the latter allowing recognition by 
the microprocessor complex (Bartel, 2004).  
miRNA biogenesis begins in the nucleus with transcription by RNA polymerase II to 
produce the long primary miRNA (Pri-miRNA). This houses a hairpin that holds the mature 
sequence (Winter et al., 2009). The hairpin is then cleaved at the 3' poly-A tail and the 5' cap 
by a microprocessor processing complex that includes the endonuclease III type protein, 
Drosha, acting in conjunction with the protein DGCR8 and an RNase III enzyme. This 
results in a hairpin looped precursor miRNA (pre-miRNA) of about 60-70 base pairs in 
length. RAN-GTPase and the transport protein Exportin-5 then actively export the pre-
miRNA from the nucleus. 
The following step to maturation is processing by the RNAse III protein, Dicer, which 
removes the hairpin loop and cleaves the pre-miRNA into a 21-24 nucleotide duplex 
miRNA. The duplex is then unwound by the Argonaute 2 (Ago2) complex producing a 
mature and complimentary minor strand, sometimes termed the passenger or star (*) strand. 
The Ago2 complex incorporates the mature strand into the multiprotein complex RNA-
Induced Silencing Complex (RISC) (Osman and Falker, 2011).  
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Using imperfect pairing, the RISC then binds the miRNA to the 3'UTR of the target mRNA. 
The binding occurs on what is identified as the "seed region" of the miRNA that is normally 
6-8 nucleotides long, beginning at the second nucleotide. Usually, the star strand is degraded 
quickly after the mature strand has been incorporated into RISC, although it is sometimes 
possible for both strands to be cleaved into mature, functional miRNA, depending on the 
tissue or cell type (Bhayani et al., 2012). Depending on which strand side (either 3' or 5') is 
incorporated into RISC, the miRNA is subsequently labelled as miRNA 3' or miRNA 5'.  
Once incorporated into RISC, miRNAs regulate gene expression by either of two 
posttranscriptional mechanisms: mRNA degradation or translational repression. The degree 
of complementarity between the target mRNA and miRNA decides which mechanism 
occurs. If full complementarity between the strands is achieved, mRNA degradation will be 
the process of choice. Otherwise, translation will be repressed with sufficient 
complementarity (Bartel 2004). In the majority of mammals, miRNA induces mRNA 
degradation in over 80 % of cases (Guo et al., 2010). Although deeply conserved, many 
miRNA express a modest effect on their target mRNA often less than 2 fold (Bartel et al., 
2004). However, several miRNAs often work together to co-target an mRNA. This is 
possible as many mRNA 3’UTRs have more than four highly conserved seed sequences. 
The full biogenesis of miRNA is depicted in Figure 1.15. 
Turnover of mature miRNA is required for rapid changes in miRNA expression profiles. 
Regulation of miRNA maturation occurs during various steps throughout their biogenesis at 
both a transcriptional and post-transcriptional level (Finnegan and Pasquinelli et al., 2013). 
Transcriptional regulation involves alterations to the expression of a host gene such as 
epigenetic regulation (where miRNA genes located near CpG islands in the genome are 
found to be hypermethylated). Post-transcriptional mechanisms define modifications in 
miRNA processing and stability (Gulyaeva and Kushlinskiy, 2016).  
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Figure 1.15: The biogenesis of microRNA. miRNA genes are usually transcribed by RNA 
polymerase II. This transcript folds into a hairpin loop structure called the pri-miRNA. The pri-
miRNA is processed in the nucleus by the microprocessor complex of Drosha/DCGR8 to form an 
approximate 70 bp pre-miRNA. The pre-miRNA is exported to the cytoplasm by Exportin-5 and 
processed by Dicer to generate the miRNA-miRNA* duplex. The mature miRNA strand is 
incorporated into the RISC by Ago2. Here, the seed region of the miRNA binds to the 3’-untranslated 
region of the target mRNA resulting in either mRNA degradation or translational inhibition.  (Figure 
adapted from Winter et al., 2009). 
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1.5.3 Platelet miRNA 
Platelet function is a highly regulated process. Despite their anucleate nature, platelets 
accommodate a small but competent transcriptome that is employed for translation of 
various proteins with significant physiological functions. Platelets have been shown to retain 
genetic material derived from their megakaryocyte precursor (Figure 1.16). Approximately 
32% of all human genes are present in platelets at the mRNA level (Ple et al., 2012). It is 
well accepted that platelets contain the necessary splicing machinery, rough ER and 
polyribosomes that allow the synthesis of proteins required for their functions in haemostasis 
and beyond (Bijak et al., 2013). Perhaps due to the requirement of sustaining a proteome 
over an ~ 8-day life span, the fact that the average half-life of a cellular protein is 46 hours, 
or the necessity to adapt to environmental stimuli, it is equitable to assume that the platelet 
must also retain its transcriptome, as well as processes of nucleated cells such as splicing, 
translating and posttranscriptional RNA mechanisms (Corey and Edelstein 2016). 
The fact that platelets contain mRNA and are capable of protein synthesis has raised the 
issue of how these mRNAs are regulated. Notably, stored platelets in blood banks can 
synthesis integrin β3 (Thon and Devine, 2007). The existence and functionality of a miRNA 
pathway in the anucleate human platelet was first described in a landmark study by Landry 
and co-workers (2009), who showed by locked nucleic acid (LNA) microarray profiling, that 
platelets harboured an impressive number (219) of miRNA. They reported that the three 
most abundant miRNA in platelets were miR-223, miR-19a and Let-7c. Further analysis 
discovered the presence of functional processing miRNA machinery in platelets – Dicer and 
Ago2, suggesting that partial biogenesis of mature miRNA from pre-miRNA could occur 
within platelets themselves (Landry et al., 2009; Thum and Dangwal, 2013) as pre-miRNAs 
have been identified at low levels (21 transcripts) in platelets (Ple et al., 2012). Star or 
passenger strand miRNA have also been identified (Bray et al., 2013). Accordingly, the 
detection of nuclear miRNA microprocessor Drosha and DGCR8 in platelets has not been 
observed, consistent with their anucleate nature. Moreover, miRNA-associated Ago2 
complexes were identified, in addition to the presence of P2Y12 in Ago2 precipitates, 
suggesting a regulation of P2Y12 by miRNAs (Landry et al., 2009).  
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The next breakthrough study in platelet miRNA biology revealed that a protein involved in 
platelet granule release, platelet vesicle-associated membrane protein 8 (VAMP8), was 
associated with distinctly different platelet aggregation responses to epinephrine in healthy 
donors, and that VAMP8 was regulated by miR-86 (Kondkar et al., 2011). Since then the 
platelet-miRNA field has grown exponentially, whereby a number of studies have suggested 
a physiological role for miRNA in the regulation of platelet function. Most notably, research 
by Nagalla and colleagues (2011), who focused on the roles of miRNA as biomarkers of 
platelet reactivity and controllers of platelet mRNA disparity, demonstrated that miRNA 
profiles of healthy subjects (n=19) were associated with the response of platelet aggregation 
to epinephrine. They also employed a computational approach to produce possible miRNA-
mRNA pairs (miR-200b: PRKAR2B, miR-495: KLHL5 and miR-107: CLOCK), pairings 
which were experimentally validated in cell lines. Networks of miRNA-mRNA pairs also 
associated with age and gender and race (Simon et al., 2013; Simon et al., 2014). Other 
reports on agonist-induced platelet activation by thrombin (Osman and Falker, 2011) and 
ADP (Cimmino et al., 2012) show differential expression of platelet miRNA compared to 
resting platelets.  
Progression in miRNA detection techniques has led to the revelation of 40 new miRNA 
sequences, expanding the total amount of platelet expressed miRNAs to more than twice that 
(544) of the initial finding (Ple et al., 2012; Thum and Dangwal, 2013; Teruel Montoya et 
al., 2014). Transcriptomic approaches show that miRNA make up the majority (80 %) of all 
small RNAs in platelets (Ple et al., 2012). Furthermore, comparison of RNA and miRNA by 
cell type showed that despite low RNA yields, platelets express high quantities of miRNA 
compared to their nucleated counterparts (Teruel-Montoya et al., 2014).  
1.5.3.1 Abundantly expressed platelet miRNA 
Evidently, a number of highly expressed miRNA have been characterised in human platelets, 
some of which are involved in myeloid cell differentiation, megakaryocytopoiesis and 
thrombopoeisis (Ple et al., 2012). miR-223 has been identified as the most highly expressed 
platelet miRNA (Nagalla et al., 2011; Edelstein and Bray, 201l; Halkein and Windt, 2013) 
and has roles in thrombopoeisis and megakaryocyte differentiation (Laffont et al., 2013).  
miR-223 regulates ADP P2Y12, a target for existing antiplatelet drug therapy. The 3’-UTR 
of P2Y12 mRNA has been identified as complementary to the miR-223 seed region. Platelet 
miR-223 has also been observed to be decreased in subjects who show high levels of platelet 
activation whilst on clopidogrel therapy. Furthermore, miR-223-deficient mice show 
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reduced bleeding times, larger thrombi, and elevated sensitivity to low doses of thrombin, 
suggesting an important role of miR-223 in modulating platelet function (Landry et al., 2009; 
Shi et al., 2015).  
miR-126 plays central roles in vascular inflammation and is thought to be the second most 
highly expressed miRNA in platelets (Fish et al., 2008; Gatsiou et al., 2012). miR-126 was 
found to correlate with circulating P-Selectin levels in T2DM subjects and this level was 
sensitive to aspirin treatment, signifying a platelet origin. miR-126 is postulated to regulate 
ADAM9 and P2Y12 receptor expression in platelets and inhibition of miR-126 in mice 
distinctly reduces platelet aggregation (Kaudevitz et al., 2016).  
Existence of miRNA in platelets is multifaceted. Besides their obvious function as regulators 
of platelet protein expression, platelet miRNAs have been labelled as biomarkers of disease 
and platelet activation, markers of mature megakaryocyte miRNA and as a means of 
understanding megakaryocyte/platelet gene expression (Emmrich et al., 2012; Edelstein et 
al., 2013). The majority of platelet miRNA are supposedly formed in the megakaryocyte and 
packaged into platelets upon formation. Identification of some specific miRNA involved in 
megakaryopoieses and thrombopoeisis has been enabled by using either megakaryocyte-like 
cell lines and megakaryocytes generated from human CD34+ hematopoietic stem cells in 
vitro.  
For example, miR-146b positively regulates megakaryopoieses by targeting and down 
regulating the megakaryopoieses inhibitor PDGFRA (Zhai et al., 2014; Kamat et al., 2014). 
miR-142 has also been reported to inhibit megakaryocyte production. In miR-142 knockout 
mice, platelet counts are decreased and MK differentiation is modified, including reduced 
proplatelet network establishment (Chapnik et al., 2014). The total extent to which MK and 
platelet mature miRNA patterns correlate remains an area of active investigation. A 
significant correlation between the miRNA levels was found using three separate studies 
(Huessein et al., 2009; Landry et al., 2009; Edelestein et al., 2013). However, as platelets 
are more accessible than megakaryocytes, they provide an efficient tool in which to study 
the relationship between the two cells (Freedman et al., 2015).  
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Figure 1.16: MicroRNA regulation in platelets. Megakaryocytes produce miRNAs according to 
the basic principles of miRNA biogenesis and maturation processes. Platelets are produced from 
megakaryocytes and retain both mature and pre-miRNA in addition to miRNA machinery 
Argonaute2 and Dicer. (Adapted image from Freedman et al., 2016). 
 
1.5.4 Microvesicles and miRNA 
Cells release various types of microvesicles (MVs) – defined as exosomes and microparticles 
(MPs) – from different origins, into the extracellular environment (Loyer et al., 2014), where 
they play important physiological roles. Typically, Exosomes are described as 30-100nm in 
diameter, with MPs being larger and in the range of 100nm-1µm in diameter. Importantly, 
MVs carry both plasma membrane and cytosolic constituents (Burger et al., 2013; 
Torreggiani et al., 2014) and maintain a similar antigenic autograph to their parent cell, e.g. 
platelet and megakaryocyte specific MVs both express CD41, whereas red blood cell MVs 
express CD235a. MV release can be either pathologic or physiologic (Goubran et al., 2015). 
MVs can be released under a plethora of different conditions, for example, during the natural 
processes of apoptosis or cell activation, under shear stress, cell damage or agonist 
interaction with cell surface receptors (Herring et al., 2013). The two main types of MVs are 
shown in Figure 1.17.   
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Activated platelets release MPs by surface shedding of the plasma membrane, while 
exosomes are released by exocytosis of multivesicular bodies and alpha granules (Heijnen 
et al., 1999; Gnatenko et al., 2006). Platelet MPs are the most abundant cell-derived MPs, 
accounting for between 70-90% of all circulating MVs. Platelet MVs have been linked with 
both procoagulant activity and their levels are altered in pathological states including obesity 
and atherosclerosis (Pap et al., 2009), whilst physical activity (Sossdorf et al., 2011; Chaar 
et al., 2011) and high stress conditions and are biomarkers of platelet activation (Nunes-
Franca et al., 2015).  
 
 
Figure 1.17: Two types of microvesicles released from platelets. Schematic depicts 
activated platelets releasing exosomes by exocytosis of multivesicular endosomal bodies and 
alpha granules (A), while microparticles are released by surface shedding of the plasma 
membrane (B).   (Image adapted from Kanada and Backman, 2015).  
 
However, their function in intercellular communication is perhaps the most interesting. 
Platelet MVs harbour a multitude of cell components including proteins and genetic material. 
Different activation pathways regulate both the quantity and type of MV subpopulations 
produced from platelets (Aatonen et al., 2014), thus governing their molecular profiles and 
facilitating tailor-made participation in intercellular communication (Diehl et al., 2012; 
Mooberry and Key 2016). 
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In this respect, perhaps the most intriguing feature regarding platelet miRNA is their 
extracellular function. miRNA can be packaged and delivered to distant cells in the form of 
platelet microvesicles, fulfilling novel processes of gene regulation in target cells (Diehl et 
al., 2012). Figure 1.18 illustrates this process. Initial studies by Laffont et al., (2013) and 
Gidlöf et al., (2013) demonstrate the functionality of platelet miRNA. Functional complexes 
of miR-223 and Argonaute 2 protein (Ago2) packaged in MVs from activated platelets was 
found to modulate the expression of targeted endothelial cell endogenous mRNA transcripts 
FBXW7 and EFNA1 (Laffont et al., 2013). This miR-223/Ago2 complex has also been 
shown to reduce expression levels of insulin-like growth factor 1 receptor in endothelial 
cells, and to promote human umbilical vein endothelial cell (HUVEC) apoptosis (Pan et al., 
2014). This type of platelet MV-cell interaction is illustrated in Figure 1.18.  
Gidlof et al., (2013) suggested that platelet miRNA could modulate vascular endothelial 
inflammatory responses. They described a down regulation of intercellular adhesion 
molecule 1 (ICAM-1) gene expression in cultured human microvascular endothelial cells 
after exposure to miR-320b, which is secreted upon platelet activation and reduced in platelet 
thrombi aspirated from patients with ST-segment elevation myocardial infarction (STEMI). 
The relevance of this intercellular transfer was further reinforced when Liang et al., (2015) 
showed that platelet-released miR-223 through platelet MPs can encourage lung cancer cell 
invasion by targeting the tumour suppressor EPB41L3.  
Novel research has shown that platelet MPs containing miRNA can also be internalised by 
primary human macrophages and deliver functional miR-126-3p. miR-126-3p caused a 
downregulation in the expression of four predicted mRNA targets of miR-126-3p and a 
reduction in macrophage cytokine release. This suggests that platelet miRNA-containing 
MPs can modify the macrophage transcriptome and potentially reprogram their function 
(Laffont et al., 2016). Finally, platelet-derived exosomes have recently been shown to carry 
miR-223, miR-339 and miR-21, which can be transferred to SMCs affecting PDGRFβ (Tan 
et al., 2016). 
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Figure 1.18: Platelet MVs act as intercellular transporters of functional Ago2-miRNA 
complexes. Activated platelets release MV packages with functional Ago2-miRNA complexes that 
can be up taken by human aortic endothelial cells. Platelet-derived miRNA accumulates within the 
cell, regulating expression of endothelial genes at the mRNA and protein level, resulting in altered 
phenotype and function. 
 
1.6 Cardiovascular disease (CVD) 
CVD is an umbrella term used to describe a broad group of disorders of the circulatory 
system. It includes atherosclerosis, myocardial infarction (MI), arrhythmia, angina, 
hypertension, and stroke amongst others. Types of CVD are varied and complex; hence there 
are multiple pathological mechanisms through which disease may arise. CVD often exists 
as an underlying complication where the initiation of CVD will appear well before any 
clinical threshold, such as acute conditions of myocardial infarction or stroke. The World 
Health Organisation (WHO) predict that the number of people who die from CVDs, will 
reach 23.3 million by 2030. In Ireland, CVD accounts for over 33% of all deaths in those 
over 65 years of age (Irish Heart Foundation, IHF), as seen in Figure 1.19. 
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Figure 1.19. Causes of mortality in Ireland in 2014. A shows a pie chart representing age 0-64 
years, while B represents the older population.  CVD accounted for over 33 percent of deaths in those 
over 65 years. (Department of Health, 2014). 
 
Atherosclerosis is the most common CVD and the main cause of coronary heart disease 
(CHD) and stroke (Figure 1.20). It is regarded as a chronic inflammatory condition, 
specifically affecting the intimal layer of arterial blood vessels and is characterised by 
arterial remodelling after the sub-endothelial accumulation of fatty substances called 
plaques. Atherosclerosis is a complex disease involving the dynamic deregulation of 
different cell types including SMCs, ECs, platelets and white blood cells (Wierda et al., 
2010; Lusis, 2012). The pathogenic process of atherosclerosis begins early in life, 
specifically during childhood and adolescence.  
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Whilst multi-factorial in its development, a brief synopsis of atherosclerosis would describe 
a modulation of haemodynamics resulting in endothelial dysfunction, platelet activation and 
inflammation, with elevated expression of inflammatory cytokines, and recruitment of 
leukocytes (monocytes) to the endothelium, concomitant with a reduction in NO generation. 
Migration of monocytes into the sub-endothelium follows, leading to their activation and 
transformation into macrophages that digest oxidised LDL cholesterol molecules to form 
foam cells. Foam cells, the main component of ‘fatty streaks’ subsequently undergo 
apoptosis, releasing stored lipids and generating a necrotic lipid core within the vessel 
intima.   
Expansion of this core increases its thrombogenicity and is separated from the blood by a 
fibrous ECM cap. Atherosclerotic plaques can be classified as either stable or unstable, 
depending on their composition. The stable plaque can expand until it occludes the vessel, 
or it can rupture, releasing its thrombotic content with subsequent thrombosis (Hopkins, 
2013). 
 
 
Figure 1.20: Atherosclerosis. Figure shows a schematic of a blood vessel on the right with a ruptured 
atherosclerotic plaque, which is occluding the lumen resulting in restricted blood flow. Activated platelets 
adhere to the ruptured plaque, resulting in thrombus formation.  The healthy artery on the left is visualised with 
an unobstructed lumen. ((http://www.pharmaceutical-networking.com/merck-mk-0524b-treatment-of-
atherosclerosis/). 
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1.6.1 Role of platelets in CVD and atherosclerosis 
Platelets have central roles in CVD such as stroke (Kirkpatrick et al., 2014), coronary artery 
disease (CAD) (Angiolillo et al., 2014), and acute coronary syndromes (ACS) (Massberg et 
al., 2003) contributing to the development of acute thrombotic events.  In atherosclerosis, 
platelets contribute to both early stages of endothelial dysfunction and advanced stages of 
the plaque rupture (Badimon et al., 2012) as summarised in Figure 1.21. Platelets participate 
in early stage disease initiation through multiple mechanisms that enable adhesion to the 
dysfunctional endothelium. Activated platelets express high levels of adhesion receptors 
(e.g. ICAM1, P-Selectin, CD40L) associated with oxidised-LDL (ox-LDL) that contributes 
to vascular inflammation (Daub et al., 2010).  TLR signalling may also play a role in the 
progression of atherosclerosis by binding of lipopolysaccharides (LPS) to TLR4 on platelets 
and also mediating platelet-neutrophil interactions.  
Direct cell-cell communication through platelet P-Selectin and CD40 ligand (CD40L) 
encourages inflammatory processes (Berger, 2003; Lievens et al., 2010). CD40L is thought 
to be at the heart of the atherosclerotic process. Studies have suggested that 90% of 
circulating CD40L resides in platelets. CD40L is abundant in platelets and is sent to the 
platelet surface upon activation, where it can initiate numerous inflammatory processes. The 
release of CD40L is intrinsically linked to αIIbβ3 as αIIbβ3 antagonists can block the release 
of sCD40L from activated platelets in vitro (Nannizzi-Alaimo et al., 2001). Recently, 
platelet CD40 was shown to mediate the formation of platelet-leukocyte aggregates 
(stimulates leukocyte activation) and release inflammatory chemokines that activate 
endothelial cells, supporting atherosclerosis (Gerdes et al., 2016).  
The significance of P-Selectin in atherosclerosis has been demonstrated in P-Selectin 
deficient animals that were protected from the disease. The role of platelet P-Selectin was 
clarified further by Huo et al., (2003) who illustrated that the introduction of P-Selectin-
expressing platelets into ApoE (-/-) mice accelerated atherosclerosis, whereas mice injected 
with platelets lacking P-Selectin formed smaller plaques (Berger and Wagner, 2003). 
Platelet-derived microparticles, (one type of platelet MV) released upon activation can 
further amplify the progression of atherosclerosis through processes of adhesion, 
coagulation, inflammation and lipid metabolism (Wang et al., 2016). Platelets also provide 
a huge repertoire of additional inflammatory mediators including a vast array of chemokines 
and cytokines that contribute to the crosstalk of platelets with other inflammatory cells – e.g. 
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endothelial cells, monocytes, neutrophils, dendritic cells, T-cells (Lievens et al., 2011). The 
major function of platelets in atherosclerosis is the recruitment of leukocytes through direct 
receptor-ligand interactions or amplification of leukocyte recruitment through chemokine 
release. This bidirectional relationship is extremely important as platelets encourage 
leukocyte differentiation into a pro-adhesive and pro-migratory phenotype, and the 
leukocytes secrete mediators that reciprocally activate platelets. 
Following atherosclerotic plaque rupture in severe CVD states, the exposure of 
thrombogenic substrates (collagen etc.) to circulating platelets instantly triggers platelet 
adhesion, activation and aggregation, forming a prothrombotic surface and subsequently 
encouraging thrombosis, vasoconstriction and vascular occlusion. Activated platelets expose 
phospholipids on their surface, which also promotes the coagulation cascade and subsequent 
fibrin production (Badimon et al., 2012).  
 
 
Figure 1.21: The role of platelets in atherosclerosis. Platelets participate in early stage disease 
initiation by adhesion to the dysfunctional endothelium. Secretion of platelet P-Selectin and CD40 
ligand amongst other inflammatory molecules encourages inflammatory processes. Platelet 
recruitment of leukocytes through both receptor ligand interactions and chemokine release is a key 
step in the atherosclerotic process. (Adapted from Jackson et al., 2011). 
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Given the critical roles of platelets in the pathogenesis of atherosclerosis and the 
development of acute thrombotic events, antiplatelet therapy has been widely employed in 
the primary and secondary prevention of CVD.  Some of the current anti-platelet therapy 
drugs include Aspirin, which irreversibly inhibits cyclooxygenase to subsequently decrease 
TxA2 production and limit platelet aggregation. Clopidogrel and Prasugrel are examples of 
P2Y12 receptor antagonists that inhibit the soluble agonist ADP, whilst Tirofiban and 
Abciximab block αIIbβ3-ligand interactions. Other anti-platelet therapies include thrombin 
inhibitors and phosphodiesterase inhibitors (block degradation of cyclic nucleotides) (Papp 
et al., 2013; Metharom et al., 2015).  
1.6.2 Role of platelet miRNA in CVD 
Given the impact of miRNA gene regulation, it is unsurprising that the dysregulation of 
miRNA is implicated in CVD. miRNA are central players in modulating gene expression of 
cells/platelets collectively involved in CVD, and mediate inflammation, lipid uptake and cell 
differentiation in atherosclerosis. Platelet miRNA signatures (miR-25-3p, miR-221-3p, and 
miR-374b-5) alter between patients with ST-segment elevation myocardial infarction 
(STEMI) and those with non-STEMI (Ward et al., 2013) suggesting that levels of platelet 
miRNA could impact platelet thrombogenicity and type of infarction. Furthermore, 
circulating miRNAs associated with the risk of MI (miR-126, miR-150, miR-223 and miR-
197) are abundantly expressed in platelets. 
Platelet miRNA are implicated in premature CAD as two miRNAs in platelets are 
upregulated in patients compared to controls (miR-340* and miR-624*), although whether 
or not they are the cause or consequence is currently unknown (Sondermeiijer et al., 2011). 
Research concerning other CVDs showed that circulating levels of platelet enriched miR-
328 were associated with atrial fibrillation (AF) in the Framingham heart study (Mc Manus 
et al., 2014). Interestingly, this association was mitigated when antiplatelet therapy was 
incorporated in multivariable adjusted models. 
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Besides their roles as mediators and biomarkers of CVD, platelet miRNA act as novel 
surrogate measures of the responsiveness to antiplatelet therapies used in CVD (Zhang et 
al., 2014). miR-223 levels are significantly down regulated in low responders to anti-platelet 
therapy (Chrychel et al., 2015; Shi et al., 2013). Furthermore, expression of platelet miR-
26a has been linked with clopidogrel resistance during coronary stenting (Chen et al., 2016). 
This theory is strengthened by research demonstrating how the switch from dual anti-platelet 
treatment with clopidogrel to ticagrelor is linked with significant changes in the level of 
platelet-specific circulating miRNAs, namely miR-223, miR-126 and miR-150 and miR-96 
(Carina et al., 2016). Other research investigating the effects of antiplatelet therapy on 
platelet miRNA levels showed that in vitro platelet activation resulted in transfer of miR-
126 from platelets to plasma, whereas in aspirin-treated platelets, this process was not 
observed. In vitro aspirin intake resulted in platelet inhibition and lower circulating platelet-
derived miR-126 levels than were seen in untreated subjects (De Boer et al., 2013). Greater 
understanding of the meaning of platelet miRNA in CVD patients could aid in the diagnosis 
and treatment of these diseases. 
1.6.3 CVD risk factors 
Efforts in coping with CVD need further understanding of the science/risk factors behind it 
and developing strategies/therapeutics to control it. Epidemiological studies in adults have 
acknowledged a set of characteristics known as risk factors that predict the probability of a 
person developing clinical manifestations of disease (Dawber et al., 1969; O’Donnell and 
Elosua, 2008). CVD risk factors can be classed as modifiable or non-modifiable. Non 
modifiable risk factors include age, ethnicity, gender and family history. Modifiable risk 
factors include hypertension, smoking, diabetes, unhealthy diet, cholesterol, physical 
inactivity (PI, sedentary lifestyle and low cardiorespiratory fitness) and overweight/obesity. 
Risk factors for CVD track from childhood into adulthood (Juhola et al., 2011) and are strong 
predictors of subclinical atherosclerosis in early adulthood. The majority of CVD is caused 
by modifiable risk factors and up to 80% of CVD may be prevented if risk factors are avoided 
(Mc Neal et al., 2010) (WHO, 2014). Physical inactivity and overweight are the risk factors 
focused on in this thesis.  
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1.7 Overweight and obesity 
Overweight and obesity are major independent risk factors for CVD and are defined as 
excessive fat accumulation that adversely damages health (Hubert et al., 1983; Aflague et 
al., 2016). The fundamental cause of obesity and overweight is an imbalance in energy 
consumption in terms of calories consumed and calories expended. In general, this is due to 
an increase in both physical inactivity and intake in energy-dense, high fat foods. The global 
prevalence of obesity and overweight has more than doubled between 1980 and 2014 with a 
resulting 2.6 million deaths per year (WHO, 2014). In 2014, 40% of adults were overweight 
and 13% were obese. More alarmingly, childhood obesity is one of the most serious public 
health concerns of the 21st century. In 2013, more than 42 million children under 5 years old 
were overweight. This is of concern as overweight and obesity during adolescence are 
associated with a significantly increased risk for CVD later in life (May et al., 2012). 
 
Figure 1.22: Global prevalence of obesity. Age-standardised prevalence of obesity in women 
(above) and men (below) aged 18 years and over (BMI > 30 KG/M2) in 2014. Ireland has a 
prevalence of over 25% obesity in both male and females. (Image adapted from WHO, 2014). 
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Nationally, estimations of global trends in obesity has put Ireland on course to become the 
most obese country in Europe within a decade, with Irish men already having the highest 
BMI in Europe (Figure 1.22) (Singh et al., 2016). From self-reported data, the prevalence of 
overweight and obesity in Ireland is 36% and 14%, respectively (Kearns et al., 2014). This 
is particularly prevalent in the male population and related with hypertension, elevated 
cholesterol and CVD. The extensive costs associated with overweight and obesity in Ireland 
is estimated at €1.13 billion (Safefood, 2012).  
1.7.1 Effect of obesity on platelets 
Obesity and overweight is a multifactorial condition involving a plethora of processes 
Alterations in lipid metabolism, insulin resistance, inflammation, endothelial dysfunction, 
adipokine imbalance, oxidative stress and platelet hyper-aggregability have all been 
postulated to trigger the relationship. Indeed, platelet activation markers are described as 
elevated in obesity, contributing to the inflammatory and prothrombotic state (Bordeaux et 
al., 2011). Subjects with overweight and obesity display increased platelet activation 
markers urinary-11-deyhdro-TXB2 (Davi et al., 2002), MPV (Coban et al., 2005), and PLT 
(Samocha-Bonet et al., 2008). Greater platelet activation (P-Selectin and PMP) is also linked 
to central arterial stiffness and carotid wall thickness amongst other atherosclerotic risk 
factors in overweight and obese subjects (Csongradi et al., 2011; Cooper et al., 2014).  
The major mechanisms behind platelet function in obesity include a reduced sensitivity to 
insulin and resistance to their main inhibitory mediators PGI2 and NO, elevated oxidative 
stress and an altered intracellular environment with increased cytosolic Ca2+ (Anfossi et al., 
2004). Platelets have insulin receptors which impact platelet function by regulating platelet 
response and sensitisation of platelets to inhibitory mechanism of PGI2 and NO. In obese 
subjects, the anti-aggregating effect of insulin is diminished (Trovati et al., 1998; Anfossi et 
al., 2006).  
Elevated oxidative stress also plays important roles in obesity-related platelet dysfunction. 
Oxidative stress results from an imbalance between the generation of free radicals and 
antioxidant enzymes (Otani et al., 2011). High reactive oxygen species (ROS) generation by 
excess adipose tissue reduces NO bioavailability, enhancing surface expression of adhesion 
molecules, and enabling platelet activation and adhesion. Increased ROS also converts 
arachidonic acid into F2-isoprostanes such as 8-iso-PGF2α that can modulate platelet adhesive 
function (Patrono et al., 2005). Activated platelets also produce ROS (Victor et al., 2009), 
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amplifying their own aggregatory potential by increasing αIIbβ3 and CD40L expression 
(Begonja et al., 2005; Pignatelli et al., 2004) and stimulating intraplatelet F2-isoprostanes 
production. 
Both decreased NO synthesis and bioavailability from ECs and platelets contribute to the 
pathogenesis of obesity, likely promoting thrombosis. Research by Leite et al., (2016) 
describes a decrease of Nitric Oxide synthase (NOS) activity and cGMP levels with 
simultaneous platelet hyperaggregability in obese subjects compared to healthy controls with 
impaired antioxidant responses as potential contributors. Anfossi et al., (2004) showed that 
platelet sensitivity to antiaggregagtory effects of PGI2 and NO is reduced in obesity. A 
summary of the mechanisms involved in increased platelet activation in overweight and 
obesity is shown in Figure 1.23. 
Importantly, weight loss in obese subjects marks a reduction in platelet activation markers 
and can potentially reverse the platelet responsiveness to NO and prostacyclin (Russo et al., 
2010; Basili et al., 2006). A 10% weight reduction in obese subjects resulted in significant 
reductions in BMI, endothelial dysfunction and platelet aggregation. The changes in platelet 
function were associated with improvement in insulin sensitivity, indicating a tight 
relationship between the two. Weight loss also resulted in reduction in lipid peroxidation 
markers (Vazanna et al., 2012) and platelet P-Selectin expression in overweight CAD 
patients (Keating et al., 2013). 
Although an association between obesity and platelet activation is evident, the molecular 
mechanisms responsible have only begun to surface (Blokhin and Lentz, 2013). Platelet 
RNA is reflective of pathological disease states where inflammatory transcript profiles (e.g. 
INFG, IL1R1, IL6, and TLR2) correlate significantly with increasing BMI (Freedman et al., 
2010), supporting the hypothesis that surplus fat could unfavourably alter the inflammatory 
potential of platelets. However, obesity can also cause dysregulation of other factors that 
control haemostasis such as microRNA (miRNA). There is increasing evidence to show that 
miRNA is involved in the pathogenesis of obesity (Zampetaki et al., 2010), where plasma 
levels of miR-223 are reduced in obese compared to lean subjects, suggesting that the miR-
223/P2Y12 alliance could signify a contributing mechanism of platelet activation in obesity 
(Bray et al., 2013).  
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Figure 1.23: Summary of the mechanisms involved in the increased platelet activity in 
overweight and obesity. Chronic accumulation of excess fat in overweight and obesity lead to 
decreased sensitivity to physiological inhibitors NO and PG12. Concurrent with this is an increase in 
inflammatory mediators released from adipokines and an increase in ROS and isoprostane 
production, cumulatively resulting in elevated platelet activation and atherosclerosis. (Adapted from 
Anfosso et al., 2009).  
 
1.8. Role of physical activity in cardiovascular health and CVD  
Those who engage in regular physical activity or exercise have a reduced prevalence of 
CVD. PA has been extensively studied due to its beneficial effects on all-cause mortality. 
Evidence to support the inverse relationship between PA and either CVD, cancer, or 
depression continues to accumulate. With regard to CVD, regular PA/exercise, reduces 
blood pressure, serum triglycerides, total body fat and visceral fat, and LDL cholesterol (Li 
and Siegrist, 2012). Differences in these known factors have been demonstrated to explain a 
large proportion of the inverse relationship between physical activity and CVD risk (Mora 
et al., 2007; Kwasniewska et al., 2016). However, over 40% of the inverse association 
remains unexplained. Although the beneficial effects of regular exercise on blood lipids and 
blood pressure have been well documented, research focusing on platelet function has only 
recently gained greater attention. Since platelets play a key role in the pathogenesis of CVD, 
the protective effect of exercise against CVD may be partially due to alterations of platelet 
function (Kumar et al., 2011). 
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Aerobic fitness is measured by maximal oxygen uptake (VO2 max) during incremental 
exercise and is globally acknowledged as the best assessment of cardiovascular fitness 
(Shepard et al., 1968). VO2 max represents the maximal amount of oxygen that an individual 
can take in and use to produce energy. VO2 max is a function of the ability of the 
cardiovascular system to deliver blood and oxygen to skeletal muscle, and the ability of 
skeletal muscle to extract this oxygen and use it to produce energy.  
1.8.1 Effects of acute exercise on platelet function 
Exercise effects on platelet function in both diseased and healthy populations has elicited 
profound interest in the last decade. The majority of research surrounding platelet function 
and physical activity/exercise has focused on acute (single bout) aerobic exercise. Potential 
effects of acute exercise on platelet function (mainly aggregation) have been investigated 
through various studies in adult subjects with varying intra- and inter-individual results, 
making interpretation problematic. Differences in population type (e.g. CVD versus 
healthy), methods employed to assess platelet function, and techniques to examine reactivity 
are the main reasons for discrepancies between research groups (Aurigemma et al., 2007). 
1.8.1.2 Effect of acute exercise on platelet adhesion 
Different platelet adhesion experimental protocols have provided no definitive consensus on 
the platelet response to acute exercise in healthy adult subjects. Wang et al., (1994) were at 
the forefront of platelet and exercise physiology, investigating the effects of strenuous 
aerobic exercise in healthy sedentary, healthy active and CVD subjects. Using a tapered 
parallel plate chamber, they observed elevated platelet adhesion in the three groups after 
strenuous exercise. Follow-on studies from this group used an assay developed to measure 
the resistance of adhered platelets against detachment by shear stress applied by a buffer 
flow (Wang 1995, Wang 1997, Wang and Chen 1999, Wang 2002). They reported increased 
platelet adhesion after strenuous exercise in both healthy subjects and CVD patients, 
suggesting a resilient platelet-surface collaboration post-exercise stimulus.  
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Other studies showed reduced platelet adhesion to fibrinogen in sedentary healthy males 
after acute exercise (Wang and Liao, 2004), however they employed submaximal testing (30 
mins 60% VO2). Cuzzolin et al., (2000) showed that resting platelet adhesion (to fibrinogen), 
in addition to platelet adhesion in response to ADP and thrombin, did not change 
significantly after exercise (75% VO2), but that both pre- and post-exercise inactive subjects 
had higher platelet adhesion levels than active subjects. Bonifazi et al., (2004) suggest a role 
of exercise intensity-dependent cortisol levels in the response of platelet adhesion to acute 
exercise.  
1.8.1.3 Effect of acute exercise on platelet aggregation  
A number of studies have shown that acute exercise in either healthy individuals or CVD 
patients results in an increase in platelet function and aggregation (El Sayed, 2002; Chung 
et al., 2008, Perneby et al., 2007; Scalone et al., 2009). These studies typically used in vitro 
platelet aggregation tests to assess platelet function. Interestingly, platelet activation elicited 
by exercise in both healthy subjects and CVD patients is not attenuated by simultaneous 
aspirin or clopidogrel use, suggesting that the COX/P2Y12 pathway does not activate 
platelets during exercise. Aspirin could have a restricted anti-thrombotic impact during 
exercise (Hurlen et al., 2000; Madsen et al., 2009; El-Sayed et al., 2005) 
As previously mentioned, the integrin αIIbβ3 experiences conformational alterations upon 
platelet activation, resulting in a drastically heightened affinity for fibrinogen and therefore 
facilitating platelet aggregation. Accordingly, some studies have found an increase in αIIbβ3 
activation post-exercise in trained and sedentary middle aged subjects (Peat et al., 2010; 
Whittaker et al., 2013). High levels of plasma fibrinogen after exercise result in elevated 
blood viscosity and this along with increased vWF binding, αIIbβ3 and P-Selectin expression 
all contribute to the heighted platelet aggregation after acute exercise (Wang et al., 2004).  
Measurement of platelet aggregation in whole blood has been performed with the PFA-100 
in response to exercise. Acute strenuous exercise resulted in shorter PFA closure times in 
healthy sedentary males (Cadroy et al., 2003; Madsen et al., 2009). In the latter, almost all 
subjects showed increased platelet reactivity as measured by the PFA, however only minor 
differences were detected by LTA, emphasising the need to assess platelet function in whole 
blood. Whilst the majority of studies found increased platelet aggregation after exercise, 
some found no effect (Feng et al., 1999) or even an inhibition (Knudsen et al., 1982, El-
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Sayed et al., 2002, Aldemir and Cilic, 2005). However, these studies applied submaximal 
exercise protocols compared to the maximal protocols employed in the majority of studies.  
In general, it appears that acute vigorous exercise induces a hyperreactive haemostatic state 
(Huskens et al., 2016) and a transient increase in agonist-induced platelet adhesion and 
aggregation in vitro and ex vivo. Increased oxidative stress and excess ROS production after 
exercise can counteract the natural cellular antioxidant protection more prominently in 
sedentary subjects compared to physically active (Wang and Chen, 1999; Singh et al., 2006). 
Alteration of cytosolic Ca2+ is an important factor in the activation of platelets, and the 
elevation of intracellular free calcium levels represents an initial factor in platelet activation 
and signalling (Wu, 2012). A rise in cytosolic Ca2+ in platelets has frequently been reported 
after exercise (Tozzi-Ciancarelli et al., 2002; Wang et al., 2002), contributing to platelet 
hyperreactivity. However, there is no definitive consensus regarding the short-term effects 
of exercise on platelet function.   
1.8.2 Influence of cardiorespiratory fitness (CRF) and exercise intensity on platelet 
responses to acute exercise 
1.8.2.1 Exercise intensity 
Both exercise intensity and CRF have been suggested to impact the platelet response to acute 
exercise (Volf et al., 2015). Most studies investigating acute exercise and platelet function 
define exercise intensity as a percentage of VO2 max.  Moderate aerobic exercise appears to 
suppress platelet function in healthy subjects, whilst strenuous aerobic exercise increases 
activation and aggregation (El-Sayed, 2002). For example, moderate exercising at both 50% 
and 60% of VO2 was associated with reduced platelet adhesion and aggregation in sedentary 
subjects compared to exhaustive exercise, where there were increases in both (Wang et al., 
1994; Wang et al., 2004). Cadroy et al., (2002) compared the effect of 30-minute cycle at 
50% and 70% VO2 max on platelet function and observed shorter closure time using the 
PFA-100 in response to epinephrine and ADP at the higher intensity. P-Selectin expression 
and platelet-leukocyte formation were reduced at lower exercise intensities compared to 
higher (Wang et al., 2006; Hilberg et al., 2004; Hilberg et al., 2008). 
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1.8.2.2 Cardiorespiratory fitness 
Cardiorespiratory fitness (CRF) is the ability to perform large muscle, moderate to high 
intensity exercise for prolonged periods and depends on the respiratory, cardiovascular and 
skeletal systems. CRF represents the adaptation to long-term exercise. High CRF levels are 
also linked with reduced CVD risk factors such as hypertension, obesity in the general 
population, and CVD patients (Swift et al., 2013; Myers et al., 2015; Franklin et al., 2013; 
De Fina et al., 2015). 
CRF was first postulated as a significant determinant for changes in platelet function in 
response to acute exercise after observations that acute strenuous exercise increased platelet 
activation in sedentary, but not physically active, subjects (Kestin et al., 1993; Wang et al., 
1994). Consistent with these results, platelet activation markers (Platelet factor-4, β-
thromboglobulin and P-Selectin) were more pronounced after incremental exercise in 
sedentary compared to physically active subjects (Coppola et al., 2004). Furthermore, work 
by Sossdorf et al., (2011) showed that 90 minutes of cycling at 80% individual anaerobic 
threshold (IAT) triggered a significant elevation of PMPs and their procoagulant activity in 
both sedentary and trained subjects. However, two hours later the concentration of PMPs 
remained elevated in the sedentary group only. The reduced PMP clearance in the sedentary 
subjects could result in increased circulating levels of proatherogenic elements. 
Additionally, inflamed endothelial cells with increased adhesion receptor expression could 
bind MPs, retaining high levels (Augustine et al., 2014). Even more importantly, the exercise 
intensity of 80% IAT paralleled 60% of VO2 max in the trained group but only 45% of VO2 
max in the sedentary group.  Therefore, the trained group performed at a higher percentage 
of their VO2 max, with an elevated blood flow and subjection of platelets to increased shear 
stress. As shear stress can activate platelets, this highlights the effect of CRF on platelet 
function (Chen et al., 2013). 
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The actual relationship between CRF and platelet function has been referred to in a recent 
breakthrough study by Heber et al., (2016), who investigated platelet function and CRF in 
62 young women. Platelet function was assessed by determination of P-Selectin and CD40L 
expression and quantification of platelet ROS generation in platelet-rich plasma (PRP). 
Basal platelet activation (reflected by CD62P expression) and agonist-induced platelet 
activation (ROS, CD62P and CD40L) were higher in the LF compared to the MF and HF. 
The group found no difference between basal CD40L expression (non-agonist induced). 
Interestingly, basal platelet function in the MF and HF were almost equal, indicating a 
definite influence of CRF on platelet function. 
1.8.3 Effect of exercise training on platelet function 
A high CRF level is a result of exercise training and habitual physical activity. Therefore, 
research on the effects of longitudinal exercise training on platelet function has mainly 
shown that habitual exercise has favourable effects on platelet function. Eight weeks of 
exercise training (60% VO2 max 5x/wk 30 min/day), reduced shear stress-induced platelet 
activation and ox-LDL-potentiated platelet function (Wang and Chow, 2004; Wang et al., 
2005). Importantly, after twelve weeks of deconditioning, the beneficial effects of exercise 
on platelets were non-existent and platelet function returned to its pre-training state. 
De Meirelles et al., (2009) reported that chronic physical activity had favourable effects on 
platelet activation in hypertensive patients at rest. Twelve weeks of regular exercise (75 - 
85% VO2 max 5x/week for 45-60 mins) reduced platelet aggregation in response to collagen. 
This response was attributed to elevated NO levels as NOS activity and cGMP levels were 
greater after training. Endothelial NOS (eNOS) and NO are increased after exercise training, 
thereby increasing platelet cGMP levels and potentially reducing platelet activation under 
shear stress ((Massimo et al., 2004) Wang et al., 2005) 
Santilli et al., (2012) investigated the effects of regular high intensity (60-75%) aerobic 
exercise for two months in low and intermediate CVD risk sedentary subjects. Exercise 
training was associated with reductions in TxA2, plasma P-Selectin and platelet-derived 
CD40L, despite no reduction in CRP (representing systemic inflammation). Suggest a 
modulation in intermediate oxidative stress related determinants such as lipid peroxidation 
(8-iso-PGF2A), the RAGE pathway and lipoproteins explaining the positive effect of exercise 
on the cardiovascular system.   
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Evidently, physical activity and exercise affects nearly all facets of platelet function (Volf et 
al., 2015). Studies on the effects of acute exercise appear to heighten platelet reactivity. 
Regular exercise can improve this response, seems to have an anti-thrombotic effect on 
platelets and could represent a portion of the protective effects of exercise on CVD risk 
factors (Figure 1.24). Green et al., (2012) suggest that vascular adaptation to habitual 
exercise in athletes having a possible influence on platelet function.  Moreover, effects of 
exercise are not maintained with cessation of training.  Of importance, all of these studies 
discussed were performed in adults and not adolescents when the CVD risk factors and 
atherosclerotic process has begun. Platelet function and exercise in children or adolescents 
is in its infancy, an area that requires urgent research (Ribieria et al., 2007). 
 
Figure 1.24: Impact of inactivity and exercise on the vasculature. Pie chart represents the 
allocation of reduction of CVD events associated with physical activity. Differences in the factors in 
black and grey (Diabetes, BMI, novel lipids, traditional lipids, hypertension and haemostatic factors) 
are thought to explain over 50% of the relative cardiovascular risk reduction associated with exercise. 
This suggests that at least 40% of the risk reduction associated with exercise cannot be explained by 
established risk factors. Platelets and their molecular profiles could be associated with the protective 
effect of exercise within this unexplained category. (Figure adpated from Thissen et al., 2010).  
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1.9 Physical inactivity and sedentary lifestyle  
In contrast to physical activity, physical inactivity/sedentary behaviour is a universal leading 
cause of death and independent CVD risk factor (Blair, 2009, Khohl et al., 2012). Sedentary 
behaviour refers to any waking activity characterized by an energy expenditure ≤ 1.5 
metabolic equivalents in a sitting or reclining posture (Chevance et al., 2016). In general, 
this means that any time a person is sitting or lying down, they are engaging in sedentary 
behaviour.  
Alongside obesity and overweight, physical inactivity and sedentary behaviour patterns in 
Ireland have increased dramatically in the last 10 years. This is highlighted by the launch of 
Ireland’s inaugural National Physical Activity Plan aiming to increase the number of Irish 
people participating in regular physical activity by 1% per year for the next decade (DH, 
2013). Only 32% of Irish adults are meeting the national physical activity recommendations 
of at least 30 minutes a day of moderate intensity activity on 5 days a week.  Worrying data 
from Woods et al., (2010) indicate that 88% of Irish adolescents do not meet the current PA 
recommendations of 60 minutes of daily moderate-to-vigorous physical activity. 
Remarkably, sedentary behaviour and physical activity can co-exist in the same person – 
even though some people may be reaching the recommendations for regular physical 
activity, the detrimental effect of 8 hours sitting may be negating the positive effects of 
physical activity (Ekelund et al., 2016). 
However, in contrast to the evidence supporting the benefits of acute and chronic exercise, 
relatively little is understood about the mechanisms underlying the physiological, cellular 
and molecular responses to physical inactivity. Incomplete understanding of this relationship 
is a huge barrier to combating the development of CVD and its ancillary risk factors. Our 
knowledge of physical inactivity is somewhat indirect and is mainly based on the positive 
effects of exercise training on the sedentary population.  As a sedentary lifestyle is often 
associated with obesity and overweight (Van Gaal et al., 2006), some mechanisms involved 
in the pathogenesis of physical inactivity are similar to that of obesity such as insulin 
resistance (Hamburg et al., 2007), hypertension, and increased inflammation (Nosova et al., 
2013). However, distinct factors associated with sedentary behaviour include reduced 
muscular activity of lower extremities, decreased blood flow, and reduction of shear stress, 
which increases oxidative stress, endothelial dysfunction (Thosar et al., 2012) and arterial 
remodelling (Thissen et al., 2012). 
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1.9.1 Models of experimental physical inactivity 
Experimental models to mimic physical inactivity can be achieved through various 
techniques (Figure 1.25). Reducing ambulatory activity from > 10,000 steps to < 2000 steps 
per day has been previously employed (Krogh-Madsen et al., 2010). However, compliance 
is problematic in this type of study.  The European Space Agency (ESA) use ground-based 
models of microgravity to assess the effect of space flight on human physiology. 
Microgravity is the condition in which objects or people appear to be weightless, where g-
forces are extremely low, but not quite zero (NASA). Ground-based models used include 
horizontal or head down bed rest and dry water immersion (DI). These models are unique 
and allow the study of human physiology in extremely controlled environments (Dignat-
George et al., 2007; Lee et al., 2010; Treffel et al., 2016). Comparative studies indicate that 
the unique DI is the best model of microgravity for short-term studies (Clement et al., 2016) 
as, unlike bed rest, DI provides a means to study the physiological responses to the lack of a 
supporting structure – a phenomenon called ‘supportlessness’.  
While the DI method is used for the study of human physiology in space, it is also employed 
as a model to study the physiological adaptations associated with physical inactivity. While 
the level of physical inactivity experienced during DI and bed rest studies may appear to be 
extreme compared to that experienced in the normal ambulatory population, studies have 
shown that these physical activity levels are close to those measured in sedentary individuals 
(Bergouignan and Momken, 2010).  
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Figure 1.25: Models of physical inactivity. Models of experimental physical inactivity vary 
from a reduction of daily steps (left) to head down bed rest studies (middle) to the more 
recent method of dry immersion studies (right). In the dry immersion set up, subjects are 
immersed up to the neck and separated from the water with the unique waterproof fabric. 
(Bottom right image from http://www.nasa.gov). 
 
1.9.2 Physiological responses to dry immersion 
Weightlessness causes several physiological changes that impact the musculoskeletal, 
sensory, nervous and cardiovascular systems to name a few (Figure 1.26). Various factors 
act simultaneously on the body during immersion such as supportlessness, hydrostatic 
compression and extensive physical inactivity. In comparison to everyday standing and 
supine positions, where specific areas of the body (feet and back) carry weight, pressure 
forces in DI are almost equal around the whole body (Naviaslova et al., 2011). The lack of 
supporting structures establishes a state called ‘supportlessness’ that is similar to 
weightlessness. The absence of perceptible signals from the feet results in a huge decrease 
in postural muscle activity (Koslovskaia et al., 2008).  
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Hydrostatic pressure is the pressure applied by a fluid at equilibrium, owed to the force of 
gravity (Gunga et al., 2016). Hydrostatic pressure intensifies with depth of immersion and 
therefore has a significant effect on lower body parts.  During immersion, hydrostatic 
compression of blood vessels and superficial tissues reduces the peripheral vascular 
capacity, causing a reduction in vascular skin volume and an increase in transcapillary 
reabsorption (transfer of fluid from interstitial to intravascular space). This fluid shift is 
mainly due to changes in pressure gradient between the interstitial to intravascular space and 
results in rapid redistribution of blood volume/body fluid towards the thoracic-cephalic 
region (Miki et al., 1989; Boussuges et al., 2007; Noskov et al., 2014). In blood circulation, 
both spaceflight and its proxies result in an initial decrease of plasma volume (approximately 
10-15% on the first day), after which it remains stable (Navasiolava et al., 2010; Larina et 
al., 2008).   
Hypokinesia and hypodynamia are the main characteristics of physical inactivity brought on 
by DI. Hypokinesia is a decrease in motor activity due to decreased bodily movement 
(Bhidayasiri et al., 2016), whereas hypodynamia is a decrease in postural muscle load due 
to the absence of weight bearing. These mechanisms are accompanied by a substantial 
reduction in muscle tone and tension (Grigor’ev et al., 2004) that cannot be attained with 
prolonged bed rest models.  
The initial responses to DI are caused by the aforementioned immediate alterations in body 
fluid distribution and absence of support stimulation. Fluid-electrolyte, cardiovascular, 
muscle tone, and hemodynamic changes occur within 12 hours of DI. Congestion of the 
central vascular area is believed to be the main reason for water-electrolyte changes (Somody 
et al., 1999). The redistribution of fluid results in relative central hypovolemia leading to 
cardiac output increase, suppression of the renin-angiotensin-aldosterone system (Epstein 
2006), and reduction in vasomotor tone. Normally, muscle tone (the incessant partial muscle 
contractions that aid in posture maintenance without causing fatigue) is maintained. The 
rapid decrease in muscle tone in supportlessness is an acute response to DI (Grigorev et al., 
2004; Kozlovskaya et al., 2007) and is manifested as a 40-50% decrease in postural muscle 
within the hours of exposure to DI.  
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Figure 1.26: Flow chart summarising the physiological responses to dry immersion and 
physical inactivity. Alterations to various systems and processes occur during DI and physical 
inactivity – such as bone health changes, altered kidney dynamics and metabolic alterations. 
Cardiovascular modifications result in blood flow alterations and a reduced exercise capacity. 
(Adapted from Vernikos et al., 1996; Bergouignan et al., 2011). 
 
1.9.2.1 Cardiovascular deconditioning  
Changes induced by long-term exposure range from muscular deconditioning, bone health, 
sensorimotor alterations, hormonal changes and cardiovascular alterations, summarised in 
Figure 1.26. The cardiovascular changes induced by spaceflight, bed rest and DI are 
collectively termed ‘cardiovascular deconditioning’ – a state in which the CV system does 
not respond efficiently to challenge (Naviaslova et al., 2011; Hackney et al., 2015) This is 
symbolised by a reduced exercise capacity, a predisposition to orthostatic intolerance, and 
tachycardia (Coupe et al., 2009). Other effects include a decrease in shear stress with a 
resultant disturbed flow, endothelial dysfunction, and vascular remodelling.  
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A major symptom of CV deconditioning is reduced aerobic capacity, as measured by 
maximal oxygen consumption (VO2 max). A decline in the adaptive ability to exercise has 
been reported after just one day of DI (Beliaev 1981) and in 3-7 days of DI VO2 max falls 
by 10-18% (Anashkin and Beliav, 1982; Sonkin et al., 1996; Vinogradova et al., 2002). 
Reduced aerobic capacity is well documented in bed rest and space flight. Additional factors 
that signify exercise capability include cardiac load, oxygen pulse, VO2 peak, stroke volume, 
heart rate and oxygen ventilatory equivalent are also affected by DI. 
Increases, decreases or no change of heart rate and blood pressure have all been described 
in DI. Most studies have not found significant changes in resting blood pressure after 3-7 
days of DI (Eshmanova et al., 2009; Iwase et al., 2000, Bravyi et al., 2008). Other authors 
have described 15-20% increases in diastolic BP after 7 days (Vil-Viliams and Shulzenko, 
1980). In general, DI causes an initial increase in stroke volume and cardiac output that is 
followed by a substantial decline after 2-3 days (Atkov and Bdnenko 1992; Naviaslova et 
al., 2011). In terms of cardiac morphology, one study suggested a slight reduction in left 
atrium diameter and increase in left ventricle size (Atkov and Bdnenko 1992), whilst another 
showed that DI induces changes in myocardial electrophysiological properties (Eshmanova 
et al., 2009). 
Other vascular responses involve decreases in blood velocity (Moreva et al., 2008) and 
endothelial dysfunction characterised by reduced endothelial dependent vasodilation and 
elevations of endothelial MPs and diminished plasma VEGF levels suggesting a loss of anti-
apoptotic tone (Navasiolava et al., 2010). The reason for CV deconditioning is mainly owed 
to the absence of both the static G-force along the longitudinal body axis and the body’s 
exertion against this G-force during movement. There have been no studies on the effect of 
DI on platelet function in humans to date.  
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1.9.3 Dry immersion applications 
Undoubtedly, models of extreme physical inactivity such as DI are advantageous for 
understanding the underlying mechanisms involved in sedentary behaviour. Understanding 
the deleterious effects of sedentariness may help with optimal exercise prescription for 
cardiovascular health (Hughson and Shoemaker, 2015). The DI model enables research into 
the mechanism of microgravity-induced changes and subsequent assessment of various 
countermeasures to prevent deconditioning upon return to earth (Clement et al., 2016). Such 
countermeasures include centrifugation (Clement et al., 2004), antigravity suits, cycle 
ergometer training, (Eshmanova et al., 2009), and pharmacological agents (Osbourne et al., 
2014). Apart from its excellent use as a research tool for microgravity and physical 
inactivity, DI also has significant healthcare applications. DI has been used in the recovery 
phase of children with central nervous system diseases (Kazanskaya et al., 2008) in the 
treatment of oedema (Ivanov and Bogomazov 1998), and has been recommended for 
rehabilitation of neurological diseases (Berger et al., 2001). Furthermore, DI has been 
suggested as a recovery method for elite athletes after strenuous training (Radzijewska and 
Radzijewski, 2007). 
1.9.4 Physical activity/inactivity specific miRNA 
The plasticity of platelets and other blood cells is vital for responding to environmental 
changes in response to physical (in) activity patterns. However, understanding of the 
molecular factors influencing platelet function/response/adaptation to physical (in)activity 
remain poorly understood. Recently identified miRNAs have gained attention as modulators 
of platelet function (Landry et al., 2009).  
Evidence for miRNA involvement in exercise-associated gene expression changes in a 
number of cell types including peripheral blood mononuclear cell, neutrophil, and skeletal 
muscle in non-trained and trained subjects has been illustrated (Radom-Azik et al., 2012; 
Radom-Azik et al., 2010; Nielson et al., 2010). Work by Baggish et al., (2011) showed 
altered expression of circulating miRNA (c-miRNA) in response to acute and chronic 
exercise in athletes. Eight c-miRNA involved in cellular processes related to exercise 
adaptation (muscle contractility, inflammation, and angiogenesis) were examined. They 
observed four distinctive signatures of c-miRNA; c-miRNA upregulated by acute exhaustive 
exercise pre- and post-exercise intervention, c-miRNA responsive to acute exercise pre- but 
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not post-intervention, c-miRNA only responsive to exercise intervention and non-responsive 
miRNA.  
A number of cell types can release miRNA into plasma, in response to physiological or 
cellular stress. This could play a role in the adaptation to exercise and act as distinctive 
biomarkers of varying CRF levels (Nielson et al., 2014). A global down regulation of plasma 
miRNA after acute exercise, followed by an up regulation after 1 and 3 hours of recovery 
was also observed (Nielson et al., 2014). Another study revealed that low CRF is linked with 
high expression levels of three c-miRNAs (Bye et al., 2013). As platelets contribute 
substantially to the circulating miRNA pool (Willeit et al., 2013) their unique miRNA profile 
could be representative of adaptations to exercise.  
Moreover, evidence of these physical activity specific microRNA signatures (Kangas et al., 
2013; Bye et al., 2012 and Altana et al., 2015) have ingrained concepts of physical inactivity-
specific miRNA profiles. Epigenetic variation could therefore be a potential mechanism 
allowing for independent or synergistic effects of physical inactivity on platelet function. 
Hibler et al., (2015) recently described indications for epigenetic variation (by miRNA 
expression) as a link between physical activity and sedentary lifestyle. An epigenetic 
adaptation to habitual exercise has been described (Ling et al., 2014; Pareja-Galeano et al., 
2014). Similarly, an epigenetic adaptation to physical inactivity may exist.                 
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1.10 Study background, hypothesis and objectives  
Study background 
CVD begins in childhood, progressing silently over a long preclinical stage before 
manifesting as a clinical event. Efforts in coping with CVD need further understanding of 
the risk factors behind it and development of strategies to control it. CVD risk factors can be 
classed as modifiable or non-modifiable. Modifiable risk factors included smoking, diabetes, 
unhealthy diet, cholesterol, physical inactivity (sedentary lifestyle and low cardiorespiratory 
fitness) and overweight and obesity. Risk factors for CVD track from childhood into 
adulthood and are strong predictors of subclinical disease in early adulthood (Juhola et al., 
2011). Up to 80% of CVD may be prevented if modifiable risk factors are evaded (Mc Neal 
et al., 2010; WHO). This thesis focuses on the risk factors of physical inactivity and 
overweight/obesity.  
Platelets are small, versatile, anucleate cells that circulate in blood. The small size of platelets 
and their proximity to the vessel wall facilitates their role as ‘guardians of the vasculature’, 
and potential to detect any vascular damage. (Zucker & Nachmias 1985; McFadyen and 
Kaplan, 2015). They travel as resting discoid fragments in circulation, however elaborate 
morphological properties allow shape changes to occur when they come in contact with an 
injured blood vessel. This enables platelets to perform their main physiological function to 
prevent blood loss in primary haemostasis by the formation of a ‘platelet plug’ through 
processes of adhesion, activation and aggregation (Cimmino and Golino 2013). 
Platelets play a central role in CVD, both in the pathogenesis of atherosclerosis and in the 
development of acute thrombotic events (Maiwand et al., 2015). It has been recognised that 
regular exercise may reduce the risk of major vascular thrombotic events and protect against 
CVD (Blair and Norris, 2009). Differences in known factors explain a large percentage of 
the inverse relationship between physical activity and CVD risk (Mora et al., 2007; 
Kwasniewska et al., 2016). However, over 40% of the inverse association remains 
unexplained. Although the beneficial effects of regular exercise on blood lipids and blood 
pressure have been well accepted, research focusing on platelet function has only recently 
gained greater attention.  
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In contrast to the accumulating evidence supporting the benefits of regular exercise, 
relatively little is acknowledged about the deleterious mechanisms underlying the 
physiological, cellular and molecular responses to physical inactivity, specifically with 
regard to platelet function. Small non-coding RNAs such miRNAs have been shown to play 
important post-transcriptional regulatory roles in cells. The role of microRNA (miRNA) in 
regulating platelet function in is a recent area of investigation (Landry et al., 2009; Kaudevitz 
et al., 2016). Platelets are highly reflective of physiological and lifestyle changes, making 
them extremely sensitive biomarkers of human health.  
The purpose of this thesis is to build on previous knowledge surrounding the involvement 
of platelets in physiological health and overweight/obesity, their profile in physical activity 
and inactivity and the mechanisms that regulate their activity in response to such stimuli.   
Overall hypothesis 
This thesis hypothesises that physical inactivity, overweight/obesity and low 
cardiorespiratory fitness adversely impact platelet function. miRNA expression could 
influence and modulate the platelet function response to physical inactivity. 
Objectives 
The objectives for this project were to: 
 Investigate associations between risk factors of CVD (such as obesity/overweight 
and physical inactivity) overall physiological health, and platelet function by 
performing a cross-sectional study.  
 Determine the usefulness of platelet indices as biomarkers of health in the cross-
sectional population. 
 Investigate the effect of varying cardiorespiratory fitness levels on basal platelet 
function in adolescent and adult males 
 Examine the effect of acute strenuous exercise on platelet indice markers and platelet 
function in adolescent and adult males of varying cardiorespiratory fitness levels 
 Investigate the effects of 3 days of dry immersion, acting as a model of acute physical 
inactivity, on platelet function in 12 healthy males. 
 Determine if the miRNA profile of platelets is altered with physical inactivity. 
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See Figure 1.27 below for a schematic depiction of the experimental approaches used in this 
thesis. 
 
 
Figure 1.27: Schematic depiction of studies undertaken in this thesis. This PhD thesis consists 
of three interrelated studies that were designed to provide a more in depth understanding of the 
physiological, cellular and molecular responses to physical inactivity and physical activity. Study 
one involved a cross-sectional method approach. Study two examined the relationship between 
exercise and platelet function, and study three examined the impact of physical inactivity on platelet 
function.  
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Chapter Two: Materials and Methods 
 
2.1 Materials 
2.1.1 Reagents and chemicals  
Bio-Sciences (Dun Laoighaire, Dublin) 
mirVana®  miRNA isolation Kit 
Megaplex™ RT Primers Human Set (A & B) v2.0 
Megaplex™ PreAmp Primers, Human Set (Pool A) v2.0 
Megaplex™ PreAmp Primers, Human Set (Pool B) v3.0 
TaqMan® Array Human MicroRNA A+B Cards set  
High Capacity miRNA cDNA reverse transcription Kit 
Rhodamine Phalloidin 
TaqMan® Pre Amp Master Mix 2X  
TaqMan® Array Human miRNA Cards Set v2.0 (A & B) 
Taqman® Universal Master Mix II, no UNG  
RNaseZap  
DNAZap 
 
Becton Dickinson (Oxford, UK) 
anti-CD62 Mouse Monoclonal IgG1 Antibody (PE) 
anti-CD41a Mouse Monoclonal IgG Antibody (FITC) 
anti-CD42b Mouse Monoclonal IgG1 Antibody (APC) 
FACS Clean™  
FACS Rinse™ Solution 
FACS Flow™ Sheath Fluid 
 
BDH Chemicals (UK) 
Tween-20 
 
Bio-Rad, (Hercules, CA, USA) 
Ammonium Persulfate 
2-mercaptoethanol 
10X TGS (Tris/Glycine/SDS) 
TEMED 
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Biocytex (Marseille, France) 
PLT VASP/P2Y12 Kit 
 
DAKO (Glostrup, Denmark) 
Fluorescent Mounting Media 
 
Davidson and Hardy (Belfast, Northern Ireland)  
Carl Zeiss High Performance Coverslips 
 
Enzo Life Sciences (Exeter, UK) 
Convulxin, lyophilised 
 
GE-Healthcare (Buckinghamshire, UK)  
Goat-anti-rabbit HRP-conjugated monoclonal secondary antibody 
Goat-anti-mouse HRP-conjugated monoclonal secondary antibody 
 
Lennox Laboratory Supplies LTD (Dublin, Ireland) 
100% Industrial Methylated Spirits (IMS) 
 
Merck Millipore (Nottingham, UK) 
Anti-GAPDH rabbit monoclonal primary antibody 
Anti-Drosha rabbit monoclonal primary antibody 
Anti-Dicer1 mouse monoclonal primary antibody 
Anti-Ago2 rabbit polyclonal primary antibody  
 
EasyCheckTM Kit for HT Systems 
ICF Cleaning Fluid for HT systems 
LuminataTM Forte HRP Substrate 
Fibrinogen, Human Plasma  
HRP substrate  
 
Roche Molecular Systems (Pleasanton, CA, USA) 
Complete (EDTA-Free) Protease Inhibitor Cocktail Tablets  
Real-time Ready Catalog Assays 
Transcriptor First Strand cDNA synthesis Kit 
Fast start essential DNA Green Master 
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Sigma Aldrich Chemical Company Ltd (Dorset, UK) 
Acetone  Acrylamide/BIS acrylamide solution  
Agarose Ammonium Persulfate 
Bovine Serum Albumin Bromophenol blue 
Chloroform Dextrose 
Dimethyl sulfoxide EDTA 0.5M  
Ethanol  Fetal Bovine Serum 
Formaldehyde Glycerol 
Glycine HEPES salt 
Human Collagen Type 1 Magnesium Chloride 
Magnesium Sulphate May Grunwald Stain solution 
Methanol Paraformaldehyde 
PGE1, lyophilised Phosphate Buffered Saline Tablets 
PIPES Salt Ponceau S Solution 
Potassium chloride Sepharose 2B 
Sodium Chloride Sodium Deoxycholate 
Sodium Dodecyl Sulfate Sodium Fluoride 
Sodium Orthovanadate Sodium Phosphate 
Sodium Phosphate Dibasic Sucrose 
Thrombin (from human plasma) TritonX- 100 
Trizma Base Sterile filtered water 
 
StemCell Technologies (Vancouver, British Columbia, Canada) 
EasySep Human Whole Blood CD45 Depletion Kit  
 
Thermo Fisher Scientific (Leicestershire, UK) 
Hydrochloric Acid 
Methanol          
10x PBS Solution         
Isopropanol   
BCA Protein Assay Reagent  
Buffer Solution pH4 (Phthalate) J/2825/15  
Buffer Solution pH7 (Phosphate) J/2855/15  
Buffer Solution pH10 (Borate) 
PageRuler Plus Prestained Protein Ladder 
Spectra Multicolour High Range Protein Ladder 
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2.1.2 Consumables and plastics  
Becton Dickinson (Oxford, UK) 
1, 10, 20, 30, 60 ml Syringes 
19 g, 21 g and 22 g Needles 
21 g Butterfly Needles 
VacutainerTM Stretch Tourniquet 
BDTM Alcohol Swabs 
BD Vacutainer® Sodium Citrate 
BD Gauze Pads 
Round-bottomed FACS Tubes (5 ml & 15 ml) 
 
Eppendorf (Cambridge, UK) 
Safe-lock 2 ml PCR Clean Eppendorf tubes 
1.5 ml sterile Eppendorf Tubes 
0.2/0.5 ml Eppendorf tubes 
 
Fannin Healthcare (Ireland) 
Econo-Columns 
 
GE-Healthcare (Buckinghamshire, UK) 
Whatman Filter Paper 
 
Matis Medical (Beersel, Belgium) 
Impact R Cones and Plates 
 
Pall Life Science (NY, USA) 
Nitrocellulose Transfer Membrane 
 
Roche Diagnostics (Pleasanton, CA, USA) 
xCELLigence E-Plate 16 
LightCycler PCR Strips 
LightCycler 96 well PCR plates  
LightCycler Sealing Foil 
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Sarstedt AG & Co (Numbrecht, Germany) 
Individually wrapped 2, 5, 10 and 25 ml Serological Pipettes 
Aspiration blow-out Pipette 
1.5ml Transfer Pipettes 
15ml polypropylene reagent and centrifuge tubes 
50ml polypropylene reagent and centrifuge tubes 
Cell scrapers 
Weigh boats 
6 well plates 
96 well plates 
 
StarLab (Hamburg, Germany) 
1000 µl Graduated Filter Tips 
200 µl Graduated Filter Tips 
20 µl Graduated Filter Tips 
10 µl Graduated Filter Tips 
0.2 µm syringe filters 
 
Vygon (Wiltshire, UK) 
Red Universal Plugs 
 
2.1.3 Instrumentation 
Accoson (Harlow, Essex) 
Dekamet Sphygmanometer 
Classic II 3M Littman Stethoscope 
 
Life Technologies (Carlsbad, CA, USA)  
7900HT Fast Real-Time PCR System with Sequence Detection Software (SDS) 
QuantStudioTM 12K Flex Real-Time PCR System 
QuantStudioTM 12K Flex OpenArray® Plates 
 
Beckman Coulter (Brea, CA, USA) 
Beckman Coulter CBC Ac. Diff Analyser 
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Becton Dickinson (Oxford, UK) 
BD FACS Aria™ 
Accuri C6™ 
Bennett Scientific Limited (Devon, UK) 
Clifton Duo Water Bath 
 
Bio-Rad (Hercules, CA, USA) 
MJ-Mini Gradient Thermocycler 
Mini-PROTEAN Tetra Cell System (4 x electrode assembly, electrophoresis powerpak® 
basic, companion running module, tank, lid with power cables, mini cell buffer dam, gel 
casting stands, 10 x well combs, gel casting frames, 5 x short plates, 5 x spacer plates 
and transfer electrode rig) 
 
BioTEK (Winooski, VT, USA) 
Microplate Reader ELX800 
 
Carl Zeiss (Oberkochen, Germany) 
Zeiss 710 Confocal Microscope 
 
Eppendorf (Cambridge, UK) 
Centrifuge 5702, 5403R, 5810R, 5415D 
 
Matis Medical (Beersel, Belgium) 
Impact R Cone & Plate Analyser  
 
Fluidigm Corporation (South San Francisco, CA, USA) 
BiomarkTM HD PCR System 
Dynamic ArrayTM IFC 
Heraeus (Frankfurt, Germany) 
HERA Safe Laminar Air Cabinet 
 
ThermoFisher Scientific (Leicestershire, UK) 
Jouan GR412 Centrifuge 
 
Labtech (East Sussex, UK) 
Nikon® Eclipse TS100 Phase-Contrast Microscope 
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Medical Supply Company (Dublin, Ireland) 
Horizontal Agarose Gel Electrophoresis Rig 
Liebherr 4 °C Refrigerator 
Liebherr Profiline -20 °C Freezer 
 
Malvern Instruments Ltd. (Malvern, UK) 
NanoSight NS300  
NanoSight Syringe Pump 
 
Mason Technology (Dublin, Ireland) 
Nanodrop 1000 ™ Spectrophotometer 
S220 pH Seven Compact 
 
Memmert (Schwabach, Germany) 
Cell Culture Incubator INC 246 
 
Merck Millipore (Nottingham, UK) 
Guava® Easy Cyte™ 8HT Bench Top Flow Cytometer 
 
Nalgene (Rochester, NY, USA) 
Cryo-Freezing Container 
 
Roche Molecular Systems (Pleasanton, CA, USA) 
LightCycler® 96 Real Time PCR System  
 
SensorMedics Corp (Yorba Linda, CA, USA) 
Vmax 229 System 
Treadmill 2000 
 
Stuart Scientific Ltd (Staffordshire, UK) 
Block Heater SBH130D        
Orbital Shaker SSM1      
Rotator PTR30      
See-Saw Rocker SS24       
Vortex SA8  
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StemCell Technologies (Vancouver, British Columbia, Canada) 
EasySep™ Magnet  
 
Syngene (Cambridge, UK) 
G-Box Chemi-Luminescence Analysis System 
 
Sysmex Ltd (Milton Keynes, UK) 
XS-1000i Automated Haematology Analyser  
Sysmex XN-3000TM Automated Haematology Analyser  
 
Taylor-Wharton (Theodore, AL, USA) 
Liquid Nitrogen Cryo-Freezer Unit (VHC-35 ®) 
 
Tanita (Amsterdam, The Netherlands) 
Tanita SC-331S Body Composition Analyser 
 
Polar Electro (Kempele, Finland) 
Polar Heart Rate Monitors 
 
ThermoFisher Scientific (Leicestershire, UK) 
Holten LaminAir Laminar Flow Cabinet 
-80 °C Freezer 
HERA Cell 150 Cell Culture Incubator 
 
2.1.4 Preparation of stock solutions and buffers  
Physiological buffers 
ACD anticoagulant 
Sodium Citrate 85   mM 
Dextrose 111 mM 
Citric Acid 71   mM 
Make up to 500 mls with distilled water 
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JNL Physiological Buffer (Ph 7.4)  
JNL A 
Dextrose                                        60 mM 
 
JNL B  
Sodium Chloride                           1.3    M 
Sodium Bicarbonate                      90  mM 
Sodium Citrate                              100 mM 
Tris-Base                                       100 mM 
Potassium Chloride                       30   mM 
 
JNL D  
Monopotassium Phosphate           8.1 mM 
 
JNL E 
Magnesium Chloride Hexahydrate 90 mM  
JNL A, B, D & E were stored at 4 °C. For combined JNL, 10 mls of JNL A/B/D and 1 
ml of JNL E were added to and made up to 70 mls with dH20, then pH to 7.35 with ACD. 
Buffer was allowed to stand at RT for 5 minutes and made up to a further 100 ml with 
distilled water. 
2.1.4.1 Immuno-blotting 
RIPA Cell Lysis Buffer Stock (1.28X) 500 ml 
HEPES, pH7.5      64  mM 
Sodium Chloride   192 mM 
Triton X-100    1.28% (v/v) 
Sodium Deoxycholate   0.64% (v/v) 
SDS     0.128% (w/v) 
dH2O to final volume – 500 ml 
 
RIPA Cell Lysis Buffer (1x) 
1.28X RIPA Stock   1x 
Sodium Fluoride    10 mM 
EDTA, pH8.0    5   mM 
Sodium Phosphate   10 mM 
Sodium Orthovanadate   1   mM 
Protease Inhibitors   1x 
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      Sample Solubilisation Buffer (4x) 
Tris-HCl, pH6.8    250 mM 
SDS     8% (w/v) 
Glycerol     40% (v/v) 
β-Mercaptoethanol   4% (v/v) 
Bromophenol Blue   0.008% (w/v) 
Filter the Sample Solubilisation Buffer using a 0.25 μm filter 
 
Transfer Buffer (1x) 
Tris-HCl     25   mM 
Glycine     192 mM 
SDS     0.1% (w/v) 
Methanol     20% 
 
Running Buffer (1x) 
Tris    25   mM  
Glycine    192 mM  
SDS     0.1% (w/v) 
 
Tris Buffered Saline (10x)  
Tris    2.4% (w/v)   
Sodium Chloride    8.8% (w/v) 
 
Coomassie Stain 
Coomassie Brillant Blue R250  0.2% 
Methanol    45%  
Glacial Acetic acid   10% 
dH2O     44.8% 
Filter the Coomassie stain using a 0.25 μm filter. 
 
Coomassie Destain Solution 
Methanol    20% 
Glacial Acetic acid   10% 
dH2O    70% 
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2.1.4.2 Molecular biology buffers 
PFE Buffer 
PBS    1X  
FBS    100% 
EDTA    0.5 M 
 
TE Buffer 
Tris    10 mM 
EDTA (pH 8.0)     1  mM 
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2.2 Methods  
2.2.1 Preparation of platelet suspensions 
2.2.1.1 Blood draw 
Before all blood draws, ethics were sought and subjects were questioned on use of anti-
platelet drugs and anti-inflammatory drugs (e.g. NSAIDS, Aspirin) during the previous 
14 days. Blood was drawn from the antecubital forearm vein in a relaxed atmosphere 
using a 21 g needle into sodium citrate vacutainer or plastic syringes of varying volumes 
(10-60 mls) depending on the experimental procedure. Care was taken to ensure a steady 
blood flow was achieved to avoid haemolysis or contamination by tissue factor and the 
tourniquet was released quickly. Blood samples were maintained at room temperature 
and gently inverted every 10 minutes until further use.  
Anticoagulants of choice were sodium citrate (for functional studies) or acid citric-acid-
dextrose (ACD) for washed platelets (low pH 4.5). For blood draws using ACD, the 
volume of anticoagulant used was 1/10 the volume of the blood sample drawn. When 
drawn into a syringe, blood was aliquoted into 15 ml tubes using a transfer pipette. 
2.2.1.2 Platelet indices and blood counts 
Full blood counts were performed on every sample immediately after the blood draw 
using semi-automated haematology analysers requiring minute sample volumes. 
Haematological and platelet indices values were obtained this way. Semi-automated 
counters employ electrical impedance to measure the volume of particles (cell types) as 
they individually pass through an aperture of defined size. Particles are suspended in a 
dilute conducting liquid and electrodes are introduced on both sides of the aperture. As 
particles are pulled by a vacuum through the aperture, they displace a volume of 
conductive liquid equal to their size. This generates measureable pulses which can be 
analysed with advanced electronics and results in simultaneous analysis of particle 
concentration and size (see Figure 2.1 for analysers used in this thesis). The Sysmex XS-
1000i aspirated 20 µl of blood and was used for the cross-sectional study. The Beckman 
Coulter aspirated 12 µl and was used for the exercise studies. The Sysmex XN-3000TM 
aspirated 12 µl and was employed for the inactivity study.  
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Figure 2.1: Automated counters used for blood cell measurements. Left: Sysmex XN-3000TM 
Haematology System; Middle: Sysmex XS-1000i Haematology System; Right: Beckman 
Coulter CBC Ac. Diff Analyser (www.beckmancoulter.com; www.sysmex.co.uk) 
 
2.2.1.3 Preparation of washed platelets 
The initial stage of platelet preparation is the preparation of platelet rich plasma (based 
on the method of Watson and Authi (2002). After blood draw, vacutainers/syringes were 
gently mixed by inversion. When working with large quantities of blood (20-60 mls), 
blood was aliquoted into 15 ml tubes, 5 ml of blood in each tube. Blood was centrifuged 
(with the brake off to reduce platelet activation) in an Eppendorf centrifuge at 150 xg for 
10 minutes at RT resulting in three layers as shown in Figure 2.2.  
 
Figure 2.2: Layers produced after centrifugation of blood. Red - contains packed red cells, 
minimal white blood cells and minimal platelets. Buffy coat – middle layer containing an 
interphase of white cells. Platelet Rich Plasma (PRP) - upper pale yellow layer containing 
platelets. (www.abcam.com). 
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PRP was removed with a transfer pipette and placed into a fresh 50 ml tube. Care was 
taken not to disturb the buffy coat or packed red cells. Platelets were isolated from PRP 
by a second centrifugation step, involving pelleting platelets and subsequent 
resuspension in a suitable buffer (a degree of activation can occur during this step and 
therefore a platelet activation inhibitor was used to minimize this – PGE1). Samples with 
greater than 10 ml per tube were split into two tubes to ensure leukocytes pelleted. 
The pH of PRP was brought to 6.5 using ACD to aid platelets from becoming activated. 
Prostaglandin E1 (PGE1), a platelet aggregation inhibitor, was added (1 µl per 1 ml of 
PRP). This helped to prevent platelet activation by raising cyclic AMP (Samuelsson et 
al., 1978). PRP was centrifuged at 2000 xg for 12 minutes with the brake on to pellet the 
platelets. The supernatant (PFP) was carefully removed and discarded, ensuring no 
disruption to the platelet pellet. 
The platelet pellet was carefully resuspended in 1 ml of buffer (either PBS/PFE/JNL) by 
gently pipetting up and down with the opening of the pipette tip angled just above the 
pellet to dislodge it. The sample was pipetted up and down without fully emptying the 
tip or fully aspirating the liquid from the tube to completely resuspend the pellet. Care 
was taken not to introduce bubbles and pipetting continued until there were no visible 
clumps of platelets remaining and a cloudy suspension was visible. 
A further 1 ml of buffer was added. 2 µl of PGE1 was added and the washing step was 
repeated twice, adding PGE1 before each wash. The platelet pellet was resuspended in 
buffer to the required concentration and platelets were allowed to sit at room temperature 
for 45 minutes to allow the PGE1 to dissipate. Resuspended platelets were transferred to 
a fresh tube for further analysis. Platelets were then ready for use – stimulated or resting. 
Calcium chloride (CaCl2) was added prior to aggregation or stimulation studies to 
reactivate platelets. 
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2.2.1.4 Gel filtered platelets  
For a very pure platelet population, gel filtered platelets were prepared. This is a gentler 
method of isolating platelets whereby they are passed through a gel filtration column of 
sepharose 2B (Watson and Authi, 2002) Platelets are generally more quiescent, however 
it is impossible to concentrate the platelets using this technique.  
A 20 ml plastic column (15cm x 1.5cm) was prepared as depicted in Figure 2.3. The 
Sepharose 2B was well shaken before pouring to ensure an even distribution of the gel 
and diluted with 50 mls of dH20 in a beaker. Depending on the volume of blood taken at 
the initial draw, the column was packed with sepharose 2B accordingly:  
 30 ml original blood volume: 5-6 ml packed column 
 40 ml original blood volume: 6-7 ml packed column 
 
The diluted sepharose was added to the column using a transfer pipette. The contents 
were allowed to settle before adding more sepharose in order to get an accurate 
measurement of the column. The packed column was washed with 10 times its volume 
of dH20 and then with 4 times its volume with the buffer of choice (JNL/PBS). This 
equilibrated the column to pH 7.4 (the natural environment of platelets). As the last few 
drops of buffer had passed through the gel, PRP was applied directly onto the top of the 
column and eluted using the JNL/PBS buffer. Platelets were eluted as a white cloudy 
fraction which were collected in a 15 ml tube and kept at RT for use.  
 
Figure 2.3: Isolating gel filtered platelets. PRP was placed on top of the sepharose 2B packed 
column. Buffer was applied to encourage the PRP to move fown the column. Gel filtered Platelets 
were eluted as a white cloudy fraction into a 15 ml tube (Image adapted from Tangen et al., 1978). 
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2.2.1.5 Leukocyte (CD45) depletion of platelets  
Washing platelets removes plasma contaminants, effectively diluting out plasma proteins 
and therefore leaving a pure platelet sample. Where a highly pure platelet population is 
required, further purification was necessary. For RNA analysis, the lesser RNA content of 
platelets may be contaminated by a relatively small number of white blood cells (WBCs), 
relative to platelet number (as each WBC can potentially contain over 10,000 times the RNA 
mass of platelets (Fink et al., 2003)). 
To prepare CD45-depleted platelets for RNA analysis, EasySepTM magnetic technology was 
used, as outlined in Figure 2.4. This combines the specificity of monoclonal antibodies with 
the simplicity of a column-free magnetic system for rapid isolation of highly pure platelets 
ready for downstream applications. Cells are cross linked to EasySepTM magnetic particles 
using the Tetrameric Antibody Complex (TAC) technology and easily separated from 
unwanted message rich leukocytes (and CD45+ cells – a leukocyte specific marker) using 
the magnet.  
PFE Buffer (PBS + FBS + EDTA) was fresh each day RNA was prepared. For 19.5 ml of 
PFE buffer, 0.4 ml of FBS, 40 µl of 0.5 M EDTA and 19.5 ml of PBS were prepared in a 50 
ml tube. This assay included the preparation of PRP as previously described. Platelets were 
suspended in 1 ml of PFE buffer after the second centrifugation step in a FACS tube. After 
a cloudy suspension of platelets was visible, a further 1 ml of PFE buffer was added and 
mixed by gentle pipetting and platelets were counted using semi-automated counters as 
described in section 2.2.1.6.  
The EasySepTM whole blood depletion cocktail was then added to washed platelets 
depending on starting blood volume (200 µl for 40 mls and 50 µl for 10 mls, diluted 
accordingly for lower blood volumes). This sample was mixed gently by pipetting up and 
down and incubated for 15 minutes at RT. The EasySepTM magnetic nanoparticles were 
mixed vigorously by pipetting to ensure they were in a uniform suspension and 200 µl was 
added to the sample mixture (or reduced equivalent for smaller blood volumes).  
The sample was mixed by pipetting and incubated at room temperature for 10 minutes. After 
the incubation, PFE buffer was added to a total volume of 5 mls and the sample was mixed 
gently. The tube was placed into the magnet and incubated without the cap for 10 minutes 
at RT. The magnet was picked up and inverted in one continuous motion, pouring off the 
supernatant into a 15 ml RNAse-free tube. The magnet and tube were held inverted for 2-3 
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seconds and then returned to the upright position. Platelets in the fresh tube were CD45-
depleted platelets. 5 µl PGE1 was added to the CD45-depleted platelets and mixed by 
inversion. The tube was centrifuged at 2000 xg for 10 minutes at RT with the brake on to 
pellet the platelets. The plasma supernatant was removed and the pellet was ready for RNA 
extraction (lysed with mirVana® lysis buffer at this point). 
 
Figure 2.4: Isolating leukocyte-depleted platelets. 1 - EasySepTM CD45 depletion cocktail is added 
to the platelet suspension. 2 -  EasySepTM magnetic particles are added and incubated and 3 – The 
suspension is incubated in the magnet and CD45-depleted platelets are poured off. 
(www.stemcell.com ). 
 
2.2.1.6 Counting platelet suspensions 
Different experimental procedures required enumeration of platelet count in the final 
suspension. This was achieved using semi-automated counters (as explained previously for 
full blood counts). If the original blood draw was large, the platelet suspension was diluted 
1:1000 in the buffer. Appropriate dilution factors were then applied to calculate the final 
platelet count.  
 
 
                 
 
2 
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2.2.1.7 Platelet-free plasma isolation  
Platelet free plasma (PFP) was isolated for microvesicle work. To generate PFP, a double 
centrifugation method was employed. Blood was drawn using a 21G needle into a sodium 
citrate vacutainer (0.32% v/v final concentration). The first 3-5 mls of blood was discarded 
to avoid contamination from cell fragments or tissue factor from venepuncture being 
collected. The blood sample was mixed by gentle inversions to ensure even distribution of 
the anticoagulant. Within 15 minutes of collection, it was centrifuged at 1550xg for 20 
minutes at room temperature (20-22oC) to pellet the cells. The supernatant PFP containing 
the microvesicles (MVs) was carefully aspirated leaving a layer of approximately 0.5 cm 
undisturbed on top of the cells. The collected PFP was placed in a sterile 1.5 ml 
microcentrifuge tube and centrifuged again at 13,000xg for 2 minutes to remove any 
contaminating cells or debris. The PFP was then collected, leaving 20% of the sample at the 
bottom of the tube to be discarded. The PFP was separated in 250 µl aliquots in Sarstedt 
screw cap tubes, snap frozen in liquid nitrogen and then stored at -80°C until further analysis, 
at which point it was thawed on ice.  
 
2.2.2 Immuno-detection techniques  
2.2.2.1 Western blotting 
2.2.2.1.1 Preparation of platelet lysates 
For western blot assays, platelets were harvested in the following manner. Platelet pellets to 
be lysed were placed on ice and the buffer was removed. Platelets were lysed with 1x radio 
immunoprecipitation assay (RIPA) buffer (30 µl per well of a 6 well plate/ 60 µl per pellet) 
and collected using a cell scraper or pipetted to mix the sample. The lysate was collected in 
a sterile 1.5 ml micro-centrifuge tube and rotated at 4 °C for 45 minutes to ensure full lysis 
of platelets. The lysate was then centrifuged at 10,000 xg for 20 minutes at 4 °C to ensure 
the sedimentation of triton insoluble material to a compact pellet. The protein containing 
supernatant was then carefully lifted off into 20 µl aliquots and frozen at -80 °C. 
Alternatively the lysate was used straight away in a BCA assay and ultimately a western 
blot. 
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2.2.2.1.2 Bicinchoninic acid assay (BCA assay) 
To ensure that samples are in the proper range for detection of the assay, and so they can be 
compared on an equivalent basis, it is important to know the concentration of total protein 
in each sample. This was achieved using a BCA assay (Smith., 1985). The assay depends on 
two reactions, firstly the ability of peptide bonds to reduce Copper (Cu2+) ions to Cu+ and 
secondly, the ability of bicinchoninic acid (green) to chelate with each Cu+ to form a complex 
(purple) that strongly absorbs light at 562 nm.  
A sterile 96-well plate was used for this assay. 10µl aliquots of the protein samples, BSA 
protein standards (concentration range 0-2 mg/ml) and 1x RIPA (buffer used to lyse 
platelets) were added in triplicate to the plate. The BCA kit reagents came as two solutions; 
(A) an alkaline bicarbonate solution and (B) a copper sulphate solution. These were mixed 
in a ratio of 50 parts A to 1-part B so that 200 µl of this mixture was added to each well to 
be assayed on the 96-well plate. The plate was immediately covered to protect from light 
and incubated for 30 minutes at 37 °C. The absorbance was then read at 562 nm on an 
ELx800 Microplate Reader and the unknown concentrations calculated using standard curve 
analysis. 
2.2.2.1.3 Preparing samples 
Samples were prepared in a solution of 4x sample solubilisation buffer (SSB), (recipe 
outlined in section 2.1.4) which contained glycerol to enable the sample to sink to the bottom 
of the well, and bromophenol blue which allowed separation to be tracked as the sample 
migrated through the gel. SDS and β-mercaptoethanol were added to fully reduce and 
denature the protein and remove any higher order structure. Samples were then heated to 95 
°C for 5 minutes to further aid in denaturing. 
2.2.2.1.4 Polyacrylamide gel electrophoresis (SDS-PAGE) 
After the samples were prepared, they were separated by size using sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) according to the protocol of Laemmli 
(Laemmli, 1970). 10x100 mm glass plates (one short one long containing 1 mm spacers) were 
cleaned with 70% v/v (ethanol) and dried completely. They were assembled and sealed tight 
using the casting frame and stand. Resolving gels of 7.5% and 10% were prepared as 
described in Table 2.1. 7-8 ml of the resolving gel was poured between the glass plates, 
avoiding air bubbles, this was then topped with a layer of 70% v/v ethanol to remove any 
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surface air bubbles and give an even surface to the gel. The gel was allowed polymerise for 
30-40 minutes at room temperature. Following this the ethanol was carefully poured off and 
the stacking gel was prepared as described in Table 2.2. The stacking gel was added on top 
of the polymerized resolving gel and a 1.0 mm comb was gently inserted to create the loading 
wells. A 4% v/v polyacrylamide stacking gel was used throughout all experiments.  
Table 2.1: Recipe for SDS-PAGE resolving gel. 
Solutions Gel (%) 
 7.5% 10% 12% 
Distilled Water 4.85 ml 4.00 ml 3.35 ml 
1.5 M Tris-HCL, pH 8.8 2.5 ml 2.5 ml 2.5 ml 
Bis Acrylamide (30%) 2.5 ml 3.33 ml 4.0 ml 
10% SDS 100 µl 100 µl 100 µl 
10% Ammonium persulfate 50 µl 50 µl 50 µl 
TEMED 5 µl 5 µl 5 µl 
Total Volume 10 ml 10 ml 10 ml 
 
Table 2.2: Recipe for SDS-PAGE stacking gel. 
Solutions 4% 
Distilled Water 6.1 ml 
0.5M Tris –HCL, Ph6.8 2.5 ml 
Bis- Acrylamide (30%) 1.3 ml 
10% SDS 100 µl 
10% Ammonium Persulfate 100 µl 
TEMED 5 µl 
Total Volume 10 ml 
 
 94 
 
Upon polymerization, the comb was carefully removed and the gel was inserted into the 
cassette and loaded into the electrophoresis tank. The chamber between the gel and buffer 
dam was filled with running buffer and any loose acrylamide flushed from the wells using a 
pipette. The tank was filled to the mark with the remaining running buffer. The wells were 
then loaded with 30 µl of prepared sample in SSB buffer in addition to 5 µl of the molecular 
weight marker in specific lanes. The samples and marker then underwent electrophoresis at 
80 V for 20 minutes, after which the voltage was increased to 100 V for 80 minutes. 
2.2.2.1.5 Electrophoretic transfer 
Electrophoretic transfer is the transfer of proteins from a gel to a blotting membrane while 
simultaneously preserving their relative position. The wet transfer technique was employed 
in this thesis and the membrane of choice was nitrocellulose. The nitrocellulose membrane 
and transfer components were soaked in ice cold transfer buffer for 10 minutes prior to use. 
Following electrophoresis, the gel was removed from the glass plates encasing it and the 
stacking gel was removed. The gel and blotting membrane were assembled into a sandwich 
outlined in Figure 2.5. 
 
Figure 2.5: Assembly of a wet tank transfer cassette. The gel and membrane are securely placed 
between a sandwich of filter papers and fibre pads. (www.bio-rad.com). 
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The sandwich was then pressed with a roller wetted in transfer buffer to eliminate possible 
air bubbles. The gel/membrane sandwich was then placed in the transfer cassette. The 
cassette was submersed in the electrophoresis tank filled with ice cold transfer buffer and an 
ice pack subjected to an electrical field. The cassette was organised so that the membrane 
sat between the gel surface and the positive electrode so that the negatively charged proteins 
migrate from the gel to the membrane (Figure 2.6). Transfers were performed overnight at 
4 °C in a cold room. The transfer buffer was agitated using a magnetic stirring bar and 
voltage set to 50V.  
2.2.2.1.6 Blocking 
To reduce non-specific binding of the antibody, the membrane was blocked by incubating 
with either 5% non-fat dried milk or BSA in 0.05% Tween PBS at room temperature for 40 
minutes on a see-saw rocker. Post-block the membrane was washed 3 times for 5 minutes 
on a see-saw rocker with 0.05% Tween PBS. 
2.2.2.1.7 Antibody incubation 
After blocking and washing, the blot was incubated, usually overnight at 4 °C with gentle 
rocking, with the appropriate primary antibody. The antibody was made up in a solution of 
1-5% BSA in 0.05% PBS Tween or TBS Tween. See Table 2.3 for antibodies used in this 
thesis.  
Table 2.3: List of antibodies used for immunodetection. 
1° Antibody Block Tween % Species Dilution 
Factor 
2° Antibody Species 
Argonaute2 PBS/BSA 0.05 Rabbit 2 µg/ml 1:3000 Rabbit 
Dicer PBS/BSA 0.05 Mouse 1:200 1:3000 Mouse 
GAPDH PBS/BSA 0.05 Rabbit 1:3000 1:5000 Rabbit 
Drosha  PBS/BSA 0.05 Rabbit 1:1000 1:3000 Rabbit 
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After incubation with the primary antibody, the blot was washed 3 times with 0.05% 
TBS/PBS Tween for 5 minutes with gentle rocking. The blot was then incubated with the 
appropriate species of secondary antibody conjugated with HRP (horse radish peroxidase) 
in 1-5% BSA 0.05% TBS/PBS Tween for 2 hours at room temperature. HRP is a small stable 
enzyme with specificity and rapid turnover. See Table 2.3 for appropriate secondary species 
and the dilution factor for each protein. Finally, the membrane was washed for 3 x 5 minutes 
in 0.05% TBS/PBS Tween with gentle rocking. 
2.2.2.1.8 Blot development 
Detection of target proteins was possible once they were specifically tagged with the 
appropriately labelled antibody. This was achieved through use of either Millipore 
Luminata® Enhanced Chemiluminescent (ECL) substrate or Thermo Scientific 
SuperSignal® West Pico Chemiluminescent Substrate. When probing for an abundant 
cellular protein with a reliable antibody, the less sensitive SuperSignal® West Pico 
Chemiluminescent Substrate was used. The peroxide solution and luminal enhancer solution 
were mixed in equal parts and approximately 1 ml of this mixture was added for an entire 
10 well blot. When probing for minimally expressed proteins or using weak antibodies the 
Millipore, Luminata® was used, capable of detecting picogram (pg) amounts.  
Approximately 500 µl was added to a full 10 well membrane. In both cases, detection 
imaging was carried out immediately. The light emission was captured using a Syngene G-
Box. Exposure times ranged from 30 seconds to 10 minutes depending on the signal strength.  
2.2.2.1.9 Ponceau-S membrane staining 
Ponceau S is a red stain applied in an acidic solution which reversibly stains all protein 
present on the membrane prior to any immuno-blotting. This was used to confirm the transfer 
and help to show equal transfer of protein from the gel. The stain was subsequently removed 
by washing in distilled water. 
2.2.2.1.10 Coomassie gel staining 
Coomassie gel staining was used to visualise proteins on the SDS-PAGE gel, which was 
useful to ensure an efficient transfer by showing protein left behind. In brief, the SDS-PAGE 
gel was covered with filtered coomassie solution and agitated by gentle rocking for up to 4 
hours. The solution was then poured off and the gel de-stained using a mixture of methanol 
and acetic acid (50:50) until the protein bands appeared clear with no background.  
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2.2.2.1.11 Membrane stripping 
To allow for re-probing of the membrane with different antibodies or to optimize antibody 
concentration, the membrane was stripped with RESTORE® stripping buffer. This was used 
as per the manufacturer’s instruction. In brief, the blot was washed in 0.05% TBS/PBS 
Tween to remove any previous ECL substrate then covered with stripping buffer and agitated 
by rocking gently for 15 minutes. Removal of both primary and secondary antibody was 
confirmed by first incubating the membrane with the appropriate secondary and subsequent 
detection with ECL substrate. If no bands were detected the blot had been successfully 
stripped. It was then washed again to remove ECL substrate and reprobed with alternative 
antibodies as previously described.  
 
Figure 2.6: Apparatus used to run an SDS-PAGE gel. (www.bio-rad.com). 
 
2.2.2.2 Human protein biomarker assay - Proseek multiplex immunoassay 
(* as performed in collaboration with Olink, Sweden) 
Proseek® multiplex CVD II96x96 & Proseek® multiplex inflammation I96x96 are high-
throughput multiplex immunoassays, each enabling analysis of 92 CVD- or inflammation-
related protein biomarkers using 1 µl of sample and across samples simultaneously. This 
high level of multiplexing is achieved by proximity extension assay (PEA) technology 
(Figure 2.8).  A comparison of Proseek probes against conventional immunoassay is 
depicted in Figure 2.7.  
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A pair of oligonucleotide-labelled antibodies (Proseek probes) specific for each biomarker 
are allowed to pair-wise bind to each target protein in the sample. When two Proseek probes 
are in close proximity, a new PCR target sequence is created by a proximity-depended DNA 
polymerization reaction. Each oligonucleotide pair holds a unique DNA sequence enabling 
hybridisation only to each other. This sequence can then be detected by real time PCR and 
measured.  
 
Figure 2.7: Proseek multiplex probes. A – represents conventional immunoassays where cross 
reactivity occurs due to unspecific binding of antibodies, thereby limiting the degree of multiplexing. 
B - unique DNA oligo sequences report only matched DNA-pairs (e.g. 1A+1B) and cross reactive 
events are not identified. (www.olink.com) 
 
2.2.2.2.1 Sample preparation and run 
Citrated PFP samples were thawed, centrifuged briefly and 20 µl of each sample was 
aliquoted into a well on a 96 well plate and shipped to Olink Bioscience on dry ice. Proseek 
assays were performed by Olink Bioscience (Upsala, Sweden) to evaluate the expression of 
two panels of potential CVD and inflammatory biomarkers (see appendix C for full 
biomarker lists). Overlap between panels resulted in the total measurement of 152 
biomarkers in the PFP samples.  
Briefly, 1 μl of each sample or negative control was incubated with the conjugated antibodies 
at 4 °C overnight (day 1). On day 2, the PEA mixture was added and the products were 
extended and pre-amplified using PCR (ABI 2720 Thermal cycler, Life Technologies). The 
detection reagent was added to 2.8 µl of the extended and pre-amplified product, mixed and 
then loaded into the Fluidigm Gene Expression 96x96 Dynamic arrays (Fluidigm 
Corporation) on one side and the Primer plate with specific primers on the other side of the 
chip. The chip was primed using Fluidigm IFC controller HX and afterwards loaded into a 
Fluidigm Biomarker system.  
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Detection and sample analysis was performed by high-throughput real-time PCR analysis 
using the Fluidigm® BioMark™ HD System. This PCR platform enables simultaneous 
detection of 96 analytes in 96 samples creating 9,216 data points from a single run. The 
BioMark HD platform uses microfluidic distribution of sample and assays requiring only 7 
nl reactions. The BioMark HD platform consists of a real-time PCR instrument, 96x96 
Dynamic Array™ IFC for multiplexing the samples and biomarkers, and an IFC loader to 
load the 96x96 Dynamic Array IFC.  
Raw data was analysed using Fluidigm PCR software. The Proseek assay generated Cq 
values for each biomarker and data was normalized using the extension control and a 
background value. The data used for statistical analysis was expressed on a log2 scale, where 
a high value corresponded to a high protein expression and vice versa with a low value. The 
limit of detection (mean negative control plus 3 x standard deviation) was determined for 
each biomarker for each sample. The data was normalised and analysed using GenEx 
software (MultiD, Gothenburg, Sweden). All statistical analyses (dynamic principal 
component analysis and one-way ANOVA) were performed on normalized data.  
  
 
 
Figure 2.8: The main steps in the Proseek assay. Part 1- Two oligonucleotide labelled antibodies 
called proseek probes, bind to the target protein in the sample. Part 2 – The close proximity of the 
probes results in the formation of a new PCR target sequence by a proximity-dependent DNA 
polymerisation event. In part 3 – the resulting sequence is then detected and quantified using standard 
real time PCR. (www.olink.com) 
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2.2.3 Molecular techniques  
As RNA is easily damaged and degraded by ubiquitous ribonuclease (RNase), all RNA work 
was carried out according to the protocol outlined by Sambrook (Evans, 1990). To prevent 
genomic DNA contamination, prior to RNA work, surfaces and equipment were cleaned 
down with DNA Zap (Invitrogen). This consists of two solutions that are innocuous when 
used alone, but become a potent nucleic acid degrading solution when mixed. This mixture 
is able to instantaneously degrade high levels of contaminating DNA and RNA from 
surfaces. Gloves were used and changed frequently throughout the procedure. 
2.2.3.1 RNA isolation 
The mirVana® RNA extraction kit was used for isolation and purification of total RNA from 
platelet samples and plasma samples. This was found to obtain an increased RNA yield and 
superior purity compared to other methods including Trizol-based extraction. The mirVana® 
kit uses an organic extraction method followed by immobilisation of RNA on glass-fibre 
filters to purify total RNA. 
Platelets were prepared as previously outlined and pelleted by centrifugation at 2000xg for 
12 minutes at RT. 400 µl of total lysis binding solution was added to the cells (for adhesion 
assays, in the case of a 6 well plate, 100 µl into each well). The cells were then scraped and 
collected, using a rubber cell scraper, into a 1.5 ml RNase-free micro centrifuge tube). The 
sample was pipetted for 30-60 seconds to obtain a homogenous lysate and vortexed briefly. 
The volume of the lysate was recorded and 1/10 of this volume of miRNA homogenate 
additive was added to the lysate. This solution was well mixed by vortexing for 30-60 
seconds. The solution was then incubated on ice for ten minutes after which the volume prior 
to addition of the miRNA homogenate additive was the volume of acid phenol chloroform 
added (ensured it was taken from the bottom phase of the acid phenol chloroform). The 
lysate solution was again vortexed for 30-60 seconds before being centrifuged for 5 minutes 
at 10,000 xg at room temperature to separate the aqueous and organic phases. 
Following centrifugation, the lysate solution was checked for a compact interphase and if 
this was not evident the centrifugation step was repeated. The upper aqueous phase was 
transferred to a fresh tube taking care not to disturb or carry over any of the bottom organic 
phase. The volume of upper aqueous phase recovered was noted and 1.25x of this volume 
of room temperature 100% high grade ethanol was added to the fresh tube. A maximum of 
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700 µl of this lysate/ethanol mixture was pipetted onto a glass-fibre filter cartridge, which 
was placed in a fresh tube. This was centrifuged at 10,000xg for 15 seconds to pass the 
mixture through the filter. This step was repeated until all of the lysate/ethanol had been 
passed through the filter and the flow-through was discarded each time. 700 µl of wash 
buffer 1 was then added to the filter column and passed through by centrifugation at 10,000 
xg for 15 seconds. This was repeated using 500 µl of wash buffer 2/3 again with the flow-
through being discarded each time. After the third wash the filter column was centrifuged at 
10,000xg for 1 minute to dry off the filter column and prevent ethanol carry over to the new 
tube in which filter column was placed. The total RNA was then eluted into a fresh collection 
tube by centrifugation at 10,000 xg for 30 seconds using 100 µl of elution buffer, which was 
pre-heated to 95 °C. The RNA was quantified and qualified on a NanoDrop® 
Spectrophotometer. The sample was stored at -80 °C. 
2.2.3.2 RNA/DNA quantification 
The NanoDrop® ND-1000 Spectrophotometer was used to determine nucleic acid sample 
concentrations and integrity (Figure 2.9). An undiluted 1.2 μl sample was pipetted onto the 
end of a fibre optic cable (the receiving fibre). A second fibre optic cable (the source fibre) 
was then brought into contact with the liquid sample causing the liquid to bridge the gap 
between the fibre optic ends. A pulsed xenon flash lamp provides the light source and a 
spectrometer is used to analyse the light after passing through the sample. The instrument is 
controlled through use of specific PC-based software. 
The NanoDrop® automatically calculates the purity of the nucleic acid samples by reading 
the absorbance at 260 nm and the absorbance at 280 nm and then determining the ratio 
between the two (Abs@260/Abs@280). Pure DNA, which has no protein impurities has a 
ratio of 1.8, whereas pure RNA has a ratio of 2.0. Lower ratios indicate the presence of 
protein; higher ratios imply the presence of organic reagents. 
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Figure 2.9: The NanoDrop instrument used to determine nucleic acid sample concentration 
and integrity. Left: NanoDrop Instrument, middle: NanoDrop technology, right: Typical output. 
(www.nanodrop.com). 
 
2.2.3.3 Polymerase Chain Reaction (PCR) 
PCR is a process used to amplify specific sequences of DNA at an exponential rate for use 
in a variety of applications. Standard (“bench top”) PCR was used for creating 
complementary DNA (cDNA) and as a cost effective method before the samples were 
subjected to quantitative real time PCR (qPCR).  
 
2.2.3.4 Quantitative RealTime PCR (qPCR) 
qPCR reactions follow the standardized principles of PCR. It is used to amplify target DNA 
with a view to simultaneously quantifying the targeted DNA sequence as it accumulates 
during the reaction. This technique was used for both microRNA profiling and gene 
expression work and was facilitated by the use of TaqMan hydrolysis probes shown in Figure 
2.10. This chemistry, also known as “fluorogenic 5’ nuclease chemistry uses a fluorogenic 
labelled 5’ probe. This relies on the nuclease activity of Taq DNA polymerase. An 
oligonucleotide probe is constructed containing a reporter fluorescent dye on the 5' end and 
a quencher dye on the 3' end.  
While the probe is intact, the proximity of the quencher dye greatly reduces the fluorescence 
emitted by the reporter dye by fluorescence resonance energy transfer (FRET). If the target 
sequence is present, the probe anneals downstream from one of the primer sites and is 
cleaved by the 5' nuclease activity of Taq DNA polymerase as this primer is extended. This 
cleavage of the probe:  
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 Separates the reporter dye from the quencher dye, increasing the reporter dye 
signal. 
 Removes the probe from the target strand, allowing primer extension to continue 
to the end of the template strand. Thus, inclusion of the probe does not inhibit the 
overall PCR process. 
Additional reporter dye molecules are cleaved from their respective probes with each cycle, 
resulting in an increase in fluorescence intensity proportional to the amount of PCR product 
produced.  
 
Figure 2.10: TaqMan Probe chemistry. Images A-D highlight the behaviour of taqman probes 
during PCR. Taqman probes carry two fluorescent dyes in close proximity, one of which (quencher) 
quenches the fluorescence from the other (reporter) while the probe is intact. In the denaturation 
phase (A) DNA strands separate as temperature increases. During the annealing phase (B), the 
primers and probes specifically anneal to the target sequence. As DNA polymerase extends the 
primers, the 5’ nuclease activity of the enzyme cleaves the probe (C), allowing the reporter dye to 
emit green fluorescence. The probe fragments are then displaced from the target and polymerisation 
of the new amplicon continues (D). Accumulation of PCR products is detected directly by monitoring 
the increase in green fluorescence from the reporter dye.  
 
2.2.3.5 MicroRNA (miRNA) profiling 
2.2.3.5.1 miRNA isolation and amplification 
miRNA profiling was carried out using the Applied Biosystems® TaqMan® Low Density 
Array (TLDA) Human miRNA A (v2.0) and B (v3.0) cards set. For analysis on the TLDA 
cards, total RNA was firstly extracted from platelets using the Ambion™ miRVANA 
miRNA® isolation kit. 
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2.2.3.5.2 Reverse transcription of RNA for TaqMan® array analysis 
Single stranded cDNA was synthesised from total platelet RNA using the Applied 
Biosystems TaqMan® miRNA Reverse Transcription (RT) Kit. For a full miRNA profile 
two RT reactions were needed incorporating primers for both pool A and B miRNA panels. 
This kit uses specific stem-looped RT primers (Figure 2.11) to lengthen the target cDNA 
(Kramer, 2011), as the short length of miRNA make it difficult for traditional primers to 
anneal for the RT reaction. The RT reaction had a final volume of 7.5 µl and contained: 3 µl 
(1-350 ng) total RNA and 4.5 µl of RT master mix. The master mix was made up as shown 
in Table 2.4 in a 2 ml RNAse-free tube. 
 
Table 2.4: Recipe for reverse transcription of miRNA to cDNA (pool A and B).  
RT reaction mix components Volume for one samples 
(µl) 
 
Volume for ten samples 
(µl) * 
Megaplex RT primers  
(Pool A & B) 10x 
0.8 9.00 
dNTPs (100 mM) 0.2 2.25 
Multiscribe reverse 
transcriptase  
(50 U/µL) 
1.5 16.88 
10 X RT Buffer 0.8 9.00 
MgCl 0.9 10.12 
RNase Inhibitor  
(20 U/µL) 
0.1 1.12 
Nuclease free water 0.2 2.25 
Total 4.5 50.62 
* volume includes 12.5% excess for volume loss from pipetting. 
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The samples were mixed by gentle pipetting and then incubated on ice for 5 minutes. The 
samples were then run on the bench top PCR thermo cycler under the conditions found in 
Table 2.5. 
Table 2.5: Thermocycler conditions for miRNA specific reverse transcription. 
Stage Temp °C Time 
Cycle 
(40 cycles) 
16 2 min 
42 1 min 
50 1 min 
Hold 85 5 min 
Hold 4 ∞ 
 
 
Figure 2.11: Reverse transcription of microRNA using stem-looped primers. A RT binding site 
is created using a stem loop specific primer set binding to the 3’ end of the miRNA. The stem-looped 
primer is highly specific for miRNA and can differentiate between mature and pre miRNA. (Image 
adapted from Kramer, 2011). 
 
2.2.3.5.3 Pre-amplification of cDNA 
As the total RNA yield from platelets is generally lower than nucleated cells (less than 350 
ng), a preamplification step was carried out prior to committing the cDNA to the TaqMan 
miRNA arrays. This uniformly pre-amplifies desired cDNA prior to quantification with the 
TLDA cards. The preamplification reaction had a final volume of 25 µl containing 2.5 µl RT 
product and 22.5 µl Pre-amp reaction mix The master mix was made up as shown in Table 2.6 
in a 2 ml RNAse-free tube. The sample was then mixed by gentle pipetting and run on a 
bench top PCR thermocycler under the conditions found in Table 2.7. 
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Table 2.6: Recipe for pre-amplification master mix. 
PreAmp reaction mix  
components 
Volume for one 
sample (µl) 
Volume for ten 
samples (µl) 
TaqMan PreAmp  
master mix (2x) 
12.5 140.62 
Megaplex PreAmp  
primers (10x) 
2.5 28.13 
Nuclease Free Water 7.5 84.37 
Total 22.5 253.12 
Table 2.7: Thermocycler conditions for miRNA cDNA pre-amplification. 
Stage Temp °C Time 
Hold 95 10 min 
Hold 55 2 min 
Hold 72 2 min 
Cycle (12 cycles) 95 15 secs 
60 4 min 
Hold (for enzyme inactivation) 99.9 10 min 
Hold 4 ∞ 
Following PCR, the sample was diluted with 75 µl of 0.1x TE buffer (pH 8) and used 
immediately for array analysis or stored for up to one week at -20 °C/ -80 °C for future use.  
2.2.3.5.4 Running the TaqMan® microRNA array 
A 7900HT PCR system was used for initial miRNA profiling and a QuantStudio™ 12K Flex 
Real-Time PCR system was used for large scale profiling. DNA polymerase from the 
TaqMan® Universal PCR Master Mix amplifies the target cDNA using sequence-specific 
primers and a probe on the TaqMan microRNA array. The presence of the target is detected 
in real time through cleavage of the TaqMan probe by the polymerase 5’-3’ activity. The 
master mix for the cards was made up as shown in Table 2.8 for pre-amplified cDNA. 
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Table 2.8: Recipe for miRNA array sample when using a pre-amplified product. 
Component Volume for One Array (µl) 
TaqMan Universal PCR master mix 
450 
Diluted Pre-Amp Product 
9 
Nuclease-Free Water 
441 
Total 900 
 
The sample was mixed by gentle pipetting and centrifuged briefly. The arrays were allowed 
to come to room temperature after which, 100 µl of the master mix was dispensed into each 
chamber of the array. The card was centrifuged twice for 1 minute at 1000 x g to fill each of 
the 384 wells of the card in an Eppendorf 5810R centrifuge. The card was then sealed and 
the loading chambers were cut off. The card was run on the Applied Biosystems® 7900 HT 
thermocycler using the parameters contained within the SDS setup file on the supplied CD 
as shown in Table 2.9. 
Table 2.9: Real time thermocycler parameters for the miRNA array. 
Temperature(°C) Time (min) Cycles 
50 2 40 
94.5 10 40 
97 30 (seconds) 40 
59.7 1 40 
 
OpenArray® plate technology on the QuantStudio™ 12K Flex Real-Time System (Paris, 
France) was used for large scale miRNA profiling to achieve high sample throughput. One 
OpenArray plate can hold the equivalent of eight traditional 384-well cards and three open 
array plates can run simultaneously. This technology uses a microscope slide sized plate 
(PCR chip) with 3,072 pores. Each pore is 300 μm in diameter and 300 μm deep and is pre-
treated with hydrophilic and hydrophobic coatings. Reagents are then retained in the through 
holes/pores by surface tension. Each through-hole accepts 33±1 nl of sample and master 
mix. 
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Figure 2.12: PCR systems used for miRNA quantification. Image above shows the OpenArray 
plate technology (left) and QuantStudio™ 12K Flex Real-Time System to the right. The image below 
(left) shows the 384 well miRNA taqman card and the 7900HT PCR system it is used with (right). 
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2.2.3.4 Gene expression work 
2.2.3.4.1 Reverse transcription of platelet RNA 
Reverse transcription was performed using the Transcriptor First Strand cDNA synthesis kit 
(Roche Diagnostics). The kit is designed to reverse transcribe RNA for gene expression 
studies via two-step RT-PCR using qPCR on the LightCycler®96 instrument. cDNA 
synthesis for a two-step RT-PCR was performed using a combination of Anchored 
Oligo(dT) priming and random hexamer priming which are explained in Table 2.10. This 
was the method of choice used to increase sensitivity. The enzyme used - Transcriptor 
reverse transcriptase, is a recombinant reverse transcriptase expressed in E coli and has an 
RNA-directed DNA polymerase activity, unwinding activity and RNase H activity that 
degrades RNA in RNA: DNA hybrids. Thus, there is no need to perform an additional RNase 
H incubation step after reverse transcription, shortening the reaction time.  
Table 2.10: Overview of priming methods used for cDNA synthesis. 
Type of RT primer Binding site Advantages 
Anchored 
Oligo(dT)18 
Very beginning of 
the poly (A) tail 
 Prevents priming from internal sites of 
the poly(A) tail.  
 Generates full-length cDNA.  
 Preferred priming method for most 
two-step RT-PCR. 
Random hexamer Many sites 
throughout the 
length of an RNA 
 Provides uniform representation of all 
RNA sequences in mRNA.  
 Can prime cDNA transcription from 
RNAs that do not carry a poly(A) tail.  
 The ratio of random primers to RNA in 
the RT reaction determines the average 
length of cDNA’s generated. 
 Short cDNA transcripts may help to 
over-come difficulties caused by RNA 
secondary structures. 
 
2.2.3.4.2 Preparing the reverse transcription mix  
All frozen reagents were thawed before use, centrifuged briefly and kept on ice while 
preparing the reaction. The template-primer mixture was prepared in a nuclease-free PCR 
tube on ice, by adding the components in Table 2.11.  
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Table 2.11: Template-primer mix for cDNA synthesis. 
Template-primer mix (for one 20µl reaction) 
Component Volume Final concentration 
Total RNA 10 µl 10 ng- 5 µg total RNA or 
Anchored Oligo(dT)18 
primer (50 pmol/µl) 
1 µl 2.5 µM 
Random hexamer 
primer (600 pmol/ µl) 
2 µl 60 µM 
PCR grade water Variable To make total volume = 
13 µl 
Total volume 13 µl  
 
The template-primer mix was heated for 10 minutes at 65 °C in a thermal block cycler with 
a heated lid (minimises evaporation). This ensured denaturation of RNA secondary 
structures if present. The tube was immediately cooled on ice. The remaining components 
of the RT mix were then added to the tube containing the template-primer mix, in the order 
listed in Table 2.12. 
Table 2.12: Reverse transcription mix. 
Component Volume Final 
concentration 
Transcriptor Reverse Transcriptase Reaction Buffer 
(5X concentration) 
4 µl 1x (8 mM MgCl2) 
Protector RNase Inhibitor (40 U/ µl) 0.5 µl 20 U 
Deoxynucleotide Mix, 10 mM each  2 µl 1 mM each 
Transcriptor Reverse Transcriptase (20U/ µl) 0.5 µl 10 U 
Final volume 20 µl  
The reagents were mixed carefully and centrifuged briefly to pull the sample to the bottom 
of the tube. The tube was then placed in the thermal cycler block. Depending on the length 
of the target mRNA, the RT reaction was ran using according to manufacturer’s instructions 
(10 mins at 25 °C, 60 mins at 50 °C and 5 mins at 85 °C). The reaction was stopped by 
placing the tube on ice and the sample was stored at -20 °C for further analysis. 
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2.2.3.4.3 Running the qPCR assay 
The assay was performed using RealTime Ready (RTR) function tested custom qPCR assays 
(Roche Diagnostics) to detect different targets. Each RTR assay contained gene specific 
primers for the target gene and a Universal Probe Library (UPL) probe, a short FAM-labelled 
hydrolysis probe with locked nucleic acid. PCR mixes were prepared in PCR tubes on ice. 
PCR reaction mix was arranged by adding the components listed in the order in Table 2.13. 
15 µl of the PCR mix was placed into each well of the LightCycler®96 multi-well plates. 5 
µl of the template (cDNA of varying concentration depending on the experiment) was added 
to the PCR mix (to make a 20 µl reaction) and the plate was sealed with sealing foil. It was 
centrifuged for 2 minutes at 1500 xg in a swing bucket and placed into the LightCyler®96. 
Using the PCR program described according to manufacturer’s instructions, the reaction was 
performed. The LightCyler®96 software was used to analyse relative quantification of target 
genes (Figure 2.13). 
Table 2.13: PCR mix for RTR assays. 
Component  Concentration Volume 
PCR grade water - 4 µl 
Probes master  2x conc 10 µl 
Real time ready Assay 20x conc 1 µl 
Total volume - 15 µl 
 
 
 
 
 
 
Figure 2.13: LightCycler® 96PCR application software and system 
(www.lifescience.roche.com).  
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2.2.4 Platelet function assays 
2.2.4.1 Impact-R cone and plate analyser 
The Impact-R device tests platelet function in anticoagulated whole blood under near 
physiological conditions. The test involves the application of laminar shear stress on a blood 
sample placed on a well, using a rotating cone. This results in platelet adhesion and 
aggregation on the bottom of the well. An image analyser measures the adhered platelets and 
results are expressed as a percentage of the well surface covered by aggregates (SC %) as an 
index of platelet adhesion, and average size of the aggregates (AS µm2) as an index of 
aggregation. Figure 2.15 shows the system, components and workflow for testing samples. 
For this assay, blood samples drawn into sodium citrate vacutainers were analysed 1-hour 
post-draw (manufacturers recommend that whole blood samples should be tested not earlier 
than 45 minutes and no later than 3 hours after collection).  
2.2.4.1.2 Sample incubation and activation of platelets by applied shear force 
At 1 hour, blood samples were mixed for 1 minute at 10 rpm prior to loading on the 
apparatus. The well, cone and bell housing were set up on the instrument, and the bell was 
then removed by lifting from the side to ensure the cone was attached and placed beside the 
well. A 130 µl aliquot of the blood sample was taken from the midpoint of the blood tube 
and the sample was applied to the centre of the polystyrene well with appropriate care to 
ensure the tip did not contact the bottom of the well and that no bubbles were introduced 
(damages formation of aggregates). Immediately after the blood was placed onto the well, 
the bell housing with cone attached was placed on top. The selected programme was started 
(arterial shear rate of 1800 per second for 2 minutes was the programme used in all studies 
– This included a 15 second static time to allow sample to spread evenly across well. A 
maximum of two wells were ran at any given time.  
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2.2.4.1.3 Washing and staining 
Once the run was complete, the bell housing with the cone attached was removed and the 
collet pin was pulled to release the cone into a waste container. Excess red cells/white 
cells/plasma mix were pipetted off ensuring that the tip did not touch the well sides or 
surface. The well was then gently washed with a Pasteur pipette (wide orifice) and deionised 
water. The water was directed on the inner sidewall of the well in a circular motion. Excess 
water was then pipetted off when the well was cleaned. 500 µl of May Grunwald stain 
solution was added to the well to stain adherent platelets and incubated for 1 minute. The 
stain solution was pipetted off and the well left to dry at room temperature for 3-4 minutes. 
See Figure 2.15 for the workflow for Impact R analysis.  
2.2.4.1.4 Image analysis 
The well was inserted into the sample tray and the first image was captured. It was then 
rotated manually 6 times with an image captured at each stop point. Seven images were 
captured in total. The software analysed the captured images by eliminating the four least 
readable images and calculating the average of the remaining three. Results were expressed 
as SC and AS with a visual and graphical result provided for each test.  
         
 
Figure 2.15: The Impact-R cone and plate device.  Left: Impact R Cone and Plate Device with 
attached microscope. Right: Workflow for sample analysis using the Impact-R. 
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2.2.4.2 Flow cytometry 
Flow cytometry is a sensitive technology which can give a quantitative and qualitative 
measurement on the size, complexity and condition of an individual cell. As the name 
suggests, it involves flowing single cells through a capillary past a point of detection. 
Detection is typically achieved through use of lasers and detectors. The technology has been 
increasingly used in platelet studies enables studies of a multitude of cell functions such as 
apoptosis, cell surface markers, platelet function and mitochondrial assays. Forward scatter 
is a measure of the size of the cell, whereas side scatter refers to the granularity of the cell. 
Fluorescence is the property of a molecule to absorb light and re-emit it at a different 
wavelength. This is depicted in Figure 2.16. 
Flow cytometry experiments in this thesis were performed on either the FACS Aria or the 
Accuri C6 (Physical inactivity and dry immersion study). To ensure day-to-day sample 
reproducibility, all cytometers were calibrated daily.  
 
 
Figure 2.16: The principle of flow cytometry. Single cells flow through a capillary past laser 
detector, emitting light scatter and fluorescence. (www.abcam.com). 
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2.2.4.2.1 VASP/P2Y12 phosphorylation assay 
VASP (vasodilator stimulated phosphoprotein) is an intracellular actin-binding protein 
expressed at high levels in platelets and negatively regulates platelet secretory and adhesive 
functions which play a role in platelet aggregation. It is non- phosphorylated at basal resting 
state. VASP phosphorylation is regulated by cAMP (cyclic AMP). PGE1 (prostaglandin E1) 
activates this cascade whereas ADP inhibits it through P2Y12 receptors (Figure 2.17).   
 
Figure 2.17: Regulation of platelet adhesion by VASP phosphorylation.  
To determine the VASP phosphorylation state of whole blood, a standardized flow 
cytometric assay (BioCytex, France) was used. This was an  adaptation of the method of 
(Schwarz et al., 1999). The advantage of this kit was the use of small volumes of whole 
blood, allowing platelets to be analysed in their natural environment. 
 
Reagents were brought to room temperature before use and all procedures were performed 
at room temperature. The VASP-P analysis was performed within 4 h after blood collection. 
Blood samples were incubated with PGE1 alone or PGE1+ADP. After cellular 
permeabilisation, phosphorylated VASP was labelled by an indirect no wash 
immunofluorescence using a specific monoclonal antibody. Dual colour flow cytometry 
analysis allows a comparison of the two conditions and evaluation of each samples capacity 
of ADP to inhibit phosphorylation.  
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2.2.4.2.1.2 Sample processing 
Blood samples for VASP analysis were collected in 3.8% sodium citrate tubes (BD, Austria). 
10 µl of whole blood was added to three separate sterile 1.5 ml Eppendorf tubes. 5 µl of 
prostaglandin E1 (PGE1) was added to tube 1, while 5 µl of ADP&PGE1 was added to tube 
2 and tube 3. Samples were vortexed and incubated for 10 mins before fixation.  5 µl of 
fixative was added to the three tubes which were lightly vortexed and incubated for 5 
minutes. Platelets were permeabilised and labelled with a primary antibody against serine 
239-phosphorylated VASP by adding 5 µl of anti VASP-P mouse monoclonal antibody and 
permeabilisation agent to tubes 1 and 2 and 5 µl negative isotype control (mouse monoclonal 
antibody) + permeabilisation agent to tube 3. Tubes were vortexed and incubated for 5 
minutes. Fluorescent staining and platelet counter staining was performed by adding 5µl of 
polyclonal antibody anti-mouse IgG-FITC, platelet counter-staining reagent-PE (anti CD61-
PE) and permeabilisation agent to each tube. Tubes were vortexed and incubated for 5 min. 
500 µl of diluent was added to each tubes, which were then vortexed and stored at 4 °C until 
flow cytometric analysis. 
2.2.4.2.3 Flow cytometric analysis 
Tubes were vortexed briefly before analysis to ensure even sample distribution.  
The platelet population was identified by its forward and side scatter distribution and by 
expression of platelet specific antibody (CD61-PE) and 10,000 platelet events were gated. 
The median and geometric mean fluorescence intensity (MFI) of VASP-P was determined. 
When performing the flow cytometric analysis using the BD Accuri C6TM, the background 
threshold was reduced from 80,000 events to 20,000 in order to ensure all platelet events 
were identified. A threshold of 5000 was set on the BD FACS Aria for the same purpose.  
2.2.4.2.1 Results analysis 
The value of the “corrected” MFI (MFIc) for each tube was obtained. MFIc was obtained 
after subtraction of the negative control tube (T3) from the value obtained for VASP-P (tubes 
one and two). The results from this test are labelled by the manufacturer as the “platelet 
reactivity index” (PRI) expressed as a percentage change in VASP fluorescence intensity 
between resting (+PGE1) and activated (+ADP stimulated) platelets.  
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The PRI % was calculated from the median MFI using the calculation; 
PRI % = (MFIPgE1 – MFIPgE1+ADP / MFIPgE1) x 100 
For comparisons, the PRI was also calculated from the mean fluorescence intensities. The 
working range of this assay was between 0-100%.  
 
2.2.4.3 Microvesicle quantification 
The NanoSight NS300 and Syringe Pump (Figure 2.18) were used to quantify microvesicles 
(both exosomes and microparticles) in PFP samples. Nanoparticle tracking analysis 
technology (NTA) used in this device combines the properties of light scattering and 
Brownian motion to attain measurements including concentration and size distribution of 
particles in a liquid suspension. A finely focused laser beam is introduced to the sample 
(particles in dilute suspension) through a glass prism and illuminates the particles in the 
sample chamber. The particles in the beam path scatter light and are visualised by 20x 
magnification microscope fitted with a video camera. The camera functions at 30 frames per 
second and captures a video file of the particles moving under Brownian motion. The 
software tracks particles individually and uses the Stokes-Einstein equation to calculate their 
hydrodynamic diameters and particle size;  
 
Where Kb is Boltzmann’s constant, T is temperature, n is solvent viscosity, and Dt is particle 
diffusion coefficient (hence sphere equivalent).  
 
 
Figure 2.18: The Nanosight NS300 and syringe pump. (www.malvern.com). 
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2.2.4.3.1 Microvesicle analysis 
The syringe was loaded with 1ml of 10% EtoH to rinse the chamber slowly (10 second run) 
and repeated with 1ml of PBS. The cleanliness of the chamber was confirmed by checking 
for particles visible on the NTA screen and considered clean if < 3 particles were visible. 
This procedure was performed between each sample. If sample particles persisted in the 
image after rinse through cleaning, the flow-cell was cleaned manually. A 1:2500 dilution 
of PFP and high pure PBS was used after serial dilution optimisation (dilution 1= 4 µl of 
sample and 996 µl of PBS to make a 1:200 dilution, dilution 2= 100 µl of dilution 1 and 900 
µl of high pure PBS). Diluted samples were kept on ice until ran on the Nanosight.  
Video capture (camera gain and shutter speed (1206), syringe pump speed (50)) and analysis 
(background subtraction, minimum track length) setting were adjusted, allowing optimal 
particle identification for platelet poor plasma. The camera level was set to obtain an image 
that had sufficient contrast to clearly identified particles while minimising background noise. 
The sample was loaded into a fresh 1 ml syringe which was loaded into the chamber. 
Continuous pressure was applied to the syringe pump to ensure a smooth flow. Upon image 
identification on the capture screen, the focus was fine-tuned to give a sharp image of 
particles. The number and duration of captures was set to 15 x 60 second captures, providing 
15 replicates of the same sample. After the 15 videos for each sample were taken, the NTA 
software tracked the Brownian motion of individual vesicles by automatically locating and 
following the centre of each and every particle, measuring the average distance it moved per 
frame. NTA converted the distances moved into a particle size and plots accumulated results 
in real time as a particle size distribution profile. NTA analysed the raw data, and calculated 
size and concentration and displayed different particle parameters (size versus relative 
intensity versus number) against each other. 
2.2.4.3.2 Results analysis 
Settings were optimised and maintained between samples. For each 60 second video, the 
concentration and size of the particles (from 0-1000 nm) were recorded. Each video provided 
the mean vesicle size together with an estimate of the total concentration. An experiment 
summary file was automatically generated, displaying the concentration of the sample at 
each vesicle size. The sum of the concentrations at each size were calculated and the average 
taken.  
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2.2.5 Human physiological tests 
2.2.5.1 Maximal oxygen uptake (VO2 max) 
VO2 max is the gold standard for measuring aerobic fitness and is the maximum rate of 
oxygen consumption as measured during incremental exercise. This test was employed as a 
cardiovascular stressor and to measure aerobic fitness.  
Vmax machines were used to test VO2 max and were calibrated before each test. The flow 
sensor was calibrated initially where different speed strokes of the syringe were used to 
simulate different breathing rates. Before every test the oxygen and carbon dioxide analysers 
were calibrated. This ensured that all variables measured were correct and reliable. During 
the calibration three known quantities of gases are delivered to the machine.  
VO2 max was determined using an incremental treadmill protocol with open circuit 
spirometry.  The treadmill protocol was dependent on the fitness level of the subjects. For 
the adolescent’s acute exercise study, the treadmill protocol was determined by the results 
of their MSST. For the adults, a physical activity questionnaire gave an indication of their 
fitness levels and protocols were chosen accordingly.  
2.2.5.1.2 Rating of perceived exertion (RPE) 
RPE was obtained using the 15 point Borg category RPE scale (Borg, 1990). Prior to the 
test, subjects read a set standard set of perceptual scaling instructions. Low and high 
“perceptual anchors” were established during the test, which involved asking the subjects to 
assign a rating of 6 (low anchor) to the lowest exercise intensity and 20 (high anchor) to the 
highest exercise intensity. Subjects were instructed to make their own subjective assessment 
of perceived exertion relative to these minimum and maximum standards (perceptual 
anchors). 
 2.2.5.1.3 Preparing the subject 
Prior to each VO2 max test, the testing procedures were explained to the subjects. They 
signed a consent form and completed a medical history questionnaire. The RPE scale was 
explained and their height, weight, resting heart rate and blood pressure were recorded. 
Subjects wore a Polar heart rate monitor (Polar Team2 Pro, Polar Electro Inc., NY, USA) for 
the entirety of the test to record heart rate. This was clipped to a belt and worn on the centre 
of the chest. The subject was connected to the Vmax machine with the flow sensor and line 
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attached while standing on the treadmill. The head-gear was placed on the subject’s head 
and adjusted for a tight but comfortable fit (Figure 2.19). The subject placed the mouthpiece 
in their mouth ensuring a tight seal and a nose clip was placed on their nose. Subjects were 
then familiarized with the treadmill and safety instructions issued. They were instructed to 
signal a thumb down to end the test at any stage. A baseline measurement of O2 and CO2 
were taken for two minutes at rest. 
 
Figure 2.19: VO2 max test using an open circuit spirometry during an incremental exercise 
test.  
 
2.2.5.1.4 Running the VO2 max test 
All VO2 max exercise tests took place under standard laboratory conditions: 19-21 °C, 40-
55% relative humidity and with a physician in close proximity. Each protocol was tailored 
to elicit a VO2 max measurement within 8 – 12 minutes. The subject was instructed to 
straddle the treadmill until it reached starting speed, at which point they eased themselves 
onto the treadmill using the bars. There was a warm up of two minutes at 0% gradient and 
(for the adolescent’s acute exercise study, 6-8 km/h and 9 km/h for the low/moderate fit and 
high fit groups respectively), (for the adult acute study: warm up 8 km/h and speed increased 
by 2 km/h until reaching 12 km/h and at this point the gradient increased).  This warm up 
was followed by the exercise stage where treadmill speed increased by 1 km/h every two 
minutes until maximum speed was achieved. The maximum speed for the low/moderate 
group and high fit groups were 10-11 km/h and 12-13 km/h respectively (.2% every 12 
seconds). If necessary, a stage was added or removed prior to incline to tailor for the 
estimated VO2 max.  
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RPE was taken during the last ten seconds of each stage. Systolic and diastolic blood pressure 
were measured by the physician during the last minute of each stage of exercise. Heart rate 
was recorded in the last 20 seconds of each stage.  
Expired oxygen, carbon dioxide, ventilatory volume, respiratory exchange ratios and VO2 
max were determined by indirect calorimetry using the Vmax systems.  Subjects exercised 
until reaching volitional fatigue. The test was terminated by volitional exhaustion or if 
contraindications arose.  Subjects were verbally encouraged throughout the test to encourage 
maximal effort. Oxygen uptake was deemed to have peaked if two or more of the following 
criteria were satisfied (I) plateau of oxygen consumption with increasing power output 
(increase of less than 2 ml/kg/min), (ii) heart rate within 10 beats of the subjects’ age 
predicted maximum heart rate (220bpm – age in years) and (iii) respiratory exchange ratio 
>1.10. O2max was determined as the highest minute average recorded for oxygen uptake 
during the test. 
2.2.5.2 Vital signs  
2.2.5.2.1 Blood pressure and heart rate 
Subjects were required to sit upright for ten minutes after which systolic and diastolic blood 
pressure was recorded using either a fully automated arm blood pressure monitor (Omron 
M2 blood pressure monitor) (Cross-sectional study) or manually using a  mercurial 
sphygmomanometer (Dekamet Accoson Sphygmomanometers, Harlow Essex) and 
stethoscope (Classic II 3M Littmann, St. Paul, MN) (Acute exercise study) Heart rate was 
measured using automated HR monitors which were placed around subjects chests.  
2.2.5.3 Anthropometric measurements 
2.2.5.3.1 Height and weight 
Height (m) was measured to the nearest centimetre and weight (kg) was measured to the 
nearest 0.1 kg. Both were measured in light clothing without shoes.  
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2.2.5.3.2 Body composition 
Body composition is a key component of health in both individuals and populations. 
Different methods were applied in order to obtain body composition measurements. 
Circumferences, bioelectric impedance analysis (BIA) and BMI measurements were 
performed to estimate body composition.  
2.2.5.3.3 Body mass index (BMI) 
BMI was used to measure weight relative to height and was calculated by dividing body 
weight in kilograms by height in meters squared (kg▪m-2). It was determined by the following 
formula: 
BMI = Weight (kg)/Height (m2) 
2.2.5.3.4 Circumferences 
The pattern of body fat distribution is recognized as an important predictor of the health risks 
of obesity. Android or visceral obesity which is characterized by more abdominal fat is 
linked with an increased risk of hypertension, metabolic syndrome, coronary artery disease 
etc., compared with those who show fat distributed in the hip and thigh (gynoid or gynaecoid 
obesity). Waist circumference was used as another measure of abdominal obesity. Subjects 
stood upright with their feet together. Waist circumference was measured with the subject 
standing arms at side, feet together and abdomen relaxed and a horizontal measure taken at 
the narrowest part of the torso.  
2.2.5.3.5 Bioelectrical impedance analysis (BIA)  
Techniques of BIA are used for general health fitness testing and body composition 
monitoring. The Tanita SC-331S Body Composition Analyser (Figure 2.20) is a medical 
device that uses Bioelectrical Impedance Analysis (BIA) technology with a scales and 
control panel. Subjects removed their shoes and socks and stood on the scales for the 
measurement. An electrical signal (50 kHz, 90µA) was sent through the body via 8 pressure 
contact electrodes, positioned to ensure that the electric current was supplied from the 
electrodes on the tips of the toes of both feet, and voltage was measured on the heels of both 
feet. The current then flowed into the lower limbs.  
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Fat allows little electricity to pass through, whereas water found in muscles allows electricity 
to pass through easily. Electrical resistance is the degree of difficulty with which electricity 
passes through a substance and the percentage of fat and other body constituents can be 
calculated from this measurement of resistance. The machine provided a result sheet in 20 
seconds with readings for the following parameters of physiological health; weight, 
impedance, body fat percentage, fat mass, fat free mass, total body water percentage, total 
body water mass, muscle mass, basal metabolic rate (BMR), metabolic age, bone mass, 
visceral fat rating and BMI.  
 
 
 
Figure 2.20. Tanita SC-331S body composition analyser and height measurement apparatus. 
(www.tanita.com). 
 
2.2.5.4 Physical inactivity model - dry immersion method  
A European Space Agency (ESA) funded Dry Immersion (DI) study was used to investigate 
physical inactivity. DI studies, along with bed rest studies are utilised as an important 
platform to prepare for future human exploration in space. Additionally, they provide a 
unique experimental design to investigate human physiology in the setting of extreme 
physical inactivity. This DI study took place from Jan 2015 – Feb 2015 in the Medes Clinic, 
Toulouse, France. All subjects provided informed consent in compliance with the Helsinki 
Declaration. The experimental protocol was approved by the local ethics committee (CPP 
Sud-Ouest Outre-Mer I, France) and the French Health Authorities. The study was 
conducted and organised by the Institute for Space Medicine and Physiology (MEDES) 
Toulouse, France. 
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2.2.5.4.1 Subject recruitment  
Subjects were recruited by internet advertisement on the MEDES website 
(http://www.medes.fr/en/index.html) and by media advertisements.  
2.2.5.4.2 Subject selection 
This section was carried out in two phases. The preliminary selection was based on 
applications files comprised of two questionnaires on 1) the subject’s way of life, education 
and professional experience; and 2) the subject’s medical background, both personal and on 
his family. 24 volunteers were pre-selected based on their applications, to have a final 
selection of 14 volunteers (12+2 backup). The second selection phase consisted of a visit to 
the Medes Space Clinic where subjects underwent clinical and paramedical examinations.  
This included the following measurements;  
 Medical and surgical history including habits, alcohol, caffeine intake, smoking 
status, previous/current medication 
 A complete clinical examination including an electrocardiogram test (ECG) 
systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR) 
performed in both a supine position and a standing position after both 3 and 10 
minutes (stand test). These tests checked for the absence of orthostatic 
hypotension. 
 A measurement of maximal oxygen consumption (VO2 max test) 
 A DEXA measurement of bone density 
 An alcohol breath test 
 A biological screening comprising of biochemistry, urine drug screen 
haematology, molecular screening (research for the factor V Leiden mutation and 
prothrombin gene. A positive result for phlebitis markers or the presence of one 
of these mutations was considered as an exclusion criteria) serology, urine drug 
screen, urinalysis, and vitamin and mineral status.  
 
The full Dry Immersion Inclusion and Exclusion Criteria is listed in Appendix C. 
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2.2.5.4.3 Hospitalisation periods 
When the final 12 subjects were certified healthy by the comprehensive medical assessment, 
they began their participation in the study. Each subject attended the clinic twice.  A first 
hospitalization of one day (7 am to 7 pm) was required to perform a muscle biopsy and to 
take blood samples. One/two weeks later, the main hospitalization period of 8 days began. 
This phase was organised as follows; each 3-day immersion began with a four-day 
ambulatory control period (BDC: Baseline data collection). Subjects arrived on BDC-4 and 
during this period, subjects were allowed to be ambulatory during the day while remaining 
in the clinic for baseline evaluations. This was followed by a 3 day DI plus two recovery 
days. 
2.2.5.4.4 Verification of selection criteria  
 
The subjects completed an interview and complete clinical examination on their day of 
arrival to check the permanence of the selection criteria. A second biological screening was 
performed during the baseline data collection (BDC) period to ensure that all parameters 
were still within the normal range.  
 
2.2.5.4.5 Daily medical supervision 
Adherence to all study rules were controlled by the study nurse manager. Additionally, 
compliance with the study requirements were monitored with 24-hour video surveillance 
using random real-time control. During each hospitalisation phase, the daily medical 
supervision included the following measurements; 
 A clinical assessment 
 Arterial BP measurements and HR measured twice daily at 6.30am and 6.30pm 
 Weight was recorded three times daily using a scales (weighing trolley) designed to 
weigh subjects in the bed rest position 
 Body temperature was measured with a tympanic thermometer twice daily 
 Hydric intake and 24-hour dieresis  
 Body temperature monitoring  
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2.2.5.4.6 Dry immersion method 
 
DI involves immersing a subject in thermoneutral water, covered with a waterproof fabric 
(Figure 2.21). Consequently, the immersed person, who is freely suspended in the water, 
remains dry. For a relatively short duration, the model can realistically reproduce the 
physiological effects of microgravity, hypokinesia and therefore, act as model of physical 
inactivity.  
 
The experiment was performed in a specially designed bath filled with tap water. The bath 
was 2.2 m long, 1.1 m wide and 0.85 m deep. A unique highly elastic waterproof fabric was 
attached to a metal rim around the external margin of the bath. The area of the fabric greatly 
exceeded the area of the water surface (if the bath was empty, the fabric would reach the 
bottom). The bath contained a built in lift for lowering and raising the subject. Subjects were 
dressed in under garments and placed on the waterproof fabric (after the fabric was first 
covered by a cotton sheet for hygiene reasons). Subjects were slowly lowered into the water 
on the lift and their bodies were gradually covered with the folds of fabric, together with the 
water they contained. The fabric is thin and of sufficient area to allow the subject to appear 
to be freely suspended in the water mass, under conditions that are similar to a complete lack 
of structural support. The subjects were allowed to put their hands out to eat, drink, work 
with a computer and perform experimental tasks.  
The water temperature was regulated automatically and was initially set to 32-24.5 °C 
(thermoneutral) and adjusted for comfort within those limits at the subject's request. The air 
temperature was approximately 24 °C to maintain the heat balance when subjects were raised 
from the bath. The subjects remained under constant medical observation 24 hours a day. 
For physical tests, the folds of fabric could be moved apart without changing the 
experimental conditions substantially.  Subjects followed a “normal” day/night cycle and 
were woken at 6.30 am and light was turned off at 11 pm. There was no artificial light. 
 
 
 
 
 127 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.21: The Dry immersion (DI) method. Subjects were immersed up to the neck and 
separated from the water with the unique waterproof fabric. (Right figure from Navisaslova et al. 
2011). 
 
2.2.5.4.7 Nutritional intake 
 
To reduce confounding factors on those being investigated, nutritional intake was quantified 
and monitored during the study. Food was selected and supplied in order to characterise its 
contents through standard nutritional databases. Dietary intake was quantified by measuring 
the weight of each dish before and after each meal and by calculating the intake for each 
nutrient. The calculation of the food content was done using a database specifically built 
from validated European databases. Subjects received three main meals and one snack per 
day. On the first hospitalisation day, subjects BMR was calculated in kcal/day using the 
WHO equation; 
 
Age<30y: BMR=15.3 x body weight (kg) + 679 
Age>30y: BMR=11.6 x body weight (kg) + 879 
 
The reference weight was the weight measured on the morning on BDC-3, before breakfast 
and after the first void. During the pre-immersion period and the recovery ambulatory period, 
caloric intake was equal to 160% of BMR. During the immersion period, caloric intake was 
equal to 130% BMR. The measured BMR was used for diet planning instead of the 
calculated value whenever it was feasible to do so. Macronutrient intake was controlled to: 
protein 1-1.2 g/KGBW/day, total fat 35-38% TEE and carbohydrates: remaining.  
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Electrolyte intake was controlled to; sodium: 2000 – 4500 mg/day, potassium: 3000 – 5000 
mg/day, calcium: 900-1200 mg/day chloride: 750 - 4500 mg/day. Liquid intake was 
controlled; between 35 and 50ml/kg/day (total water taking into account beverages and 
food). No coffee, tea or alcohol were allowed. As part of the study rules, there was a 
requirement to finish all meals.  
2.2.5.4.8 Leisure time 
During the entire experiment, subjects had to perform extensive scientific tests. There was 
free time between these and subjects were permitted various leisure activities including 
reading and computer activities. No nap was allowed during the pre and post immersion 
periods. The subjects were allowed to make phone calls to family after scientific tests and 
between 6 pm – 11 pm each day.  
2.2.5.4.9 Blood sampling and assays  
A total of 45 ml of blood was taken at the selection phase and a total of 420 mls of blood 
was taken throughout the study, with an allocation of 13.5 mls of blood for platelet function 
analysis at selected time points.   
2.2.5.4.10 Medical check-up post experiment 
At the end of the second hospitalisation period, subjects underwent a final clinical 
examination including blood pressure and heart rate measurements in supine and after two 
and five minutes in the upright position to re check orthostatic tolerance. Furthermore, 
recommendations for physical training to allow for full recuperation was advised to each 
subject.  
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2.2.5.4.11 Visual analogue Scale 
The VAS scale is an ease of use measurement of pain intensity (Hawker et al., 2011) 
including a horizontal line, 10cm in length with a verbal descriptor at each end to highlight 
symptom limits (Figure 2.22). The subjects completed the scale each day during the DI. 
Using a ruler, the subject marked a point on the line to best represent their pain intensity. 
The distance from “pain free” to their mark is measured in millimetres (mm) and provides 
their VAS score (1-100).  
 
Figure 2.22: The visual analogue scale.  (Image from Hawker et al., 2011). 
 
2.2.5.5 Acute exercise methods  
2.2.5.5.1 Adolescent population 
In conjunction with an ongoing research study in the school of health and human 
performance school, male adolescents were recruited for testing procedures. The 
experimental protocol was approved by the Dublin City University Ethics committee.  
2.2.5.5.1.1 Research design 
Contact was made with principals of post primary schools within the greater Dublin area to 
provide a brief outline of the study. Cluster sampling was used to recruit male, consensual 
adolescents of varying physical fitness and in transition year, from schoolsclose to DCU. All 
subjects were recruited based on fitness level, proximity to DCU and their willingness to 
participate. Ethical approval was obtained from the Dublin City University Research Ethics 
Committee. 
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Exclusion criteria: 
 Failure to present an informed consent form signed by a parent/guardian 
 current smokers, 
 Medical condition which prevented them from engaging in exercise 
 Systolic BP >180 mmHg and/or diastolic BP >100 mmHg.  
 
The first school visit provided detail on the study, physical activity readiness questionnaire 
(PAR-Q), informed consent forms to be completed by the student and parent/guardian. Each 
student received forms on the study and testing procedures.  
The second school visit included a 20 m multi stage shuttle test (MSST) during a physical 
education class. The MSST required students to run back and forth between two lines 20m 
apart, while keeping time to a series of audio signals or “bleeps” from a CD. Initial running 
speed was 8.0 km/hr and increased every minute by .14 m.s-1. A test was ended if the student 
voluntarily dropped out or was unable to maintain the set pace and failed to reach the line 
for two consecutive shuttles. Subjects wore heart rate monitors to provide data on maximum 
age predicted heart rate during the MSST to ensure that they were not dropping out for 
reasons other than fatigue.  
The scores from the 20m MSST were used to provisionally categorise subjects into groups 
of fitness (Low/moderately fit or high fit) categories using percentile data proposed by 
FITNESSGRAM and used on data collection during a 20 m MSST as part of the HELENA 
(Healthy Lifestyle in Europe by Nutrition in Adolescence) Study (Moreno et al., 2014), 
illustrated in Table 2.14. This was subsequently used to determine the VO2 max treadmill 
protocol that subjects used during their visit to the health and human performance (HHP) 
labs in DCU. 
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Table 2.14: Percentile norms for low, moderate and high fit adolescent males  
aged 15-17 years. 
Gender Age Low Fit Moderately Fit High Fit 
Male 15 3.2-4.3 5.9-7.3 8.9-13.3 
Male 16 3.3-4.3 5.8-7.2 8.7-12.8 
Male 17 3.4-4.5 6.1-7.5 9.1-13.2 
 
2.2.5.5.1.2 Visit to DCU HHP labs 
On completion of the MSST and consent, the selected subjects came to DCU at 9am 
following an overnight fast. Anthropometrics and body composition was assessed by 
standard procedures as explained previously. Resting BP and electrocardiogram (ECG) were 
recorded to ensure no contraindications to exercise were present. Blood samples were drawn 
at selected time points. Fitness categories used to separate groups was based on VO2 max 
(ml/kg/min) values using the percentile data from a study undertaken on youths aged 12-19 
years illustrated in table below: The percentile cut off for the high fit group was determined 
as >53.0 and <48.0 for the moderate/low fit. 
Table 2.15: Deciles of estimated VO2 max for adolescents by sex and age group.  (Adapted from 
Eisenmann et al., 2011). 
 
Mean VO2 max (ml/kg/min) 
Age Percentile 
 10th 20th 30th 40th 50th 60th 70th 80th 90th 
14-15 
years 
38.1 
(36.8-
39.4) 
40.0 
(39.5 
– 41.) 
41.9 
(40.3-
43.6)  
43.8 
(42.6-
45) 
45.8 
(44.2-
48.1) 
48.2 
(46.6-
49.3) 
50.2 
(48.5-
51.5) 
52.5 
(51.3-
54.4) 
58.8 
(54.9-
61.7) 
16-17 
years 
36.4 
(35.0-
37.8) 
38.9 
(38.2-
41/0) 
42 
(41.0-
43.5) 
44.4 
(42.8-
45.9) 
46.2 
(45.1-
47.3) 
47.9 
(46.5-
49.4) 
50.2 
(48.8-
51.9) 
53.8 
(51.5-
55.4) 
58.3 
(56.8-
60.5) 
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2.2.5.5.2 Adult population 
Healthy males were recruited from the School of Health and Human performance. Subjects 
were informed of testing protocols and procedures prior to consenting. All subjects adhered 
to the same pre testing protocol; no strenuous exercise 24 hrs pretesting, no consumption of 
alcohol 48 hrs prior and free of NSAID consumption. Prior to testing all subjects complete 
a general questionnaire to ensure suitability for testing and signed consent forms. This testing 
procedure followed the same principle as the adolescent population. Subjects arrived in the 
HHP at 9am fasting and lifestyle data was collected. Anthropometric, body composition 
measurement, resting heart rate (RHR) pressure (BP) were taken at different time points. 
Blood samples were drawn at selected time points. 
2.2.6 Statistical analysis 
Results are expressed as mean ± SD. Statistical comparisons were performed using a variety 
of tests, depending on the experimental procedure. Main tests included independent t-tests, 
paired samples t-tests, repeated measures analysis of variance (ANOVA) and one-way 
ANOVA. Pearson product coefficient and partial correlations were used to examine 
relationships between variables. Statistical significance was set at a level of 0.05. SPSS v19 
statistical package was used to analyse results.  
To control for potential covariates which could act as a confounder (a variable whose 
presence affects the variables being analysed) such as age, analysis of covariance 
(ANCOVA) was used in place of ANOVA and partial correlations were used in place of 
Pearson product coefficient variables. For example, to assess the relationship between 
platelet count and BMI, a Pearson product coefficient was used. However, if it was suspected 
that a third variable may influence this relationship (e.g. age), a partial correlation was used. 
In this procedure, SPSS controls for the effect of the third variable, also known as a covariate 
using a unique algorithm. Similarly, analysis of variance (ANOVA) was the statistical model 
used to identify differences between the means of three or more groups. Analysis of 
covariance (ANCOVA) is a more complex form of ANOVA, which is used to observe the 
difference between the means of three groups, while controlling for the variability of other 
variables. This statistical procedure was used when a covariate (such as BMI, VO2 max) 
were suspected to influence the means. SPSS uses a specific algorithm to compute this data 
(Green and Salkind, 2010).  
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Chapter Three 
Outputs:  
 High platelet counts and plateletcrit were associated with measures of overweight 
 Platelet adhesion was significantly increased in both males and females with an 
overweight BMI 
 BMI and body fat percent were the most sensitive adiposity measures in reflecting 
the changes in platelet parameters, whereas waist circumference was specific for 
alterations in females only 
 There were variances in platelet indices and function according to fitness levels. As 
fitness levels decreased, platelet indice values increased. This was particularly 
relevant to males 
 
Contributions from others: 
 Sysmex Ireland kindly provided the Sysmex XS-1000i automated haematology 
analyser which was used throughout this study 
 Science Gallery, Trinity College Dublin facilitated the exhibition “Fat” providing 
the platform for a large population to be recruited for the study 
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Chapter Three: A Cross-sectional Study of Platelet Function and 
Lifestyle Factors 
3.1 Introduction 
The pathogenesis of atherosclerosis in CVD is multifactorial and evidently, lifestyle factors 
including physical activity, smoking, diet and obesity exert significant influences on CVD. 
Sedentary behaviour and concordantly, obesity, represent a growing problem worldwide 
whose prevalence has more than doubled between 1980 and 2014. Subsequently, it is one of 
the biggest health burdens in the world and Ireland. Metabolic syndrome (metS), a condition 
epitomising a group of cardiometabolic risk factors including central obesity, hypertension 
and insulin resistance, is also an increasing concern (Depres and Lemieux, 2006; Esser et 
al., 2014).  
Platelets are versatile cells that have a pivotal role in atherosclerosis, not only due to their 
influence in haemostasis but also as a result of their cytokine, chemokine, growth factor and 
proinflammatory mediator release (Lievens et al., 2011). Therefore, they are intricately 
involved in inflammation, one of the most important pathogenic mechanisms of 
atherosclerosis. Importantly, some CVD risk factors are found to be elevated years before 
manifestation of acute events and cardiovascular dysfunction is implicated in early stages of 
disease.  
Most studies demonstrate that platelet function is altered in CVD or in obese individuals 
displaying risk factors for CVD (Santilli et al., 2011). Whilst it is known that platelet indices 
and markers of platelet health are expressed differently in diseased populations (Goshal, 
2014), only a minority of studies have solely examined the relationship between overall 
physiological health and platelet function in healthy subjects. Platelet indices have been 
recently investigated as possible biomarkers for a range of diseases including inflammatory 
bowel disease (Ozturk et al., 2013), severe endometriosis (Avioglu et al., 2014), malaria 
(Leal-Santos et al., 2013), CVD in arthritic patients (Jurcut et al., 2010), Alzheimer’s disease 
(Wang et al., 2013) and as early predictors of growing risk of cardiovascular complications 
in Diabetic and Non-Diabetic subjects (Ashraf et al., 2015). This study explored the 
feasibility of platelet indices and whole blood platelet function measurements, as useful, 
non-invasive initial biomarkers of early/subclinical CVD risk and unhealthy lifestyle. 
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3.1.1 Chapter aims and experimental approach 
This cross-sectional study was carried out to investigate associations between risk factors of 
CVD (including obesity/overweight and physical (in) activity), overall physiological health, 
and platelet function.  
Hypothesis: 
Platelet function and platelet indice markers will be elevated in subjects with unhealthy 
lifestyle habits, in particular with regard to those who are overweight and physically inactive. 
Main aims: 
 The primary aim of the study was to elucidate if platelet function is related to 
overall physiological health, and to investigate the relationship between platelet 
function and lifestyle factors 
 A secondary aim was to establish if the Impact-R cone and plate device is a 
reliable device to measure platelet function across a heterogeneous population. 
 To determine if platelet indices could be employed as biomarkers of health in a 
disease-free population 
3.1.2 Study design 
Platelet function was profiled in apparently healthy adults (n=155) between 18 and 90 years 
to determine the relationship between platelet function, platelet count, and various 
parameters of physiological health, reflective of lifestyle, including but not limited to BMI, 
waist circumference, body fat percentage, visceral fat and physical (in) activity levels.  
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Subject recruitment 
This study took place from May-June, 2014 in the Science Gallery, Trinity College Dublin, 
in conjunction with an exhibition “Fat” which explored all aspects of obesity. It was a 
completely randomised selection of subjects. Subjects visited the gallery and were informed 
about the various tests by different researchers (see https://dublin.sciencegallery.com/fat) for 
more information. There was a seven-day reflection period before consenting to various 
tests, in which subjects were provided with information and returned one week later for 
voluntary testing. All subjects gave informed consent. This study received ethical approval 
from the Faculty of Trinity Health Science and Dublin City University ethics boards. Each 
subject provided a citrated blood sample for analysis. 
Assessment of covariates 
Participants provided information on demographic characteristics and lifestyle habits by 
completing questionnaires (Appendix A). Information on race was categorized as Irish, any 
other white background, Asian or Indian. Smoking status was defined as current, past, or 
never smoker. Information was obtained on individuals’ perception of their own physical 
fitness/physical activity levels. This was measured using a scale from 1-5, 1 being unfit and 
5 being very fit. Participants self-reported any medication use, or NSAID intake in the 
previous 10 days. 
 
Blood sample  
A single blood sample was taken from each subject in a resting position. Blood was obtained 
by standard venepuncture from the antecubital forearm vein and collected into vacutainer 
tubes containing 3.2% sodium citrate. Platelet, Erythrocyte and Leukocyte indices were 
measured by the Sysmex XS-3000i. 
Platelet function 
Two parameters of platelet function were evaluated using the Impact R: surface coverage 
(SC, %) representing platelet adhesion, and the average size (AS, μm2) of the polystyrene 
bound platelet clusters/aggregates representing platelet aggregation. 
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3.2 Results 
3.2.1 Characteristics of the study population 
In total, 155 subjects volunteered to partake in this study. The age range of the subjects was 
18-90 years (Figure 3.1). Except for BMI, there was a significant difference between 
anthropometric and body composition characteristics between males and females, shown in 
Table 3.1 below. Medication, Cardiovascular and Demographic characteristics are shown in 
Tables 3.2, 3.3 and 3.4 respectively. Haematological characteristics are displayed in Table 
3.5. 
Table 3.1:  Anthropometric and body composition characteristics of the subjects. Values are 
mean ± SD. BMI - Body mass index, VAT - Visceral adipose tissue, WC - Waist circumference, 
TBW - Total body water, BMR - Basal metabolic rate. *P<0.05. Independent t-test. See appendix A 
for reference ranges for these parameters.  
 
       Gender  
 Male 
n=68 
Female 
n=87 
P value  
Age (years) 37.4 ± 17.47 39.4 ± 17.66 .850  
Height (cm) 176.6 ± 7.98 166.3 ± 669 *  
Weight (Kg) 76.8 ± 10.44 66.9 ± 9.79 *  
BMI (kg/m2) 24.8 ± 4.48 24.3 ± 4.17 0.298  
Body fat (%) 18.63 ± 5.56 28.88 ± 7.69 *  
Visceral adipose tissue 6.1 ± 5.77 4.4 ± 3.12 *  
WC (in) 34.9 ± 3.45 33.05 ± 3.75 *  
Fat mass  14.1 ± 5.27 20.8 ± 7.32 *  
Fat free mass 63.5 ± 6.34 46.1 ± 3.88 *  
Muscle mass 60.4 ± 6.05 43.9 ± 3.65 *  
TBW (%) 56.7 ± 4.03 49.7 ± 5.09 *  
Bone mass  3.19 ± 0.68 2.14 ± 0.88 *  
BMR (kcal)      7802 ± 885 5859 ± 524 *  
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Figure 3.1: Distribution of age in the study population. The youngest subject was 18 years and 
oldest aged 90, with the average age falling between 20-35. 
 
 
Table 3.2:  Medication characteristics of the subjects. Values are numbers of participants taking 
medication. NSAIDS – Non-steroidal anti-inflammatory drugs.  
 
 
 Gender 
 Male Female 
Statins 2 3 
Blood pressure 3 3 
NSAIDS 0 3 
Contraceptive pill 0 45 
Insulin 0 1 
Antiplatelet 1 1 
Anaemia  0 2 
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Table 3.3: Blood pressure and resting heart rate characteristics of the subjects. Values are mean 
± SD. SBP - Systolic blood pressure, DBP - Diastolic blood pressure, RHR - Resting heart rate. 
*P<0.05. Independent t-test and one-way analysis of covariance (ANCOVA) adjusting for age.  
 
 Gender  
 Male Female P value 
SBP (mmHg)  121 ± 16.53 116 ± 14.93 0.082 
DBP (mmHg) 73 ± 9.22 72 ± 11.33 0.486 
RHR (bpm) 70 ± 11.36 76 ± 13.14 * 
 
 
Table 3.4: Demographic and lifestyle characteristics of the subjects. Values are percentage of 
subjects in each category. AOWB – Any other white background, including Asian and Indian.  
 
  Gender 
  Male  Female  
Physical activity levels    
 Unfit 15% 13% 
 Fairly fit 54% 42% 
 Fit – very fit 30% 46% 
Smoking status    
 Non-Smoker 83% 79% 
 Smoker 8.5% 8% 
 Past smoker 8.5% 13% 
Ethnicity    
 Irish 65% 79% 
 AOWB 29% 15% 
 Other 6% 6% 
 
 
 
 
 
 141 
 
Table 3.5:  Haematological characteristics of the subjects. Values are mean ± SD. WBC - White 
blood cell count, RBC - Red blood cell count, HGB - Hemoglobin, HCT - Haematocrit, MCV - Mean 
corpuscular volume, RDW - Red cell distribution width. *P<0.05. One-way ANCOVA adjusting for 
age. 
 
  Gender  
 Reference range Male Female P value 
WBC (106/µl) 3.98 – 10.04 6.17 ± 1.64 6.25 ± 1.51 0.750 
RBC (106/µl) 3.9 -  6.1 4.50 ± 0.65 4.05 ± 0.43 * 
HGB (g/dL) 11.2 – 17.5 13.85 ± 1.58 11.96 ± 1.26 * 
HCT (%) 34.1 – 51.0 40.07 ± 4.25 35.76 ± 3.30 * 
MCV (fL) 79.0 – 94.1 88.61 ± 3.51 89.74 ± 5.42 0.090 
RDW (fL) 35.0 – 46.3  40.26 ± 4.22 41.22 ± 2.53      * 
 
 
3.2.2 Comparison of platelet parameters according to gender  
 
In order to assess the variance in platelet indices and function according to gender, 
comparisons between male and female subjects were performed. As shown in Table 3.6, 
although all platelet indices were elevated in females, there was no statistical difference 
between gender. Table 3.7 compares platelet function values between gender and showed no 
statistically significant difference between platelet adhesion/aggregation in male and female 
subjects. 
 
Table 3.6: Platelet indice characteristics of the subjects. Values are mean ± SD. PLT - Platelet 
count, PDW -  Platelet distribution width, MPV- Mean platelet volume, PLCR - Platelet large cell 
ratio, PCT - Plateletcrit. One-way analysis of covariance (ANCOVA) adjusting for age. 
 
 
  Gender  
 Reference range Male Female P value 
PLT (103/µl) 160.0 – 400 192 ± 40.88 200 ± 42.05 0.285 
PDW (fL) 9.3 – 16.0 11.29 ± 1.77 11.47 ± 1.87 0.317 
MPV(fL) 8.8 – 12.50 10.11 ± 0.81 10.26 ± 0.89 0.269 
PLCR (%) 1-2 25.6 ± 6.52 26.8 ± 6.11 0.236 
PCT (%) 19 – 40 19.2 ± 4.01 20.4 ± 4.23 0.080 
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Table 3.7: Platelet function characteristics of the subjects. Values are mean ± SD. SC - Surface 
coverage, AS- Average size. One-way ANCOVA adjusting for age.  
 
 Gender  
 Male Female P value 
SC (%) 12.27 ± 3.02 11.84 ± 3.25 0.471 
AS (µm2) 42.7 ± 21.23 43.9 ± 20.54 0.432 
 
3.2.3 Body composition measurements of obesity/overweight 
To assess the relationship between platelet parameters and adiposity, several body 
composition measurements were performed including BMI, Waist circumference and 
bioelectrical impedance analysis. Correlation analysis and comparisons between subjects of 
varying body composition allowed us to examine variances in platelet parameters.  
 
3.2.3.1 Body Mass Index (BMI) 
136 subjects chose to have their BMI measured. To explore the relationship between BMI 
and platelet parameters, correlations analysis was performed (Table 3.8). The most pertinent 
finding was the significant positive correlation between BMI and PLT, BMI and PCT and 
BMI and SC in females as shown in Figure 3.2. The WHO (World Health Organisation) 
scale for BMI was utilised to categorise subjects based on BMI, illustrated in Table 3.9. 
Comparisons were then performed to examine the variance in platelet indices according to 
BMI categories highlighted in Figure 3.3, with significant increases in platelet adhesion in 
the overweight group in both genders.  
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Table 3.8: Correlation between BMI and platelet parameters. PLT - Platelet count, PDW - 
Platelet distribution width, MPV - Mean platelet volume, PLCR - Platelet large cell ratio, PCT – 
Plateletcrit, SC – surface coverage, AS – Aggregate size. *P<0.05. Partial correlation adjusting for 
age. 
 
 Platelet parameter 
  PLT PDW MPV PLCR PCT SC AS 
BMI Male .251 -.254 -.259 -.271 .132 .277 .060 
 Female .319* -.018 -.088 -.053 .351* .332*     .124 
 
 
Table 3.9: BMI categories. Values are the number and percentage of participants in each category. 
 
BMI category and reference range 
 Healthy 
18-24.9 kg/m2 
Overweight 
25-29.9 kg/m2 
Obese 
30+ kg/m2 
Male 46% (32) 33% (29) 8% (5) 
Female 63% (55) 22% (20) 9% (8) 
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Figure 3.2: Correlation between BMI and platelet parameters in females. A - Platelet count and 
BMI, B - Plateletcrit and BMI, C - Platelet adhesion and BMI, D -  Platelet aggregation and BMI, E 
-  Platelet distribution width and BMI, F – Mean platelet volume and BMI.  
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Figure 3.3: Comparison of platelet parameters between healthy and overweight subjects 
according to BMI. Graphs represent mean ± SD variance in A – Platelet count, B – Plateletcrit, C -  
Platelet adhesion and D – Platelet aggregation. *P<0.05. One-way ANCOVA adjusting for age. 
* * 
* * 
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3.2.3.2 Waist circumference (WC) 
Most of the study population (n=120) consented to have WC measurements taken and 
therefore were included in this analysis. To examine the association between WC and 
platelet parameters, correlations between variables were performed and are shown in Table 
3.10. The main findings include a significant relationship between PLT and WC, plateletcrit 
and WC and platelet adhesion and WC in female subjects only, shown in Figure 3.4. To 
compare variances in WC, subjects were categorised using the disease risk criteria for waist 
circumference in adults (Bray GA 2004) outlined in Table 3.11. When stratified by WC, 
results show a significant difference in PLT, PCT and platelet adhesion between low and 
high risk groups in females (Figure 3.5). 
 
Table 3.10: Correlation between waist circumference and platelet parameters. PLT - Platelet 
count, PDW -  Platelet distribution width, MPV - Mean platelet volume, PLCR - Platelet large cell 
ratio, PCT – Plateletcrit, SC – surface coverage, AS – Aggregate size. *P<0.05. Partial correlation 
adjusting for age. 
 
 Platelet parameter 
   PLT PDW MPV PLCR PCT SC AS 
WC Male  .174 -.054 -.055 -. 067 .001 .275 .071 
 Female  .305* .015 .060 .044 .295* .310*  .121 
 
 
Table 3.11: Proportion of subjects in each waist circumference category. Values are 
percentages and numbers of subjects in each category. 
 
Waist circumference (in) and reference ranges 
Risk category Female  Male  
Very low < 28.5  0 < 31.5  0 
Low 28.5 - 35.0  75% (51) 31.5 - 39.0 82% (42) 
High 35.5 - 43.0 23.5% (16) 39.5 - 47.0 16% (8) 
Very high  > 43.5 2.9% (2) > 47.0 2% (1) 
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Figure 3.4: Correlation between waist circumference and platelet parameters in females. 
Scatterplot A - relationship between PCT and WC, B - relationship between platelet adhesion and 
WC, C-  PLT and WC, D -  MPV and WC, E – Aggregation and WC and F – PDW and WC. 
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Figure 3.5: Comparison of platelet parameters between low and high risk waist circumference 
groups. Graphs represent mean ± SD. A -  Platelet count, B – Plateletcrit, C -  Platelet adhesion, D -  
Platelet aggregation. *P<0.05. One-way ANCOVA adjusting for age. 
* * 
* 
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3.2.3.3 Bioelectric impedance analysis (BIA) 
Bioelectric impedance analysis was utilised to measure multiple components of body 
composition including weight, body fat %, fat mass, fat free mass, total body water %, 
muscle mass, basal metabolic rate, bone mass and a unique indicator called visceral adipose 
tissue (VAT) which measures visceral fat. The Tanita SC-331S body composition analyser 
provided healthy range indicators which compares several measurements to their respective 
healthy range. To assess the associations between the BIA measures and platelet parameters, 
correlation analysis was performed. Table 3.12 displays correlations between platelet indices 
and BIA measurements. Figure 3.6 shows scatterplots of selected associations. The platelet 
volume indices MPV, PDW and PLCR were inversely correlated with BF, VAT, FM and 
positively correlated with MM, TBW in males. In females there was no correlation between 
the platelet volume indices and BIA measurements.  
 
Table 3.12: Correlation between Tanita body composition measurements and platelet 
parameters. PLT- Platelet count, PCT – Plateletcrit, SC - Surface coverage, AS - Aggregate size, 
BF % - body fat percent, VAT - Visceral adipose tissue, FM - Fat mass, FFM - Fat free mass, MM - 
Muscle mass, TBW % - Total body water percent, P<0.05. Partial correlation adjusting for age.  
 
BIA Body Composition Measurement 
Male  BF VAT FM FFM MM TBW 
PLT .295* .262 .245 .034 .007 -.289* 
PCT .178 .137 .245 -.044 .053 -.206 
SC .345* .065 .313* -.244 -.244 .136. 
AS .106 .160 .067 -.253 -.254 .304* 
Female BF VAT FM FFM MM TBW 
PLT .265* .301* .216* -.045 -.016 -.194 
PCT .226* .293* .282* .037 .026 -.110 
SC  .288* .262* .292* .247 .211 -.181 
AS .071 .058 .184 .017 .062 -.074 
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Figure 3.6: Correlations between selected BIA measurements and platelet parameters. A – 
Relationship between body fat % and platelet count in males. B – Relationship between body fat % 
and platelet count in females. C – Relationship between body fat % and platelet adhesion in males, 
and D – Relationship between body fat % and platelet adhesion in females. 
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3.2.3.3.1 Body fat percentage (BF %) 
As BMI or WC cannot distinguish body fat from muscle mass, BIA analysis enabled us to 
examine these variables separately. In order to examine variability in platelet parameters 
according to body fat, subjects were split into subgroups according to percentile norms for 
body fat % for age and gender (Thompson et al., 2008), shown in Table 3.13. Differences in 
the means of platelet parameters according to the subgroups are shown in Figure 3.7. 
Table 3.13: Body fat percent categories. Values represent the number of subjects in each category. 
Good – body fat percent between the 60th-90th percentile, Fair - body fat percent between the 40th-
55th percentile and Poor - body fat percent between the 15-35th percentile. 
 
 Body fat percent category 
 Good Fair Poor 
Male 31 16 9 
Female 21 13 44 
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Figure 3.7: Difference in platelet parameters between body fat percent categories. Graphs 
represent mean ± SD. A – variance in PLT, B – variance in PCT and C – variance in SC. One-way 
ANCOVA adjusting for age. *P < 0.05.  
 
* 
* * 
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3.2.3.3.2 Fat mass (FM) 
Fat mass was measured by BIA. The Tanita scales provided a dimensionless number for fat 
mass, with 1 = lowest possible fat mass and higher values corresponding to an increasing fat 
mass. Fat mass was significantly correlated with PLT and PCT and SC, shown in Table 3.12. 
Subjects were categorised as having very low, low, moderate or high fat mass to compare 
platelet parameters. The distribution of subjects in each fat mass category is shown in the 
Table 3.14.  As shown in Figure 3.8, there was a significant increase in platelet adhesion in 
the High group for females compared to the moderate group. PLT and PCT were highest in 
the High groups for both male and females. 
Table: 3.14: Fat mass categories. Values represent the number of subjects in each category. 
 
 Fat mass category and reference range 
 Very low 
4-10 
Low 
11-19 
Moderate 
20-29 
High 
30+ 
Male 22 24 12 0 
Female 10 36 19 15 
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Figure 3.8: Difference in platelet function between fat mass groups. Graphs represent mean ± SD 
variance in A – PLT, B – PCT and C – SC.  *P< 0.05. One-way ANCOVA adjusting for age. 
* 
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3.2.4 Self-reported physical activity levels 
Questionnaire data enabled the stratification of subjects depending on self-assessed fitness 
levels. Figure 3.9 shows variances in platelet indices and function according to fitness levels. 
Although no significance was reached between groups, as fitness levels increased, platelet 
indices decreased, and this was particularly evident in males. 
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Figure 3.9: Comparison of platelet parameters between physical fitness categories. Graphs 
represent mean ± SD variances in A – platelet count, B – Platelet distribution width, C – Platelet 
large cell ratio, D – Plateletcrit, E – Platelet adhesion and F – Platelet aggregation. One-way 
ANCOVA adjusting for age.  
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3.3 Discussion 
Modifiable lifestyle components including physical inactivity, obesity, smoking, and 
hypertension, and non-modifiable risk factors comprising ethnicity, gender and age, 
contribute to CVD and atherosclerotic risk. There is increasing evidence that these traditional 
CVD risk factors such as type 2 diabetes mellitus (T2DM) and hypertension in diseased 
patients are associated with increased platelet reactivity (Kakouros et el. 2011) and that 
improvements in these risk factors are linked with a reduced prothrombotic tendency 
(Mittendorfer, 2008).  
Studies have shown that platelet function is altered in CVD or in obese individuals with 
multiple CVD risk factors (Santilli et al., 2011). Whilst it is known that platelet indices and 
markers of platelet health are expressed differently in diseased populations (Goshal, 2014), 
only a minority of studies have solely examined the relationship between overall 
physiological health, CVD risk factors and platelet function in healthy subjects. Some 
studies have presented data on the relationship between PLT, MPV and PDW according to 
gender and age (Zhang et al., 2015). 
However, the relationships between physical inactivity, overweight, amongst other lifestyle 
habits with platelet function are less well recognised, in particular in healthy subjects. This 
study aimed to address the deficit in this area by analysing the relationships between these 
parameters and also to evaluate the differences in platelet parameters according to non-
modifiable risk factors including gender and age. We therefore explored the feasibility of 
platelet indices and whole blood platelet function measurements, as useful, non-invasive 
initial biomarkers of early/subclinical CVD risk and unhealthy lifestyle. 
To accomplish this, correlations analysis and comparisons were performed for each lifestyle 
factor and platelet parameter. In this single site cross-sectional study of an apparently 
healthy, random population, platelet count, plateletcrit and platelet adhesion measurements 
were slightly elevated as physiological health measurements reflective of lifestyle, reached 
unhealthy levels. This was particularly evident in female subjects. 
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3.3.1 Characteristics of the study population 
Table 3.1 shows the clinical characteristics of the study population. The average age was 
37.4 years for males and 39.4 for females. The distribution of age in the population shows a 
centring around age 20-35 years (Figure 3.1) The average BMI was similar between male 
and females and as anticipated body fat % was significantly higher in women compared to 
men as is generally the case due to sex-characteristic fat related to child bearing (Blaak, 
2001). Fat mass was significantly higher in females compared to males and this has been 
reported frequently in the literature (Schutz et al., 2002). VAT levels were higher in males 
compared to females, the only other adiposity measure besides WC which was greater in 
males. Although women generally have a higher body fat percent than men, much of their 
adipose tissue is stored in the gluteal-femoral region, whereas men have been shown to store 
more fat in the abdominal area (Blaak, 2001) explaining this observation. Women had a 
significantly higher resting heart rate (RHR) than males as shown in Table 3.3. Gender 
related differences in leukocyte and erythrocyte parameters are illustrated in Table 3.5. As 
expected, erythrocyte parameters including RBC, HGB and HCT were significantly 
increased in males compared to females, a common finding in other studies (Murphy et al., 
2010) whereas RDW and MCV were higher in females. WBC was similar across gender 
(Charles et al., 2007). The majority of the population was of Irish descent. 
 
3.3.2 Gender differences in platelet function and platelet indices 
CVD develops approximately 7-10 years later in women than men (Maas and Appelman, 
2010). It has been suggested that exposure to endogenous estrogens delays this development 
as men are at greater risk of heart disease than pre-menopausal women, but once past the 
menopause, a woman’s risk is parallel to a man’s (WHF). Tables 3.6 and 3.7 compare 
platelet parameters between male and female subjects. All platelet indices were slightly 
elevated in females compared to males. Supporting this data, platelet indices were increased 
in females in the large cross-sectional Moli-Sani study (Santimone et al., 2011) but, 
analogous to other studies, there were no significant differences observed for platelet indices 
(Giovanetti et al., 2011).   
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Baseline PLT in females was 5% higher than males compared to other studies where the 
gender-related variances in adults was slightly higher at 10% (Balduni and Noris, 2014; 
Sloan et al., 2015). Further studies have also shown similar results whereby female PLT 
have exceeded those of their male counterparts (Segal et al., 2006; Zhang et al., 2015). The 
minimal changes in MPV between gender (.15 fL) are consistent with findings by Sloan et 
al., (2015) and Butkiewicz et al., (2006) where MPV was not found to be dissimilar between 
the sexes. There were negligible changes in PDW between males and females and (0.28 fl) 
whereas slightly higher changes in PLCR and PCT were observed. Giovanetti et al., (2011) 
and Zhang et al., (2015) have reported significant differences in PCT between males and 
females.  
It has been postulated that the higher PLT and PCT levels in females may partially exist due 
to hormonal influences and in particular the presence of estrogen which has a role in 
generating platelet production in mice, although no human studies have been performed to 
date (Nagata et al., 2003). Estradiol has been revealed to stimulate proplatelet production in 
megakaryocytes and furthermore, estrogen–receptor antagonists prevent platelet production 
in vivo, ancillary to a role of estrogens in platelet production (Segal and Moliturno, 2006). 
Changes in hormonal profiles between gender therefore may be proposed to end in different 
platelet phenotypes.  
Regarding platelet function parameters, mean platelet adhesion values for male and female 
were 12.2 and 11.8% respectively, similar to values reported for healthy volunteers in the 
literature (Shenkman et al., 2008). Mean platelet aggregation was almost identical. Evidence 
that platelet function varied according to gender was first recognised by Johnson et al., 
(1975) and has been established in more recent years where females have displayed 
increased platelet aggregation compared to males after stimulation with a number of agonists 
in whole blood and platelet rich plasma (PRP) (Becker et al., 2006). Other studies did not 
find any sex related platelet function disparities (Rubak et al., 2012; Beyan et al., (2006) 
Furthermore, Cho et al., (2008) found no difference in platelet function between gender in a 
Korean population using the PFA-100. Overall, we found minimal differences in platelet 
function between gender but a larger sample size may display differences between gender.  
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3.3.3 Body composition/adiposity measures  
Body composition is used to describe the percentage of fat, bone, water and muscle in the 
body and can be measured using a variety of techniques including body mass index (BMI), 
waist circumference (WC), bioelectrical impedance analysis (BIA) which are important 
health outcomes (Wells and Fewtrell 2006). Overweight and obesity are defined as excessive 
fat accumulation and are rapidly growing global problems (WHO, 2015). Estimations of 
global trends in obesity has put Ireland on course to become the most obese country in 
Europe within a decade, with Irish men already having the highest BMI in Europe (Singh et 
al., 2016). This study aimed to examine the relationship between platelet parameters and 
body composition before a disease threshold is apparent, to determine if overweight subjects 
display a similarly enhanced platelet profile to obese subjects. A number of adiposity 
measures were assessed in each subject. 
3.3.3.1 Body mass index (BMI)  
BMI measurements were performed to determine its relationship with platelet parameters 
due to its useful population measure of overweight and obesity. It is widely accepted that a 
high BMI is a predictor of CVD morbidity (WHO, 2015). In adults, being overweight is 
defined as a BMI of 25 - 29.9 kg/m2 and obesity is defined as having a BMI ≥ 30 kg/m2 
(Lavie et al.,  2009). For the majority of people, obesity related health problems increase 
after a BMI of 25 kg/m2. In this population, 33% of males and 22% of females had a BMI 
of greater than 25 kg/m2, classed as overweight. 
Table 3.8 displays the relationship between BMI and platelet parameters. There was a 
positive relationship between BMI and PLT in males and females, with a weak significant 
correlation only amongst females (Figure 3.2). This finding is in concordance with other 
studies who have demonstrated a correlation between BMI and PLT in women only (Sloan 
et al., 2014; Chen et al., 2016; Kotani et al., 2007). As shown in Figure 3.2, PCT was 
positively correlated to BMI in females but not males, which also remained significant when 
adjusted for age. PCT has been correlated with C-reactive protein (CRP), a marker of 
inflammation (Sahin et al., 2012) supporting the hypothesis that platelet activation is 
elevated in overweight individuals. While all platelet volume indices were inversely 
correlated to BMI, none of these associations were significant. Another large cross-sectional 
study found no association between BMI and MPV in healthy subjects (Sansanayudh et al., 
2016).  
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Samuel-Bonet et al., (2008) suggest that the relationship between BMI and PLT in females 
can be explained by simultaneously high CRP levels, indicating inflammation (Samuel-
Bonet et al., 2008) and alterations in platelet production from megakaryocytes can be 
modified by cytokines involved in inflammation. The latent chronic inflammation could 
have a certain bearing for females who generally have a higher body fat percent than men 
with the same BMI. Additionally, higher thrombopoeitin (TPO) (the major governor of 
platelet production) levels have been observed in inflammation and this could partly explain 
the elevated platelet production and count in overweight subjects (Cerisa et al., 2007).  
Comparisons of platelet indices and function was facilitated by stratifying subjects into two 
BMI groups, outlined in Table 3.9 (healthy weight and overweight). Figure 3.3 compares 
platelet parameters according to BMI category. PLT was elevated in overweight males and 
females compared to healthy weight and this trend was more pronounced and statistically 
significant in females. Similar results have been reported amongst women elsewhere 
(Farhangi et al., 2013). PCT was significantly higher in overweight females and remained 
unchanged in overweight males.  
Platelet adhesion is intricately linked to activation in obesity however, it is unclear whether 
platelet activation is enhanced in overweight subjects. In a cross-sectional study by Leit et 
al., (2016), obese subjects demonstrated reduced platelet nitric oxide synthase (NOS) 
activity and increased platelet adhesion compared to non-obese subjects. Other large 
population based studies demonstrate that obese subjects present enhanced markers of 
platelet activation including P-selectin plasma concentrations (Pergola et al., 2008), and 
urinary 11-dehyrdo-TxB2 (Davi et al., 2002). Likewise, we found a slight significant 
positive relationship between platelet adhesion (SC%) and BMI (Table 3.9). Figure 3.3 
shows that there was also a significant difference between SC% between the healthy and 
overweight BMI group in males (10.7-12.8%) and females (11.2 – 13.4%), showing 
increased platelet adhesion in the overweight groups suggesting that platelet activation is 
heightened in overweight subjects.  
In obesity, platelets develop a resistance to their main anti-aggregating mediators, PGI2 and 
NO. This is likely caused by the impairment of cyclic nucleotide production and subsequent 
action (Anfossi et al., 2004). Cyclic nucleotides are the primary anti-aggregatory mediators. 
Therefore, a resistance to them could be a factor in platelet hyperactivity in obesity, making 
platelets more prone to adhesion. The increase in platelet adhesion in the overweight group 
could be as a result of a chronic resistance to these mediators, as a result of lifestyle as Leite 
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et al., (2016) suggested that long-term conservation of excessive body weight is detrimental 
to platelet function. 
The lack of correlation between BMI and platelet aggregation (AS) indicates that although 
subjects with an increasing BMI appear to possess a more adhesive platelet profile, these 
changes are not being translated at the aggregatory level. Although these subjects were 
overweight and beginning to show signs of subclinical platelet activation, they have not yet 
reached a disease state and therefore the risk of CVD and thrombosis is substantially lower. 
Accordingly, there were minimal differences in aggregation between both groups (Figure 
3.3).  
The limited number of studies investigating the association between BMI and platelet 
aggregation have focused on the link between platelet aggregation and BMI in diseased 
populations such as metS, T2DM, or in obese subjects. Angiollio et al., (2004) found that 
platelet aggregation was elevated in patients with an overweight BMI compared to normal 
weight patients. ADP-induced platelet aggregation was significantly elevated in overweight 
patients than in normal-weight patients undergoing percutaneous coronary intervention 
(Bonello-Palot et al., 2009). Corsonello et al., (2003) examined platelet function in normal 
weight, overweight and obese males in a small (n=49) cross-sectional study. They assessed 
ADP-induced platelet aggregation and platelet calcium release in PRP with varying 
concentrations of leptin which can encourage platelet aggregation through activation of its 
receptor on the platelet surface. ADP-induced platelet aggregation was increased in 
overweight and obese subjects compared to controls.  However, our study had low numbers 
of obese subjects, and perhaps a larger number would have shown similar results. 
3.3.3.2 Waist circumference and visceral obesity 
Although obesity predisposes to CVD, the pattern of body fat distribution is also recognised 
as an extremely important predictor of the health risks of obesity. Visceral obesity is the 
most dangerous type of fat and is specifically linked to cardiovascular morbidity (Davi et 
al., 2002). Visceral obesity relates to an excess of intra-abdominal adipose tissue and is 
distinguished from gynoid obesity by more fat on the trunk, carrying increased risk of 
hypertension and CVD compared with gynoid obesity. The pathophysiology of visceral 
obesity comprises distinct intertwined elements including an accrual of ectopic fat, insulin 
resistance and an increased ability to release inflammatory cytokines and free fatty acids 
than other types of fat deposition, all of which contribute to CVD. Therefore, while BMI is 
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an extremely useful measure of obesity, not every overweight or obese subject (BMI >30) 
carries visceral fat, and, non-obese individuals can accumulate disregarded visceral fat. We 
measured visceral obesity by waist circumference (WC), which can be used alone as an 
indicator of health risk as it directly measures abdominal obesity (Janssen et al., 2004).  
Table 3.11 illustrates that visceral obesity appeared to manifest itself more in females as 
24% of the population compared to 16% in males had a WC which was in a high risk 
category. Partial correlation analysis shown in Table 3.10 indicate a positive relationship 
between WC and PLT in females and no evident relationship in males. This has been found 
in other cross-sectional studies of platelet indices where platelet number increased with a 
rising WC (Vuong et al., 2014). PCT was also positively correlated to WC in females. As 
PCT has been employed as a biomarker of platelet activation, one could hypothesise that 
WC is accompanied by elevated platelet activation in overweight females. In fact, this is 
supported by the observation that platelet adhesion was positively correlated to WC in 
females, indicating slight platelet hyperactivity when visceral obesity is present (Figure 3.4). 
This increased platelet adhesiveness is probably due to the same multitude of mechanisms 
involved in central obesity such as LDL oxidation (Colas, 2011), insulin resistance (Ferreira 
et al., 2006), increased TxA2 production, (Davi et al., 2002) and the resistance to anti-
aggregating effects of NO, PGI2 and their mediators (Anfosso,2004; Russo, 2010).  
Increased MPV as a consequence of inflammation has also been noted in visceral obesity 
(Ozhan et al., 2010; Sansanayudh et al., 2016), however, there was no evident association 
between WC and platelet volume indices MPV, PDW or PLCR in this population, probably 
due to the fact that subjects were healthy/overweight and not obese.  Additionally, there were 
positive correlations between RBC and WC and between WBC and WC in females only, 
suggesting an overall increase in haematological parameters in females. 
To examine the variation between platelet indices according to WC, subjects were divided 
into four groups shown in Table 3.11, according to their overall disease risk for T2DM, 
hypertension and CVD, relative to normal WC and gender (Thompson et al., 2009). This 
was subsequently reduced to two groups (low and high risk) to facilitate comparisons. Figure 
3.5 compares platelet parameters between the risk groups. There were minimal differences 
in platelet volume indices between low and high risk subjects, reflecting the lack of 
correlations between the parameters. In females, PLT and PCT were significantly higher in 
the high risk group compared to the low risk group.  
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Furthermore, SC% in females was significantly elevated in the high risk group (11.3% 
compared to 13%) suggesting a more reactive platelet profile. Similarly, to variations in 
platelet aggregation when stratified by BMI, there were no large changes in AS (µm2) in 
either gender.  
Mechanisms for increased platelet activation in visceral obesity are under investigation. A 
number of metabolic alterations such as enhanced free fatty acids, oxidised LDL, TNF-α, 
are evident in patients with visceral obesity which contribute to reactive oxygen species 
(ROS) production. High ROS subsequently affects platelet function by reduction of NO 
bioavailability, overexpression of integrin αIIbβ3 and production of isoprostanes, the latter 
activating platelets through interaction with the TxA2 receptors (Anfossi et al., 2009). 
Visceral fat plays a key role in the development of metS, a condition epitomising a group of 
cardiometabolic risk factors including central obesity, insulin resistance and hypertension. 
metS is characterised by increased adipose tissue, which secretes a number of pro-
inflammatory cytokines (e.g. Leptin and interleukin-6 (IL-6)) which lead to chronic low-
grade inflammation and can influence platelet count and function. Leptin is a saiety hormone 
mainly produced from adipose tissue which increases platelet Ca2+ levels and simultaneously 
reduces the effect of platelet inhibitors such as cAMP (Elbatarney and Maurice, 2005; 
Konstantinides et al., 2001; Santilli et al., 2012). 
Platelet count in females with metS are significantly higher than those without metS, 
whereas males with metS only show a slight increase (Park et al., 2012) agreeing with results 
from this study. Studies using the Impact-R system have demonstrated that those with metS 
have enhanced baseline platelet adhesion compared to their healthy counterparts 
(Vaduganathan et al., 2008). Although subjects in this study did not have metS, it appears 
that the females with increased WC have a tendency to show similar platelet profiles to those 
with visceral obesity and metS.  
It is also possible that the systemic effects of visceral obesity are influencing the properties 
of platelets before/during their synthesis from megakaryocytes. Alterations in 
megakaryocyte ploidy numbers has been described in TD2M as a result of high IL-7 levels 
present in visceral obesity (Brown et al., 1997). 
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3.3.3.3 Body fat percentage and fat mass 
Although correlated with body fat percent, BMI or measures of visceral adiposity cannot 
distinguish between body fat and lean mass or muscle. More specific measurements of body 
composition, including body fat % (weight of fat/total body weight) and fat mass (FM) 
(actual weight of fat in the body) were measured by BIA. Some body fat is essential for 
physiological health, with a range of 10-22% and 20-30% for men and women considered 
acceptable for health. Contrarily, too much fat is detrimental for cardiovascular long-term 
health and reducing excess levels of body fat has been shown to directly reduce the risk of 
various conditions such as hypertension, T2DM, and CVD.   
Table 3.12 shows the relationship between platelet indices and BIA measurements. PLT and 
PCT were positively associated with FM in both genders. However, only these relationships 
in females were statistically significant, consistent with the other adiposity measures in 
females. Interestingly, there were small significant positive correlations between BF% and 
PLT and between BF% and PCT in both genders. Scatterplots depicting these relationships 
are shown in Figure 3.6. 
Similarly, to BMI, the platelet volume measurements MPV, PDW and PLCR were inversely 
related to BF% and FM in males, however these associations were not significant. A solitary 
study has solely examined the relationship between PLT and body fat % using 15 healthy 
males and finger prick for a blood draw and saw no relationship with PLT and body fat %, 
possibly due to very low sample size and dated techniques. (Marley and Linnerd, 1978).  
Other studies have illustrated changes in MPV with increasing body fat %. Muscari et al., 
(2008) examined the relevance of body fat on MPV in an elderly population and found that 
body fat percent was independently associated with high MPV. However, this was measured 
by skinfolds.  
Table 3.12 illustrates the significant positive relation (weak) between FM and platelet 
adhesion in both genders. This was further highlighted by the disparity in platelet adhesion 
between FM groups in Figure 3.8. There was no correlation between FM and platelet 
aggregation in either gender and no study has reported on a specific correlation between fat 
mass and platelet function, even though other adiposity measures (BMI, WC) already 
discussed, are linked to enhanced platelet activation.  
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Table 3.12 shows positive significant associations between platelet adhesion and BF in males 
and females. In adults, there have been no studies to date investigating platelet adhesion and 
body fat %, however a recent study in an adolescent population demonstrated that at an early 
age, platelet activation is associated with increasing body fat %. Garcia et al., (2014) 
demonstrated that the platelet activation marker P-Selectin was positively correlated with 
BIA measured body fat % in obese children. Again there were no tangible correlation 
between aggregation and BF in either gender. 
To compare platelet parameters according to body fat %, subjects were categorised into 
groups based on body fat % norms for their age and gender according to the American 
College of Sports Medicine normative values (Thompson et al., 2009). The number of 
subjects in each category is displayed in Table 3.13. There was a significant difference in 
platelet adhesion (SC %) between groups in females, as shown in Figure 3.7.  PLT and PCT 
appeared to be the most reliable platelet indices measured when groups were stratified by 
body fat %, as MPV, PDW and PLCR showed no major differences between groups. The 
data presented in Figure 3.7 show a stepwise increase in PLT between the three BF % groups 
across genders, which was more pronounced in females. In males, PCT was increased in the 
group displaying highest BF levels compared to the other two groups. There was a significant 
difference in PCT between the good and fair groups in females.  
We expected that platelet aggregation would be enhanced in those with higher body fat 
percentages, however we saw no major differences between groups. This inconsistency 
could be explained by the limited ratio of subjects in the high fat groups. Platelet adhesion 
was significantly increased in the fair body fat group compared to the good body fat group 
in females, similar to results obtained for BMI. The higher adhesion and PLT values in those 
with higher body fat percentage point toward a more reactive platelet profile in overweight. 
Although an association between obesity and platelet activation is evident, the cellular and 
molecular mechanisms responsible have only begun to surface (Blokhin and Lentz, 2013). 
RNA from platelets are reflective of pathological disease states and inflammatory transcript 
profiles from platelets, including INFG, IL1R1, IL6, and TLR2, all of which were reported 
to be significantly correlated with increasing BMI (Freedman et al., 2010), supporting the 
hypothesis that surplus fat could unfavourably alter the inflammatory potential of platelets. 
However, obesity can also cause dysregulation of other factors which control haemostasis 
such as microRNA (miRNA). miRNA are involved in the pathogenesis of obesity 
(Zampetaki et al., 2010) where plasma levels of miR-223 are reduced in obese compared to 
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lean subjects, proposing that the miR-223/P2Y12 alliance could signify a contributing 
mechanism of platelet activation in obesity (Bray et al., 2013).  
Each of the adiposity measurements (BMI, WC and body fat %) showed increased adhesion 
levels in subjects displaying unhealthy physiological measurements, whereas in general, 
aggregation levels remained unchanged. Platelet adhesion and aggregation are frequently 
considered as distinctive processes by which platelets create contact with extracellular 
exteriors or stick to one another. However, they are intrinsically linked as both mechanisms 
involve the alteration of platelets from free flow to attach to a surface, sometimes facilitated 
by the same adhesive ligand and receptors (Ruggieri et al., 2007). In this study, it appears 
that adiposity may regulate the adhesive receptors such as α2β, GPVI and GPIb-IX-V, but 
is not at this point affecting the aggregatory potential of platelets and activation of their main 
adhesion receptor, αIIbβ3, which is present at extremely high density on the platelet surface. 
A comparison of gene and protein expression of adhesive receptors in overweight and 
healthy subjects would provide further detail on the platelet function changes occurring in 
these cohorts. 
3.3.4 Physical activity and fitness  
The primary lifestyle factor investigated in this chapter was various measures of overweight, 
which is associated with physical inactivity and sedentary behaviour.  Epidemiologic studies 
have illustrated an undisputable relationship of increased fitness/exercise/physical activity 
with reduced cardiovascular risk (Knoops et al., 2004). Self-assessed physical fitness 
questionnaires enabled the comparison of platelet indices across subjects of varying fitness 
levels (Unfit, fairly fit and fit). Approximately 50% of the study population reported 
themselves as fairly fit or fit (Table 3.5), which was interesting considering sedentary 
behaviour patterns in Ireland have increased dramatically in the last 10 years (Department 
of Health, 2013).  Since platelets are involved in the pathogenesis of atherosclerosis, the 
protective effect of exercise against cardiovascular diseases may be partially due to 
alterations of platelet function. 
Figure 3.9 compares platelet indices and platelet function between fitness groups adjusting 
for age and gender. Although not significant, there appeared to be a linear decrease in PLT 
from unfit to fit in females. The same trend appeared in the male cohort and this may be 
indicative of varying platelet phenotypes relating to habitual exercise. MPV remained 
relatively unchanged between groups but PDW was elevated in the unfit group compared to 
 165 
 
both the fairly fit and fit groups across both genders. As PLCR and PCT have only emerged 
as important markers in platelet health, there is limited data concerning their variance in an 
exercise capacity. There was a linear decrease in PLCR in males from unfit to fit. PCT 
showed the largest changes out of the platelet indices parameters. These patterns are 
interesting as although qualitative data does not compare to quantitative measures of aerobic 
fitness (such as a VO2 test), the trend suggests an inverse relation between aerobic fitness 
and platelet indices.  
Karakilcik et al., (2014) showed that PLT, MPV and PCT were decreased after exercise 
training in soccer players compared to those who did not partake in exercise training, 
suggesting a less thrombotic profile in trained individuals. Furthermore, a comparison of 
resting platelet indice levels on athletes (aged 22 years) who participated in regular sports 
for 5+ years with those of sedentary subjects, showed that PLT and PCT were significantly 
decreased in the athletes (Rba et al., 2015). 
We could identify no clear trend with platelet adhesion. Wang et al., (1995) demonstrated 
that long-term exercise training in sedentary males had the potential to suppress in vitro 
platelet adhesion. Furthermore, Singh et al., (2006) showed that baseline platelet activation 
is enhanced in trained males compared to sedentary males. Figure 3.9 shows there were no 
changes in platelet aggregation between the three groups in males. Others report that exercise 
training does not affect resting platelet aggregability (Davis et al., 1990). In females, there 
was a linear decline in aggregate size from the unfit to the very fit group. Consequently, 12 
weeks of exercise training decreased resting platelet aggregation in sedentary females (Wang 
and Chen 1985). Possible mechanisms for beneficial effects of exercise training on platelets 
include a reduction in resting plasma catecholamine levels and platelet α2- adrenergic levels, 
diminishing platelet P-Selectin expression. eNOS and NO are increased after exercise 
training, thereby increasing platelet cGMP levels and potentially reducing platelet activation 
under shear stress (Wang et al., 2005).  
Overall, regular exercise participation appears to have a favourable effect on platelet 
function, with reports that exercise training is associated with encouraging effects on platelet 
aggregation and activation in both men and women. Long-term intervention studies in this 
area are required to elucidate the effects of habitual exercise on platelet function.  
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This chapter primarily focused on the relationship between platelet function and modifiable 
CVD risk factors (overweight and obesity, and physical inactivity) and physical activity. We 
collected additional data on other modifiable CVD risk factors including smoking and 
hypertension with regard to both platelet and haematological parameters. We also examined 
the role of non-modifiable CVD risk factors (ethnicity and age).  This data can be found in 
appendix A.  
3.4 Limitations 
This study represents a snapshot of the population and a larger sample size may improve the 
strength of associations and subsequently highlight better the effects of lifestyle/CVD risk 
factors on platelet function in healthy people. The sample size was small in certain subgroups 
and the ratio of female to male subjects was slightly uneven and could have been a limiting 
factor for some results. The cross-sectional design of the study suggests that caution should 
be used in causal interpretations. Subjects were informed to arrive for testing in the morning, 
having abstained from vigorous exercise/alcohol/a high fat meal in the previous 24 hours to 
reduce the effect of these confounders as each can affect platelet function (Guerrero et al., 
2004, Pearson et al., 2005; Bonacciao et al., 2014; Sinzinger and Berent, 2012). However, 
it cannot be said for certain that this was the case and this could have impacted the results.  
While no solitary measure of body composition is globally accepted as the gold standard 
(Ackland et al., 2012), dual-energy X-ray absorptiometry (DEXA) is considered the most 
precise technique but is costly and time consuming. BIA is often used in population-based 
studies due to its promptness of results and non-invasive approach. However, BIA may 
compromise accuracy for efficiency of use and although studies have shown it is 
comparative to other measurements, it is dependent on factors including food and fluid 
intake, temperature, menstruation and exercise, all of which could have influenced results 
(Heyward, 1991; Deghan, 2008; Mialich et al., 2014). Physical activity/fitness levels were 
self-assessed by individuals using a questionnaire. Ideally, aerobic fitness levels should be 
quantitatively assessed and therefore results must be carefully interpreted given the lack of 
distinction between self-reported and objective physical activity. However, this study aimed 
to acquire a broad view of the subjects’ lifestyle.  
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3.5 Summary and conclusion 
This chapter examined a range of CVD risk factors in a nationally representative population 
to examine the relationships between platelet function and physiological health. Results 
showed that higher platelet counts and plateletcrit were associated with less favourable 
cardiovascular risk profiles, in particular with measures of overweight Other platelet indices 
(PDW, MPV and PLCR) were not associated with overweight. Sahbaz et al., (2016) also 
found that plateletcrit had higher sensitivity and specificity than other platelet indices when 
predicting disease states.  
Importantly, platelet adhesion was significantly increased in male and female adults who 
had a BMI classed as overweight compared to those with a healthy weight BMI. BMI and 
body fat percent were the most sensitive adiposity measures in reflecting the changes in 
platelet parameters, whereas waist circumference was specific for alterations in females 
only. Although BIA measurements such as fat mass and body fat % showed similar results 
to WC and BMI, the VAT scale was not a reliable indicator of body composition. The 
elevated PLT, PCT and SC levels in overweight subjects indicate a more reactive platelet 
profile and could imply the occurrence of subclinical CVD symptoms.  
It is important to note that while some changes were significant, often there was not a huge 
difference between subgroups. A more effective approach to detect changes in platelet 
function in overweight subjects could be to stress the cardiovascular system by exercise, 
rather than taking single one-point measurements. Furthermore, as the association of the 
variables was mainly directed toward a risk profile for CVD, such a relationship may be 
stronger in pathological conditions such as obesity, TD2M and hypertension. Nonetheless, 
it is possible that changes in platelet parameters in overweight subjects are associated with 
disease risk and these patterns may offer new insights into platelet function.  
The search for simple biomarkers that allow for early identification of subclinical/CVD risk 
is ongoing. Work from this chapter demonstrates that platelets can reflect changes in 
unhealthy lifestyle patterns. The Impact-R test is a relatively inexpensive test which can 
reliably detect changes in platelet adhesion and could be employed for CVD risk evaluation 
amongst subjects who are asymptomatic. Platelet indice and function markers should be 
further tested in larger cross-sectional studies and during lifestyle interventions, to determine 
their reliability as surrogate markers for evaluating cardiovascular health. 
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Chapter Four  
Outputs:  
 Varying levels of cardiorespiratory fitness (CRF) resulted in no major basal 
differences in platelet function in male adults or adolescents 
 Male adults with a moderate CRF had higher basal platelet counts and plateletcrit 
than those with a high CRF 
 Acute aerobic exercise resulted in increased platelet adhesion and aggregation  
 This increase was more pronounced in those with a low CRF, particularly in 
adolescents 
 
Contributions from others: 
 The adolescent cohort from this study was part of a large study investigating 
cardiorespiratory fitness, physical activity and vascular health in Irish adolescent 
males, conducted in DCU by Prof Niall Moyna 
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Chapter Four: The Effect of Acute, Strenuous Exercise on Platelet 
Function  
4.1 Introduction 
Physical inactivity and obesity are prominent behavioural risk factors, which lead to 
cardiovascular disease (CVD). It has been recognised that regular exercise may reduce the 
risk of major vascular thrombotic events and protect against cardiovascular disease (Blair 
and Norris, 2009). Differences in known factors explain a large percentage of the inverse 
relationship between physical activity and CVD risk (Mora et al., 2007; Kwasniewska et al., 
2016). However, over 40% of the inverse association remains unexplained. Although the 
beneficial effects of regular exercise on blood lipids and blood pressure have been well 
accepted, research focusing on platelet function has only recently gained greater attention.  
Cardiorespiratory fitness (CRF), also known as aerobic fitness/capacity, is defined as the 
ability to deliver oxygen to the muscles and to use it to produce energy during exercise. It 
consequently relies upon pulmonary, cardiovascular and haematological constituents of 
oxygen delivery and the oxidative mechanisms of the exercising muscles (Armstrong et al., 
2006). Low CRF represents a major risk factor for atherosclerosis. Since platelets play a key 
role in the pathogenesis of atherosclerosis, the protective effect of exercise against CVD may 
be partially due to alterations in platelet properties.  
Chapter 3 examined a cross-sectional cohort of the population to determine the relationship 
between platelet function and physiological health. Rather than taking basal single point 
measurements, stressing the cardiovascular system using in vivo instead of in vitro or ex vivo 
stress models, by prescribed exhaustive exercise may provide much more valuable and 
conclusive evidence in relation to the body’s response to stress. This chapter extended our 
research using a ‘human laboratory’ approach, evaluating the effect of controlled aerobic 
exercise, as a cardiovascular stressor, on platelet function in male adolescents (n=30) and 
adults (n=16) of varying CRF. Inconclusive information is available on the effect of acute 
exercise on platelet function in adults and even less have investigated platelet function in 
healthy adolescents and with respect to acute exercise. (Heber and Volf, 2015). Therefore, 
the purpose of this study was to assess the relationship between CRF and platelet function 
and to examine the effect of varying CRF levels on the platelet response to acute aerobic 
exercise. 
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4.1.1 Chapter aims and experimental approach 
Hypothesis: 
Basal platelet function measurements will differ between low and high fit adolescent and 
adult males. Acute exercise will induce a change in platelet function in both groups, with a 
more pronounced change in subjects with a lower cardiorespiratory fitness level. 
Main aims:  
 Investigate differences in basal platelet function in males of varying age and CRF 
levels. 
 Examine the effect of acute strenuous exercise on platelet indice markers (Platelet 
count, plateletcrit and platelet volume markers of platelet activation) and platelet 
function (adhesion and aggregation) in high fit, and moderately – low fit adolescent 
and adult male subjects. 
 Elucidate the relationship between CRF and platelet function in both healthy 
adolescent and adult males. 
 
4.1.2 Study design 
Subject recruitment 
The subject selection for adults and adolescents was explained in detail in Chapter two 
(Section 2.2.5.5). In brief, the thirty adolescent subjects in this study were selected upon 
completion of a 20 m MSST (multi-stage shuttle test) to determine fitness levels and then 
provisionally categorised as high fit (HF) or moderate – low fit (MLF). Permanent fitness 
categorisation into separate groups was based on VO2 max (ml/kg/min) values using the 
percentile data from a study undertaken on youths aged 12-19 years, illustrated in Chapter 
2. This was part of a larger study investigating CRF, physical activity, sedentary behaviour 
and vascular health in male adolescents.  
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The adult cohort (n=16) was recruited from the School of Health and Human Performance 
and provisionally defined as moderately fit (MF) or high fit (HF) based on responses from a 
physical activity questionnaire. This determined their VO2 max testing protocol and based 
on their VO2 results they were categorised into two definite groups according to normative 
VO2 data for healthy males for their age (Adapted from Astrand et al., 1960). The MF group 
had a VO2 between 44-55 ml/kg/min, and the HF group between 58-66 (ml/kg/min). All 
subjects (and parents for the adolescents) gave informed consent. Ethical approval for both 
cohorts was provided by DCU ethics. 
Blood sample  
Two bloods sample were taken from each subject in a resting position, one pre exercise and 
one immediately post exercise. Blood was obtained by standard venepuncture from the 
antecubital forearm vein and collected into vacutainer tubes containing 3.2% sodium citrate. 
Platelet, Erythrocyte and Leukocyte indices were measured by the Beckman Coulter Ac·T 
diff™ Analyser.  
Platelet function 
Two parameters of platelet function were evaluated using the Impact R: surface coverage 
(SC, %) representing platelet adhesion, and the average size (AS, μm2) of the polystyrene-
bound platelet clusters/aggregates representing platelet aggregation. 
Exercise test 
Cardiorespiratory fitness (VO2 max) was assessed using an incremental exercise test on a 
treadmill with continuous breathing gas analysis and HR monitoring using a modified Bruce 
protocol (Bruce et al., 1973). Two minutes of warm up were performed before subjects 
performed the selected test described in Chapter 2. Blood pressure and rate of perceived 
exertion were continuously monitored during the test. Subjects were verbally encouraged 
throughout the test until the finish. End criteria used for VO2 max attainment were 
VO2 levelling off, RERmax ≥1.0, >18 on the Borg Scale6–20 rating, and HRmax ≥95% of the 
age-predicted HRmax (220 – age) and subject requesting to stop.  
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Body composition 
Height and body weight were measured to the nearest 0.5 cm and 0.1 kg, respectively, with 
subject wearing no shoes and light clothes. BMI was calculated as previously described in 
Chapter 3. Waist circumference was measured in both adults and adolescents as an indicator 
of visceral obesity. Body fat % was measured by BIA analysis in the adult cohort and by 
skinfold analysis in the adolescent cohort. 
Assessment of covariates 
Participants abstained from any exercise for >24 h prior to testing and (Adults) were tested 
after an overnight dietary fast. The adolescent cohort was allowed to have a simple cereal 
based breakfast on the morning of the test. On the morning of testing, participants were 
permitted and encouraged to drink water. All participants were required to abstain from non-
steroidal anti-inflammatory (NSAID) use for at least 7 days prior to testing. The adolescent 
cohort signed consent and assent forms and completed the PAR Q & U questionnaire, while 
the adult cohort completed an adapted physical activity questionnaire (Appendix B). 
 
              
 
Figure 4.1: Workflow for testing both adults and adolescents. Subjects had basal measurements 
and blood samples taken and then performed acute exercise. Post exercise, the same measurements 
were performed.  
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4.2 Results 
4.2.1 Characteristics of the study population 
Characteristics of the adolescent subjects are displayed in Table 4.1, categorised into two 
groups according to their VO2 max moderate-low fit (MLF) (16) and high fit (HF) (14). 
There were significant differences between the MLF and HF group for all characteristics 
except for height. Physical fitness characteristics of the adolescents are summarised in Table 
4.2. HF subjects had significantly higher VO2 max and MSST shuttle parameters compared 
to MLF subjects. Characteristics of the adult cohort are displayed in Table 4.3. VO2 max 
was significantly higher in the HF group compared to the MF group. Body composition 
characteristics were similar between groups, with the largest difference in body fat % 
between the two. Figure 4.1 shows the difference in CRF between the two groups in both 
cohorts. Table 4.4 shows the categorisation of subjects according to BMI and Figure 4.2 
highlights the association between BMI and VO2 max in both cohorts. There was a 
significant inverse relationship between BMI and VO2 max in the adolescent cohort, but not 
in the adult cohort. 
Table 4.1: Anthropometric characteristics and RHR characteristics of the adolescent cohort. 
Values are mean ± SD. BMI -  Body mass index, Waist – Waist circumference, SBP – Systolic blood 
pressure, DBP – Diastolic blood pressure. *P<0.05. Independent samples t- test. 
  
Adolescent cohort  
 MLF 
(n=16) 
HF 
(n=14) 
P value 
Age (yrs) 15.5 ± 0.63 16.07 ± 0.73 * 
Height (cm) 177.36 ± 5.42 177.46 ± 6.41 .965 
Weight (kg) 85.4 ± 14.51 68.4 ± 8.08 * 
BMI  27.4 ± 5.58 21.7 ± 2.32 * 
Waist (cm) 84.9 ± 9.28 73.01 ± 5.35 * 
Body fat (%)  21.9 ± 8.19 10.6 ± 6.29 * 
SBP (bpm) 130 ± 8.98 115 ± 6.52 * 
DBP (bpm) 81 ± 4.51 73 ± 4.21 * 
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Table 4.2: Multi-Stage shuttle test and VO2 characteristics of the adolescent cohort. Max HR -  
Maximal heart rate attained during exercise test, Max RER - Maximal respiratory exchange ratio 
attained during exercise test. VO2 max – Maximal aerobic capacity. Values are mean ± SD. *P<0.05. 
Independent samples t-test.  
 
Adolescent cohort  
Performance 
parameter 
MLF HF P value 
Shuttle level 5.8 ± 1.15 10.2 ± 2.34 * 
Shuttle number 40.1 ± 10.42 87.4 ± 20.85 * 
Shuttle distance  802 ± 208.12 1748 ± 337.13 * 
Max HR 206.1 ± 14.01 200.1 ± 4.70 .250 
Max RER 1.08 ± 0.05 1.12 ± 0.04 .071 
VO2 max 41.7 ± 5.01 62.2 ± 5.9 * 
 
Table 4.3: Anthropometric characteristics and RHR and VO2 characteristics of the adult 
cohort. BMI - Body mass index, WC -  Waist circumference, SBP - systolic blood pressure, DBP -  
Diastolic blood pressure, VO2 max - Maximal aerobic capacity. RHR -  Resting heart rate. Values 
are mean ± SD. *P<0.05. Independent samples t-test.  
 
Adult cohort  
 MF 
(n=8) 
HF 
(n=8) 
P value 
Age (yrs) 21.75 ± 2.06 21.38 ± 1.61 .653 
Height (cm) 181.08 ± 7.25 181.5 ± 7.53 .986 
Weight (kg) 80.12 ± 2.3 77.12 ± 3.6 .598 
BMI (kg/m2) 24.3 ± 2.61 23.4 ± 2.08 .421 
WC (cm) 78.1 ± 1.9 79.2 ± 3.1 .809 
Body fat (%)  15.7 ± 1.5 12.1 ± 1.1 .073 
SBP (mmHg) 121 ± 3.5 122 ± 2.2 .811 
DBP (mmHg) 77 ± 2.6 81 ± 3.5 .258 
VO2max(ml/kg/min) 50.1 ± 3.91 60.2 ± 3.19 * 
RHR (bpm) 77 ± 6.5 66 ± 4.9 .230 
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Figure 4.2: Comparison of the differences in CRF between the adolescent and adult cohorts. 
A: Comparison of CRF levels between the HF and MLF adolescents, B: Comparison of CRF levels 
between the HF and MF adults. Each subject is represented on the graph with mean ± SD shown by 
the lines. *P<0.05. Independent samples t-test. 
 
 
 
* 
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Table 4.4: BMI classification of adult and adolescent cohorts. A BMI between 18-25 kg/m2 is 
considered a healthy weight, a BMI > 25 kg/m2 and < 30 kg/m2 is considered overweight, and a BMI 
> 30 kg/m2 is categorised as obese. Values are numbers and percentages of subjects in each category. 
 
 BMI category 
 Healthy Overweight/Obese  
Adolescents 19 (64%) 11 (36%)  
Adults 12 (75%) 4 (25%)  
 
 
 
 
 
 
 
 
 
 
 
       
Figure 4.3: Relationship between BMI and VO2 max. A - shows the correlation between BMI and 
VO2 in the adolescent cohort and MLF and HF subjects are displayed. B shows the lack of 
relationship between BMI and VO2 in the adult cohort and HF and MF subjects are shown by the 
black and grey colours respectively. *P<0.05. Partial correlations adjusting for age. 
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4.2.2 Basal platelet and haematological characteristics of the study population 
To compare the basal platelet and RBC/WBC characteristics between adults and adolescents 
of varying CRF levels, the same groups were used. Tables 4.5 and 4.6 below compare white 
blood cell and red blood cell counts in addition to the difference in morphological features. 
As seen in Table 4.6, WBC was higher in the MF group compared to the HF group in adults, 
almost reaching statistical significance. There were no major differences between any of the 
other haematological parameters at basal time point.  Figures 4.4 – 4.6 compare basal platelet 
indices and functions in the adult and adolescent populations. 
Table 4.5: Basal RBC and WBC characteristics of the adolescent cohort. Values are mean ± SD. 
RBC – Red blood cell count, WBC – White blood cell count, HCT – Haematocrit, HGB – 
Haemoglobin, MCV – Mean corpuscular volume, RDW – Red cell distribution width.   Independent 
samples t-test.  
 
Adolescent cohort  
 MLF HF P value 
WBC (103/µl) 5.64 ± 1.54 6.15 ± 1.69 .404 
RBC (106/µl) 4.98 ± 0.31 4.86 ± 0.65 .705 
HCT (%)  44.37 ± 2.33 42.64 ± 3.64 .991 
HGB (g/dl) 14.84 ± 0.81 14.19 ± 1.27 .160 
MCV (fl) 88.86 ± 2.32 87.84 ± 1.91 .465 
RDW (%) 13.02 ± .90 13.35 ± 0.98 .230 
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Table 4.6: Basal RBC and WBC characteristics of the adult cohort. Values are mean ± SD. RBC 
– Red blood cell count, WBC – White blood cell count, HCT – Haematocrit, HGB – Haemoglobin, 
MCV – Mean corpuscular volume, RDW – Red cell distribution width. *P<0.05. Independent 
samples t-test. 
 
Adult cohort  
 MF HF P value 
WBC (103/µl) 7.95 ± 2.03 5.98 ± 0.98 .051 
RBC (106/µl) 4.72 ± 0.25 4.61 ± 0.28 .439 
HCT (%)  43.35 ± 1.87 42.7 ± 0.1.97 .702 
HGB (g/dl) 14.1 ± 0.82 14.2 ± 0.79 .782 
MCV (fl) 89.40 ± 1.12 92.70 ± 0.97 * 
RDW (%) 12.81 ± 0.99 12.73 ± 0.87 .826 
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Figure 4.4: Comparison of adolescent platelet indices at baseline. Graphs represent the mean ± 
SD value of each group. A – Basal platelet count comparisons, B – basal platelet distribution width 
comparisons, C – Basal mean platelet volume comparisons, D – Basal plateletcrit comparisons. 
Independent t-test and One-way ANCOVA adjusting for age.  
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Figure 4.5: Comparison of adult platelet indices at baseline. Graphs represent the mean ± SD 
value of each group. A – Basal platelet count comparisons, B – basal platelet distribution width 
comparisons, C – Basal mean platelet volume comparisons, D – Basal plateletcrit comparisons. 
*P<0.05. Independent t-test and One-way ANCOVA adjusting for age.  
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Figure 4.6: Comparison of adolescent and adult platelet function at baseline. Graphs represent 
the mean ± SD value of each group. A – basal comparison of platelet adhesion in adolescents, B – 
basal comparison of platelet aggregation in adolescents. C – Basal comparison of platelet adhesion 
in adults and D – basal comparison of platelet aggregation in adults.  Independent t-test and One-
way ANCOVA adjusting for age.  
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4.2.3 Effect of acute, strenuous exercise on platelet indices   
The second and main focus of this chapter was to assess the effect of a single bout of 
strenuous exercise on platelet properties in adolescent and adult males of varying CRF 
levels. Post-exercise, there were significant changes in the platelet indices, platelet count and 
plateletcrit, in adolescents (Figure 4.7) and adults (Figure 4.8). There were no significant 
changes in platelet volume indices.  
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Figure 4.7: Effect of acute, strenuous exercise on platelet indices in adolescents. Graphs 
represent the mean ± SD value of each group. Graph A shows changes in platelet distribution width 
after exercise, Graph B shows changes in the mean platelet volume, Graph C shows changes in 
platelet count and Graph D shows changes in plateletcrit. Image E and F depict the absolute 
significant changes in platelet count and plateletcrit. *P<0.05. Paired samples t-test.  
* * * * 
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Figure 4.8: Effect of acute strenuous exercise on platelet indices in adults. Values are mean ± 
SD. Graph A shows the changes in platelet distribution width after exercise, Graph B shows the 
changes in mean platelet volume, Graph C shows the changes in platelet count and Graph D shows 
the changes in plateletcrit. Graphs E and F depict the absolute changes in platelet count and 
plateletcrit respectively. *P<0.05. Paired samples t-test.  
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4.2.4 Effect of acute, strenuous exercise on platelet function 
The effect of a single bout of strenuous exercise on platelet function in male adults and 
adolescents of varying CRF levels was assessed by Impact R analysis. Figure 4.9 shows the 
adolescent responses to exercise. There was a significant increase in platelet adhesion and 
aggregation in the MLF adolescents after exercise, whereas a minor increase was observed 
in the HF group. This is highlighted in Figure 4.10 – Outputs from the Impact R cone and 
plate analyser show a visual representation of the changes seen in a randomly selected HF 
and MLF subjects. Figure 4.11 shows the effect of exercise on platelet function in the adult 
cohort.  While platelet adhesion was elevated in the MF group after exercise, there were no 
statistically significant changes observed. 
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Figure 4.9: Effect of acute strenuous exercise on platelet function in adolescents. Bar charts A 
and B represent the mean ± SD and show the effect of exercise on platelet adhesion and platelet 
aggregation respectively. Graphs C and D show the absolute change in adhesion and aggregation for 
each subject. HF and MLF subjects are identified. *P<0.05. Paired samples t-test.  
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Figure 4.10: Visual representation of the platelet function changes in adolescents after acute 
strenuous exercise. Images are taken from the Impact R device after capture analysis and represent 
the Graphs in Figure 4.8. Image A represents basal platelet function in a HF male adolescent with 
Image B the corresponding post exercise test. Image C represents basal platelet function in a MLF 
male adolescent with Image D showing the change in platelet function in the same subject after acute 
exercise. Two values are shown in each bracket (platelet adhesion -SC % and platelet aggregation – 
AS µm2). 
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Figure 4.11. Effect of acute strenuous exercise on platelet function in adults. Values are mean ± 
SD. Graph A shows the effect of exercise on platelet adhesion and graph B shows the effect of acute 
exercise on platelet aggregation. MF and HF subjects are identified in each graph. Paired samples t-
test. 
 
4.2.5 Relationship between CRF and platelet function 
To assess the relationship between CRF and platelet function, VO2 max was correlated to 
parameters of platelet function in the adolescent and adult male cohorts. In adolescents, the 
platelet parameters PLT, MPV, PDW, as well as platelet adhesion and aggregation were 
inversely correlated with VO2 max at baseline, however, these associations were not 
significant. Partial correlation coefficients adjusting for age and BMI showed significant 
inverse relationships between VO2 max and post exercise platelet adhesion and aggregation 
and significant inverse relationships between PLT pre (adults) and PLT pre and post 
(adolescents) shown in Table 4.7 and Figure 4.12/4.13. There were no significant 
relationships between other haematological parameters and VO2 max. 
 
Table 4.7: Correlation between CRF and platelet parameters in adults and adolescents. 
*P<0.05. VO2 max – Maximal aerobic capacity, PLT – Platelet count, SC – Surface coverage and 
AS – Aggregate size. *P<0.05. Pearson product and partial correlations adjusting for age. 
 
Platelet parameter and time point  
  PLT (pre) PLT (post) SC (post) AS (post) 
Adolescents VO2 max -.217 -.381* -.403* -.256 
Adults  VO2 max -.574* -.564* -.674* -.560* 
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Figure 4.12: Correlation plots between VO2 max and the pre/post exercise values for platelet 
parameters in adolescents. MLF and HF subjects are identified for the adolescent population. A – 
Correlation between VO2 max and platelet adhesion post exercise in adolescents, B -  Correlation 
between VO2 max and platelet aggregation post exercise in adolescents and C – Correlation between 
VO2 max and platelet count post exercise in adolescent. *P < 0.05. Pearson product and partial 
correlations adjusting for age. 
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Figure 4.13: Correlation plots between VO2 max and the pre/post exercise values for platelet 
parameters in adults. MF and HF subjects are identified for the adult population. A – Correlation 
between VO2 max and platelet adhesion post exercise, B – Correlation between VO2 max and platelet 
aggregation post exercise and C – Correlation between platelet count and VO2 max pre exercise. *P 
< 0.05. Pearson product and partial correlations adjusting for age. 
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4.3 Discussion 
The purpose of this study was to assess the relationship between CRF and platelet function 
and to examine the effect of varying CRF levels on the platelet response to acute aerobic 
exercise. Concurrent with the obesity and overweight epidemic, there has been a striking 
decline in physical activity levels in recent years. Physical activity is the most robust 
modifiable determinant of cardiorespiratory fitness (CRF), the ability to perform large-
muscle whole-body exercise at a moderate to high intensity (Saltin et al., 1973). Maximal 
oxygen uptake (VO2 max), is considered the gold standard measurement of CRF. While CRF 
is a sensitive measure of regular physical activity (Wang et al., 2010), it is also an important 
inexpensive and valuable health indicator for both healthy individuals and CVD patients 
(Gulati et al., 2005; Myers et al., 2009). Physical inactivity with a simultaneous low CRF 
epitomises the most important independent risk factor for atherosclerosis (Lee et al., 2010; 
Barry et al., 2014; Lavie et al., 2015; Farrell et al., 2015; Holterman et al., 2015).  
Cardiovascular disease (CVD) begins in childhood, primarily due to exposure to lifestyle-
mediated risk factors such as inactivity and low CRF. Alarming data from Woods et al., 
(2010) indicate that 88% of Irish adolescents do not meet the current PA recommendations 
of 60 minutes of daily moderate to vigorous physical activity. The Growing up in Ireland 
(2012) study of over 8000 children showed that 1 in 4 children were either overweight/obese. 
High CRF in late adolescence is linked with a reduced risk of MI later in life whereas 
inactivity pooled with obesity/overweight during adolescence increases the risk of future 
CVD (Hogstrom et al., 2014). 
The relationship between CRF and platelet function has only been referred to once in recent 
literature (Heber et al., 2016) and therefore we investigated this relationship further. We 
hypothesised that acute exercise would induce increases in platelet function in adult and 
adolescent males, with a more pronounced change in those with a lower CRF. Using a 
clinically relevant human experimental model of thrombosis, we evaluated the effect of 
controlled aerobic exercise, as a cardiovascular stressor, on platelet function in male 
adolescents (n=30) and adults (n=16) of varying cardiorespiratory fitness (CRF). The main 
finding was that a low CRF favoured a pro-thrombotic platelet phenotype after exercise in 
both groups with more pronounced changes in the adolescent group. Young male 
adolescents with a low CRF exhibit a hyperreactive platelet phenotype in response to acute 
exercise compared with their fitter counterparts.  
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4.3.1 Characteristics of the study population 
The first aim was to compare basal anthropometric, platelet and haematological parameters. 
The adolescent cohort was split into two groups according to their VO2 max for their age – 
a high fit (HF) and moderate to low fit (MLF) group. The adult cohort was split into two 
groups – a high fit (HF) and moderately fit (MF) group based on their VO2 max for their 
age. This was an all Irish male population. Table 4.1 outlines differences between 
anthropometric characteristics in the adolescent cohort. As anticipated, the HF group had 
significantly lower body fat %, BMI and waist circumferences than the MLF group. Similar 
results were observed in a large study examining physical fitness and body composition in 
adolescents (Monyeki et al., 2012).  
Resting blood pressure was measured twice when the subjects arrived in the morning. The 
mean systolic and diastolic blood pressures were also significantly higher in the MLF group, 
with eight of the MLF subjects classed as prehypertensive for SBP. This observation is 
consistent with research by Mansour et al., (2016) who observed that the mean systolic and 
diastolic BP in obese adolescents was higher than non-obese, suggesting that the 
inflammatory condition of obesity could contribute to increased BP. As expected, the HF 
group had significantly higher physical fitness characteristics than the MLF – in terms of all 
aspects of their shuttle test and had distinctly higher VO2 max results (Table 4.2). A graphical 
representation of the difference in CRF between the groups is shown in Figure 4.1.  Max 
RER (respiratory exchange ratio), one of the criteria for completion of VO2 max was slightly 
higher in the HF group compared to the MLF group (Edvardsen et al., 2014) suggesting the 
HF group were pushing themselves slightly harder to exhaustion than the MLF group.  
Table 4.3 shows differences in anthropometric, RHR and fitness levels in the adult cohort. 
The mean age of both the MF and HF groups was similar, 21.7 years and 21.3 years 
respectively with the eldest subject 25 years old. Unlike the adolescents, there were no major 
differences between the MF and HF groups in terms of body composition, with the mean 
BMI and body fat % only slightly higher in the MF group. Of the cardiovascular parameters 
measured, RHR was higher in the MF group compared to HF, whereas their blood pressure 
measurements were similar. 
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Although CRF was the primary method of comparison for this chapter, it was relevant to 
examine the extent of obesity and overweight amongst the two cohorts. As outlined in Table 
4.4, a substantial percentage (23%) of the adolescent cohort were overweight, with an 
additional 4% categorised as obese. The smaller adult cohort had only four subjects 
categorised as overweight. Figure 4.2 examines the relationship between BMI and CRF in 
both subject groups. The scatterplots illustrating the relationship between CRF and BMI in 
both cohorts show as significant inverse relationship between BMI and CRF in adolescents 
but not in adults. As there was not a huge discrepancy between BMI in the MF-HF adults, 
results showed a non-significant relationship between BMI and VO2 max. A larger, more 
disperse adult cohort with subjects with a very low CRF would probably have followed the 
same trend as the adolescents. 
4.3.2 Haematological characteristics of the study population 
Table 4.5 shows red and white blood cell characteristics between the two groups in 
adolescents. Though all values except WBC were higher in the MLF group, there were no 
significant differences between the two groups at a resting level. It was expected that WBC 
may be elevated in the MLF group as prior studies have described a chronic low-grade 
inflammatory state in obese (Tenorio et al., 2014; Ferrari et al., 2015) and overweight 
(Oliveria et al., 2014) adolescents. Similarly, there were no significant differences between 
basal RBC and WBC parameters in adults, even though the MF group had higher WBC 
levels (Table 4.6). This baseline observation was expected as results from Chapter 3 showed 
that those who were categorised as “fit” had lower WBC levels than unfit adults, and 
furthermore, overweight adults displayed increased WBC compared to healthy weight 
adults. Similarly, Church et al., (2002) also showed that healthy male adults with increased 
fitness have lower WBC concentrations. Athletes tend to have an increased total mass of 
RBC and HGB in circulation compared to sedentary individuals, but often in endurance 
sports, trained subjects can have a decreased HCT generated by increased plasma volume 
(Mairbaul, 2013). Some of the HF adults and adolescents were extremely fit and their 
slightly lower resting RBC values and subsequent morphological features could be explained 
by this occurrence.  
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4.3.3 Comparison of basal platelet indices according to CRF 
Chapter 3 illustrated elevated platelet indices in adult subjects with overweight/obesity or 
indications of unhealthy lifestyle compared to healthy subjects. This chapter used CRF 
compare differences between groups. In our first approach, we examined basal platelet 
parameters. Figure 4.5 outlines basal differences in platelet indices between the HF and MF 
adults. The platelet indices PLT and PCT were significantly higher in MF compared to HF 
adults. Other studies have shown similar results (Mansour et al., 2016). This is similar to 
results from the cross-sectional study in Chapter 3 whereby PLT and PCT were the platelet 
indices displaying most variance between the groups when stratified by adiposity measures. 
However, as the MF and HF groups were comparable in terms of BMI and other adiposity 
measurements, this suggests that CRF is a superior indicator of basal platelet activity. We 
observed no differences in basal MPV and PDW between the MF and HF adult cohort 
groups. A recent study comparing platelet indices according to fitness levels showed 
comparable results whereby PLT was slightly higher in sedentary subjects compared to 
trained, but no major differences in the rest of the platelet indices were observed (Alis et al., 
2016).  
Research around platelet indices is in it’s infancy with regard to younger populations. Some 
studies have shown basal platelet indice alterations in child and adolescent populations with 
respect to disease, such as elevated MPV levels in children with bicuspid aortic valve 
condition Ayan et al., (2015). However, there is a lack of research surrounding platelet 
indices in healthy adolescents. 
Figure 4.4 compares basal platelet indices in the adolescent cohort. The MLF group had 
slightly higher platelet indice values compared to the HF group. Similarly, to the adults, the 
trend showed increased PLT levels in MLF group. There was no difference in basal MPV 
and PDW levels. MPV has been identified as higher in obese adolescents compared to 
healthy controls (Arslan and Makay, 2010) and has also been linked with common carotid 
artery (CCA) thickness in obese adolescents (Arslan et al., 2013). However, as outlined in 
Table 4.4, only four adolescent subjects had a BMI > 30 (obese), a possible explanation for 
the similarity in MPV between the two groups. Overall, further research around the indices 
of platelet count and plateletcrit are required, to determine their usefulness as biomarkers of 
CRF.  
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4.3.4 Comparison of basal platelet function according to CRF 
Figure 4.6 compares basal platelet function characteristics of the adult and adolescent 
cohorts. In the adolescents, there were no notable differences between platelet adhesion or 
platelet aggregation between the two groups. Both the HF and MLF groups had a mean basal 
surface coverage (platelet adhesion) of 10% and platelet aggregate size was also similar 
revealing values of 49 µm2 and 47 µm2 for the MLF and HF groups respectively.  
There have been no specific studies on platelet adhesion variabilities in adolescent cohorts 
in relation to CRF to date. However, basal platelet function in obese children and adolescents 
has previously been investigated. Platelet aggregation in PRP was significantly increased in 
hypertensive obese adolescents compared to healthy adolescents (15.5 years old) (Hazon et 
al., 2003). Recent work by Desideri et al., (2009) evaluated endothelial dysfunction and 
platelet activation in 40 obese and 40 non-obese children (mean age 10 yrs). Also utilising 
PRP, they established that obese children had higher plasma levels of soluble P-Selectin and 
CD40L compared to non-obese children, suggesting increased platelet activation. When they 
stratified subjects based on their BMI, biomarkers of endothelial cell and platelet activation 
were similar despite varying body fatness levels.  
As referred to in Chapter Three, the physiological milieu of whole blood is sometimes 
preferred for platelet function studies. Using whole blood lumi-aggregometry, Lohse et al., 
(2010) reported that paediatric overweight subjects displayed platelet hyperaggregability 
compared to healthy weight controls. They also noted a positive correlation between 
triglycerides, total cholesterol and collagen-induced aggregation in the overweight children 
and adolescents. Desideri et al., (2009) did not find significant correlations between platelet 
activation and the adiposity measures BMI, visceral fat or WHR in obese children.   
Unlike the adolescent cohort there were subtle changes in basal platelet function values 
between MF and HF adults with the MF group showing slightly increased platelet adhesion 
(11.5% compared to 10.3% in HF) and aggregation (50 um2 compared to 46 um2 in the HF). 
This indicated that rising measures of adiposity may not necessarily be responsible for all 
changes in platelet function and that physical fitness status may be a participating factor, as 
the MF subjects were not overly different in terms of body fat % or BMI compared to the 
HF subjects. Based on results from Chapter Three, we were expecting to see minimal basal 
differences between the two groups.  
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Lippi et al., (2006) also compared platelet function between elite male cyclists and healthy 
sedentary males at rest. Platelet adhesion and aggregation were tested by the PFA-100. 
Platelet adhesion and closure time to collagen-ADP was significantly increased in the 
sedentary controls compared to elite athletes, highlighting that changes in platelet function 
are more pronounced in sedentary individuals. However, their population size was 
significantly larger (n=140).  
A recent breakthrough study by Heber et al., (2016) investigating platelet function and CRF 
in women (n=62), was the first research to combine CRF and platelet physiology in an adult 
population. Platelet function was tested by determination of P-Selectin and CD40L 
expression and quantification of platelet ROS generation in PRP. Basal platelet activation 
(reflected by CD62P expression) and agonist induced platelet activation (ROS, CD62P and 
CD40L) were higher in the LF compared to the MF and HF. The group found no difference 
between basal CD40L expression (non-agonist-induced). Interestingly, basal platelet 
function in the MF and HF were almost equal. Similar to this group, we found no major 
differences in basal platelet activation between the MF and HF adults, and addition of LF 
subjects could have resulted in interesting results and would be of benefit in future studies. 
However, the study cannot be applied to a male population as platelet function can be varied 
between gender.  
4.3.5 Effect of acute, strenuous exercise on platelet indices 
The main aim of this chapter was to compare platelet indice and function responses to acute 
exercise in male adolescents and adults of varying CRF. At the onset of exercise, the 
physiological systems respond, proportional to the intensity and duration of exercise, to 
maintain homeostasis (Riviera-Brown and Frontera, 2012). Indeed, in the cardiovascular 
system there are various responses to the increased demands of exercise. Cardiac output 
increases linearly with increasing oxygen demand. Blood flow patterns are dramatically 
altered in response to exercise where more blood is distributed to skeletal muscle.  
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Figure 4.7 displays the effect of acute exhaustive exercise on platelet indices amongst 
adolescents. PLT was significantly increased in both HF and MLF after exhaustive exercise. 
This difference was slightly more enhanced in the MLF group but there were no significant 
changes in absolute PLT numbers between the MLF and HF groups as shown in Figure 4.7 
(E). In the adult cohort, PLT was significantly increased after exhaustive exercise (Figure 
4.8 (A)), and similarly to adolescents, the increase was more pronounced in the MLF group. 
An increase in PLT in adults after acute exercise has been described by numerous groups in 
the literature (Ghaediyan, 2012; Cadroy et al., 2002; Dabis et al., 1990) with only one study 
showing the same trend in adolescents (Ribeiro et al., 2007).  
The spleen harbours one third of the body’s platelets in an interchangeable pool which can 
be discharged into circulation by alpha adrenergic stimulation (Chamberlain, 1990; Shepard, 
2016). The increase in PLT after acute exercise is attributed to platelet release from the liver, 
lungs and spleen, and hemoconcentration – the decrease in plasma volume which causes an 
increase in other blood cell components. Increased epinephrine after intense exercise causes 
splenic contractions (Bakovic et al., 2013; Gao et al., 2016). Additionally, disintegration of 
confined megakaryocytes in the lungs and bone marrow may result in exercise induced 
thrombocytosis. As the change in platelet count was similar between all groups (shown in 
Figure 4.7 and 4.8) after exercise, the activated and hyper-aggregable profile of the platelets 
observed in the MLF group in adolescents could be a result of platelet integrity loss initiated 
by the low CRF – where subjects may have higher oxidative and inflammatory conditions 
in addition to alterations in lipid and body composition profiles.  
As shown in Figure 4.7, there was no major change in platelet volume markers MPV or 
PDW in either adolescent group after exercise. This is consistent with recent work by Alis 
et al., (2015) who described the increase in MPV after acute strenuous exercise as less than 
their within-subject variation stated for that parameter, concluding that increased MPV does 
not suggest clinical importance. In the adult cohort, there were no major changes in MPV in 
both groups post exercise (Figure 4.8). To support our findings, other studies have shown 
that MPV does not change hugely with concurrent thrombocytosis (excessive platelet count) 
after exercise (Watts, 2009; Singh et al., 2006).  and therefore, MPV was not a significant 
marker of performance in exhaustive exercise. The effects of marathon running on platelet 
activation markers demonstrated no significant changes in MPV or PDW post marathon 
(Kratz et al., 2006). In the adult cohort there was a very small increase in PDW in both 
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groups post exercise. Some studies have reported a small increase in PDW and MPV after 
acute exercise in healthy subjects (Ghaediyan, 2012). 
There is less information on the effect of acute exercise on PCT, which increased drastically 
in both groups by nearly 25% after the VO2 max test, in both adults and adolescents (Figure 
4.7 and 4.8) likely due to the increase in PLT after exercise. Only two studies have measured 
PCT with regard to training status. Karakilcik et al., (2014) showed that PCT (along with 
PLT) was significantly decreased with exercise in young (mean 23 years) male soccer 
players. Rba et al., (2015) showed that regular exercise participation decreased PLT and 
PCT levels compared to sedentary subjects. Similarly, to our results, novel data from Alis et 
al., (2016) found that although exhaustive exercise also caused an increase in all platelet 
parameters PLT, MPV, PDW and PCT in sedentary and trained males, training status did 
not produce any alterations in baseline or post exercise increases in platelet indices.  
4.3.6 Effect of acute, strenuous exercise on platelet adhesion 
Potential effects of acute exercise on platelet function (mainly aggregation) have been 
investigated by a plethora of studies in adult subjects with varying intra and inter individual 
results, making interpretation problematic. Differences in population type (e.g. CVD vs 
healthy), methods employed to assess platelet function and techniques to examine reactivity 
are the main reasons for discrepancies between research groups (Aurigemma et al., 2007).  
There have been no studies to date examining the effect of acute exercise on platelet adhesion 
in adolescents. Figure 4.9 (A) show that acute exercise resulted in elevated platelet adhesion 
in both MLF and HF adolescents.  However, the MLF group displayed much larger changes 
than the HF group. This is further illustrated in Figure 4.10 with a visual representation of 
the changes in platelet adhesion in a MLF and HF adolescent subject. Platelet function and 
exercise in children or adolescents is in it’s infancy. A sole study by Ribieria et al., (2007) 
showed that platelet count increased after acute exercise in 10 sedentary males with a mean 
age of 13 years. Other available studies have mainly examined the effect of aerobic exercise 
in disease cohorts. Kumar et al., (2016) investigated the effect of aerobic exercise on 
haemostatic indices in paediatric subjects with haemophilia. Platelet function analysis was 
performed using the PFA-100 before and after 3 minutes of cycling at 85% of max heart 
rate.  
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Similarly, in the adult cohort, acute exercise caused an increase in platelet adhesion in both 
the HF and MF group, with a significant increase in the MF group only (over 25% increase 
from 11.5% – 14.5%) (Figure 4.11). While a substantial amount of research has been devoted 
to the exercise and platelet function in adults, different platelet adhesion experimental 
protocols have provided no definite response to exercise in healthy adult subjects. Wang et 
al., (1994) were the first to investigate the effects of aerobic exercise on platelet adhesion, 
quantified by a tapered parallel plate chamber. Results from the adult cohort are consistent 
with results from Wang et al., (1994) who showed that platelets from sedentary male subjects 
displayed increased adhesion after an incremental exercise test performed on a bicycle 
ergometer, compared to physically active male subjects. More recent research by Wang and 
colleagues found increased platelet adhesion after strenuous exercise, suggesting a resilient 
platelet-surface collaboration post exercise stimulus. These studies used an assay developed 
to measure the resistance of adhered platelets against detachment by shear stress (Wang 
1995, Wang 1997, Wang and Chen 1999, Wang 2002).  
The change in platelet adhesion in adults after exercise was not as profound as the variations 
observed in adolescents. However, the difference in CRF between the two adult groups was 
not as large as the gap between the groups in the adolescent cohort and could be partially 
responsible for this (VO2 max differences). Other studies investigating platelet function in 
sedentary and trained males have had VO2 averages of 59 ml/kg/min for high fit and 37 
ml/kg/min for the low fit (Singh et al., 2006) compared to our averages of 50.1 ± 1.3 
ml/kg/min for the MF and 60.2 ± .98 ml/kg/min for the HF. 
4.3.7 Effect of acute, strenuous exercise on platelet aggregation 
Effects of platelet acute exercise on platelet aggregation were also analysed. A number of 
studies have shown that acute exercise in healthy individuals or CVD patients results in an 
increase in platelet function and aggregation (El Sayed, 2002; Chung et al., 2008, Perneby 
et al., 2007; Scalone et al., 2009). These studies typically used in vitro platelet aggregation 
tests to assess platelet function. 
Figure 4.9, graphs B and C show the change in platelet aggregation after exercise in 
adolescents. There was an increase in aggregate size in both the HF and MLF group, with 
significant increases in aggregation post exercise in the MLF group (mean size increased 
from 49 um2 to 73 um2). Figure 4.11 (B) shows the effect of acute exercise on platelet 
aggregation in the adult cohort. Similarly, exhaustive exercise incurred an increase in platelet 
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aggregation in the MF group. However, these changes were not significantly different to pre 
exercise measurements. Interestingly, average platelet aggregation dropped slightly in the 
HF group, post exercise.  
Acute exercise was shown to increase platelet reactivity in healthy sedentary subjects but 
not in healthy subjects were regularly engaged in physical activity (Wang et al., 1994; Kestin 
et al., 1993). Coppola et al., (2005) also compared sedentary with active subjects and showed 
that exercise increased circulating platelet aggregates, whose levels were much higher in the 
sedentary compared to active group. Furthermore, ADP induced P-Selectin expression in 
addition to platelet aggregation were only increased in the sedentary group after exercise.  
The platelet integrin αIIbβ3 is found at high densities on the platelet surface and platelet α-
granules, existing in an inactive form on resting platelets (Rumbaut and Thiagarajan 2011). 
Upon platelet activation, it experiences conformational alterations resulting in a drastically 
heightened affinity for fibrinogen, facilitating platelet aggregation. Some studies have found 
increases in αIIbβ3 activation post exercise. Whittaker et al., (2013) used flow cytometry to 
test platelet activation after high intensity aerobic exercise in 12 healthy males, and reported 
increases in the platelet activation marker PAC-1, which binds to the activated form of 
αIIbβ3. Peat et al., (2010) assessed the platelet response to acute exercise in trained and 
sedentary middle aged subjects using an incremental treadmill test. Platelet function was 
assessed by flow cytometry and results displayed an increase in platelet αIIbβ3 expression 
post exercise. Wang et al., (2004) have also shown that intense exercise increases shear 
induced platelet aggregation in males. They also advocate that this is a result of increased 
Von Willebrand factor (vWF) binding, αIIbβ3 and heightened P-Selectin expression. These 
results could have been a factor in the increase in platelet aggregation in the MLF adolescents 
and MF adults post exercise in our study.  
As previously mentioned, the PFA-100 measures platelet activation in whole blood by the 
combined action of shear stress and various platelet agonists. It is representative of platelet 
aggregate formation. Acute strenuous exercise has resulted in shorter closure times induced 
by collagen-epinephrine and collagen-ADP in healthy sedentary males (Cadroy et al., 2003). 
Madsen et al., (2009) also showed that brief strenuous exercise enhanced platelet 
aggregation in healthy men, however LTA using PRP showed minor increases when 
compared to whole blood PFA-100 measurements, reinforcing the need for whole blood 
analysis. They also observed increases in plasma vWF which could be partially responsible 
for increased aggregation.  
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Interestingly there was a slight decrease in aggregation post exercise in the HF group, as 
outlined in Figure 4.11 (B). Some studies have revealed an inhibition of platelet aggregation 
by exercise, however the majority of these showed that submaximal, not maximal exercise 
induced these changes (Aldemir and Kilic, 2005) reported that ADP-induced platelet 
aggregation was decreased after exercise in 10 moderately active males.  It is possible that 
in healthy subjects with an intact endothelium possessing normal anti-thrombotic properties, 
vigorous exercise does not present a risk of thrombosis. 
Of note, the change in platelet aggregation post exercise was much greater in the adolescent 
MLF cohort compared to the change observed in the adult cohort, suggesting that in low fit 
adolescents, there exists a baseline hyper-aggregable platelet state. The absolute change in 
platelet aggregation is shown in Figure 4.9, (D) whereby all subjects are represented on the 
graph.  There was a significant difference in the change in platelet aggregation between the 
adolescent groups.  
4.3.8 Overall effect of acute, strenuous exercise on platelet function 
Some hypotheses have been suggested to explain the mechanism whereby acute exercise 
affects platelet function. The responses depend on various factors including exercise 
intensity, duration, fitness of subject and assays employed to test platelet function 
(Aurigemma et al., 2007). Evidently, exercise causes circulatory activation, which could 
result in the mobilisation of newly produced platelets and more metabolically active ones 
from the pulmonary vessels (Bakovic, 2013).  
After high intensity exercise, there is a large production of ROS resulting in oxidative stress 
and cellular damage. Singh et al., (2006) suggest that excess ROS production can counteract 
the natural cellular antioxidant protection and that this process is more prominent in low fit 
subjects. Exercise-induced oxidative stress may be responsible for platelet hyperactivity in 
sedentary males. Strenuous exercise resulted in diminished total antioxidant capacity and 
enhanced susceptibility of LDL to in vitro oxidation in sedentary males (Tozzi-Ciancarelli 
et al., 2002). The oxidative stress elicited by acute strenuous exercise might affect platelet 
responsiveness by encouraging oxidised LDL-mediated platelet activation.   
The elevation of intracellular free calcium levels represents an initial factor in platelet 
activation and signalling. (Wu, 2012). A rise in cytosolic Ca2+ in platelets has frequently 
been reported after exercise (Tozzi-Ciancarelli et al., 2002; Wang et al., 2002) which could 
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be a factor contributing to the platelet hyperreactivity noticed in the MLF subjects. Lee et 
al., (1999) also reported that cytosolic free Ca2+ concentrations were increased after aerobic 
exercise in sedentary, but not fit males.  
The release of ADP and thromboxane A2, (TxA2) initiate positive feedback loops to maintain 
aggregation after platelet activation. Increased urinary and plasma levels of the TxA2 
degradation product thromboxane B2 have been reported post exercise (Weber et al., 2007; 
Whittaker et al., 2013; Santilli et al., 2013). Degranulation of platelets after acute exercise 
results in the expression of soluble mediators P-Selectin, platelet factor 4 (PF4) and 
thromboglobulin, whose levels have been increased after acute exercise. This, in 
combination with increased αIIbβ3 activation could have contributed to excessive adhesion 
and aggregation in MLF subjects (Mockel, 2001; Weber 2007; Peat and Dawson, 2010). 
Elevated catecholamine levels after maximal exercise have also been suggested to increase 
the platelet surface α2 -adrenoreceptor numbers, augmenting their binding affinity to 
fibrinogens. However, unlike maximal exercise, acute moderate exercise does not seem to 
elicit platelet activation to the same extent and would be an interesting area of research (Chen 
and Lip, 2014). 
Juskens et al., (2016) indicated that vigorous exercise induces a hyperreactive overall 
rebalanced haemostatic state, concurrent with increased platelet reactivity in healthy men. 
In addition, other markers of risk factors for CVD were also increased after exercise 
including cardiac troponin T level, inflammatory markers IL-7, Il-8, MCP-1, RANTES and 
PDGF, and endothelial markers vWF were increased in this study.  
4.3.9 Influence of exercise training and CRF on platelet responses to exercise  
A high CRF level is a result of exercise training and habitual physical activity. Therefore, 
research on the effects of longitudinal exercise training on platelet function has mainly 
shown that habitual exercise has favourable effects on platelet function. Therefore, CRF 
might represent a serious determinant for changes in platelet function in response to acute 
exercise.  
Platelet derived microparticles (PMPs) can be released upon platelet activation. After 
strenuous exercise, some studies have reported an increase in PMPs in sedentary men which 
could contribute to the platelet hyperaggregability seen in the MLF subjects in our study 
(Chen et al., 2013; Chen et al., 2014).  Sossdorf et al., (2011) examined the effect of acute, 
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moderate exercise on the manifestation of PMPs and their procoagulant action. In sedentary 
and trained subjects, 90 minutes of cycling at 80% individual anaerobic threshold (IAT) 
triggered a significant elevation of PMPs and an increase in their procoagulant activity. 
Conversely, two hours later the concentration of PMPs remained elevated in the sedentary 
group only. The reduced PMP clearance in the sedentary subjects could result in increased 
circulating levels of proatherogenic elements (Augustine et al., 2014).  
Prostacyclin (PGI2) and nitric oxide (NO) inhibit platelet function. Training can cause a rise 
in NO released from platelets and endothelial cells and perhaps a long-term adaptation to 
exercise resulting in inhibition of platelet aggregation.  (Chen et al., 1993; Green et al., 
2004). The aggregating agent TxA2 was reduced by exercise training. The PGI2/ TxA2 ratio 
has been suggested to have an influential role in defining the extent of platelet aggregation 
(Moncada and Vane, 1979). This could be one of the reasons why HF (and trained) subjects 
could be less sensitive to the same physiological stimulus compared to the MF/MLF. 
Heber et al., (2015) investigated the relationship between CRF and various aspects of platelet 
function in low fit, medium fit and high fit women. This study stratified subjects in a similar 
way to this chapter. Platelet function was assessed by basal and agonist induced surface 
expression of CD62P and CD40L and analysis of intraplatelet ROS. CD40L encourages 
atherosclerosis by altering platelet function (Lievens et al., 2010; Wang et al., 2013). In the 
LF group, basal platelet activation and agonist induced platelet activation were higher 
compared to MF and HF. After 8 weeks of aerobic exercise training (40 minutes of 
walking/running three times per week) in the LF group, their CRF improved and platelet 
function aligned with that observed in the MF and HF groups.  
Culminating the above mechanisms, despite inconsistency in the literature, it appears that 
exercise exerts a substantial influence on nearly all facets of platelet activation and results 
in this chapter are consistent with that theory. Regular exercise training alleviates the 
activating consequence of acute strenuous exercise on platelet function, and recently, long-
term habitual exercise training has been shown to affect platelet function at rest. High levels 
of physical activity represent the normal physiological state (Cordain et al., 1998; Booth and 
Laye, 2010) and subsequently elevated platelet adhesion and aggregation in the MLF and 
MF groups can be viewed as non-physiological and therefore pathological platelet 
hyperreactivity. 
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4.3.10 Correlation analysis between VO2 and platelet parameters 
The relationship between CRF and platelet function has not been exactly defined. We 
assessed degree of bivariate relationship between CRF and platelet function using Pearson 
product coefficient and partial correlation analysis (Table 4.7). We found a significant 
inverse correlation between VO2 and PLT (pre) in the adult cohort which remained 
significant when adjusting for age and BMI. The fact that partial correlation coefficients 
were almost equivalent to Pearson correlations coefficients without accounting for the 
control variables suggests that our results were not majorly influenced by the subjects’ age 
and BMI. Additionally, PLT post was significantly correlated to VO2, but this was attenuated 
when age and BMI adjusted. There was no significant association between basal values for 
platelet indices MPV, PDW, PCT and VO2 max in either the adolescent or adult cohorts, 
consistent with recent research by Alis et al., (2016). Another study investigating the 
relationship between platelet indices and fitness showed that basal MPV was directly 
correlated to endurance performance (21 k half marathon) after adjusting for age, sex, BMI 
and PLT, indicating a relationship between platelet metabolism and aerobic performance. 
(Lippi et al., 2014) 
We found no significant correlations between CRF and basal platelet function parameters 
SC and AS in adolescents or adults. Heber et al., (2016) noted significant correlations 
between VO2 max and platelet function in 62 young women. Basal CD62P expression was 
inversely correlated to VO2 max and so was agonist induced expression of CD62-, CD40L 
and ROS formation. There was a significant inverse correlation between VO2 and platelet 
adhesion (post) in the adolescent cohort and adult cohort as shown in Figure 4.12 and 4.13. 
There was also a significant inverse correlation between VO2 max and aggregation (post) in 
the adult cohort (Figure 4.13) but not in the adolescent cohort. Perhaps epigenetic drift could 
affect older individuals (adults) more due to increased temporal changes as we were 
beginning to see changes in the adolescents, which were not yet significant but followed the 
same trend as the adults. 
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4.3.10 CRF related microRNA  
Work in this chapter shows that platelet function changes are also associated with CRF. 
However, the molecular mechanisms by which exercise affects platelet function remain 
poorly defined. Recently identified miRNAs have gained attention as modulators of platelet 
function (Landry et al., 2009). Evidence for miRNA involvement in exercise-associated 
gene expression changes in a number of cell types in non-trained and trained subjects has 
been illustrated (Radom-Azik et al., 2012). Work by Baggish et al., (2011) showed altered 
expression of circulating miRNA (c-miRNA) in response to acute and chronic exercise in 
athletes. Eight c-miRNA involved in cellular processes fundamental to exercise adaptation 
(muscle contractility and inflammation and angiogenesis) were examined. Four distinctive 
signatures of c-miRNA were observed, including; c-miRNA upregulated by acute 
exhaustive exercise pre and post exercise intervention, c-miRNA responsive to acute 
exercise pre but not post intervention, c-miRNA only responsive to exercise intervention and 
non-responsive miRNA. Furthermore, low CRF was linked with high expression levels of 
three c-miRNAs in the large Nord-Trøndelag Health Study (HUNT) study (Bye et al., 2013). 
As platelets contribute substantially to the circulating miRNA pool (Willeit et al., 2013), 
their unique miRNA profile could be representative of adaptations to exercise.   
4.4 Limitations 
This study was carried out in males only and therefore, the results cannot be generalised for 
the total population. Additionally, the sample size was small for the adult cohort (n=18) 
compared to the adolescent cohort (n=30) and the results of the study are also age limited 
for the adolescent cohort (15-17-year-old) and the adult cohort (mean age 21 years). It would 
be desirable to confirm the observations from this study in larger populations with varying 
ages and to include female subjects. This would add weight and further significance to 
platelet function and CRF following maximal exercise. The inclusion of a control group 
would be beneficial in reinforcing the results of the study highlighting the benefits of regular 
exercise and consequently high CRF levels. Although VO2 max is considered the gold 
standard measurement of aerobic fitness, it is often not attained by those of an 
overweight/obese nature, due to its dependency of effort (Marinov et al., 2013) and while 
every attempt was made to encourage low fit subjects to complete the treadmill test, some 
may not have reached their peak VO2. The results are also limited to an acute bout of maximal 
exercise as we did not investigate submaximal exercise.  
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4.5 Summary and conclusion 
This study aimed to develop the array of literature on the effects of acute vigorous exercise 
on platelet function and is the first to compare both basal and exercise induced platelet 
function in healthy Irish adolescents and adults. Results showed minimal basal differences 
between MLF and HF adolescents whereas MF adults had a significantly higher platelet 
count than HF adults. Acute exhaustive exercise increased platelet function in adults and 
adolescents, and this increase was more pronounced in moderate to low fit adolescents. The 
same effect of exercise in the HF adults and adolescents was not observed, possibly due to 
adaptive mechanisms from habitual physical activity and exercise.  
It appears there is a collective proinflammatory milieu of all blood cells after strenuous 
exercise but nonetheless platelets are important players in this response. The results suggest 
this hyperreactive haemostatic state is much more pronounced in subjects with a lower CRF. 
Our results support past studies highlighting the different effect of CRF on platelet function 
in adults with novel findings showing more pronounced changes occurring in adolescents. 
Those with a low CRF level are at increased risk of thrombotic events following maximal 
exercise. These findings highlight the need to develop a strategy to increase activity amongst 
adolescents and adults to combat the early development of subclinical CVD.  
In conclusion, this study demonstrates that acute, strenuous aerobic exercise enhances the 
thrombotic tendency depending on the individuals CRF level. CRF is an independent and 
reproducible quantitative measure reflecting physical activity patterns and may better mirror 
the adverse consequences of a sedentary lifestyle than adiposity measures. 
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Chapter Five 
Chapter outputs 
 Physical inactivity resulted in significant increases in platelet count, plateletcrit and 
platelet adhesion in healthy males 
 Physical inactivity resulted in a slight elevation in aggregation, platelet reactivity 
index (PRI) and microvesicle concentration in healthy males 
 Physical inactivity resulted in altered expression of 15 protein biomarkers  
 We identified a set of 22 ‘physical inactivity’ related miRNA, with potential targets 
involved in pathways associated with platelet function 
 
Contributions from others 
 Olink Bioscience (Sweden) performed the Proseek Biomarker Assay on isolated 
plasma samples. 
 Applied Biosystems (France) ran the RT-PCR microRNA assay using The miRNA 
profile was determined by RT-qPCR using Applied Biosystems OpenArray® plate 
technology on the QuantStudio™ 12K Flex Real-Time System. 
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Chapter Five: The effect of Physical Inactivity on Platelet Function 
5.1 Introduction 
Chapters 3 and 4 demonstrated that both regular physical inactivity (PI), otherwise known 
as sedentary behaviour, and low cardiorespiratory fitness (CRF), both negatively impact 
platelet function. In particular, physical inactivity has major health effects globally, 
contributing to the 4th leading cause of death. Evidence has shown that physical inactivity 
and sedentary behaviour have direct effects on CVD risk factors including obesity and 
hypertension (Prentice and Jebb, 2004). Despite attempts to encourage a physically active 
lifestyle, rates of inactivity have remained high with a staggering 68% of Ireland’s 
population not meeting minimum guidelines for regular physical activity (WHO 2009; 
Healthy Ireland, 2015). 
However, in contrast to the accumulating evidence supporting the benefits of regular 
exercise, relatively little is understood about the deleterious mechanisms underlying the 
physiological, cellular and molecular responses to PI, specifically with regard to platelet 
function. Experimental models to mimic physical inactivity can be achieved through various 
techniques. Reducing ambulatory activity from >10,000 steps to <2000 steps per day has 
previously been employed (Krogh-Madsen et al., 2010). The European Space Agency 
(ESA), use ground-based models of microgravity (the condition in which people or objects 
appear to be weightless). One model is that of dry immersion (DI), frequently used to study 
the effects of spaceflight on human physiology in a precisely controlled environment. DI 
involves immersing a subject in a bath of thermoneutral water covered by a waterproof fabric 
for a specific time period (Coupe et al., 2013).  
Several factors act simultaneously on the human body during immersion, including 
hydrostatic compression, supportlessness and extensive physical inactivity. Hypokinesia and 
hypodynamia are the major characteristics of physical inactivity induced by dry immersion. 
Hypodynamia involves a reduction in postural muscle load, whereas hypokinesia is a decline 
in motor activity. For these reasons, DI has been well accepted as a valuable tool to study 
physical inactivity (Widlansky, 2010). Subjecting twelve healthy men to three days of DI 
presented a unique opportunity to analyse the specific effects of physical inactivity on 
platelet and related biomarkers. Therefore, the aim of this study was to examine the effect 
of three days of acute physical inactivity on platelet function. 
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5.1.2 Chapter aims and experimental approach 
Hypothesis: 
It was expected that the 3 days of Dry Immersion would be sufficient to induce the 
physiological effects of microgravity. In particular, the support withdrawal by dry immersion 
should induce alterations at a higher rate than bed rest. 
We hypothesised that three days of physical inactivity, induced by DI would result in 
increases in platelet activation, adhesion and aggregation, as well as inflammatory processes. 
Furthermore, as microRNA (miRNA) expression patterns likely influence platelet function, 
we further hypothesised that physical inactivity would alter the platelet miRNA profile. 
Main aims:  
 The main aim of the study was to investigate the effects of 3 days of Dry immersion, 
acting as model of acute physical inactivity on platelet function – Platelet indices, 
Impact-R analysis and VASP phosphorylation in 12 healthy males. 
 Investigate changes in cardiovascular and inflammatory related protein biomarkers, 
and microvesicle levels, in platelet-poor plasma as biomarkers of platelet activation. 
 A secondary aim was to assess the clinical aspects (adverse events, comfort of the 
subjects etc.) of the study 
 Establish a shortlist of the most highly expressed microRNA in platelets 
 Determine if the miRNA profile of platelets is altered with physical inactivity by way 
of DI. Elucidate changes in miRNA profile pre- and post-immersion 
 Discover biomarkers of platelet function induced by sedentariness/physical inactivity 
in healthy males. 
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5.1.3 Study design 
A detailed overview of the experimental design was provided in Chapter 2 (Section 2.2.5.4). 
Briefly, 12 healthy French males participated in the study. All subjects provided informed 
consent in compliance with the Helsinki Declaration. The experimental protocol was 
approved by the local ethics committee (CPP Sud-Ouest Outre-Mer I, France) and the 
French Health Authorities. The study was organised by the Institute for Space Medicine and 
Physiology (MEDES) Toulouse, France. The subjects were selected based on a clinical 
investigation consisting of a detailed medical history, physical examination, an 
electrocardiogram, general blood screening, and urine analyses. Participants were free from 
muscular or neurological pathologies. 
General dry Immersion method (outlined in detail in Chapter 2) 
In brief, DI involves immersing the subject, who is covered with a unique elastic waterproof 
fabric, in a large tank of thermoneutral water (Figure 5.1). The subject, suspended in the 
water mass, remains dry, protected by the waterproof film. The fabric is thin and large 
enough to guarantee that the water’s hydrostatic pressure is equally distributed over the body 
surface, generating conditions similar to the complete lack of structural support experienced 
in microgravity.  
 
Figure 5.1: The dry immersion method. The left figure shows a subject in a dry immersion bath 
used in the study and the right figure depicts the supportlessness and lack of structure experienced in 
the bath. 
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Blood samples 
Blood samples were drawn by a nurse in MEDES, at 7am in the morning after an overnight 
fast. Blood sampling in pre and recovery periods was also performed after the subject had 
rested in the supine position for 30 min. The division of blood samples is outlined Table 5.1  
Table 5.1: Division of blood during the three day DI study. 10 millilitres of blood for platelet 
work was collected on BDC-3 (pre), R+0 (post) and R+1 (recovery). 
 
Stage Baseline data collection Dry Immersion Recovery 
Day -x -3 -2 -1 1 2 3 0 1 
Blood volume (mls) 9 32 32 111 18 111 34 18 55 
Platelet allocation (mls)   10      10 10 
 
Complete blood count analysis 
Complete blood counts were performed on every sample after blood draw, using the Sysmex 
XN-3000TM Haematology system. Haematological and platelet indices parameters were 
obtained this way. Calculation of percent changes in plasma volume were calculated from 
changes in HGB and HCT using the Dill and Costil method (Dill and Costil, 1974). DPV (%) 
= 100 × [HbB (1 − 0.01Hcti)]/ [Hbi (1 − 0.01HctB)] – 100. 
Platelet function analysis 
Platelet function (adhesion and aggregate size) was measured by Impact- R Cone device 1-
hour post blood draw.). Platelet function was also measured by the assessment of platelet 
VASP phosphorylation. Platelet VASP phosphorylation was measured by flow cytometry 
and a standardised P2Y12/VASP kit (Biocytex, Stago, France) according to the 
manufacturer’s instructions. 
Protein biomarker analysis  
Platelet poor plasma (PPP) samples were sent to Olink Bioscience (Upsalla, Sweden) to 
measure the expression of 184 cardiovascular/inflammatory protein biomarkers using 
unique Proximity extension assay (PEA) technology. Protein biomarkers were measured 
each time point during the DI.  
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MicroRNA analysis 
Platelet miRNA profiles were assessed at the pre and post DI time points. Total leukocyte-
depleted RNA from platelets was extracted using the miRVANA RNA extraction kit. The 
miRNA profile was determined by RT-qPCR using Applied Biosystems OpenArray® plate 
technology on the QuantStudio™ 12K Flex Real-Time System. For a complete miRNA 
profile, 754 human miRNAs were quantified using two panels of 384 miRNA. The A panel 
contains miRNA targets which are highly expressed and tend to be functionally defined, 
whereas miRNA targets on the B panel are usually less abundant and not as well functionally 
defined.  
Microvesicle analysis  
PPP samples were analysed by the Nanosight NS300 to determine microvesicle size and 
concentration at each time point. This device employs Nanoparticle Tracking Analysis 
(NTA) technology using the properties of both light scattering and Brownian motion to 
analyse particles in liquid suspension. Mean ± SD output for the concentration, mean size 
and SD of the sample are provided from the NS300 software after sample analysis. 
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5.2 Results 
5.2.1 Effect of dry immersion on physiological characteristics  
Table 5.2 shows the characteristics of the study population. Heart rate (HR) and blood 
pressure (BP) were continuously monitored throughout the experiment. HR rose 
significantly at post and subsequently decreased significantly at recovery. Body weight 
during immersion decreased significantly by approximately 1.3 kg (Figure 5.2). 
Table 5.2: Characteristics of the study population. BMI - Body mass index, VO2 max – Aerobic 
capacity. 
Characteristic Mean ± SD 
Age (yrs) 31.75 ± 4.81 
Weight (kg) 74.54 ± 7.21 
Height (m) 1.78 ± 0.07 
BMI (kg/m2) 23.48 ± 1.54 
VO2max (ml/kg/min) 38.75 ± 3.98 
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Figure 5.2: Changes in heart rate, blood pressure and weight during the dry immersion. Graphs 
represent the mean ± SD of each parameter at each time point. A – Systolic blood pressure, B – 
Diastolic blood pressure, C -  Heart rate and D – Weight. * P<0.05. Paired samples t-test and repeated 
measures ANOVA adjusted for Age, BMI and VO2).  
 
* * 
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5.2.2 Effect of physical inactivity on haematological characteristics 
Changes in haematological parameters in response to DI were measured (Figure 5.3). There 
was a significant increase in WBC, RBC concentration, HGB and HCT at the post time point. 
There was a significant decrease in WBC, RBC concentration and HCT between post and 
recovery, almost to basal levels.  
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Figure 5.3: Effect of dry immersion and physical inactivity on RBC and WBC characteristics. 
Graphs represent the mean ± SD of each parameter at each time point. A – White blood cell count, 
B – Red blood cell count, C – Haemoglobin and D -  Haematocrit. * P<0.05. Paired samples t-test 
and repeated measures ANOVA (adjusted for age, BMI and VO2).  
 
 
 
 
* * 
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* * 
* * 
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5.2.3 Effect of physical inactivity on platelet indices 
The effect of DI on various platelet indices, as a marker of platelet activation, was also 
evaluated. There were no changes in platelet large cell ratio, mean platelet volume and 
platelet distribution width between any time points. There was a significant increase in 
platelet count and plateletcrit from pre to post immersion and subsequently, a significant 
decrease in these parameters from post time point to recovery (Figure 5.4). 
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Figure 5.4: Effect of dry immersion and physical inactivity on platelet indices. Graphs represent 
the mean ± SD of each parameter at each time point. A – Platelet count, B – Mean platelet volume, 
C – Platelet distribution width, D – Platelet large cell ratio and E – Plateletcrit. * P<0.05. Paired 
samples t-test and repeated measures ANOVA (adjusted for age, BMI and VO2).  
 
* * 
* * 
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5.2.4 Effect of physical inactivity on platelet function  
Platelet adhesion and aggregation were measured by Impact R analysis pre, post and at 
recovery. Figure 5.5 and 5.6 show the effect of physical inactivity on platelet function. There 
was a significant increase in platelet adhesion post-immersion and a subsequent decrease 
between the post and recovery time points. There was also a significant increase in platelet 
aggregation from pre to post DI.  
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Figure 5.5: Effect of dry immersion on platelet function assessed by Impact R analysis. Graphs 
represent the mean ± SD of each parameter at each time point. A – Platelet adhesion and B- Platelet 
aggregation. * P<0.05. Paired samples t-test and repeated measures ANOVA (adjusted for age, BMI 
and VO2). 
 
 
 
 
 
 
 
Figure 5.6: Impact R images from subject J at each stage of dry immersion. Image shows platelet 
adhesion and aggregation at A – pre immersion, B –post immersion, and C –at the recovery time 
point. 
 
 
 
* * 
* 
A. Pre B. Post C. Recovery 
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5.2.5 Effect of physical inactivity on platelet VASP phosphorylation 
Platelet VASP phosphorylation is frequently employed as a marker of platelet activation. To 
assess if basal platelet VASP phosphorylation was affected by physical inactivity, the 
standardised P2Y12/VASP kit was used in a flow cytometry assay. The platelet reactivity 
index (PRI) represents changes in VASP phosphorylation. There was a small insignificant 
increase in PRI post DI (Figure 5.8). There were individual fluctuations in VASP 
phosphorylation during the DI. 
 
Figure 5.7: Gating strategy for the analysis of platelet VASP phosphorylation. Platelets were 
gated by side and forward scatter (A) and then by expression of CD61 (B). VASP-P phosphorylation 
was quantified by median and geometric mean fluorescence intensities (C). All data was analysed 
with Flowjo software. 
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Figure 5.8: Effect of dry immersion on overall platelet VASP phosphorylation. Graph represents 
the mean ± SD of the PRI at each time point. PRI = Platelet reactivity index. Paired samples t-test 
and repeated measures ANOVA (adjusted for age, BMI and VO2).  
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5.2.6 Effect of physical inactivity on protein biomarker expression 
Protein biomarker expression of platelet poor plasma (PPP) was assessed using the 
Cardiovascular and Inflammatory protein biomarker panels (Olink Bioscience). Biomarker 
overlap between panels resulted in simultaneous evaluation of the expression levels of 157 
protein biomarkers in each sample. The levels of 15 proteins differed significantly between 
time points (Table 5.3). Labelled in red are proteins discussed in this chapter. Results are 
expressed as normalised protein expression (NPX) on a log2 scale. Therefore, a normalised 
increase of 1 is equal to a two-fold increase in protein amount. Protein changes are shown in 
Figure 5.9 and 5.10.  
Table 5.3: Protein biomarkers which were differentially expressed after the DI. The column on 
the left shows proteins from the CVD panel and the column on the right shows proteins from the 
inflammation panel. Highlighted in red are proteins discussed in this chapter. 
 
Protein Biomarker Panel 
Cardiovascular panel Inflammatory Panel 
Protein name Main  
function 
Unique 
gene 
symbol 
Change in 
expression 
post DI 
Protein name Main function Unique 
gene 
symbol 
Change in 
expression 
post DI 
Adreno-
medulin 
Vasodilation 
and regulation 
of hormone 
secretion 
ADM ↓ Axin-1 Negative 
regulator of 
the WNT 
signalling 
pathway 
AXIN1 ↑ 
Dickkopf 
related 
protein-1 
WNT 
signalling 
pathway 
inhibitor  
DKK1 ↑ Interleukin-6 Pro-
inflammatory 
cytokine 
IL6 ↑ 
Heat shock 
protein-27 
Stress 
resistance, 
actin 
organization 
HSPB1 ↑ STAM-
binding 
protein 
Cytokine-
mediated 
signalling  
STAMBP ↑ 
Lectin like 
oxidised 
LDL 
receptor-1 
Binds, 
internalises, 
degrades 
oxidized LDL 
OLR1 ↑ Sulfotransfera
se 1A1 
Catalyse the 
sulfate 
conjugation of 
hormones and 
neurotransmitter
s  
SULT1A1 ↑ 
NF-Kappa B 
essential 
modulator 
Activation of  
Inflammatory, 
immune 
genes  
IKBKG ↑ Sir-2 like 
protein  
Unknown but 
possible role in 
epigenetic gene 
silencing 
SIRT2 ↑ 
Renin Activation of 
angiotensinoge
n pathway 
REN  ↑ Matrix 
metalloprotein
ase-10 
Degradation of 
extracellular 
matrix  
MMP10 ↓ 
Proto-
oncogene 
non receptor 
tyrosine 
kinase 
Regulation of 
cell growth 
SRC  ↑ Matrix 
metalloprotein
ase -3 
Degradation of 
extracellular 
matrix normal  
MMP3 ↓ 
Tissue 
plasminogen 
activator 
Disintegration 
of blood clots 
PLAT ↑     
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Figure 5.9: The effect of dry immersion on plasma cardiovascular protein biomarkers. The 
graphs represent mean ± SD of the subjects at time points pre, post and recovery. A – Heat shock 
protein 27, B – Lectin like oxidised LDL receptor, C – NF-Kappa-B essential modulator, D – Proto-
oncogene tyrosine protein kinase and E – Dickkopf related protein. * P<0.05. Paired samples t-test 
and repeated measures ANOVA (adjusted for age, BMI and VO2). 
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Figure 5.10: Effect of dry immersion on inflammatory protein biomarkers. Graphs represent the 
mean ± SD. A- Axin-1, B – Sir2 like protein, C -  Interleukin 6, D – Matrix metalloproteinase 3 and 
E – Matrix metalloproteinase 10. Axin and MMP-3 were specific to INF panel while Il-6, SIRT-2 
and MMP-10 were also found on the CVD panel.  * P<0.05. Paired samples t-test and repeated 
measures ANOVA (adjusted for age, BMI and VO2). 
 
* 
* 
* * * 
* 
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5.2.7 Effect of physical inactivity on platelet poor plasma microvesicles 
Platelet poor plasma (PPP) samples were analysed by Nanosight technology to determine 
MV size and concentration at each time point. There was a decrease in the average MV size 
and an increase in average MV concentration at post DI. There was a significant decrease in 
MV size standard deviation after the DI (Figure 5.11). For further analysis, MVs were 
divided into three categories: Exosomes, microparticles and larger microparticles with 
modest increases in each category after DI, however the changes were not statistically 
different.   
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Figure 5.11: Effect of physical inactivity on microvesicle size and concentrations. Graphs represent the 
mean ± SD of each parameter at each time point. A – Average microvesicle size, B – Average microvesicle 
concentration, C - Exosome concentration, D – Microparticle concentration and E – Large microparticle 
concentration. * P<0.05. Paired samples t-test and repeated measures ANOVA.  
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5.2.8 Effect of physical inactivity on platelet microRNA expression 
miRNA expression profiles were analysed from non-normalized leukocyte-depleted platelet 
RNA (ranging from 3.5 to 7.0 ng) extracted from equal volumes of platelet rich plasma from 
8 of the 12 subjects at the time points pre and post immersion. Western blots of miRNA 
regulatory proteins are shown in Figure 5.12 (A) and the number of detectable miRNA after 
the DI is shown in part (B). Heat maps comprised of the most highly expressed platelet 
miRNA (miRNA across all subjects with the lowest CT value) were then constructed for 
both the A and B panel of miRNA. This allowed visualisation of basal miRNA expression 
profiles between subjects (pre DI) by comparing the expression of each subject’s miRNA 
targets to that of a randomly selected subject, subject C.  This is shown in Figures 5.13 and 
5.14. A shift in colour from red to blue indicates decreasing expression of that miRNA 
compared to subject C. 
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Figure 5.12: Confirmation of miRNA processing machinery in human platelets and miRNA numbers 
during the dry immersion study. Graphs represent the mean ± SD of each parameter. A – shows the presence 
of regulatory miRNA components Dicer and Argonaute 2 in platelets compared to endothelial cell controls. 
Western blot gels were loaded with 25µg of endothelial or platelet protein. B – shows the number of miRNA 
either up or downregulated after the dry immersion on the A and B panel. 
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Figure 5.13: Heat map showing the most highly abundant A panel platelet miRNA before DI. 
Each miRNA is listed on the right hand side and the subjects are listed on the bottom of the panel. 
The colour key is shown on the left. A change in colour from dark red to blue indicates a decrease in 
miRNA expression levels compared to the miRNA target expression of subject C.   
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Figure 5.14: Heat map showing the most highly abundant B panel platelet miRNA before DI. 
Each miRNA is listed on the right hand side and the subjects are listed on the bottom of the panel. 
The colour key is shown on the left. A change in colour from dark red to blue indicates a decrease in 
miRNA expression levels compared to the miRNA target expression of subject C.    
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5.2.8.1 Identification of miRNA affected by physical inactivity 
By comparing the miRNA expression profiles of the subjects between pre and post dry 
immersion, we identified 22 significantly differentially expressed miRNA with a fold change 
of more than 1.2 (12 of which were upregulated and 10 which were downregulated). Most 
reported miRNA fold changes are small (~ 1.5 fold) (Daniels et al., 2014). The miRNA that 
were differentially expressed on the A card are shown in Figure 5.15, parts A and B, while 
the miRNA differentially expressed on the B card are shown in the same Figure, parts C and 
D.  
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Figure 5.15 Differentially expressed miRNA at the post dry immersion time point. miRNA 
profiles were assessed only at the pre and post time points. This figure shows miRNA which were 
differentially expressed at the post compared to pre time point. All data are expressed mean + SD. 
Graph A shows miRNA that were up regulated after DI on the A card, and graph B shows miRNA 
that were downregulated after DI on the A card. Graph C shows B card up regulated miRNA, whilst 
graph D shows B card downregulated miRNA. * P<0.05. Paired samples t-test and repeated measures 
ANOVA. 
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5.2.8.2 Bioinformatic analysis of differentially expressed miRNA  
To extrapolate biological meaning from miRNA that were significantly up or downregulated 
after the DI, bioinformatics was performed. This involved determination of putative targets 
using online software tools including Targetscan and microRNA.org. Following this, 
involvement of these targets in pathways of interest from the Kyoto Encyclopaedia of Genes 
and Genomes (KEGG) were analysed using the DAVID bioinformatics database. To help 
visualise the regulatory potential of each miRNA we examined, a table was constructed 
illustrating the number of potential genes the miRNA could target and the number of KEGG 
pathways the predicted targets were part of (Table 5.4).  
Table 5.4: Bioinformatics of differentially regulated miRNA. Table of miRNA regulated by DI 
from the A and B panels. Table shows the number of in-silico predicted conserved targets of each 
miRNA, in addition to the number of GO biological processes and KEGG pathways that these 
miRNA are putatively involved in. 
 
 miRNA  Fold 
change 
direction 
Conserved 
targets 
KEGG 
Pathways 
A card     
 miR-143 ↓ 497 24 
 miR-199a ↓ 631 16 
 miR-200a ↓ 896 18  
 miR-500 ↓ 185 8  
 miR-203 ↓ 964 32  
 miR-888 ↓ 3350 36  
 miR-302a ↓ 1022 32 
 miR-30b ↑ 6957 14 
 miR-211 ↑ 2809 46 
 miR-210 ↑ 4046 38  
 miR-484 ↑ 2696 26 
 miR-15a ↑ 3213 33 
 miR-299-5p ↑ 279 1 
 miR-494 ↑ 620 28  
B card     
 miR-145* ↓ 891 22 
 miR-15* ↓ 1508 44  
 miR-374a* ↓ 4289 24 
 miR-744* ↑ 3696 22 
 miR-24-2* ↑ 741 18 
 miR-190b ↑ 224 10 
 miR-34a* ↑ 4289 22  
 miR-106B* ↑ 698 21 
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Table 5.5: Involvement of differentially regulated miRNA in KEGG cell pathways. 
Bioinformatics of differentially regulated miRNA. Table shows KEGG pathways common to a 
number of differentially expressed miRNA and which are involved in platelet function. 
 
KEGG pathway 
Wnt signalling  Regulation of 
Actin 
cytoskeleton 
ECM receptor 
interaction  
Toll like 
receptor  
miR-888 miR-143 miR-143 miR-143 
miR-299a-5p miR-199a miR-302a miR-15a 
miR-484 miR-500 miR-199a miR-34a* 
miR-199a miR-302a miR-484  
miR-200a miR-374a   
miR-500 miR-34a*   
miR-203 miR-744   
miR-302a miR-494   
miR-190b miR-15a*   
miR-15a* miR-106b*   
miR-145    
miR-106b*    
miR-34a*    
miR-24-2    
miR-211    
miR-15a    
miR-494    
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5.2.8.3 KEGG pathway analysis 
Maps of key pathways involved in platelet function and activation (Figures 5.16-5.18) were 
downloaded from the KEGG database using DAVID. Pathways were chosen based on their 
involvement in platelet function and signalling, specifically in adhesion and aggregation, but 
also their inflammatory potential. Included in these were the Wnt signalling pathway, 
regulation of actin cytoskeleton, ECM interaction and Toll-like receptor pathway, of which 
the Wnt signalling pathway appeared repeatedly in both the up and downregulated miRNA 
targets. Genes within the pathways that were predicted targets for the miRNA were circled. 
Genes that were potential targets for multiple miRNA were circled red, genes that were 
targets for a single miRNA were circled yellow. Potential miRNA targets of genes involved 
in the Wnt signalling pathway are shown in Figure 5.16, potential miRNA targets of genes 
involved in the reorganisation of the actin cytoskeleton pathway are shown in Figure 5.17 
and potential miRNA targets of genes involved in the ECM receptor-interaction pathway are 
shown in Figure 5.18.  
 
Figure 5.16: KEGG map of the Wnt Signalling pathway. Wnt signalling negatively 
regulates platelet function and miRNA targeting genes in this pathway were relevant to this study. 
Genes circled in red are predicted targets for multiple miRNA, and genes circled in yellow are 
predicted targets of single miRNA.   
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Figure 5.17: KEGG map of the regulation of actin cytoskeleton pathway. Reorganisation of the 
actin cytoskeleton is a key event in platelet activation and adhesion, and therefore this pathway was 
of interest with regard to platelet function. Genes circled in red are predicted targets for multiple 
miRNA, and genes circled in yellow are predicted targets of single miRNA. 
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Figure 5.18: KEGG map of the ECM – receptor interaction pathway. Platelets express 5 
different integrin’s, which facilitate platelet adhesion to ECM proteins including collagen, laminin 
and fibronectin, amongst others, during platelet adhesion. This pathway was therefore chosen as it 
was relevant to platelet adhesion functions. Genes circled in red are predicted targets for multiple 
miRNA, and genes circled in yellow are predicted targets of single miRNA. 
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5.2.6.3.1 miRNA targets of the Wnt signalling pathway 
The Wnt signalling pathway involved the largest number of differentially regulated miRNA 
post DI, as shown previously in Table 5.5. The protein biomarkers Axin1 and DKK1 were 
also differentially expressed post DI. Their gene targets can be regulated by multiple 
miRNA, which, together can affect gene expression and protein expression. We used online 
databases to determine additional miRNA which could target Axin1 and DKK1 (Figure 
5.19). The differentially expressed miRNA are shown with an asterisk above them, while 
other potential targets do not have an asterisk. The combined action of multiple down or 
upregulated miRNA could have affected the gene and subsequent protein expression of 
Axin1 and DKK1.  
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Figure 5.19: Potential miRNA targets of genes involved in the Wnt signalling pathway. All data 
are expressed mean ±SD. Graph A shows miRNA which are potential targets of DKK1 and graph B 
shows downregulated miRNA which are potential targets of Axin-1. 
* * 
* 
* 
* 
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5.3 Discussion 
Despite the strong links between physical inactivity and CVD risk (Prasadi and Das 2009), 
there remains a relative scarcity of experimental investigation into the effects of physical 
inactivity in healthy subjects, making it difficult to quantify the cellular and molecular 
effects of physical inactivity. Using the DI method, this study allowed us a unique 
opportunity to investigate the effects of physical inactivity on platelet function.  
Exposure to microgravity induces modification of all physiological systems, and in 
particular the cardiovascular system. DI is characterised by enforced physical inactivity 
(Grigor’ev et al., 2004). During DI, the muscle atrophy, bone mass loss, cardiovascular 
deconditioning and other alterations mimic the adaptation observed in astronauts. CV 
deconditioning is a state whereby the CV system does not react efficiently to challenge, 
distinguished by a reduced capability for exercise, increased resting heart rate, orthostatic 
intolerance and tachycardia (Coupe et al., 2009). Initial reactions to DI occur in the first 12 
hours and are caused by immediate modifications in body fluid distribution and a removal 
of support structure (Naviaslova et al., 2011). Primary responses include haemodynamic and 
water-electrolyte changes (Larina et al., 2011). 
We aimed to investigate the effects of physical inactivity on the cellular and molecular 
aspects of platelet function using a number of techniques. The main finding of this chapter 
was that physical inactivity by way of DI induced subtle / modest changes in platelet function 
and platelet biomarkers in healthy men. The degree of changes in parameters of platelet 
function was found to vary among individuals. These changes were characterised by a rapid 
onset. Twenty-four hours of normal physical activity appeared sufficient to reverse signs of 
cardiovascular impairment and to restore plasma volume and platelet activation markers to 
near basal levels.  Evaluation of platelet poor plasma protein and platelet microRNA 
expression before and after the DI resulted in identification of 15 proteins, which were 
differentially expressed (DE) after the DI and 22 miRNA, which were DE expressed after 
the dry immersion. 
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5.3.1 Characteristics of the study population 
The study included a group of 12 French healthy male volunteers with a mean age of 31.75 
± 4.38 years and mean BMI of 23.48 ± 1.54 kg/m2 (Table 5.2). Aerobic fitness measured 
by VO2 max had an average of 38 ml/kg/min. During immersion, the subjects remained in 
the supine position for all activities, except for hygiene procedures, which were performed 
in a lateral position. Overall, the 3-day DI was well tolerated by the study group with no 
drop-outs. However, all subjects experienced moderate back pain at the beginning, as shown 
in the VAS scale (Appendix C). Analysis of cortisol levels in DI studies usually indicates an 
increase on the first day of DI, reflecting emotional stress (Naviaslova et al., 2011). 
5.3.2 Effect of physical inactivity on physiological characteristics 
Figure 5.2 displays changes in physiological parameters during the DI. Body weight 
decreased by approximately 1kg at the end of the DI. Other studies have reported weight 
loss of approximately 1kg at the end of a 3-day DI (Iwase et al., 2000) and 2kg at the end of 
a 7 day DI (Larina et al., 2008; Naviaslova et al., 2011). Grigorev and Shulzhenko (1979) 
state that the weight loss is due to increased fluid loss. A reduction in lean body mass but an 
increase in adipose tissue was shown by BIA analysis in a 5-day DI in 14 healthy males 
(Noskov et al., 2014).  
We observed an increase in systolic and diastolic blood pressure after the DI, with decreases 
in both parameters after the recovery period, suggesting a quick cardiovascular adaptation 
upon return to normal activity. Most studies have not found significant changes in resting 
blood pressure after 3-7 days of DI (Iwase et al., 2000, Bravyi et al., 2008). Other authors 
have described 15-20% increases in diastolic BP after 7 days (Vil-Viliams and Shulzhenko, 
1980). There was a significant increase in Heart Rate (HR) post DI and a significant decrease 
between the post and recovery stages (Figure 5.2). This data agrees with other studies which 
reported increased HR after DI (Pavy-Le Tron et al., 2007; Coupe et al., 2013).  
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5.3.3 Effect of physical inactivity on haematological parameters 
Figure 5.3 highlights changes in red and white blood cell parameters before, after and at the 
recovery time point of the DI. Both spaceflight and its proxies result in an initial plasma 
volume decrease (approximately 10-15% on the first day) after which it remains stable 
(Navasiolava et al., 2010; Larina et al., 2008). We noted a 14 % decrease in plasma volume 
post DI and a 4% increase at the recovery time point. Blood viscosity usually increases due 
to the decrease in plasma volume. With the reduction of plasma volume in space, 
corresponding decreases in RBC is required to maintain blood viscosity (Watenpaugh et al., 
2016). However, hemoconcentration was reflected by an increase in RBC post DI. There 
were also significant increases in HGB and HCT after the immersion, although these values 
remained within the normal limits for healthy individuals. These findings were expected; as 
lower plasma volume would result in increased concentrations of RBCs. In general, real and 
simulated microgravity results in changes to physical properties of RBCs (Naviaslova et al., 
2011) 
Other groups have reported similar results after both simulated and real microgravity 
experiments. Both a 7-day DI (Ivanova et al., 2011) and 5-day DI (Ivanova et al., 2013) 
resulted in an increase in RBCs and altered morphological composition of red blood in 
healthy males. Navasiolava et al., (2010) reported a significant increase in RBC, HGB and 
HCT after seven days of DI, which returned to normal after recovery. Unlike our study, they 
did not observe a significant difference in WBC. Bedendeeva et al., (2009) noted a 40% 
increase in leukocytes after DI. Overall, most haematological indices appear to increase after 
DI.  
5.3.4 Effect of physical inactivity on platelet indices 
Similar to chapters 3 and 4, we investigated the effect of DI on all platelet indices as primary 
indicators of platelet activation and function. This is highlighted in Figure 5.4. There was an 
increase in platelet count (PLT) between pre and post time points, probably reflecting the 
loss of plasma volume during the DI. There was a significant decrease in PLT between post 
and recovery suggesting that platelet count returned to pre-immersion levels once subjects 
began to resume ambulatory activity. Navasiolava et al., (2010) found no significant 
difference in PLT after 7 days of DI. Other studies have indicated a significant increase in 
PLT after 7 day DI (Kirichenko et al., 1985, 1988).  
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There were no changes in MPV, PDW or PLCR after three days of DI. There was a 
significant increase in plateletcrit from pre to post and a significant decrease in plateletcrit 
from post to recovery. Plateletcrit appears to be one of the more sensitive platelet indice 
markers, as not only is it reflecting changes in this intervention, it also reflected changes in 
the exercise study. Overall, the combined increases in PLT and PCT platelet could be a 
reflection of the activation status of platelets after the DI.  
5.3.5 Effect of physical inactivity on platelet function 
The effect of physical inactivity on platelet function was quantified using the Impact R cone 
and plate analyser and results are shown in Figure 5.5. We observed a significant increase in 
platelet adhesion (SC) from pre to post immersion suggesting stronger platelet-surface 
interactions in response to physical inactivity and DI. Accordingly, there was a significant 
decrease in SC from post to recovery indicating platelet adhesion levels had returned to their 
basal state. There was a significant increase in AS from pre to post suggesting that PI results 
in elevated platelet aggregation with increased activation of the αIIbβ3 receptor and 
increased affinity for fibrinogen binding. Platelet aggregation decreased slightly from post 
to recovery. The reduction in blood volume as a consequence of reduced total body water in 
the body during microgravity has been suggested as a factor for thrombotic tendencies, 
which could have been a determinant of increased platelet activation in this study 
(Watenpaugh, 2001). Figure 5.6 highlights the changes (increases) in platelet adhesion and 
aggregation observed using the Impact R pre and post DI and following one day of recovery. 
Physical inactivity can cause endothelial dysfunction (Moyna and Thompson, 2004; Di 
Francesco-Marino 2009) which can affect platelet function. The decrease in shear stress 
forces during physical inactivity and DI can negatively impair both endothelial and platelet 
function. Laminar shear stress exerts an atheroprotective effect on the endothelium (Pan, 
2009) causing a release of vasoactive substances such as nitric oxide (NO) and prostacyclin, 
which negatively regulate platelet activation. In contrast, regions of low or oscillatory shear 
stress, such as that induced by DI, results in the procoagulant phenotype of endothelial cells 
(ECs) and are associated with atherosclerotic plaque development, attracting platelets and 
enhancing the thrombotic potential. Increase in soluble von Willebrand factor (vWF), tissue 
factor (TF) expression and activity and endothelial microparticle production can act as 
mediators to induce platelet activation under disturbed flow, inferring that altered shear 
stress may not activate platelets directly (Ruggeri et al., 2009; Yin et al., 2016).  
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Haemoconcentration, body fluid redistribution, hypodynamia experienced during DI may 
increase the risk of thrombosis and could also have contributed to enhanced platelet adhesion 
and aggregation observed after the DI (Naviaslova et al., 2011). The increase in blood 
viscosity after 24 hours of DI could also have been a contributory factor to the platelet 
hyperaggregability (Ivanov et al., 1983). This could be tested by the use of a viscometer and 
in parallel with platelet function tests could provide informative data (Kim et al., 2000). 
Interestingly, Kuzichkin et al., (2010) observed an increase in plasma fibrinogen 
concentration after short-term space flights and 7-day DI. Increased availability of plasma 
fibrinogen could influence platelet aggregation and assessment of fibrinogen levels and 
αIIbβ3 activation levels by flow cytometry would provide an insight into the increased 
platelet aggregation post DI (Vij, 2009).  
A major symptom of CV deconditioning is the effect of DI on maximal oxygen consumption 
(VO2 max). A decline in the adaptive ability to exercise has been reported after just one day 
of DI (Beliaev 1981) and in 3-7 days of DI VO2 max falls by 10-18% (Anashkin and Beliav, 
1982; Sonkin et al., 1996; Vinogradova et al., 2002 (NASA, 2012) and this could 
subsequently affect platelet function as work in chapter 4 showed that subjects with a lower 
CRF had a tendency for increased platelet reactivity. 
To our knowledge, there have been no studies on the effect of DI on platelet function in 
humans to date. Some research on other experimental physical inactivity models has been 
carried out on platelet function. Arinell et al., (2013) examined the effect of 60 days’ head 
down bed rest (HDBR) on platelet activation markers P-Selectin and PDGF in 15 healthy 
females. While expecting platelet activation to be elevated, both platelet activation markers 
decreased during HDBR and remained at lower levels for 8 days in the recovery period. 
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5.3.6 Effect of physical inactivity on platelet VASP phosphorylation 
A commonly used assay to assess platelet function is the phosphorylation of vasodilator-
stimulated phosphoprotein (VASP) (Shumacher et al., 2007). VASP is an intracellular 
regulator of actin dynamics in platelets and plays a key role in regulating platelet adhesion 
and aggregation. VASP is phosphorylated by cAMP and cGMP-regulated protein kinases on 
three phosphorylation sites (Ser157, Ser239 and threonine 278). VASP phosphorylation is 
paralleled with the inhibition of platelet activation, inhibition of αIIbβ3 and a restriction of 
VASP to bind to F-actin (Wentworth et al., 2006). Consequently, decreased VASP 
phosphorylation can result in platelet hyperreactivity.  
We examined the impact of physical inactivity on platelet reactivity and the VASP 
phosphorylation status.  The results of the VASP test are reported as a percentage value of 
the platelet reactivity index (PRI) whereby increases in the PRI reflect elevated P2Y12 
mediated platelet reactivity (Gaglia et al., 2011). Values obtained for PRI before and after 
DI in our subjects varied between 65 -95%. Normal PRI values for healthy individuals not 
on clopidogrel treatment are between 70-95% (Bagoly et al., 2013) or between 69 -100% 
(Siller-Matula et al., 2008) as non-treated patients exhibit high PRI results. After DI, while 
we observed a minor non-significant increase in the average PRI (5%) suggesting a reduction 
in VASP phosphorylation and increase in platelet activation. This is shown in Figure 5.8. 
However, there were individual fluctuations with some subjects showing greater degrees of 
changes.  
As the VASP/P2Y12 assay is primarily used to test responses to effectiveness of clopidogrel 
treatments, there is a scarcity of studies examining the relationship between obesity/physical 
inactivity and platelet VASP phosphorylation in healthy subjects. However, obesity is linked 
to elevated PRI levels (Gremmel et al., 2013; Pankert et al., 2014). Russo et al., (2007) 
reported that VASP phosphorylation was significantly lower in obese subjects compared to 
healthy controls after platelets were treated with cyclic nucleotide analogs. This suggests 
that obesity, and possibly physical inactivity/sedentariness reduces the ability of cyclic 
nucleotides to inhibit platelet adhesion and aggregation resulting in platelet hyperactivity. 
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Furthermore, endothelial prostacyclin and NO inhibit platelet function. Their actions are 
mediated by platelet adenylyl and guanylyl cyclases which produce cAMP and cGMP to 
phosphorylate a number of proteins including VASP (Smolenski et al., 2012). Reduced NO 
production in endothelial cells resulted in vascular inflammation and decreased 
phosphorylation of VASP at the Ser239 site in (Cheng et al., 2014). A reduction in NO 
bioavailability would have downstream effects on platelet VASP phosphorylation, 
encouraging platelet adhesion and aggregation. 
Smoking also induces a loss of sensitivity to prostacyclin and NO generated by the 
endothelium and has been characterised by elevated platelet αIIbβ3 levels and release of 
platelet microparticles (Pamukcu et al., 2011). Assinger et al., (2010) showed that VASP 
phosphorylation at basal levels on the Ser239 residue was significantly reduced in smokers. 
In response to picomolar and nanomolar concentrations of PGE1, smokers still had reduced 
VASP phosphorylation, which was linked with elevated P-selectin expression. However, at 
maximal PGE1 concentrations (hugely exceeding concentrations that can be achieved in 
vivo) they noted no difference between smokers and non-smokers. Similarly, using the 
VASP/P2Y12 kit, PRI (which uses maximal effective doses of PGE1) was virtually identical 
between the smokers and the non-smokers, suggesting that the assessment of VASP 
phosphorylation in the presence of submaximal quantities of PGE1 could be more beneficial. 
Physical inactivity could produce similar responses and require the same level of 
investigation, as we only observed small decreases in VASP phosphorylation. Also, other 
platelet signalling pathways could have contributed to the elevated platelet adhesion and 
aggregation.   
5.3.7 Effect of physical inactivity on protein biomarker expression  
We also examined the effect of physical inactivity on platelet poor plasma (PPP) based 
protein biomarkers. The Proseek® Multiplex assay is a sensitive and specific assay 
developed for biomarker research which enabled the screening of 157 protein biomarkers 
related to CVD and inflammation using only 1µl of sample. The Proseek® assays use PEA 
technology, where samples are treated with matched antibody pairs tagged with DNA 
reporter molecules. Once the antibodies bind to their respective antigens, the corresponding 
DNA primers form an amplicon that is quantified by real time PCR, generating a measurable 
fluorescent signal which correlates with protein abundance (Figure 5.20) Problems with 
cross-reactivity are practically abolished in PEA assays as only matched DNA reported pairs 
are amplified during real-time PCR.  
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Figure 5.20: Novel Proseek Proximity Extension Assay.  Part A shows (1) Proseek probes (DNA 
oligo-labelled antibodies) bind in proximity to target proteins (2) Only correct matched sequences 
hybridise and extension and creation of real-time PCR amplicons occur and (3) Proseek amplification 
and detection by real-time PCR on the BioMark HD system. Part B (1) represents conventional 
immunoassays where cross reactivity occurs due to unspecific binding of antibodies, thereby limiting 
the degree of multiplexing and (2) unique DNA oligo sequences report only matched DNA-pairs 
(e.g. 1A+1B) and cross reactive events are not identified.  
 
The expression profiles of these proteins were analysed at pre, post and recovery. 131 out of 
157 of the proteins were detected in all samples. We expected that a number of inflammatory 
and CVD proteins would be differentially expressed after the DI. As displayed in Table 5.3, 
the expression levels of 15 proteins differed significantly between different stages of the DI. 
For the purpose of this discussion, we focused on some key differentially expressed proteins 
related to platelet function. On the CVD panel, key proteins affected by physical inactivity 
included Heat shock protein 27 (HSP27), Lectin-like oxidised LDL receptor (LOX-1), NF-
Kappa-B essential modulator (NEMO), Proto-oncogene tyrosine protein kinase (SRC) and 
Dickkopf-related protein (DKK1). The expression levels of these proteins are displayed in 
Figure 5.9. 
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Numerous environmental and physiological stresses such as inflammation cause the 
expression of heat shock proteins (HSPs) found in several cell types (Batulan et al., 2016). 
HSPs have been identified in atherosclerosis (Majid et al., 2012) and post exercise (Periard 
et al., 2012). HSP-27 was significantly elevated after DI suggesting a stress response to the 
effects of acute physical inactivity. HSP27 has been proposed as a key player in actin 
polymerisation during platelet shape change (Zhu et al., 1994; Polanowska-Grabowska and 
Gear, 2000).  Studies by Tokuda et al., (2015) show that HSP27 is released from human 
platelets upon collagen activation, and this release is associated with the acceleration of 
platelet aggregation. Kageyama et al., (2013) suggest that the GTPase, Rac, controls this 
collagen-induced HSP27 phosphorylation. Enomoto et al., (2011) also showed that ADP 
induces phosphorylation of HSP27 with resultant platelet activation markers PDGF and 
sCD40L release. Elevated HSP-27 post DI indicates that it was not in response to changes 
in temperature (as they remained consistent) but probably in response to the physiological 
stress of physical inactivity.  
Lectin-like oxidised low-density lipoprotein receptor-1 (LOX-1) is a scavenger receptor, 
which binds to and degrades oxidised low-density lipoprotein (Reiss et al., 2009). High 
plasma levels of LDL-cholesterol are a significant risk factor for atherosclerosis. LOX-1 is 
expressed on numerous cells including platelets (Chen et al., 2001) but importantly is 
expressed in an activation dependent manner. LOX-1 was significantly elevated post DI 
(Figure 5.9). As LOX-1 recognises and binds to activated platelets, exposure of LOX-1 on 
the surface of activated platelets might encourage thrombus formation. Furthermore, 
inhibition of LOX-1 in platelets was shown to prevent platelet aggregation (Chen et al., 
2001; Marwali et al., 2007). LOX-1 is associated with obesity and physical inactivity and 
could represent a marker of platelet activation in response to sedentary behaviour (Yan et 
al., 2011). 
DKK1 was another CVD panel protein that was significantly upregulated post DI. Platelets 
represent a major source of circulating DKK1, which is an antagonist of the Wnt signalling 
pathway (Ueland et al., 2009). DKK1 is released from platelet α-granules (Voorzanger-
Rousselot et al., 2009) upon activation.  
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Plasma DKK1 levels are significantly higher in disease states including T2DM (Lattanzio et 
al., 2014) and atherosclerosis (Ueland et al., 2009). Increased levels of DKK1 were 
associated with urinary levels of TXB2 and plasma CD40L, suggesting that DKK1 levels 
could echo platelet activation. DKK1 can also influence platelet-mediated endothelial cell 
activation involving the Wnt/β-cat signalling pathway and necrosis factor-KB pathways.  
The role of platelets in atherosclerosis is not only related to their prothrombotic properties 
but also their inflammatory properties (Morrell et al., 2014) and platelets exert inflammatory 
effects on a scale that exceeds their individual size. A number of proteins on the 
inflammatory array were also differentially expressed post DI. These are shown in Figure 
5.10 and included Axin-1, Interleukin-6 (IL-6) and Sir2 like protein (SIRT2). Axin-1 is a 
key member of the Wnt signalling pathway, acting as a scaffold protein and a negative 
regulator of the Wnt signalling pathway (Kilikuchi, 1999; Pronobis et al., 2015). As Wnt 
signalling negatively regulates platelet function and modulates the major platelet receptor 
αIIbβ3, (Steele et al., 2009), an increase in Axin-1 levels could also have contributed to 
platelet adhesion and aggregation levels in this study.  
IL-6, a pleiotropic inflammatory cytokine directly involved in the inflammatory cascade and 
linked to the pathogenesis of many chronic diseases was significantly increased after the DI. 
IL-6 has been adversely linked with sedentary time in a large study of >500 participants aged 
~63 years and at high risk for T2DM (Henson et al., 2013) and appears to be elevated after 
physical inactivity in our study. While platelets do not express IL-6 (Marino et al., 2013), its 
production from other cells can affect platelet activation, as Il-6 activates platelets in vitro 
(Oleksowicz et al., 1994; Soslau et al., 1997; Bester, 2016). IL-6 is also involved in the 
regulation of haematopoiesis. IL-6 is also a potent thrombopoietic factor promoting 
maturation of human megakaryocytes in vitro (Ishibashi et al., 1989).  IL-6 appears to affect 
platelet function in a manner that predisposes the vasculature to thrombosis development. 
IL-6 has been suggested as a mediator of platelet hyperactivity, thrombocytosis and 
increased thrombus development in conditions of experimental colitis (Senchenkova et al., 
2013) and perhaps influenced platelet activation during the course of this study. 
The effect of DI on protein expression has mainly revolved around muscle and urine samples 
(Pastushkova et al., 2014). However, a serum proteome study by Pakharukova et al., (2009) 
described significant increases in apolipoprotein CIII indicating an elevation in blood 
triglycerides and cholesterol after DI. Additionally, Pastushkova et al., (2011) demonstrated 
increases in fibrinogen levels and apolipoprotein CI of blood plasma proteome during a 5-
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day DI. Increases in fibrinogen levels can occur during acute inflammation, stress and 
alterations of physical activity (Gomez-Marcos et al., 2013). The propensities of total plasma 
cholesterol, LDL and triglyceride concentrations to increase after DI were also observed by 
Markin et al., (2008). Another 3 day DI experiment on male subjects measured lipid 
peroxidation products and antioxidant activity in blood serum. Results showed in increase 
in lipid peroxidation products after the DI and the index of antioxidant activity (tocopherol 
content) was distinctly reduced. This suggested a pronounced stress reaction after exposure 
to DI (Zhuravleva et al., 2012). Most of these changes, similar to our study, were 
characterised by both a rapid development and quick restoration after return to normal 
conditions.  
Evidently, a number of inflammatory and CVD proteins were differentially expressed after 
our DI, suggesting that extensive physical inactivity affects both immune and platelet 
function. However, we cannot state that PPP is reflective of changes purely in the platelet 
proteome as there will inevitably be some protein from other cell types including RBC and 
WBCs. Future work on the platelet proteome and proteins identified here would be essential. 
5.3.8 Effect of physical inactivity on platelet poor plasma microvesicles 
Microvesicles (MVs) are constitutively produced from the cell surface, but their generation 
can be elevated by activation or apoptosis (Loyer et al., 2014). Exosomes have a size range 
of 30-100nm in diameter while microparticles represent the larger class of MVs (100nm-
1µm). Activated platelets release MVs, rendering MVs as useful biomarkers of platelet 
activation (Heijnen et al., 1999; Nunes-Franca et al., 2015). Platelet MVs levels are altered 
in pathological states including obesity and atherosclerosis (Pap et al., 2009), and also after 
physical activity (Sossdorf et al., 2011; Chaar et al., 2011). We investigated the effect of 
physical inactivity on the number and size of MVs in PPP. Nanoparticle tracking analysis 
enabled the use of small sample volumes.  
Figure 5.11 summarises the changes in microvesicles in response to DI. There was no change 
in average MV size after DI. We found non-significant increases in overall MV 
concentration. For separate analysis of MV subpopulations, MVs were divided into three 
distinct categories; Exosomes (30-100nm), microparticles (100-255nm), and large 
microparticles (>255nm). There were non-significant increases in exosome and MP 
concentrations post-immersion.  
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Interestingly, there was a modest, non-significant increase in larger MP concentration after 
the DI, which could suggest the generation of larger and potentially more procoagulant MPs. 
Different activation pathways regulate both the quantity and type of MV subpopulation in 
platelets (Aatonen et al., 2014), thus governing their different molecular profiles and 
facilitating tailor-made participation in intercellular communication.  
Other studies have shown that endothelial MP levels increased on the third day of a seven-
day DI experiment (Navasiolava et al., 2010). Reduced daily physical activity (<5000 steps) 
in healthy males was significantly associated with elevated EMPs (Boyle et al., 2013). As 
DI results in reduced stroke volume and cardiac output, it was suggested that an endothelial 
dysfunction to NO and deterioration in hemodynamic conditions could contribute to 
increases in EMPs. The changes in endothelial vasodilatory capacity could also have resulted 
in platelet hyperreactivity and increased MV levels in our study.  
Platelet-derived MVs represent the most abundant MV source (70-90%) released into blood 
circulation, and we aimed to provide an estimate of overall levels and sizes. However, as 
previous data in this chapter suggested increased platelet activation post DI, we expected to 
see a larger increase in the quantity of microvesicles produced post DI. Concerning the exact 
origin of the microvesicles, it would be necessary to stain them with a fluorophore linked 
antibody, specific for surface markers on certain cell types, e.g. CD42b to bind to GP1b on 
platelets. This would have resulted in more accurate reflection of platelet specific MVs. 
5.3.9 Effect of physical inactivity on platelet microRNA (miRNA) 
Experimental results outlined in this chapter so far have demonstrated that physical inactivity 
using the DI model, has an impact on platelet phenotype and health. This was exposed 
through quantification of platelet activation/adhesion/aggregation markers and changes in 
expression of PPP protein biomarkers. To further understand the significance of physical 
inactivity in the regulation of platelet function, and the molecular mechanisms that underpin 
and fine tune platelet function, we hypothesised that miRNA play a large role in the 
regulation of platelet function. In brief, miRNA are short (18-24) nucleotide long non-coding 
RNA molecules. They regulate gene expression by hybridising to the 3’ UTR of mRNA, 
causing mRNA degradation or translational inhibition, depending on the complementarity 
between the strands (Ambros et al., 2001).  
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The existence and functionality of miRNA pathway in the anucleate human platelet has 
recently been described in the literature (Landry et al., 2009).  miRNA constitute 80% of all 
small RNAs in platelets (Ple et al., 2012) and, even though only small RNA yields were 
possible in this study, research by Teruel-Montoya et al., (2014) comparing RNA and 
miRNA by cell type showed that despite a low RNA yield, platelets expressed relatively 
high quantities of miRNA compared to their nucleated counterparts.  
Various components of the miRNA processing components including Dicer, Argonaute 2 
(Ago2) have been reported in platelets (Landry et al., 2009). In order to validate the 
expression of the miRNA processing components in platelets, western blots to detect protein 
expression of Drosha, Dicer and Ago2 were performed in leukocyte-depleted platelet lysates. 
Dicer and Ago2 were identified by western blot analysis and, in line with research from the 
literature, we were unable to identify the nuclear processing component drosha in the 
platelet. This is demonstrated in Figure 5.12. The lack of the nuclear protein, Drosha, is 
consistent with the anucleate nature of platelets. Therefore, concerning the origin of platelet 
miRNA, the likelihood that they are derived from pri-miRNA transcripts within platelets is 
highly improbable, as Drosha is necessary for miRNA maturation. Indeed, the pre-miRNA 
and mature miRNA are derived from megakaryocytes. Novel research has shown that 
platelets contain a limited number of pre-miRNA, and whether these are converted into 
mature miRNA remains an area of debate.  
There exists a miRNA profile or “miRNome” characteristic to individual cell types and 
diseases states (Leidinger et al., 2014). To determine if the miRNome for platelets was 
altered by physical inactivity, platelet miRNA profiles were examined pre and post 
immersion. The miRNA profile was determined by RT-qPCR. For a complete miRNA 
profile, two panels (A and B panel) of 384 targets per panel were used, allowing accurate 
quantification of 754 human miRNAs. The A card contains miRNA which have been well 
published tending to be functionally defined and broadly expressed. The B card contains 
miRNA targets which are generally narrowly expressed and/or expressed at low levels and 
not as well functionally defined.  
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5.3.9.1 Number of miRNA detected in platelets 
The average number of miRNA detected on the A panel was 281 before the DI, and 278 after 
the DI, with the B card average at 155 and 160 pre and post DI respectively (Figure 5.12, 
B). Therefore, platelet RNA in our samples expressed a total average of 436 miRNA pre and 
438 post DI. This is similar to the 492 platelet miRNA identified in a profiling study by Ple 
et al., (2012), and 544 platelet miRNA in another comparative study by Teruel Montoya et 
al., (2014). The Applied Biosystems expression suite software was used to analyse the data. 
The global measure of miRNA expression was used as the normalising factor. Normalization 
of the data is employed to adjust the data to remove any bias/ change in expression not arising 
from the biological conditions under examination. Global normalization is based on the 
assumption that although specific miRNA may alter expression across samples, as a result 
of experimental condition or stimulus, the overall expression pattern of miRNA is invariable 
and thus can be used as a normalizing factor. This method has been shown to outperform 
other methods such as use of endogenous small nuclear RNA in terms of better reduction of 
technical variance and more accurate appreciation of biological changes (Mestdagh et al., 
2009).  
5.3.9.2 Identification of abundantly expressed platelet miRNA 
Figure 5.13 shows the most highly expressed miRNA on both the A card across the 8 
subjects. A small number of highly expressed miRNAs have been characterised in human 
platelets. miR-223 has been identified as the most highly expressed platelet miRNA (Gatsiou 
et al., Edelstein and Bray, 201l; Halkein and Windt, 2013) and has roles in thrombopoeisis, 
cell proliferation and megakaryocyte differentiation (Laffont et al., 2013). miRNA-223 is 
thought to mediate regulation of the P2Y12 platelet ADP receptor expression, as the 3’UTR 
of P2Y12 mRNA has been identified as complementary to the miR-223 seed region (Landry 
et al., 2009; Shi et al., 2015).  Similarly, in this study, miR-223 was the most highly 
expressed miRNA on the A panel across all samples, followed by miR-126, the second most 
highly expressed miRNA in platelets, and which plays central roles in vascular inflammation 
(Fish et al., 2008; Gatsiou et al., 2012). Downregulation of miR-126 in 
megakaryocytopoiesis has been suggested to unblock target genes involved in differentiation 
(Nagella et al., 2011). Of late, miR-223, miR-126, and other abundant platelet miRNAs have 
showed significant correlations with the platelet VASP assay (Kaudewitz et al., 2016). 
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As expected, miRNA on the B card were less highly expressed than A card miRNA, shown 
by the presence of light red and some blue colours on the heat map in Figure 5.14. miR-720, 
a highly expressed B panel miRNA, has also been identified as an abundant platelet miRNA 
(Nagalla et al., 2011). Some abundant miRNA on the B card are denoted with an asterisk 
beside their name such as miR-126*, miR-223*, miR-106b*, miR-222* and miR-15b*. 
These represent miRNAs which arise from two opposite arms of the same hairpin structure 
(5’ and 3’) with the same name, however the miRNA which is expressed in significantly 
lower levels in the cell is specified by the asterisk (Stakos et al., 2013). Nevertheless, these 
miRNAs still exert effects on the cell. Other abundant miRNA on the B card have previously 
been associated with platelet function; miR-409-3p is significantly downregulated in patients 
with sickle cell disease who exhibit platelet hyperreactivity (Jain et al., 2013). Overall, 
miRNA on the A card were considerably more abundantly expressed than miRNA on the B 
card. 
5.3.9.3 Identification of miRNA affected by physical inactivity 
After the data had been analysed using the default settings, the relative quantification (RQ) 
values for each condition (pre and post DI) were extrapolated in order to identify some of 
the most differentially expressed miRNA between the two time points. Therefore, using the 
pre DI samples as a baseline reference, we were able to identify changes in the post DI 
miRNA expression relative to the pre time point. Most reported miR expression fold-changes 
are small (~1.5–2-fold changes) (Daniels et al., 2014). We identified 22 miRNA which were 
significantly up or downregulated. These miRNA from each card are shown in Figure 5.15.  
Some of these miRNA have previously been associated with platelet biology with some quite 
novel miRNA which could be potentially involved in platelet biology.  
Downregulation of miRNA has been associated with mRNA translation and subsequent 
production of proteins relating to platelet activation (Edelstein et al., 2013). On the A panel, 
7 miRNA were significantly downregulated after the DI, shown in Figure 5.15 (B). 
Downregulation of miR-143 has been implicated in platelets of patients with T2DM 
compared to healthy and age-/sex-matched controls (Elgheznawy et al., 2015), with 
subsequently elevated platelet adhesion and aggregation thought to be as a result of reduced 
NO and prostacyclin production. 
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The miR-200 family is well established in miRNA biology. miR-200a was significantly 
downregulated after the DI and while miR-200a and miR-200b only differ by a single 
nucleotide, they are predicted to share mRNA targets (Howe et al., 2012). Indeed, miR-200b 
has been described to target the PRKAR2B gene that plays a role in the suppression of further 
platelet activation and aggregation. Although miR-200b did not make the shortlist for this 
experiment, it was downregulated after DI, indicating its involvement in platelet activation 
(Nagalla et al., 2011). 
Both miR-500 and miR-888 were also significantly downregulated after the DI. Neither have 
previously been described in human platelets, however the translation of the fibrinogen 
receptor subunits (αIIb and β3) were reported to be regulated by miR-500 in a dicer 
knockdown model of murine megakaryocytes, resulting in increased surface expression of 
the respective integrins and subsequent platelet aggregation (Rowley et al., 2016).  This 
miRNA could represent a new marker of physical inactivity in platelets. Another 
downregulated miRNA, miR-203, has been predicted to regulated SOCS1 gene and was 
differentially expressed in patients with essential thrombocythemia compared to healthy 
controls (Navarro et al., 2016).  
On the B panel, there were 3 downregulated miRNA post immersion; miR-145*, miR-15a* 
and miR-374a* shown in Figure 5.15 D. miR-145 is a highly expressed platelet miRNA 
(Edelstein et al., 2011) and its differential expression has been linked to thrombocytosis and 
megakaryocyte dysplasia (Banchi et al., 2016). miR-145/145a have been shown to stimulate 
megakaryopoieses (Starczynowski et al., 2010). miR-15a* has also been linked with platelet 
physiology. Yu et al., (2014) identified miR-15a as one miRNA downregulated during 
apheresis platelet storage suggesting a role in apoptosis. miR-374a family has been 
implicated in CVD whereby leukocyte miR-374 was significantly lower in CVD patients 
compared to healthy controls (Ward et al., 2013). 
Other studies have shown changes in the platelet miRNA profile in response to various 
stimuli. Tanriverdi et al., (2006) investigated the effect of thrombin induced aggregation on 
the platelet miRNA profile. Expression of 9 miRNAs were downregulated with thrombin 
activation between 0.76 fold to 0.53 fold, similar expression changes to the downregulated 
miRNA in our study. Nagalla et al., (2011) examined whether platelet miRNA levels were 
associated with reactivity and phenotype in 19 healthy donors and demonstrated that 74 
miRNAs were differentially expressed (DE) when stimulated with epinephrine and also that 
the miRNA profiles were correlated with the platelet responses to epinephrine. 
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Among the upregulated miRNA on the A panel shown in Figure 5.15 part (A), were miR-
484 and miR-299-5p. miR-484 is a highly expressed miRNA in megakaryocytes and 
platelets (Hussein et al., 2009; Edelstein et al., 2013; Pan et al., 2014). It appears to regulate 
haematopoiesis (Hunter et al., 2008; Petriv et al., 2010) and is implicated in the effects of 
the pathogen reduction system on platelet function (Osman et al., 2015). miR-299-5p was 
the one of the more upregulated miRNAs and has also been linked with megakaryocyte 
biology. Tenedini et al., (2010) reported that over expression of miR-299-5p in CD34+ cells 
caused a (1.5 fold) increase in CD41a expression of megakaryocytic colonies in collagen-
based assays and of MKC forms with polynucleotide elements. Interestingly, the same cells 
treated with an anti-299-5p exhibited decreases in CFU-mk. MiR-30b has also been 
described in platelet biology (Edelestein et al., 2013). 
Figure 5.15D shows upregulated miRNA on the B panel. These included miR-744*, miR-
24-2*, miR-190b, miR-34a* and miR-106b*, all of which have been identified in human 
platelets, except for miR-744 (Nagalla et al., 2011; Pan et al., 2014; Willeit et al., 2013). 
miR-34a, one of the most highly upregulated miRNA, is highly expressed in platelets 
(Gatsiou 2012; Edelstein et al., 2013) and is involved in megakaryocyte differentiation, 
whereby elevated levels of miR-34a appear to enhance megakaryopoieses. Higher levels of 
miR-34a have been observed to increase megakaryocyte colony formation from CD34+ cells 
(Navarro et al., 2009). 
There is limited research investigating the effect of microgravity on miRNA expression 
(Heather et al., 2006). This is the first study to quantify changes in miRNA in human cells 
(ex vivo, uncultured cells) in a simulated microgravity environment. Mangala (2011) 
examined the effects of simulated microgravity on the miRNA profile of human 
lymphoblastic cells using a high aspect ratio vessel (bioreactor), either in the rotating 
condition to model microgravity in space or in static condition as a control. Expression of 
several miRNA were altered in the simulated microgravity condition including miR-150, 
miR-34a, miR-423-5p, miR-22, and miR-222, some of which overlap with our study. 
Recently, Forty-two miRNAs from cultured human blood lymphocytes from 12 healthy 
subjects were differentially expressed in microgravity stimulated cells compared to static 
cells, with resultant mRNA gene targets involved in inflammatory and apoptotic responses 
(Girardi et al., 2014).  
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As platelets do not express the miRNA nuclear machinery Drosha and DGCR8 (Landry et 
al., 2009; Zampetaki and Mayr, 2015), the de novo synthesis of new miRNA in platelet is 
negligible. Upregulation of miRNA in response to physical inactivity could be derived from 
the processing of pre-miRNA to mature miRNA or as a reflection of increased levels miRNA 
in their megakaryocyte precursor. Recent research has shown that platelets have higher 
levels of pre-miRNA than other blood cells (Pan et al., 2014).  
As platelets can release microvesicles-containing miRNA upon activation, downregulated 
miRNA in this study may reflect this process. These findings suggest that platelet miRNAs 
might reflect quantitatively platelet activation in vivo and, as such, might have a great 
potential as biomarkers of physical inactivity. Importantly, the cellular bearing of the 
majority of miRNA-mRNA interactions is a fine-tuning of protein output and not huge 
repression of expression (Baek et al., 2008). Notably, as little as a 20% decrease in miRNA 
levels can alter cellular phenotypes (Alimonti et al., 2008). 
5.3.9.4 Bioinformatics of differentially expressed DI regulated miRNA  
To determine which genes may be affected by the DI regulated miRNA shown in Figures 
5.15, their putative targets were downloaded from online computational methods for 
miRNA-mRNA interactions including Targetscan, miRANDA and microRNAorg. 
Complementarity between the seed region of the miRNA and the 3’UTR of an mRNA is the 
underlying method used for in silico prediction of targets used in Targetscan. The results of 
the three databases were collectively used to predict the roles of DI regulated miRNA in the 
regulation of gene expression. DAVID bioinformatics software was then employed to 
highlight the involvement of these in silico predicted genes in pathways of interest from the 
Kyoto Encyclopaedia of Genes and Genomes (KEGG). DAVID bioinformatics resources 
consist of an integrated biological knowledge base and analytical tools aimed at extracting 
meaning from large protein or gene lists. The first stage is to upload putative targets 
containing any number of gene identifiers (e.g. official gene symbol). Following this, 
analysis is carried out taking advantage of the vast pathway miming tools such as KEGG 
biological pathways. 
The fold change, number of conserved targets, and number of pathways the predicted genes 
are linked to are included in Table 5.4 for each miRNA. Table 5.5 shows the miRNA 
potentially involved in the pathways of interest and whether these specific miRNAs were up 
or downregulated with DI.  
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The pathway maps downloaded using DAVID from KEGG were used to show the role of 
predicted targets in pathways of interest. These pathways are shown in Figures 5.16 -5.18. 
Genes within the pathways of interest that were targeted by a single miRNA are circled in 
yellow, while those potentially targeted by two or more miRNA are circled in red. Pathways 
were chosen based on their involvement in platelet function and signalling, specifically in 
adhesion and aggregation, but also their inflammatory potential. Included in these were the 
Wnt signalling, regulation of actin cytoskeleton, ECM interaction and Toll-like receptor 
pathways, of which the Wnt signalling pathway appeared repeatedly in both the up and 
downregulated miRNA targets. Following this, the regulation of actin cytoskeleton pathway 
was the second most frequent pathway found to be associated with the DI regulated miRNAs.  
A number of differentially expressed miRNA post DI targeted genes involved in the actin 
cytoskeleton (Figure 5.17). The shape change required for platelet adhesion, from a discoid 
to spread shape, involves extensive reorganisation of the actin cytoskeleton (Aslan et al., 
2011). The miR-143/145 cluster controls the expression and function of various components 
of the cytoskeleton in smooth muscle cells (Xin et al., 2009) and can switch the phenotype 
of SMCs (Rangrez et al., 2011). As both miR-143 and miR-145 were downregulated after 
the DI, this could have contributed to an upregulation of mRNA involved in the actin 
cytoskeleton and subsequently assisted in platelet adhesive processes. miR-199a also had 
mRNA targets involved in this pathway, including F-actin and α-actin.  
Some of the downregulated miRNA were involved in the ECM-receptor interaction pathway 
(Figure 5.18). Platelets express 5 different integrin’s which facilitate platelet adhesion to 
ECM proteins including collagen, laminin and fibronectin. miR-143 had targets involved in 
this pathway including collagen, and receptors α1, α6 and β8. In comparison, miR-199a 
targets included fibronectin and integrin subunit α3. Targets of miR-302a (downregulated) 
included integrin subunit β3 and α2, suggesting an overexpression of these mRNA, and thus 
the potential for an increased capability of platelets to adhere to ECM proteins. 
Relevant to earlier findings in this chapter was the recurrence of the Wnt signalling pathway 
(Figure 5.16), involving targets of the differentially expressed miRNA, as two protein 
biomarkers (DKK1 and Axin-1), that were altered by the DI are also involved in the Wnt 
pathway. The Wnt family consists of 19 glycoproteins which play key roles in diverse 
biological processes including the regulation of adult homeostasis (Macauley et al., 2013).  
 251 
 
Wnt ligands propagate signals through several receptors, activating one of three different 
signalling pathways; the Canonical/ Wnt-β-catenin pathway, the Planar Cell Polarity 
pathway and the Wnt/Ca2+ pathway, to mediate effects on gene transcription and cell 
adhesion.  
The literature has described not only a role for mainly the Wnt-β-catenin (Steele et al., 2009), 
but also the non-canonical Wnt signalling pathways in platelet function (Kim et al., 2011). 
Responsiveness of platelets toward Wnt ligands was recognised when a recombinant Wnt3a 
ligand was shown to inhibit platelet adhesion, shape change, dense granule secretion and 
inhibiting activation of αIIbβ3 resulting in decreased platelet adhesion to fibrinogen and 
subsequently reduced aggregation (Steele et al., 2009). 
Focusing on the β-catenin signalling pathway, Wnts bind to a platelet surface receptor 
complex composed of the lipoprotein receptor related protein 5/6 (LRP5/6) and the frizzled 
(Fzd) receptor. This signal is propagated to the cytoplasmic protein, dishevelled (Dvl), where 
downstream effectors control the stability of β-catenin (β-cat). When Wnt is absent, β-cat is 
phosphorylated by a destruction complex of casein kinase 1 (CK1), glycogen synthase kinase 
3β (GSK3β), Axin-1, FRAT-1 and adenomatous polyposis coli (APC), which mark β-cat for 
degradation by ubiquitination and then proteasomal degradation. Oppositely, in the presence 
of Wnt, Dvl negatively regulates the phosphorylation of β-cat preventing its degradation.  
Central to the Wnt/β-catenin pathway is the cytosolic level of β-cat, whose disassembly from 
the destruction complex in the cytoplasm enables nuclear transcriptional activation of genes. 
However, as platelets are anucleate, stabilised β-cat cannot have a nuclear transcriptional 
role. β-cat also forms direct associations between cadherins (CDHs) and α-catenin, the latter 
of which associates with the actin cytoskeleton. CDH6 has been associated with platelet 
adhesion and aggregation (Heuberger and Birchmeier et al., 2010; Dunne 2012). Thus, the 
amount of functional β-cat would impact platelet adhesion and aggregation (Kumari and 
Dash 2013). Steele et al., (2012) reported that Wnt3a modulates platelet function by the 
regulation of small GTPase activity and in particular four central GTPase proteins (Rap1, 
Cdc42, Rac1 and RhoA) that play key roles in platelet activation.  
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Axin-1, a key mediator of the Wnt/ β-cat pathway, was identified as one of the proteins that 
was upregulated after the DI. Axin-1 can scaffold the β-cat destruction complex to encourage 
β-cat degradation and inhibitor of Wnt signal transduction (Song et al., 2014). Interestingly, 
two downregulated miRNAs, miR-203 and miR-200a were identified as potential targets of 
Axin-1. Additionally, a number of other miRNA predicted to target Axin-1 were also 
downregulated as shown in Figure 5.19B. The simultaneous downregulation of multiple 
miRNA targeting Axin-1 could have resulted in an increase in Axin-1 mRNA expression, 
and subsequent protein production. Increased Axin-1 levels can reduce Wnt signalling in 
platelets with elevated platelet adhesion and aggregation as a result. 
In the ECM, a number of proteins bind to Wnts, preventing their interaction with either Fzd 
or LRP 5/6, to inhibit Wnt signalling, one of which comprise of Dickkopf proteins (DKKs). 
Platelet derived DKK1 is a major Wnt antagonist that binds to low-density lipoprotein 
receptor-related protein 5/6 (LRP5/6) to inhibit signal transduction from occurring 
(Macaulay et al., 2013). DKK1 was one of the significantly upregulated proteins identified 
from the biomarker panel post-DI and we therefore sought to identify miRNA (in addition 
to the DE expressed miRNA) that could be targeting DKK1. These are displayed in Figure 
5. 19A. Multiple miRNA can target DKK1. microRNA.org listed miR-302a and miR-374a 
as possible regulators of DKK1 when viewing target sites of conserved miRNA. A number 
of these miRNA were downregulated in our study, suggesting that a simultaneous 
downregulation of multiple miRNA targeting DKK1 may act together therefore increasing 
DKK1 transcript and ultimately, protein levels. In particular, miR-302a was the most 
downregulated miRNA, which also targeted DKK1. An increase in DKK1 could have 
contributed to a negative regulation of the Wnt signalling pathway and ultimately, elevated 
platelet adhesion levels. 
Guo et al., (2015) demonstrated that platelet-sourced DKK1 was the prominent Wnt 
antagonist which contributed to suppression of Wnt/β-catenin in alveolar epithelial cells in 
acute lung inflammation. Zhang et al., (2011) found that DKK1 was regulated by miRNA 
control of miR-335-3p in osteoblast lineage cells, and Xu et al., (2015) reported that a 
downregulation of miR-152 contributes to increased DKK1 expression in multiple myeloma. 
Similarly, these miRNAs were downregulated in our study, shown in Figure 5.19A. 
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Evidence of physical activity-specific microRNA signatures (Kangas et al., 2013; Bye et al., 
2012 and Altana et al., 2015), have seeded the notion that there must also be physical 
inactivity-specific miRNA profiles. Epigenetic variation could be a potential mechanism 
allowing for independent or perhaps synergistic effects of physical inactivity on platelet 
function.  Hibler et al., (2015) recently described indications for epigenetic variation (by 
miRNA expression) as a link between physical activity and sedentary lifestyle. An epigenetic 
adaptation to habitual exercise has previously been described (Ling et al., 2014; Pareja-
Galeano et al., 2014).  
Similarly, we hypothesised that an epigenetic adaptation to physical inactivity is also 
present. Inactivity could induce epigenetic changes in megakaryocytes to generate unhealthy 
platelets phenotypes with a direct change in platelet reactivity and platelet miRNA could act 
as a marker of this epigenetic drift. Importantly, we have identified changes in the platelet 
miRNA profile in response to physical inactivity. Investigating miRNA-mRNA and 
miRNA-protein interactions would provide more knowledge in this area.  
While not the main focus of this chapter, we also assessed other aspects of the effect of DI 
on platelet inflammatory function, specifically on toll-like receptor gene expression during 
the DI. This can be found in Appendix C.  
5.4 Limitations  
Although the nature of DI studies provides an extremely controlled environment, some 
limitations became apparent.  The current DI study used a random subject population and, 
while this is beneficial as subjects are their own control, some baseline measurements varied 
amongst subjects. Measurements during the baseline period were obtained whilst subjects 
were ambulatory. However, they were confined to the clinic and so these physical activity 
measurements may not reflect free-living conditions. There were twelve research teams 
working on the same study and this meant that volunteers had to follow a strict and perhaps 
stressful regime in terms of test measurements (as depicted in the VAS pain scale 
measurement). Psychological stress and time out of baths could have contributed to the 
observed baseline/differences post DI. While a lot of time and effort goes into the timing of 
each test and the order they are in, it may be seen as a limitation also.  
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5.5 Summary and conclusion 
In summary, physical inactivity had a modest effect on platelet function over three days. 
Except for plateletcrit and platelet count, the remainder of the platelet indice markers did not 
change significantly. There were significant increases in platelet adhesion, aggregation, and 
an elevation of PRI after the DI. This study has identified 15 proteins whose expression 
trends could be of importance for developing ‘biosignatures’ of physical inactivity. We also 
identified a set of ‘physical inactivity’ related miRNA which have potential targets involved 
in pathways associated with platelet function. It is evident from this study and literature 
findings that the identification of unique signatures of several miRNA, rather than a single 
miRNA in isolation may enhance diagnostic accuracy (Meder et al., 2011).  
The canonical Wnt signalling pathway may signify a novel endogenous mechanism for 
regulating platelet activity in response to physical inactivity. Investigation around the Wnt 
negative regulators Axin-1 and DKK1, in combination with miRNA involved in this 
pathway, could be an interesting avenue, as a both the protein and miRNA profiles indicated 
involvement in this pathway. In conclusion, the results suggest an inclination in healthy 
males of an unhealthier/pro-thrombotic platelet profile in response to physical inactivity. 
This could be indicative of the changes seen in sedentary individuals. Collectively, our 
results provide evidence for the early and robust deleterious impact of reduced daily activity 
on platelet function and phenotype, highlighting the vulnerability of the vasculature to a 
sedentary lifestyle. These results involving the measurement of various aspects of platelet 
function are novel and provide an interesting insight into the potential mechanisms behind 
physical inactivity-induced platelet dysfunction. 
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Chapter 6: Overall Summary and Future Perspectives 
6.1 Overall Summary 
Efforts in coping with CVD require further understanding of its etiology and the risk factors 
behind it in order to develop cost-effective preventive strategies (primordial, primary, 
secondary and tertiary) to prevent and manage it. CVD risk factors can be classed as 
modifiable or non-modifiable. Modifiable risk factors included smoking, diabetes, unhealthy 
diet, cholesterol, physical inactivity (sedentary lifestyle and low cardiorespiratory fitness) 
and overweight and obesity. Risk factors for CVD track from childhood into adulthood and 
are strong predictors of subclinical disease in early adulthood (Juhola et al., 2011). Up to 
80% of CVD may be prevented if modifiable risk factors are evaded (Mc Neal et al., 2010; 
WHO). This thesis focused on the risk factors of physical inactivity, overweight/obesity and 
low cardiorespiratory fitness. 
Platelets are small, anucleate cells, which are released by bone marrow megakaryocyte 
precursor cells into blood circulation (Laffont et al., 2013; McFadyen and Kaplan, 2015). 
They travel as resting discoid fragments in circulation, however, elaborate morphological 
properties allow shape changes to occur when they come in contact with an injured blood 
vessel. This enables platelets to perform their main physiological function to prevent blood 
loss in primary haemostasis by the formation of a ‘platelet plug’ through processes of 
adhesion, activation and aggregation (Cimmino and Golino 2013). 
Platelets play a central role in CVD, both in the pathogenesis of atherosclerosis and in the 
development of acute thrombotic events (Maiwand et al., 2015). It has been recognised that 
regular exercise may reduce the risk of major vascular thrombotic events and protect against 
CVD (Blair and Norris, 2009). Differences in known factors explain a large percentage of 
the inverse relationship between physical activity and CVD risk (Mora et al., 2007; 
Kwasniewska et al., 2016). However, over 40% of the inverse association remains 
unexplained. Although the beneficial effects of regular exercise on blood lipids and blood 
pressure have been well accepted, research focusing on platelet function has only recently 
gained greater attention.  
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In contrast to the accumulating evidence supporting the benefits of regular exercise, 
relatively little is acknowledged about the deleterious mechanisms underlying the 
physiological, cellular and molecular responses to physical inactivity, specifically with 
regard to platelet function. Small non-coding RNAs such miRNAs have been shown to play 
important post-transcriptional regulatory roles in cells. The role of microRNA (miRNA) in 
regulating platelet function in is a recent fertile area of investigation (Landry et al., 2009; 
Kaudevitz et al., 2016). Platelets are highly reflective of physiological and lifestyle changes, 
making them extremely sensitive biomarkers of human health.  
The purpose of this thesis was to build on previous knowledge surrounding the involvement 
of platelets in physiological health and overweight/obesity, their profile in physical activity 
and inactivity and the mechanisms that regulate their activity in response to such stimuli.  
The overall hypothesis, therefore, was that both physical inactivity and overweight/obesity 
adversely impact platelet function. Furthermore, miRNA expression could influence and 
modulate the platelet function response to physical inactivity. Experimental work designed 
to test this hypothesis was divided across three chapters.  
In Chapter Three, a cross-sectional study approach was employed to evaluate the 
relationship between platelet function and physiological health. Whilst it is known that 
platelet function and platelet indices (markers of platelet activation) are altered in 
pathological states such as CVD, only a minority of studies have solely examined the 
relationship between overall physiological health and platelet function in healthy subjects 
(Santilli et al., 201; Goshal, 2014).  
This study explored the feasibility of platelet indices and whole blood platelet function 
measurements, as useful, non-invasive initial biomarkers of early/subclinical CVD risk and 
lifestyle parameters in a nationally representative population of 155 adults. The most 
interesting results from this chapter showed that higher platelet counts and plateletcrit were 
associated with less favourable cardiovascular risk profiles, in particular with measures of 
overweight. Importantly, platelet adhesion was significantly increased in male and female 
adults who had a BMI classed as overweight compared to those with a healthy weight BMI. 
The elevated PLT, PCT and SC levels observed in overweight subjects indicate a more 
reactive platelet profile and could imply the occurrence of subclinical CVD symptoms.  
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Following on from Chapter 3, instead of taking basal single point measurements, we felt that 
perhaps stressing the cardiovascular system using in vivo instead of in vitro or ex vivo stress 
models, by prescribed exhaustive exercise may provide much more valuable and conclusive 
evidence in relation to the body’s response, and in particular the platelets adaptive response, 
to stress. Therefore, research in Chapter Four extended our research using a ‘human 
laboratory’ approach, evaluating the effect of controlled aerobic exercise, as a cardiovascular 
stressor, on platelet function in male adolescents (n=30) and adults (n=16) of varying 
cardiorespiratory fitness levels (CRF). Inconclusive information is available on the effect of 
acute exercise on platelet function in adults, with almost no available studies centring on 
platelet function in healthy adolescents and with respect to acute exercise. (Heber and Volf, 
2015). In this study, subjects performed the gold standard test for aerobic fitness, the VO2 
max test. Blood samples were drawn before and after exercise and platelet indices and 
function were evaluated, again using the Impact-R Cone and Plate analyser. Subjects were 
categorised into groups depending on their CRF.  
It was observed that acute exhaustive exercise resulted in increased platelet function in adults 
and adolescents, and that this increase was more pronounced in moderate to low fit 
adolescents and the moderately fit adults. The same effect of exercise in the high fit adults 
and adolescents was not observed, possibly due to adaptive mechanisms from long-term 
habitual physical activity and exercise.  Our results support past studies highlighting the 
different effect of CRF on platelet function in adults with novel findings in an adolescent 
population. Those with a low CRF level are at increased risk of thrombotic events following 
maximal exercise. These findings highlight the need to develop a strategy to increase activity 
amongst adolescents and adults to combat the early development of subclinical CVD. 
A low cardiorespiratory fitness is associated with physical inactivity (Wei et al., 2000). 
Physical inactivity has major health effects globally, with approximately 3.2 million deaths 
each year attributable to inadequate physical activity. Evidence has shown that physical 
inactivity and sedentary behaviour have direct effects on CVD risk factors such as obesity 
and hypertension (Prentice and Jebb, 2004). Moreover, in contrast to the accumulating 
evidence supporting the benefits of regular exercise, relatively little is understood about the 
deleterious mechanisms underlying the physiological, cellular and molecular responses to 
PI, specifically with regard to platelet function.  
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The European Space Agency (ESA), employs ground-based models of microgravity (the 
condition in which people or objects appear to be weightless), including dry water immersion 
(DI), to study the effects of spaceflight on human physiology in a precisely controlled 
environment. DI involves immersing a subject in a bath of thermoneutral water covered by 
a waterproof fabric (Coupe et al., 2013). Several factors act simultaneously on the human 
body during immersion, including hydrostatic compression, supportlessness and extensive 
physical inactivity. Hypokinesia and hypodynamia are the major characteristics of physical 
inactivity induced by dry immersion. Hypodynamia involves a reduction in postural muscle 
load, whereas hypokinesia is a decline in motor activity. For these reasons, DI has been well 
accepted as a valuable tool to study physical inactivity (Widlansky, 2010). Subjecting twelve 
healthy men to three days of DI presented a unique opportunity to analyse the specific effects 
of physical inactivity on platelet and related biomarkers. Therefore, in Chapter Five, we 
examined the effect of three days of acute physical inactivity on platelet function. 
Platelet function was assessed at three time points throughout this study; pre immersion, post 
immersion, and after one day of recovery. This chapter was essentially divided into two 
parts. In the first, we assessed platelet function using the Impact R and flow cytometric 
assessment of intra-platelet VASP phosphorylation, a marker of basal platelet activation. 
Platelet indices and haematological characteristics were also examined.  We found that 
physical inactivity (by way of DI) resulted in significant increases in platelet adhesion and 
aggregation post DI, suggesting a more pro-thrombotic platelet profile post DI. After DI, 
while we observed a minor increase in the average PRI (5%) suggesting a reduction in VASP 
phosphorylation and increase in platelet activation. However, as the VASP phosphorylation 
changes were minimal, other (thrombin/collagen) platelet signalling pathways could have 
contributed to the elevated platelet adhesion and aggregation.   
We also examined the effect of physical inactivity on platelet poor plasma (PPP) based 
protein biomarkers using the novel The Proseek® Multiplex assay. We observed changes in 
the expression levels of 15 proteins between different stages of the DI. In particular, 
increases in the Wnt signalling pathway proteins DKK1 and AXIN1 were observed.  As Wnt 
signalling negatively regulates platelet function and modulates the major platelet receptor 
αIIb3, (Steele et al., 2009), an increase in DKK1 and AXIN1 levels could also have 
contributed to platelet adhesion and aggregation levels post DI in this study.  
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Experimental results outlined to this point in Chapter five, demonstrated that physical 
inactivity, using the DI model, has an impact on platelet phenotype and health. This was 
exposed through quantification of platelet activation/adhesion/aggregation markers and 
changes in expression of PPP protein biomarkers. To further understand the significance of 
physical inactivity in the regulation of platelet function, and the molecular mechanisms that 
underpin and fine tune platelet function, we hypothesised that miRNA play a role in the 
regulation of platelet function. This part constituted the second half of the chapter. 
To determine if the miRNA signature or ‘miRNome’ for platelets was altered by physical 
inactivity, platelet miRNA profiles were performed pre and post immersion. To date, there 
are no reports of literature characterising platelet miRNA with regard to physical inactivity/ 
lifestyle. We generated a list of differentially expressed miRNA (downregulated and 
upregulated) from comparisons of profiles at pre to post immersion. Some of these miRNA 
have previously associated with platelet biology, in addition to novel miRNA, which could 
be potentially involved in platelet biology. miR-143 was significantly downregulated after 
the DI. Downregulation of miR-143 has been implicated in platelets of patients with T2DM 
compared to healthy and age-/sex-matched controls (Elgheznawy et al., 2015), with 
subsequently elevated platelet adhesion and aggregation thought to be as a result of reduced 
NO and prostacyclin production – this also could have been a factor in our study.  
Bioinformatics analysis was performed on the most differentially expressed miRNA post DI. 
This included downloading of in silico predicted targets of each miRNA from the online 
algorithm Targetscan. These putative targets were then entered into DAVID bioinformatics 
database, which mapped their involvement in pathways of interest. Pathways were chosen 
based on their involvement in platelet function and cell signalling, specifically in adhesion 
and aggregation. Included in these were the Wnt signalling pathway, regulation of actin 
cytoskeleton and ECM interaction, of which the Wnt signalling pathway appeared repeatedly 
in both the up and downregulated miRNA targets. Relevant to earlier findings in this chapter 
was the recurrence of the Wnt signalling pathway, involving targets of the differentially 
expressed miRNA, as two protein biomarkers (DKK1 and AXIN1), which were affected by 
the DI are also involved in the Wnt pathway. 
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This study has identified 15 proteins whose expression trends could be of importance for 
developing ‘biosignatures’ of physical inactivity. We also identified a set of ‘physical 
inactivity’ related miRNA, which have potential targets involved in pathways associated 
with platelet function. It is evident from this study and literature findings that the 
identification of unique signatures of several miRNA, rather than a single miRNA in 
isolation may enhance diagnostic accuracy (Meder et al., 2011). The canonical Wnt 
signalling pathway may signify a novel endogenous mechanism for regulating platelet 
activity in response to physical inactivity. Investigation around the Wnt negative regulators 
Axin-1 and DKK1, in combination with miRNA involved in this pathway, could be an 
interesting avenue, as a both the protein and miRNA profiles indicated involvement in this 
pathway. 
Our results from this chapter suggest an inclination in healthy males toward an 
unhealthier/pro-thrombotic platelet profile in response to physical inactivity. This could be 
indicative of the changes seen in sedentary individuals. Collectively, our results provide 
evidence for the early and robust detrimental impact of reduced daily activity and/or a low 
cardiorespiratory fitness on platelet function and phenotype, highlighting the vulnerability 
of the vasculature to a sedentary lifestyle. These results involve the measurement of various 
aspects of platelet function are novel and provide an interesting insight into the potential 
mechanisms behind physical inactivity-induced platelet dysfunction. 
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6.2 Future research avenues 
The studies conducted in this thesis reflect the first comprehensive attempt to evaluate the 
relationship between platelet function and physical activity, physical inactivity and 
overweight. While exploratory in nature, we have also enhanced the knowledge in this area. 
Naturally, several questions remain unanswered and so further studies are warranted.  
The search for simple biomarkers that allow for early identification of subclinical/CVD risk 
is ongoing. Platelets can reflect changes in unhealthy lifestyle patterns. The Impact-R test is 
a relatively inexpensive test that can reliably detect changes in platelet adhesion and could 
be employed for CVD risk evaluation amongst subjects who are asymptomatic. Platelet 
indices and function markers should be further tested in larger populations to determine their 
reliability as surrogate markers for evaluating physiological health and to test during either 
pharmacological and lifestyle interventions. 
Exercise-related studies in this thesis examined the effect of maximal exercise on platelet 
function. For subjects with a low CRF, a true VO2 max can be difficult to attain and therefore, 
submaximal exercise tests could be more useful. Future research should also contemplate 
the optimal amount and intensity of warm up exercise that could reduce negative exercise 
induced changes in the thrombotic state seen post exercise in low fit subjects. Warm ups 
prior to strenuous exercise in low fit subjects may attenuate these changes and a role for an 
active cool down may be required (Wang et al., 2006).  
A relatively low dose of exercise has been shown to be sufficient to normalise platelet 
function in low fit females (Heber et al., 2016). Larger studies incorporating exercise 
interventions at low doses over a lengthy period of time and examining more extensive 
aspects of platelet function in low fit subjects (such as flow cytometric evaluation of platelet 
activation markers) would develop this knowledge.  
MedEx (Medical Exercise) is a unique chronic rehabilitation service ran by Dublin City 
University, which delivers exercise-based programmes to individuals with chronic disease, 
including CVD. The prescription of anti-platelet therapy is frequently used to treat CVD 
patients. However, the other residual risks (oxidative stress, inflammation etc.), which occur 
due to associations between CVD risk factors, are not eliminated efficiently by these 
therapies. In this sense, physical activity has been emphasised as it promotes favourable 
physiological adaptations, which may attenuate the cardiovascular risk factors and residual 
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risks. Regular exercise could also impact platelet function in CVD patients. Exercise 
interventions in these populations could be beneficial in terms of reducing antiplatelet 
therapy dosage or combining antiplatelet therapy with exercise (Martins et al., 2016), i.e. 
prescriptive exercise medicine as adjuvant/adjacent management strategy/therapy. 
Unlike the platelet transcriptome and proteome, the investigation of epigenetic processes is 
almost a completely unexplored area in platelet biology as analysis of these mechanisms 
require DNA (Freson, Izzi and Van Geet, 2012). Platelets have functionally active 
mitochondria (Antony et al., 2012). Like nuclear DNA, mitochondrial DNA (mtDNA) can 
also be methylated, moderating control of mitochondrial gene expression. Understanding 
epigenetic regulation of mitochondrial genes in platelets may prove crucial to understanding 
their implication in CVD development. Novel research by Baccarelli and Byun (2015) 
showed that CVD patients had significantly higher platelet mtDNA methylation than healthy 
individuals in MT-CO1, MT-C02, MT-CO3, and MT-TL1, genes involved in ATP synthesis. 
These results suggest that DNA methylation in platelet mitochondria could be a potential 
contributor to CVD development through the regulation of platelet function. Furthermore, 
miRNA have recently been linked with platelet mitochondrial health in stored platelets 
(Dahiya et al., 2016) 
While the nuclear miRNA processing components Drosha and DCGR8 have not been 
identified in human platelets due to their anucleate nature, platelets contain the machinery 
to process pre-miRNA to mature miRNA (Landry et al., 2009). Platelets contain higher 
levels of pre-miRNA than other blood cells (Pan et al., 2013). Although not examined in this 
thesis, we acknowledge that the maturation of pre-miRNA could have contributed to 
upregulated miRNA after the dry immersion. It was likely that pre-miRNA could have been 
cleaved into mature miRNA, thereby increasing mature miRNA numbers. Future studies 
should therefore clarify the possible processing/levels of pre and mature miRNA in platelets 
to determine their contribution to the regulation of gene expression.  This may be a more 
focused and efficient method of monitoring platelet function.  
Targeting the levels of other biogenesis molecules in the miRNA pathway would also be an 
interesting avenue of platelet miRNA biology. Recently, Elgheznawy et al., (2015) showed 
that, Dicer was decreased in patients with TD2M compared to healthy controls, whereas 
interestingly, Argonaute 2 levels did not differ. Experiments investigating the levels of 
miRNA processing machinery such as Dicer and Argonaute 2 in physically active and 
sedentary populations would be of major interest. 
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Platelet microvesicles are released upon platelet activation. Microvesicles can carry genetic 
information such as mRNA and miRNA. In this respect, perhaps the most intriguing feature 
regarding platelet miRNA is their extracellular function. miRNA can be packaged and 
delivered to distant cells in the form of platelet microvesicles, fulfilling novel processes of 
gene regulation in target cells (Diehl et al., 2012). Downregulation of platelet miRNA upon 
platelet activation could be as a result of miRNA packaging in platelet MVs. Comparing the 
microRNA spectrum between platelets, platelet microparticle and platelet exosome miRNA 
content could provide interesting answers.  
Long-term lifestyle choices such as physical inactivity and obesity may incur epigenetic 
changes in megakaryocytes. Thus, platelet miRNA could reflect these epigenetic changes, 
holding substantial diagnostic potential of both health and disease (Figure 6.1).  Epigenetic 
changes in the megakaryocyte genome such as methylation of genes determining PLT or 
changes in histone acetylation with aging have been suggested to play an important role in 
platelet function (Daly, 2011). Prescribed exercise could induce epigenetic changes in 
megakaryocytes to produce a healthier phenotype of platelets with a direct change in platelet 
reactivity. New molecular techniques such as Bisulfite sequencing would be useful to assess 
the methylation state of megakaryocyte DNA, with subsequent detection of miRNA in 
platelets.  
                       
Figure 6.1:  Model linking epigenomics and genomics to transcriptomics and proteomics. 
Environmental factors such as physical activity/overweight can lead to stable changes in the 
epigenome which alter CVD disease susceptibility. Platelet miRNA may reflect long-term changes 
in the megakaryocyte genome such as DNA methylation changes. (Adapted from Freson et al., 
2012).  
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Concluding thoughts 
To conclude, it is evident that lifestyle factors such as physical (in) activity and overweight 
do impact platelet function in apparently healthy subjects. Work from the three chapters of 
this thesis have collectively demonstrated that platelets are indeed reflective of physiological 
and lifestyle changes, making them sensitive biomarkers of human health. Platelets represent 
a tangible link to physiological and pathological changes within the body. Research 
continuing from this thesis, in the areas discussed above, will no doubt contribute to a greater 
mechanistic understanding of the relationship between cardiovascular health, lifestyle 
factors and platelet biology. 
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Appendix 
This appendix is composed of additional and or preliminary data for each of the results 
chapters. This data was not essential to test the thesis hypothesis but is rather included in the 
appendix to demonstrate the breadth of the studies performed and potential avenues for 
future work. It also contains supplementary data for each chapter, such as questionnaires or 
report forms for exercise protocols. The appendix is split into three parts – Appendix A 
contains information related to Chapter 3, Appendix B contains information related to 
Chapter four and Appendix C contains information related to Chapter 5. 
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Appendix A  
 
FAT LAB GENERAL QUESTIONAIRE 
 
1. Gender:  Male        Female      
2. Date of birth    _______________ 
3. Is English your first language? Yes    No  
4. To which racial or ethnic group(s) do you most identify?  
Irish  Irish traveller    Any other white background     African  
Any other black background     Chinese  Any other Asian background  Other 
     
5. Do you smoke cigarettes?  Yes    (How many per day) ____  Used to       No  
 
6. How often do you have a drink containing alcohol? Never   Monthly, or less    
2-4 times a month    2-3 times a week   4 or more/week    
7. Are you taking any medication?  Yes   (Name medication)___________ No   
8. Have you taken any NSAIDS or aspirin medication in the last 10 days?  
Yes  No  
9. Do you exercise? Yes  No  If yes, how many times per week? ________ 
10. Have you performed strenuous exercise in the last 24 hours? ____________ 
11. In general, would you say your health is? Excellent   Good     Fair     Poor 
 
12. Do you have any physically limiting conditions? Yes    No   If yes specify 
details __________ 
13. Have you ever been advised by a physician to avoid any type of exercise or 
lifting any weight? Yes    No  ________ 
14. How physically fit would you consider yourself?  Unfit     Fairly fit    Fit    
Very Fit        
15. Do you (or does someone in your family) have a cardiac condition or have you 
ever had cancer? Yes    No  If yes, Details: ____________If yes to either, 
when were you diagnosed? ____ 
16. What time do you usually go to sleep and wake up? _________ 
17. Do you work during the day time or at night? ____________ 
18. At what part of the day do you consider yourself most active? _________ 
19. What have you eaten today and what time? _________________________ 
20. Do you prefer savoury or sweet foods? ___________ 
21. How many calories do you think you consume per day? ____________ 
22. How many calories do you think you ‘burn’ each day? _____________ 
23. What do you estimate your weight and height to be? _____________ 
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PARTICIPANT INFORMATION LEAFLET      
Title of study: To screen platelet function in the General Irish Population. 
Names of Researchers: Ms. Laura Twomey, Dr. Ronan Murphy. 
Location: Science Gallery, Trinity College, Dublin.  
Introduction:  
The purpose of this project is to profile platelet reactivity in a cohort of the Irish population. Platelets 
are tiny fragments of larger cells which circulate within the blood stream. Their main function is to 
aid in primary haemostasis - blood clotting. They complete this by sticking to an injured vessel wall 
and then sticking to each other to form a small clot. Platelet activity can vary amongst individuals of 
varying health status/fitness/age and is increasingly being noted as a marker of vascular health.  
Exclusion from participation: You cannot participate in this study if you are: 
1. Under the age of 18 
2. Know you are, or think you might be, infected with Hepatitis B or C 
3. Know you are, or think you might be, infected with HIV (the AIDS virus) have, or have had 
a sexual partner who is infected with hepatitis or HIV.  
4. Are, or may be pregnant.  
Procedures: 
In order to obtain results I understand that the following procedures need to take place: 
 I am required to complete a general questionnaire for FAT to complete the TANITA 
measurement before the platelet test.  
 A single, small (4.5ml) blood sample will be taken for this test. This will take about five 
minutes. 
 This blood sample will be processed on the cone and plate analyser to determine platelet 
function and the blood counter to determine platelet count.  
Why is blood sampling required? Platelet activity can only be measured in blood samples. An 
instrument called a cone and plate analyser will help to measure your platelet activity.  
Benefits:  
This test will be extremely informative and will provide you with a better understanding of how 
blood cells work in the body. You will be provided with your own full platelet function profile screen 
readout which includes platelet number, platelet activity - adhesion and aggregation.  
Risks 
There are no major risks involved. Blood will be taken by a qualified phlebotomist. You may feel a 
slight discomfort when the sample is drawn, a very small needle size is used to reduce this. A tiny 
bruise could develop where the sample took place. There is a small risk of fainting, participant can 
choose to sit or lie down for the test.  
Confidentiality:  
Your identity will remain confidential. Your name will not be published and will not be disclosed to 
anyone outside the study group. Data will be stored in password protected files at Science Gallery 
Trinity College.  
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The research may be used for a PhD thesis, published in scientific journals and / or presented and 
discussed at scientific meetings, without revealing any of my personal details.  
Compensation: This study is covered by standard institutional indemnity insurance. Nothing in this 
document restricts or curtails your rights. 
Voluntary Participation: This research is voluntary and you may decide to withdraw at any stage.  
Stopping the study: I understand that the investigators may withdraw my participation in the study 
at any time without my consent.  
Permission: This study has ethical approval from TCD and DCU ethics.  
Further information: Please contact Dr. Ronan Murphy or Ms. Laura Twomey who can be 
contacted at 017008824 or laura.twomey2@mail.dcu.ie for any further information you require.  
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FAT LAB GENERAL CONSENT FORM 
 
Letter of Consent to partake in experiments during the FAT LAB exhibition at the Science 
Gallery, Trinity College Dublin, May 16th – June 29th 2014. 
Research Team: Science Gallery Trinity College Dublin (TCD), Jennifer Fortune, Department of 
Physiotherapy, School of Medicine, Trinity Biosciences Institute,TCD: Suzanne Doyle, Joanne 
Lysaght and Jacintha O’Sullivan, Department of Surgery, School of Medicine,TCD: David Hevey, 
Department of Psychology,TCD: Helen Roche and Aoibheann Mc Morrow, Institute of Food and 
Health UCD: Laura Twomey, Ronan Murphy, Johann Issartel, School of Health & Human 
Performance, Faculty of Science and Health, DCU. 
You have received this consent form because you have indicated that you wish to take part in 
experiments conducted during the FAT LAB exhibition at the Science Gallery, Trinity College 
Dublin. FAT LAB is delivered by Science Gallery in partnership with Trinity Biosciences Institute, 
Trinity College Dublin.  
The experiments explore different aspects of the theme of FAT, using simple computerized tests, 
questionnaires and scale ratings, fitness tests and measurement of various physiological parameters. 
These hands-on, real data collecting experiments are connecting with research groups working in the 
area of nutrition, obesity and food and health research - in Trinity Biomedical Sciences Institute, 
TCD; School of Medicine, TCD; Trinity College Institute of Neuroscience and School of 
Psychology; Institute of Food and Health, Conway Institute, UCD; Obesity Research Group, St 
Vincent’s University Hospital, School of Health and Human Performance, Dublin City University. 
These will include research currently being carried out in the areas of sensory motor perception and 
coordination, changing physiological parameters in response to activity levels, energy expenditure, 
fitness, obesity and cognition, and on the type of food we eat as well as body image and perception 
of obesity. The experiments will explore these relationships across the lifespan - young adults (18 
years and up), middle aged and older people.  
If you wish to take part in these experiments, please read this consent form carefully and confirm 
your consent by signing the form. 
Signing this consent form does not yet represent agreement to participate in any of the specific 
experiments but allows us to collect and retain some background information about you and to assign 
you a unique Participant ID Code which you will need in order to volunteer for any of the individual 
experiments. As you walk around the gallery you will see that there are a variety of different 
experiments being conducted. A mediator will be available at each experiment station to explain 
what experiments are being conducted and to answer any questions you may have.  
You are under no obligation to take part but if you wish to volunteer for a particular experiment you 
may then be asked to fill out a separate consent form, specific to that experiment, and to provide 
your Participant ID Code. Please note research results take time to process and we will not be able 
to give you specific individual feedback after every experiment. Feedback or results cannot be 
emailed to any participants due to the anonymous nature of the study. 
TERMS OF CONSENT 
I hereby give my consent to participate in the experiments carried out during the FAT LAB 
exhibition. The consent I provide pertains to experiments running as part of this specific exhibition 
only and not to any other experiments conducted by members of the research team outside the 
exhibition. (in the case of which there will be a separate consent from the researcher for any 
participation in experiments outside of the exhibition). 
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Once I have signed this consent I understand that 
I will be assigned a Participant ID Code and become a member of the FAT LAB participant panel 
As a member of the FAT LAB participant panel I consent to provide demographic information to 
the researchers involved, and answer questions relating to: sex; age; education; gender; relationship 
status; family circumstances; employment status; recreational habits, general health and lifestyle.   
I understand that I can decline to provide some or all of the information requested. I understand that 
this demographic information will never be made available to anyone other than members of the 
research team or their assistants. The demographic information I have provided and the data collected 
from me will be stored anonymously under my ID code only.  I understand that my ID code cannot 
be linked to my name or other identifiable information in any way. (The Freedom of Information Act 
does not apply to data stored anonymously).  I also understand that any data obtained through my 
participation in a research study will be treated as confidential and processed only in accordance 
with the Data Protection Acts, and that they will be used only for the purposes of research. 
Signing this consent form does not represent agreement to participate in any of the experiments being 
conducted at the FAT LAB exhibition. If you wish to participate in an experiment you may be asked 
to read a separate information sheet and to sign a separate consent form. 
I may withdraw my participation at any time during any study;I will not be requested to participate 
in any study that could be foreseen to be detrimental to a person's well-being, under normal 
circumstances, and that every study that I will be invited to participate in will have received prior 
approval from the relevant ethics committees within Trinity College Dublin. (You will be informed 
of the general nature of any study before participating, and further explanation of the aims of the 
study can be provided after you have completed your participation, at which time any further 
questions may be raised). 
Please note that in the case of any measured results that concern you, please consult your GP.  
I, the undersigned, give my informed consent to take part in the FAT LAB experiments 
running at the Science Gallery, Trinity College Dublin. 
Full Name: ___________________________   Signed: ____________________    Date:        
Where the participant is incapable of comprehending the nature, significance and scope of the 
consent required, the form must be signed by a person legally competent to give consent. Participants 
must be over 18 years of age for data to be used. 
NAME OF PARTICIPANT, PARENT OR GUARDIAN: 
………………………………………………………………….......................... 
SIGNATURE: …………………………………………………………... 
RELATION TO PARTICIPANT:……………………………………… 
Statement of Investigator’s Responsibility: I have explained the nature and purpose of this 
research study, the procedures to be undertaken and any risks that may be involved. I have offered 
to answer any questions and fully answered such questions. I believe that the participant understands 
my explanation and has freely given informed consent. 
Contact emails for researchers:  
Jennifer Fortune (fortunej@tcd.ie), Suzanne Doyle (doyles4@tcd.ie), Joanne Lysaght 
(jlysaght@tcd.ie), David Hevey (heveydt@tcd.ie), Aoibheann Mc Morrow 
(aoibheann.mcmorrow@ucdconnect.ie),Laura Twomey (twomey.laura@gmail.com), Johann 
Issartel (johann.issartel@dcu.ie), Helen Roche (helen.roche@ucd.ie), Ronan Murphy 
(ronan.murphy@dcu.ie) 
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Relationship between platelet and haematological parameters 
The main finding was that platelet count and plateletcrit were significantly associated with 
platelet adhesion as shown in Figure A1. There were no significant correlations between 
platelet volume indices (MPV, PDW and PLCR) and any blood cell measurement (Table 
A1). WBC was significantly correlated to PCT and PLT (Table A2). 
 
Platelet parameter 
  PLT MPV PDW PLCR PCT SC 
Male PLT 1      
 MPV -.224 1     
 PDW -.173 .970* 1    
 PLCR -.181 .995* .980* 1   
 PCT .919* .167 .222 .167 1  
 SC .416* -.036 -.025 -.024 .470* 1 
 AS .081 .150 .172 .187 .033 .368* 
        
Female PLT 1      
 MPV -.361* 1     
 PDW -.345* .947* 1    
 PLCR -.344* .993* .965* 1   
 PCT .897* .091 .002 .021 1  
 SC .418* -.142 -.188 -.188 .387* 1 
 AS .262* .059 .041 .059 .273* .316*  
 
Table A1: Correlation between platelet indices and platelet function. Values are r squared 
values. PLT - Platelet count, PDW - Platelet distribution width, MPV - Mean platelet volume, PLCR 
- Platelet large cell ratio, PCT - Plateletcrit, SC - Surface coverage, AS - Aggregate size. *P <0.05. 
Partial correlation adjusting for age. 
 H 
 
 
 
 
 
 
 
 
Figure A1: Correlation between platelet indices and platelet function measurements.  Left: 
Scatterplot depicting relationship between PLT and platelet adhesion in males and females. Right: 
Scatterplot showing the relationship between PCT and platelet adhesion in males and females. 
 
 
Table A2: Correlation between platelet and haematological parameters. PLT - Platelet count, 
PDW - Platelet distribution width, MPV - Mean platelet volume, PLCR - Platelet large cell ratio, 
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PCT – Plateletcrit, SC - Surface coverage, AS – Aggregate size. WBC – White blood cell count, 
MCV – Mean corpuscular volume, RDW – Red cell distribution width. *P<0.05. Partial correlation 
adjusting for age. 
 
Haematological parameters 
  WBC MCV RDW 
Female     
 PLT .331* -.276* -.193 
 PCT .354* -.338* .033 
 SC  .230* .134 .108 
 AS  .190 .154 .111 
Male     
 PLT .332* -.044 .021 
 PCT .337* -.061 .043 
 SC  .138 .184 .268* 
 AS  .178 .042 .282* 
 
 
Relationship between haematological parameters and measures of obesity/overweight 
To examine the relationships between red blood cell and white blood cell parameters and 
various parameters of overweight and obesity, correlation analysis was performed between 
these variables (Table A3, A4 and A5). 
Table A3: Correlation between RBC, WBC and BMI. WBC - White blood cell count, RBC - Red 
blood cell count, HGB - Hemoglobin, HCT - Hematocrit, MCV - Mean corpuscular volume, RDW 
- Red cell distribution width. Partial correlation accounting for age. 
 
 Haematological parameter 
  WBC RBC HCT HGB MCV RDW 
BMI Male .095 .153 .226 .193 .035 .097 
 Female .192 .129 .050 .079 .048 .093 
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Table A4: Correlations between waist circumference and hematological parameters. WBC - 
White blood cell count, RBC - Red blood cell count, HGB - Hemoglobin, HCT - Hematocrit, MCV 
- Mean corpuscular volume, RDW - Red cell distribution width. *P<0.05.  Partial correlation 
adjusting for age. 
 
  Haematological parameter 
  WBC RBC HCT HGB MCV RDW 
WC Male  .072 .205 .192 .152 .153 .150 
 Female  .268* .270* .146 .179 .187 .028 
 
 
Table A5: Relationship between BIA body composition measurements and haematological 
parameters in females. WBC - White blood cell count, RBC - Red blood cell count, RDW - Red 
cell distribution width. BF % - Body fat percent, VAT - Visceral adipose tissue, FM - Fat mass, 
FFM - Fat free mass, MM - muscle mass, TBW % - Total body water percent, *P<0.05. Partial 
correlation adjusting for age. There was no correlation between HCT, HGB or MCV and any BIA 
measurement.  
 
BIA body composition measurement 
Female BF VF FM FFM MM TBW 
WBC .269* .168 .184 -.028 -.051 -.284* 
RBC .239* .211 .264* .053 .036 -.237* 
RDW .005 .028 .020 .134 .306* .024 
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Variation in platelet function according to smoking status 
Based on the questionnaire responses, subjects were categorized as current, previous or 
nonsmokers. This enabled comparisons of platelet parameters between groups shown in 
Figure A2. There was no difference in MPV between groups. PDW was slightly higher in 
current smokers in females compared to non-smokers. 
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Figure A2: Comparison of platelet parameters between smokers, non-smokers and 
past smokers. Graphs represent mean ± SEM. One way ANCOVA adjusting for age. 
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Variation in platelet function according to Ethnicity 
Variation in platelet indices according to ethnicity, a non-modifiable risk factor for CVD 
was examined. Subjects provided their ethnicity upon questionnaire completion. For 
comparison purposes, subjects were divided into three ethnic groups: Irish, Any other white 
background (AOWB) and Other (comprising Asian, middle eastern and Indian nationalities) 
shown in Figure A3. 
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Figure A3: Comparison of platelet parameters according to ethnicity. Graphs represent 
mean ± SEM. One way ANCOVA adjusting for age. *P< 0.05. 
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Variation in platelet function and haematological characteristics according to Age 
To assess the relationship between age, platelet parameters and haematological parameters, 
correlation analysis was performed, as shown in Tables A6 and Table A7. The main findings 
were that platelet count and plateletcrit decrease with aging, and platelet aggregation is 
significantly associated with aging in females only. To compare variances in platelet 
parameters between different age categories, subjects were divided into four groups based 
on their age shown in Figure A4. Main findings include a significant difference in male PLT 
between the 50-60 year and 60 + year age brackets. No changes in PDW or MPV were 
observed. 
 
Table A6: Correlation between age and platelet indices. PLT - Platelet count, PDW -  Platelet 
distribution width, MPV - Mean platelet volume, PLCR - Platelet large cell ratio, PCT – Plateletcrit, 
SC - Surface coverage, AS – Aggregate size. * P<0.05. Partial correlation adjusting for BMI. 
 
 Platelet parameter 
  Plt MPV PDW PLCR PCT SC AS 
Age Male -.279  .003 .027 .010 -.237 .017 .149 
 Female -.115 .076 .099 .087 -.111 .090 .293* 
 
 
Table A7: Relationship between age and leukocyte/erythrocyte parameters. WBC - White 
blood cell, RBC – Red blood cell, MCV – Mean corpuscular volume, RDW -  Red cell distribution 
width. *P< 0.05. Partial correlation adjusting for BMI.  
 
Blood cell parameter 
  WBC RBC MCV RDW 
Age Male -.274* -.394* .379* .125 
 Female -.262* -.170 .083 .260* 
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Figure A4: Age related changes in platelet parameters. Graphs represent mean ± SEM variances 
in A – Platelet count, B – Plateletcrit, C – Platelet adhesion and D – Platelet aggregation. *P< 0.05. 
One-way ANOVA and independent t-test.  
 
 
Variation in platelet function according to blood pressure and resting heart rate 
A cohort of subjects chose to receive blood pressure (BP) measurements. Subjects were 
categorised into groups based on their systolic and diastolic blood pressure outlined in Table 
A8. Correlation analysis was performed to elucidate the relationships between BP, RHR and 
platelet parameters (Table A9). There was no correlation between BP and platelet 
parameters in males or females. The most pertinent result was the positive correlation 
between aggregate size and diastolic blood pressure in the prehypertensive (PHT) group. 
There was a positive correlation between BP and RBC parameters in males, shown in Table 
A9. 
 
 
 
* 
* 
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Table: A8: Blood pressure classes. Numbers are percentages of the subject population in each 
category. PHT – Prehypertensive, Stage 1 HT – Stage one hypertension. 
 
Blood Pressure 
 Systolic   Diastolic  
 Male Female  Male Female 
Normal 
(<120) 
60 % 72% Normal 
(<80) 
76% 74% 
PHT (120-
139) 
24% 19.5% PHT (80-90) 18% 20% 
Stage 1 HT 
(140 +) 
16% 7.5% Stage 1 HT 
(90+) 
6% 6% 
 
Table A9: Correlation between blood pressure, resting heart rate, and platelet parameters. 
PLT - Platelet count, PDW - Platelet distribution width, PCT – Plateletcrit, SC - Surface coverage, 
AS – Aggregate size. DBP – diastolic blood pressure. PHT -  prehypertensive.  *P <0.05. Partial 
correlation adjusting for age and BMI.  
 
Platelet parameter 
  PLT PCT SC AS 
SBP      
 Male (all) .032 .095 .108 -.070 
 Female (all) .101 .157 .026 -.006 
DBP      
 Male (all) -.003 .014 -.028 .042 
 Female (all) .052  .061 -.025 .084 
 Female (PHT) .293 .246 .368 .684* 
RHR      
 Male .061  .061 -.067 -.095 
 Female .250* .298* .044 -.069 
 
Table A10: Correlation between haematological indices, RHR and blood pressure in males. 
WBC – White blood cell count, RBC – Red blood cell count, HCT – Haematocrit, HGB – 
Haemoglobin, SBP – Systolic BP, DBP – Diastolic BP.  *P<0.05. Partial correlation adjusting for 
age and BMI.  
 
Haematological parameter 
  RBC HCT HGB 
Male     
 SBP .512* .507* .496* 
 DBP .291* .300* .244 
 RHR .138 .115 .157 
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Relationship between platelet parameters and blood cells 
In peripheral blood, there is ample interplay between RBCs, WBCs and platelets (Ho, 2004) 
and altered levels of blood cells and their morphology have been associated with CVD 
(Maajid 2013; Cetin et al., 2014;). Platelet adhesion and aggregate size, as assessed by the 
Impact-R system is influenced by platelet indices, RBC and WBC (Shenkman et al, 
2000; Peerschke et al., 2007). In this view, we investigated the associations between the 
various indices of each blood cell to interpret the multicellular contribution to 
thrombogenesis and CVD risk.  
As shown in Table A1, there was no correlation between PDW, MPV and PLCR with either 
platelet adhesion or aggregation. To support this finding, PLCR was not associated with 
platelet aggregation in a study by De Luca et al., (2010), whilst Beyan et al., (2006) also 
found no correlation between MPV, PDW and platelet aggregation in healthy subjects. 
Contrarily, platelet adhesion was significantly positively correlated with PCT and PLT in 
males and females (Figure 3.1) and in female’s, aggregation was significantly correlated to 
PCT and PLT.  
Table A2 highlights the relationship between platelet and haematological parameters. Both 
PLT and PCT were positively associated with WBC in both genders, in concordance with 
the MOLI-SANI study (Santimone et al., 2011). This association remained significant when 
age, BMI, and blood pressure were adjusted for with partial correlations. Furthermore, WBC 
was positively associated with platelet adhesion in males and females, and this correlation 
was significant in females, highlighting the link between platelets and inflammation. 
Adhesive mechanisms involving the interaction between platelets and WBC include the 
binding of P-selectin on platelets to P-selectin glycoprotein ligand -1 (PSGL-1) on 
leukocytes. PSGL-1 prompts a signalling response to activate leukocytes by inducing a 
conformational change of the β-2 integrin. PSGL-1 binding to monocytes results in the 
formation of platelet-monocyte aggregates and has the potential to prompt inflammation by 
the cyclooxegenase-2 (COX-2) pathway (Lam et al., 2015). This interaction between 
activated blood cells could explain the correlation between WBC and PLT suggesting that 
platelets regulate other immune cells and mediate a broad range of physiological responses. 
To highlight the importance of the WBC/PLT interactions, a novel biomarker, the platelet 
to lymphocyte ratio (PLR) has recently been suggested as a combined biomarker of CVD 
risk (Song et al., 2016).  
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The association between RBC count and morphological features with platelet parameters 
was also studied.  We found no associations between RBC, HCT, HGB and any platelet 
parameter. Correspondingly, a cross sectional study of 215 healthy volunteers showed no 
correlation between PCT and HCT or between MPV and MCV (Wiwanitkit, 2004). 
Significant correlations between distribution widths, PDW and RDW were noted in two 
separate cross sectional studies (Wiwanitkit 2004; Saouli et al., 2007) suggesting that 
anisocytosis (unequal sized cells) of RBCs and platelets could co-occur. This association 
was not observed in this study, but there did appear to be an association between MCV and 
PLT/PCT in females (Table A2). Iron deficiency is associated with reduced MCV, increased 
RDW and increased PLT, which could explain this observation, as females tend to have 
lower iron reserves than males (Rushton et al., 2001; Akan et al., 2000). 
Lower HCT levels have been associated with abnormal platelet adhesion (Varon et al., 
1997; Kenet et al., 1998). HCT was not correlated to platelet adhesion. This was also the 
case in other studies investigating variability in platelet function in healthy volunteers 
(Neeves et al, 2013). This was likely due to the fact that HCT and PLT counts in this study 
were within the normal ranges of (.035 - .050 g/dL) and (150,000 – 450,000 x 103/µL) 
respectively. RDW was associated with platelet function and was positively correlated to 
adhesion and aggregation in males only. RBC’s are known to encourage platelets toward the 
vessel wall (Chestnut and Han, 2013) which can affect platelet adhesion and aggregation. 
This result indicated that a larger range of RBC size was linked to increased platelet adhesion 
and aggregation in males. 
Tables A3-A5 displays the association between RBCS, WBCs and measures of body 
composition. In this study, WBC was positively correlated with fat mass, body fat %, and 
visceral fat in females only (Charles et al., 2012) and RBC was positively correlated with 
fat mass in females, suggesting the simultaneous increase in all blood cells as body 
composition worsens, reaching an inflammatory state. Elevated WBC has been associated 
with obesity and inflammation (Dixon and O’Brien 2006).  
 
Smoking 
Cigarette smoking has long been identified as a major modifiable risk factor for CVD. 
Platelet activation appears to be one of the main dynamics by which smoking mediates the 
pathogenesis of CVD (Ichiki et al., 1996). Platelet hyper-activation has been associated with 
smoking status in CVD patients. (Pamukcu et al., 2011) However, there is a lack of studies 
 R 
 
evaluating all platelet indices parameters, to acquire a global view of platelet function in 
healthy subjects. We therefore elucidated the variance between platelet indices and function 
in smokers, non-smokers and past smokers in this study. 
The majority of participants were non-smokers, with only 8% and 8.5% of males and 
females’ current smokers.  A recent cross sectional study of over 500 healthy males 
demonstrated elevated PLT in smokers compared to non-smokers, and reduced PCT in the 
smoker group (Ghahremanfard et al., 2015). Similarly, PCT was reduced in smokers but in 
contrast, Figure A2 indicates that PLT was reduced in smokers and past smokers compared 
to non-smokers, with minimal differences. This is in agreement with work by Varol et al., 
(2013) who observed that PLT was significantly lower in the smoker group compared to 
control group across gender.  
Smoking can induce both long-term and short-term effects on platelets. A recent study 
showed that even brief smoking can alter PLT and cause damage to the endothelium. One 
bout of smoking increased platelet MP concentrations and percentage of MP’s exposing the 
platelet activation marker CD62P in healthy subjects, suggesting stress induced release of 
MP’s from smoking (Mobarrez et al., 2014. This study showed that chronic male chronic 
smokers had slightly elevated platelet adhesion compared to non-smokers. They also 
displayed increased platelet aggregate size (51 µm2 compared to 42 µm2). This result is in 
accordance with a recent study examining the effect of cyclooxygenase-1 (COX-1) mediated 
platelet function in healthy males whereby collagen induced platelet aggregation was higher 
in smokers than non-smokers (Loke et al., 2014).  
Ethnicity  
Ethnicity is a significant non-modifiable risk factor for developing CVD. In a population 
based study of different ethnic groups in Canada, Europeans had the highest incidence of 
atherosclerosis compared to South Asians and Chinese (Anand et al., 2000). Subjects in our 
population were primarily of an Irish descent (70%) with 21% of subjects categorised as any 
other white background (AOWB) and 5% categorised as other. Interestingly, there were 
variances observed amongst platelet indices and platelet function measurements shown in 
Figure A3.  Of the platelet indices, PLCR was highest in those of an Irish descent compared 
to other nationalities and was significantly higher in Irish males compared to males from 
any other white background (AOWB).  An initial study on platelet counts in different racial 
groups by Saxena at al. (1987) identified a discrepancy in PLT between healthy white, black, 
and latin-american people. Black women had significantly increased PLT than white 
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women. Ethnic variations have further been referred to by Segal and Moliturno (2006) 
whereby a cross sectional study of 12,000 Americans showed that PLT was highest in non-
Hispanic blacks compared to other ethnicities.  
Figure A3 compares platelet function between ethnic groups. Our study showed that platelet 
aggregation and adhesion was highest in the “other” category compared to Irish and AOWB, 
however as the number of subjects in that category was small, it is difficult to draw 
conclusions. To support this finding, variation in platelet function has been illustrated in 
other studies, where other ethnic groups have displayed enhanced platelet aggregation 
compared to Caucasians, in particular platelet aggregation in response to PAR4-AP which 
activates platelets through the PAR4 thrombin receptor (Edelstein et al., 2013).  
Age 
Data collected in this study also included information on non-modifiable CVD risk factors 
such as ethnicity and age. Aging and platelet function is a novel area of research. 
Meta-analysis of over 40,000 subjects showed a strong inverse relationship between PLT 
and age (Biino et al., 2011; Biino et al., 2013) whereby PLT decreased by 35% in males and 
25% in females when compared to early childhood. Similar results have been noted in 
population based studies in France and the US (Segal and Moliterno 2006, Troussard, 2014). 
Correspondingly, our smaller cross sectional study also highlighted an inverse relationship 
between age and PLT in males and females (Table A6). However, the strength of these 
correlations were weak and not significant, likely due to the population size and the fact that 
majority of participants were between 20-30 years. The relationship between age and PLT 
does not appear to be linear as it remains stable during middle age (25-60) and decreases in 
old age (60+). Zhang et al., (2015) also showed that age-related changes are very noticeable 
in very old age where PLT is diminished by 21% and 22 % in subjects (> 81) years compared 
to 18-30 year olds. There was no association between MPV, PDW or PLCR with age. 
Likewise, other studies have shown that the link between platelet volume indices and age 
yield contrasting results. Zhang et al., (2015).  
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Regarding the mechanisms responsible for the age-dependent decline in PLT, it has been 
postulated that reduced hematopoietic stem cell (HSC) reserves could be an important factor, 
as there is a reduction of HSC reserve with aging. Epigenetic changes in the megakaryocyte 
genome such as hypomethylation of genes determining PLT or changes in histone 
acetylation with aging have been suggested to play an important role (Daly, 2011). Further 
investigation is required to detect these epigenetic mechanisms underpinning age-related 
change.  
The variation in platelet function and age in Figure A4 point to a change in platelet 
phenotype with aging. The enduring thought was that platelet activity increases with age. 
Research on age-related changes in platelet function to date have deduced that aging results 
in increased platelet aggregation (Gleerup, 1995, Knight, 1997; Bastyr et al., 1990). Use of 
modern flow based techniques (PFA-100) found that older subjects (> 40 years) had platelet 
CTs shorter than those seen in younger subjects and that females had longer CTs than males 
(Cho et al., 2008). Contrastingly, Sestito et al., (1999) found no correlation between age and 
platelet CT in a separate group of healthy individuals.  
Kent et al., (2010) used the Dynamic Platelet Function Assay (parallel plate flow chambers 
coated with human vWF) to measure platelet activation, adhesion and translocation on vWF 
in over 100 healthy subjects (aged 18-82, but only 3 older than 65) Platelet behaviour on 
vWF was significantly altered with ageing (Cowman et al., 2015). Furthermore, these 
changes were more pronounced in women compared to men.  
Similarly, we observed alterations in platelet function with aging (A3) using the flow based 
Impact-R assay. Platelet adhesion showed little association with age whereas there was a 
small positive significant association between platelet aggregation and age in females only. 
Stratified by age groups, platelet aggregation appeared stable until 60 years in males, after 
which it increased by approximately 20% compared to the younger age groups. A similar 
trend followed for females, however the peak in aggregation was observed in the 50-60-
year-old age group compared to the younger categories. These results could be linked to the 
possible influence of sex hormones testosterone and estrogen. Testosterone has been linked 
to increased platelet TxA2 receptors and increased platelet aggregation in response to 
arachidonic acid (Ajayi et al., 1995; Campelo et al., 2012). These age-related changes in 
platelet function may contribute to the augmented prevalence of thrombotic events seen 
with aging.  
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Platelet function changes with aging is most likely caused by changes in hematopoietic 
tissue, blood composition and vascular health (Jones et al., 2016) or biochemical alterations 
in the platelet resulting in differential mRNA expression (Simon et al., 2014), and increases 
in oxidative stress (Dayal et al., 2013). However, a strong illustration of the extensive effects 
of aging is demonstrated by the age-related change in platelet mRNA and microRNAs, the 
molecular genetic mechanisms controlling the modifications (Simon et al., 2014). Analysis 
of platelet RNA from healthy male and female subjects showed that 129 mRNA and 15 
miRNAs were differentially expressed with age. The inverse correlation between these 
mRNA-miRNA pairs suggest that miRNA may regulate mRNA levels in aging. Further 
analysis of these miRNA revealed their role in platelet function pathways such as 
cytoskeletal organisation and vesicle transport. A new area of research will be how these 
changes in miRNA link to changes in the platelet proteome during ageing. This study 
showed that platelet indices varied with age and in particular PLT and PCT declined with 
aging in both men and women. Due to the cross sectional nature of this study, it is difficult 
to interpret the relationship between platelet indices and age and longitudinal studies are 
required. 
Cardiovascular measures – hypertension and resting heart rate 
Hypertension and RHR are major risk factors for CVD and increased blood pressure in 
individuals younger than 50 years old is linked to greater cardiovascular risk (Lee et a. 2012). 
Subjects were categorised into groups based on norms for age and sex and blood pressure 
(Thompson et al., 2008). Hypertension is defined as a resting/consistently elevated systolic 
blood pressure equal to or above 140 mmHg and/or a diastolic blood pressure equal to or 
above 90 mm Hg. The majority of subjects in this cohort had normal systolic and diastolic 
BP, however, there was a substantial number of subjects who were categorised as pre-
hypertensive with regard to both SBP and DBP (Table A8). Pre-hypertension, a systolic BP 
of 120-39 mmHg and/or a diastolic BP of 80-90 mmHg is the precursor to clinical 
hypertension and is associated with greater risks of CVD (Zhang and Li, 2011; Vasan et al., 
2001). Platelet dysfunction in hypertension is a potential mechanism of enhanced 
cardiovascular morbidity as some studies indicating that different parameters of platelet 
activation are returned to normal functioning levels with treatment for high BP (Yazici et 
al., 2009).  
We examined the relationship between BP, RHR and platelet parameters by correlation 
analysis (Table A9). There was no association between platelet function and SBP/DBP in 
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males or females, however when selectively examining the relationship in the pre-
hypertensive group, there was a significant positive relation between platelet aggregation 
and DBP, Yazici et al., (2009) have reported increased MPV and PCT values in pre-
hypertensive subjects and more importantly, that 12 weeks of lifestyle modifications can 
reduce MPV to the level of normotensive subjects. This was not observed in this study, 
possibly due to the low number of subjects in the pre-hypertensive group. Increased platelet 
volume indices have been associated with the Framingham risk score for CVD (Maluf et al., 
2016). In hypertension, exposure of blood vessels to high pressure generates an alteration 
between the vasoconstrictors and vasodilator balance (Lip, 2003) subsequently initiating 
platelet activation and possibly promoting platelet aggregation. Increases in body 
composition measures in females with PHT could also be responsible for the elevated 
platelet indices and platelet aggregation values. 
RHR has been identified as a predictor of cardiovascular mortality independent of CVD risk 
factors in the general population and in CVD patients (Mensink and Hoffmeister, 1997, 
Palatini, 2004, Custodis et al., 2013). In a recent meta-analysis of 46 studies and over one 
million patients from a general population, those with a RHR of over 80 bpm had a 
considerably increased risk of cardiovascular mortality (Zhang et al., 2016). In general, a 
lower RHR indicates an increased heart function proficiency and overall cardiovascular 
fitness.  
Table A9 displays correlations between RHR and selected platelet parameters. There was 
no association between RHR and platelet indices or function in males but a significant 
positive relationship between PLT and RHR and PCT and RHR in females, suggesting that 
a higher RHR was associated with increased platelet activation. This correlation was 
attenuated when adjusting for BMI, indicating that it was overweight measures, not RHR, 
were affecting platelet indices. Besides overweight, the shear stress experienced by blood 
vessels in subjects with a high RHR could be another mechanism for enhanced platelet 
activity as high shear stress can encourage platelet activation (Huang et al., 2013). Only one 
study has investigated the relationship between RHR and the platelet indice MPV in the 
context of patients with obstructive sleep apnoea (OSA). Patients without considerable CVD 
risk factors also did not have enhanced MPV levels (Akyüz et al., 2014). Pathophysiological 
mechanisms concerning RHR, platelet function and CVD include increased endothelial 
shear stress, a deficiency of NO, platelet aggregation and subsequently, the initiation of 
atherosclerosis (Arnold et al., 2008).  
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Reference ranges for body composition and anthropometric measurements  
1. Visceral adipose tissue (VAT) 
 Healthy 1-12  
 Unhealthy 12-50 
 
2. Total body water percentage  
 Females: 45 to 60%  
 Males:  50 to 65% 
 
3. Body fat percentage (see below) (From Thompson et al., 2009) 
  
 
4. Bone mass (see below) 
 
 
5. Fat free mass, muscle mass and BMR. 
No ranges for these are provided by the Tanita BIA analyser. BMR is dependent on 
calorie intake and weight and ranges were not provided.  
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Appendix B 
 
 
 
 
 School of Health and Human Performance 
Dublin City University 
Glasnevin  
18 May 2015 
 
Dear Parent,  
 
As part of the ongoing study to compare vascular health in low and high fit teenagers in the 
health and human performance department of DCU, we are looking at platelet function in a 
group of high fit adolescents.   
Your child will have a tablespoon of blood taken, before and after an exercise test which 
will last no longer than 15 minutes. They do not need to fast and should eat their normal 
breakfast on the day of the fitness test.  
If you have any questions, please feel free to contact me on 0861219423 or 
twomey.laura@gmail.com 
 
Yours Sincerely, 
Laura Twomey 
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Body Composition - Data Collection Sheet 
Name:    ___________________________________ 
ID Code: ___________________________________ 
School: ___________________________________ 
Fitness Category: _______________________________   
Date of Birth: _______/_______/__________  
 
Medical Conditions: 
Cardiovascular Disease      □ 
Pulmonary Disease       □ 
Diabetes        □ 
Asthma        □ 
Other Medical conditions: 
_____________________________________________________________ 
__________________________________________________________ 
 
Height:   _______ cm 
Weight:   _______kg 
Waist circumference: ___   _    cm  
Hip Circumference:     _______ cm 
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Adolescents Informed Consent Form  
Research Study Title  
Comparison of Cardiovascular Disease Risk Factors and Vascular Health in Low fit, 
Moderately Fit and High Fit Irish Teenagers  
Principle Investigator  
 Prof. Niall M. Moyna, Centre for Preventive Medicine, School of Health and Human 
Performance 
II. Confirmation of particular requirements as highlighted in the Plain Language 
Statement 
Participant – please complete the following (Circle Yes or No for each question) 
I have read the Plain Language Statement (or had it read to me)    Yes  No  
I understand the information provided        Yes  No  
I have had an opportunity to ask questions and discuss this study  Yes  No  
I have received satisfactory answers to all my questions     Yes  No  
III. Confirmation that involvement in the Research Study is voluntary 
Your child may withdraw from the Research Study at any point.   
IV. Advice as to arrangements to be made to protect confidentiality of data, 
including that confidentiality of information provided is subject to legal 
limitations  
Your child’s and other personal information will not be revealed, published or used in 
further studies.  Your child will be assigned an ID number under which all personal 
information will be stored in a secure locked cabinet and saved in a password protected 
file in a computer at DCU.  The named investigators will have access to the data.  Data 
will be shredded after 5 years by Prof. Moyna. 
Confidentiality is insured, but you must be aware that confidentiality of information 
provided can only be protected within the limitations of the law.  It is possible for data 
to be subject to subpoena, freedom of information claim or mandated reporting by some 
professions. 
V. Any other relevant information 
If your child is in a dependent relationship with any of the researchers their involvement 
in the project will not affect ongoing assessment/grades/management or treatment of 
health at DCU.  
VI. Signature: 
I have read and understood the information in this form.  My questions and concerns 
have been answered by the researchers, and I have a copy of this consent form.  
Therefore, I consent to allow my child to take part in this research project 
 
Participants Signature:       
Name in Block Capitals:       
Witness:         Date: 
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Adolescents Assent Form 
Study Title: Comparison of Cardiovascular Disease Risk Factors and Vascular 
Health in Low fit, Moderately Fit and High Fit Irish Teenagers 
 My physical education teacher has talked to me about being part of a research study.  
 I have been told that researchers from Dublin City University (DCU) will visit my 
school and measure by fitness using a bleep test 
 I have been told that I may be selected at random to visit the Vascular Research Unit 
at DCU to undergo additional tests.  I will also wear a small device called an 
accelerometer on my hip for 7 days to record my physical activity levels  
 The visit to DCU will take place in the morning and will last for about 3 hours. 
 I will not eat any food from 10 pm the previous evening.  I will be allowed to drink 
water. 
 I will not do any exercise that makes me tired the day before the bleep test in school 
or the tests in DCU.   
 I will have about 2 tablespoons of blood taken from a vein in my arm.  Drawing 
blood may cause a slight pain where the needle is inserted and may leave a bruise on 
my arm that will clear up in a few days 
 A special ultrasound machine will take a picture of an artery in my neck.  This will 
take about 15 minutes. 
 The health of a blood vessel in my arm will also be measured using the ultrasound 
machine.  The first step will involve blocking the blood flow in my arm for 5 minutes 
using a blood pressure cuff and then taking a picture of my blood vessel when the 
cuff in released.  The second step involves spraying a chemical under my tongue and 
taking a picture image 3 minutes later.  This test will take about 45 minutes, 
 Stopping the flow of blood in my arm for 5 minutes may feel a little uncomfortable.  
The chemical that is sprayed under my tongue may cause a headache that may last 
for 5-10 minutes 
 I will run on treadmill to see how fit I am.  During the test I will wear a nose clip on 
my nose and a mouthpiece in my mouth.  
 I will be allowed to stop any of the tests whenever I want. 
 I may feel tired or be out of breath when I am running on the treadmill and my legs 
may feel tired 
 If I wish, I can stop doing the tests at any time.   
 If I wish, I may choose not to take part in any of the tests. 
 I know that the people in DCU, my physical education teacher and my 
parents/guardian will not be upset with me if I decide not to take part in this study, 
or if I wish to stop taking part in the study. 
SIGNED: _____________________________DATE: __________ 
(Participant’s name) 
SIGNED: _____________________________DATE:   __________ 
(Witness name) 
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VO2 max Data Collection Sheet 
RHR: _____ bpm     Resting BP: ____/____ 
Date of Test: ____/____/______   Time of Test: ______ 
Tester’s Name: __________________   Polar HR Start time: ___ 
 
 
Maximal Data: 
HR max: _____ bpm, RPE-O max: _____, Absolute VO2max: _________ l/min, Relative 
VO2max:_________ ml/kg/min 
 
 
 
 
 
 
Stage Time 
(mins) 
Speed/Slope RPE-O HR 
(bpm) 
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INFORMED CONSENT FORM (Adults) 
PROJECT TITLE:  The effect of acute exercise on platelet function  
PRINCIPAL INVESTIGATORS: Ms. Laura Twomey, Dr. Ronan Murphy  
In order to obtain results, I understand that the following procedures need to take place: 
1.  I am required to complete a general questionnaire for the study.  
2. Different anthropometric tests will be completed, including TANITA, waist and hip 
circumferences, skinfolds.  
3. I am required to complete a maximal aerobic test for this study.  
4. Two small (4.5ml) blood samples will be taken for this test, one pre V02 and one 
post VO2 giving a total of 9mls. 
5. The blood samples will be processed on the cone and plate analyser to determine 
platelet function and the blood counter to determine platelet count.  
6. Flow cytometry will be used to assess platelet VASP phosphorylation and 
microparticle levels.  
 
Why is blood sampling required? Platelet activity can only be measured in blood samples. 
An instrument called a cone and plate analyser will help to measure your platelet activity.  
Assurance of Confidentiality  
I understand that my confidentiality will be protected insofar as this is permitted by Irish 
law and that the research may be published in scientific journals and / or presented and 
discussed at scientific meetings, without revealing any of my personal details.  
DECLARATION: 
I have read, or had read to me, the information leaflet for this project and I understand the 
contents. I have had the opportunity to ask questions and all my questions have been 
answered to my satisfaction. I freely and voluntarily agree to be part of this research study. 
I understand that I may withdraw from the study at any time and I have received a copy of 
this agreement 
PARTICIPANT'S NAME/ID: ………………………………………………… 
CONTACT DETAILS: ………………………………………………… 
PARTICIPANT'S SIGNATURE:……………………Date:…………………………... 
Statement of investigator's responsibility: I have explained the nature and purpose of this 
research study, the procedures to be undertaken and any risks that may be involved. I have 
offered to answer any questions and fully answered such questions. I believe that the 
participant understands my explanation and has freely given informed consent. 
INVESTIGATOR’S 
SIGNATURE:………………………Date:………………………………………. 
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PAR-Q and YOU Questionnaire  
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Global Physical Activity Questionnaire (GPAQ) 
 
I am going to ask you about the time you spend doing different types of physical activity in a typical week. 
Please answer these questions even if you do not consider yourself to be a physically active person.  
1. Does your work involve vigorous-intensity activity that causes large increases in breathing or heart rate like 
[carrying or lifting heavy loads, digging or construction work] for at least 10 minutes continuously? 
2. In a typical week, on how many days do you do vigorous-intensity activities as part of your work? 
3. How much time do you spend doing vigorous-intensity activities at work on a typical day? 
4. Does your work involve moderate-intensity activity that causes small increases in breathing or heart rate such as 
brisk walking [or carrying light loads] for at least 10 minutes continuously? 
5. In a typical week, on how many days do you do moderate-intensity activities as part of your work? 
6. How much time do you spend doing moderate-intensity activities at work on a typical day? 
 
The next questions exclude the physical activities at work that you have already mentioned. For example, to 
work, for shopping, to market, to place of worship.  
1. Do you walk or use a bicycle (pedal cycle) for at least 10 minutes continuously to get to and from places? 
2. In a typical week, on how many days do you walk or bicycle for at least 10 minutes continuously to get to and 
from places? 
3. How much time do you spend walking or bicycling for travel on a typical day? 
 
Now I would like to ask you about sports, fitness and recreational activities (leisure 
1. Do you do any vigorous-intensity sports, fitness or recreational (leisure) activities that cause large increases in 
breathing or heart rate like [running or football,] for at least 10 minutes continuously?  
2. In a typical week, on how many days do you do vigorous-intensity sports, fitness or recreational (leisure) 
activities? 
3. How much time do you spend doing vigorous-intensity sports, fitness or recreational activities on a typical day? 
4. Do you do any moderate-intensity sports, fitness or recreational (leisure) activities that causes a small increase 
in breathing or heart rate such as brisk walking, (cycling, swimming, volleyball) for at least 10 minutes 
continuously? 
5. In a typical week, on how many days do you do moderate-intensity sports, fitness or recreational (leisure) 
activities? 
6. How much time do you spend doing moderate-intensity sports, fitness or recreational (leisure) activities on a 
typical day? 
 
The following question is about sitting or reclining at work, at home, getting to and from places, or with friends 
including time spent [sitting at a desk, sitting with friends, travelling in car, bus, train, reading, playing cards 
or watching television], but do not include time spent sleeping. 
1. How much time do you usually spend sitting or reclining on a typical day? (Hours/Minutes) 
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Effect of acute exercise on haematological parameters 
We simultaneously assessed the changes in white and red blood cell haematological 
parameters in conjunction with the platelet function parameters. Table A11 and A12 display 
the changes in these parameters after acute exercise. There were significant changes in WBC 
count in all cohorts and significant changes in RBC parameters in the HF adolescents and 
MF and HF adults.  
Table A11: Effect of acute strenuous exercise on RBC and WBC characteristics in adolescents. 
Values are mean ± SEM. RBC – Red blood cell count, WBC – White blood cell count, HCT – 
Haematocrit, HGB – Haemoglobin, MCV – Mean corpuscular volume, RDW – Red cell distribution 
width. *P <0 .05. Paired samples t-test.  
 
 Adolescent cohort 
Group Time point  
MLF  Pre Post P value 
WBC (103/µl) 
RBC (106/µl) 
HCT (%)  
HGB (g/dl) 
MCV (fl) 
RDW (%) 
5.64 ± 0.41 10.20 ± 0.21 * 
4.98 ± 0.07 5.06 ± 0.10 .238 
44.37 ± 0.61 45.33 ± 0.86 .138 
14.84 ± 0.21 15.22 ± 0.31 .112 
88.51 ± 0.92 88.83 ± 0.98 .911 
13.08 ± 0.21 13.09 ± .18 .162 
HF     
WBC (103/µl) 
RBC (106/µl) 
HCT (%)  
HGB (g/dl) 
MCV (fl) 
RDW (%) 
6.15 ± 0.45 9.83 ± 0.82 * 
4.86 ± 0.12 5.06 ± 0.12 * 
42.64 ± 0.97 44.5 ± 0.95 * 
14.19 ± 0.34 14.87 ± 0.34 * 
87.84 ± 0.93 88.26 ± 0.89 .070 
13.35 ± 0.17 13.41 ± 0.17 .336 
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Table A12: Effect of acute strenuous exercise on RBC and WBC characteristics in adults. RBC 
– Red blood cell count, WBC – White blood cell count, HCT – Haematocrit, HGB – Haemoglobin, 
MCV – Mean corpuscular volume, RDW – Red cell distribution width. *P <0 .05. Paired samples t-
test. 
 
 
 Adult cohort 
Group Time point  
  Pre Post P value 
MF     
WBC (103/µl) 
RBC (106/µl) 
HCT (%)  
HGB (g/dl) 
MCV (fl) 
RDW (%) 
7.95 ± .76 11.9 ± 1.2 * 
4.72 ± .09 4.85 ± .13 .051 
43.35 ± .71 43.75 ± 1.13 * 
14.1 ± .31 14.54 ± .38 .050 
89.40 ± 0.90 90.21 ± 0.86 * 
12.81 ± 0.25 12.98 ± 0.28 .086 
HF     
WBC (103/µl) 
RBC (106/µl) 
HCT (%)  
HGB (g/dl) 
MCV (fl) 
RDW (%) 
4.61 ± .11 4.81 ± .09 * 
5.98 ± .37 9.4 ± .58 * 
42.7 ± .89 45.13 ± 1.9 * 
14.2 ± .32 14.86 ± .31 * 
92.70 ± 1.19 93.90 ± 1.36 * 
12.73 ± 0.24 13.10 ± .31 .097 
 
Effect of exercise on haematological parameters 
We simultaneously measured the effect of acute vigorous exercise on other haematological 
parameters. According to Cadroy et al., (2002) the heightened thrombotic tendency may be 
related to the observed increased concentration of circulating blood cells and coagulation 
factors such as fibrinogen and vWF. Tables A11 and A12 show the change in RBC and 
WBC in adolescents and adults after exercise. In adolescents, there was a significant increase 
in WBC in both HF and MLF subjects. The adult cohort followed a similar trend. Elevated 
leukocyte levels after exercise has previously been reported (Risoy et al., 2003) and is 
largely due to demargination (neutrophils in tissues rapidly entering into peripheral 
circulation) caused by increased blood flow, exercise- induced increases in 
epinephrine/cortisol levels and an acute inflammatory response (Kratz et al., 2002). 
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The concurrent increase in PLT and WBC post exercise points to a possible interaction 
between these blood cells, and the possibility of increased platelet-leukocyte aggregates 
(PLAs). Studies in adults have shown increased platelet P-Selectin after exercise and 
formation of PLAs. Indeed, numerous subtypes of leukocytes have shown increased 
interactions with platelets after acute exercise including platelet-neutrophil (Aldemir and 
Cilic, 2005), platelet-granulocyte and platelet lymphocyte interactions (Hilberg et al., 2008).   
Changes in HCT occur quickly during and after exercise. There was an expected rise in HCT 
in all groups, likely due to a decrease in plasma volume and fluid loss from sweating. 
Erythropoiesis (production of RBCs) is also a common process during exercise. Huskins 
(2016) report that RBCs significantly contribute to thrombin generation in whole blood and 
therefore an increase in RBC post exercise may affect platelet activation. RBC increased 
after acute exercise in all groups, as depicted in Tables A11 and A12. Cadroy et al., (2002) 
reported similar findings in HCT and blood cell counts after exercise in healthy males.  
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Appendix C 
Measurement of Pain and Length outside Baths during the DI 
 
Table A13: Visual assessment of pain during the DI. The VAS scale is an ease of use measurement 
of pain intensity. The scale was completed by the subjects each day during the DI. Using a ruler, the 
subject marked a point on the line to best represent their pain intensity. The distance from “pain free” 
to their mark is measured in millimetres (mm) and provides their VAS score (1-100).  
 
 Day 
 DI 1 DI 2 DI 3 
(post) 
R+0 
(recovery) 
Subject pm am pm am pm am 
A ND ND 0 0 50 55 
B ND ND 68 35 75 76 
C 55 72 68 35 50 54 
D 35 60 70 70 80 68 
E 24 30 53 70 60 52 
F 25 53 44 45 40 50 
G  85 59 69 58 55 
H 20 72 78 79 88 54 
I 28 0 0 0 0 0 
J 0 0 0 0 0 0 
K 24 50 34 18 11 15 
L 24 23 19 22 15 10 
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Table A14: Length outside baths during the three days of dry immersion.   For certain 
experimental procedures, hygiene reasons and other tests, subjects were removed from the baths for 
short periods of time and remained horizontal with the use of bed/trolleys. This table shows the day, 
subject and time (minutes) in which the subject was out of the baths. 
  Subject 
Day  A B C D E F G H I J K L 
DI1 Wash             
Weigh
t 
            
Sheets 5   23 12 13 3 19 10 2       
Tests 14 25 24 13 10 6 13 11 10 8 19 11 
total 19 25 47 25 23 9 32 21 12 8 19 11 
DI2 Wash 43 25 26 25 19 19 18 27 15 17 25 32 
Weigh
t 
3 3 3  3 3 5 5 2 2 3 3 
Sheets 5 5 5 32   5 7   7  
Tests    8     15     
total 51 33 42 57 22 22 28 54 17 19 35 35 
DI3 Wash 17 41 23 16 34 24 30 30 25 27 16 19 
Weigh
t 
8 3 3 4 3 3 3 3 3 3 3 2 
Sheets 5 10                     
Tests 202 218 219 212 216 195 182 180 196 187 191 173 
total 232 272 245 232 253 222 215 213 224 217 210 194 
R+1 Weigh
t 
3 4 3 3 2 2 3 3 3 3 2 2 
Tota
l 
mins 305 334 337 317 300 255 278 291 256 247 266 242 
 
Variation in subject BMI
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Figure A5: Cardiorespiratory fitness and BMI of each subject in the dry immersion study.  
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Effect of dry immersion on plasma protein biomarkers 
Below are protein biomarkers which increased after DI and may be involved in platelet 
activation/function but which were also statistically significant and were not discussed as 
such in chapter 5.  
A. Renin (REN)
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B. Adrenomedulin (AM)
BDC-3 R+0 R+1
0
2
4
6
Time point
F
o
ld
 C
h
a
n
g
e
(N
P
X
 l
o
g
2
)
 
C. Tissue-type plasminogen activator (t-PA)
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Figure A6: The effect of physical inactivity on TLR family gene expression. Graph A shows 
changes in Renin, Graph B shows changes in Adrenomedulin and Graph C shows changes in Tissue-
type plasminogen activator. All data is expressed as mean ± SEM. Paired samples t-test and repeated 
measures ANOVA. 
 
Renin (REN) was increased after DI, and unlike most of the other proteins, was elevated 
further at the recovery time point. Renin is involved in the body’s renin-angiotensin system 
(RAS) which mediates plasma sodium concentration and arterial blood pressure. 
Angiotensins 1-9 have been shown to regulate platelet function in mice (Mogielnicki et al., 
2003) and have been reported to inhibit platelet aggregation (Fraga-Silva et al., 2008). 
Adrenomedullin (AM) is a vasodilative peptide hormone which exerts significant positive 
influences on the cardiovascular system. AM also increases platelet cAMP levels. Plasma 
AM was significantly decreased post DI, suggesting the vasodilatory properties of the 
cardiovascular system were compromised. Tissue plasminogen activator (Tpa) was 
increased after the DI and further increased at the recovery period and is involved in the 
plasminogen activator system and the breakdown of blood clots.  
 MM 
 
mRNA TLR expression (gene expression) 
Platelets contain several toll-like receptors (TLR) which can be activated by TLR ligands 
(Cognasse et al., 2005). To further assess if physical inactivity had an impact on platelet 
inflammatory function, transcript expressions of TLR1-10 were quantified in total RNA 
extracted from platelets in ten subjects pre and post immersion. This is shown in Figure A7.  
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Figure A7: The effect of physical inactivity on TLR family gene expression. All data is expressed 
as mean ± SEM. 
Platelets express a collection of pattern recognition receptors called toll-like receptors 
(TLRs) that identify molecular motifs called pathogen associated molecular patterns 
(PAMPs) and initiate immune responses (Cognasse et al., 2015). Platelets express functional 
TLR 1-9, whilst TLR2 stimulation in platelets by bacteria through the activation of the PI3K 
signalling pathway induce a proinflammatory response (Blair et al., 2009). Platelet TLR9 
activation has been associated with thrombosis and oxidative stress, and is found within the 
previously mentioned novel T-granules in platelets (Thon et al., 2012). Profiling of platelet 
TLR expression pre and post dry immersion showed an overall increase in TLR expression 
post immersion. However, this was largely variable amongst the individual subjects.  
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Table A15: Real-Time Ready Gene expression targets 
mRNA target Forward (F) 
Reverse (R)  
Sequence 
GAPDH  F AGCCACATCGCTCAGACAC  
R GCCCAATACGACCAAATCC 
TLR1 
F TTGGATTTGTCCCACAACAA 
R CCAAGTGCTTGAGGTTCACA 
TLR2 
F CTCTCGGTGTCGGAATGTC 
R AGGATCAGCAGGAACAGAGC 
TLR3 
F GCGCTAAAAAGTGAAGAACTGG 
R CCAATTGCGTGAAAACACC 
TLR4 
F CAAGATGCCCCTTCCATTT 
R TCCTTAGGAATTAGCCACTAGACTTT 
TLR5 
F GACACAATCTCGGCTGACTG 
R TGTCAGGAACATGAACATCAATC 
TLR6 
F TGAAACAGTCTCTTTTGAGTAAATGC 
R TCCATTTGGGAAAGCAGAGT 
TLR7 
F GCCCCCAAGATGGTTTAAG 
R GCATCCCCAATTTCTTTGG 
TLR8 
F CAGTCCTGGGGATCAAAGAG 
R TGCAGTGACATCTGAAACACAA 
TLR9 
F CGCTACTGGTGCTATCCAGA 
R AGCCCAGGGAGGAGCTAAG 
TLR10 
F AACCTCCTTTTTCAACTCCAGA 
R TTATGGCATAGAATCAAAACTCTCA 
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Table A16: Biomarkers in Proseek Multiplex CVD II Panel 
 
2,4-dienoyl-CoA reductase, mitochondrial (DECR1) 
ADM (ADM) 
Agouti-related protein (AGRP) 
Alpha-L-iduronidase (IDUA) 
Angiopoietin-1 (ANG-1) 
Angiopoietin-1 receptor (TIE2) 
Angiotensin-converting enzyme 2 (ACE2) 
Bone morphogenetic protein 6 (BMP-6) 
Brother of CDO (Protein BOC) 
C-C motif chemokine 17 (CCL17) 
C-C motif chemokine 3 (CCL3) 
C-X-C motif chemokine 1 (CXCL1) 
Carbonic anhydrase 5A, mitochondrial (CA5A) 
Carcinoembryonic antigenrelated cell adhesion 
molecule 8 (CEACAM8) 
Cathepsin L1 (CTSL1) 
CD40 ligand (CD40-L) 
Chymotrypsin C (CTRC) 
Decorin (DCN) 
Dickkopf-related protein 1 (Dkk-1) 
Fatty acid-binding protein, intestinal (FABP2) 
Fibroblast growth factor 21 (FGF-21) 
Fibroblast growth factor 23 (FGF-23) 
Follistatin (FS) 
Galectin-9 (Gal-9) 
Gastric intrinsic factor (GIF) 
Gastrotropin (GT) 
Growth hormone (GH) 
Growth/differentiation factor 2 (GDF-2) 
Heat shock 27 kDa protein (HSP 27) 
Heme oxygenase 1 (HO-1) 
Hydroxyacid oxidase 1 (HAOX1) 
Interleukin-1 receptor antagonist protein (IL-1ra) 
Interleukin-1 receptor-like 2 (IL1RL2) 
Interleukin-17D (IL-17D) 
Interleukin-18 (IL-18) 
Interleukin-27 (IL-27) 
Interleukin-4 receptor subunit alpha (IL-4RA) 
Interleukin-6 (IL-6) 
Kidney injury molecule 1 (KIM-1) 
Lactoylglutathione lyase (GLO1) 
Lectin-like oxidized LDL receptor 1 (LOX-1) 
Leptin (LEP) 
Lipoprotein lipase (LPL) 
Low affinity immunoglobulin gamma Fc region 
receptor II-b (IgG Fc receptor II-b) 
Lymphotactin (XCL1) 
Macrophage receptor MARCO (MARCO) 
Matrix metalloproteinase-12 (MMP-12) 
Matrix metalloproteinase-7 (MMP-7) 
Melusin (ITGB1BP2) 
 
 
Natriuretic peptides B (BNP) 
NF-Kappa-B essential modulator (NEMO) 
Osteoclast-associated immunoglobulin-like 
receptor (hOSCAR) 
P-selectin glycoprotein ligand 1 (PSGL-1) 
Pappalysin-1 (PAPPA) 
Pentraxin-related protein PTX3 (PTX3) 
Placenta growth factor (PlGF) 
Platelet-derived growth factor subunit B (PDGF 
subunit B) 
Poly [ADP-ribose] polymerase 1 (PARP-1) 
Polymeric immunoglobulin receptor (PIgR) 
Pro-interleukin-16 (IL16) 
Programmed cell death 1 ligand 2 (PD-L2) 
Proheparin-binding EGF-like growth factor (HB-
EGF) 
Prolargin (PRELP) 
Prostasin (PRSS8) 
Protein AMBP (AMBP) 
Protein-glutamine gamma-glutamyltransferase 2 
(TGM2) 
Proteinase-activated receptor 1 (PAR-1) 
Proto-oncogene tyrosine-protein kinase Src (SRC) 
Receptor for advanced glycosylation end products 
(RAGE) 
Renin (REN) 
Serine protease 27 (PRSS27) 
Serine/threonine-protein kinase 4 (STK4) 
Serpin A12 (SERPINA12) 
SLAM family member 5 (CD84) 
SLAM family member 7 (SLAMF7) 
Sortilin (SORT1) 
Spondin-2 (SPON2) 
Stem cell factor (SCF) 
Superoxide dismutase [Mn], mitochondrial (SOD2) 
T-cell surface glycoprotein CD4 (CD4) 
Thrombomodulin TM 
Thrombospondin-2 (THBS2) 
Tissue factor (TF) 
TNF-related apoptosis-inducing ligand receptor 2 
(TRAIL-R2) 
Tumor necrosis factor receptor superfamily 
member 10A (TNFRSF10A) 
Tumor necrosis factor receptor superfamily 
member 11A (TNFRSF11A) 
Tumor necrosis factor receptor superfamily 
member 13B (TNFRSF13B) 
Tyrosine-protein kinase Mer (MERTK) 
V-set and immunoglobulin domain-containing 
protein 2 (VSIG2) 
Vascular endothelial growth factor D (VEGF-D 
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Table A17: Biomarkers in Proseek Multiplex Inflammation Panel 
 
Adenosine Deaminase (ADA) 
Artemin (ARTN) 
Axin-1 (AXIN1) 
Beta-nerve growth factor (Beta-NGF) 
Brain-derived neurotrophic factor (BDNF) 
C-C motif chemokine 19 (CCL19) 
C-C motif chemokine 20 (CCL20) 
C-C motif chemokine 23 (CCL23) 
C-C motif chemokine 25 (CCL25) 
C-C motif chemokine 28 (CCL28) 
C-C motif chemokine 3 (CCL3) 
C-C motif chemokine 4 (CCL4) 
C-X-C motif chemokine 1 (CXCL1) 
C-X-C motif chemokine 10 (CXCL10) 
C-X-C motif chemokine 11 (CXCL11) 
C-X-C motif chemokine 5 (CXCL5) 
C-X-C motif chemokine 6 (CXCL6) 
C-X-C motif chemokine 9 (CXCL9) 
Caspase-8 (CASP-8) 
CD40L receptor (CD40) 
CUB domain-containing protein 1 (CDCP1) 
Cystatin D (CST5) 
Eotaxin-1 (CCL11) 
Eukaryotic translation initiation factor 4E-binding 
protein 1 (4E-BP1) 
Fibroblast growth factor 19 (FGF-19) 
Fibroblast growth factor 21 (FGF-21) 
Fibroblast growth factor 23 (FGF-23) 
Fibroblast growth factor 5 (FGF-5) 
Fms-related tyrosine kinase 3 ligand (Flt3L) 
Fractalkine (CX3CL1) 
Glial cell line-derived neurotrophic factor (GDNF) 
Hepatocyte growth factor (HGF) 
Interferon gamma (IFN-gamma) 
Interleukin-1 alpha (IL-1 alpha) 
Interleukin-10 (IL-10) 
Interleukin-10 receptor subunit alpha (IL-10RA) 
Interleukin-10 receptor subunit beta (IL-10RB) 
Interleukin-12 subunit beta (IL-12B) 
Interleukin-13 (IL-13) 
Interleukin-15 receptor subunit alpha (IL-15RA) 
Interleukin-17A (IL-17A) 
Interleukin-17C (IL-17C) 
Interleukin-18 (IL-18) 
Interleukin-18 receptor 1 (IL-18R1) 
Interleukin-2 (IL-2) 
Interleukin-2 receptor subunit beta (IL-2RB) 
Interleukin-20 (IL-20) 
Interleukin-20 receptor subunit alpha (IL-20RA) 
 
Interleukin-22 receptor subunit alpha-1 (IL-22 RA1) 
Interleukin-24 (IL-24) 
Interleukin-33 (IL-33) 
Interleukin-4 (IL-4) 
Interleukin-5 (IL-5) 
Interleukin-6 (IL-6) 
Interleukin-7 (IL-7) 
Interleukin-8 (IL-8) 
Latency-associated peptide transforming growth 
factor beta-1 (LAP TGF-beta-1) 
Leukemia inhibitory factor (LIF) 
Leukemia inhibitory factor receptor (LIF-R) 
Macrophage colony-stimulating factor 1 (CSF-1) 
Matrix metalloproteinase-1 (MMP-1) 
Matrix metalloproteinase-10 (MMP-10) 
Monocyte chemotactic protein 1 (MCP-1) 
Monocyte chemotactic protein 2 (MCP-2) 
Monocyte chemotactic protein 3 (MCP-3) 
Monocyte chemotactic protein 4 (MCP-4) 
Natural killer cell receptor 2B4 (CD244) 
Neurotrophin-3 (NT-3) 
Neurturin (NRTN) 
Oncostatin-M (OSM) 
Osteoprotegerin (OPG) 
Programmed cell death 1 ligand 1 (PD-L1) 
Protein S100-A12 (EN-RAGE) 
Signaling lymphocytic activation molecule 
(SLAMF1) 
SIR2-like protein 2 (SIRT2) 
STAM-binding protein (STAMPB) 
Stem cell factor (SCF) 
Sulfotransferase 1A1 (ST1A1) 
T cell surface glycoprotein CD6 isoform (CD6) 
T-cell surface glycoprotein CD5 (CD5) 
Thymic stromal lymphopoietin (TSLP) 
TNF-beta (TNFB) 
TNF-related activation-induced cytokine (TRANCE) 
TNF-related apoptosis-inducing ligand (TRAIL) 
Transforming growth factor alpha (TGF-alpha) 
Tumor necrosis factor (Ligand) superfamily, 
member 12 (TWEAK) 
Tumor necrosis factor (TNF) 
Tumor necrosis factor ligand superfamily member 
14 (TNFSF14 ) 
Tumor necrosis factor receptor superfamily 
member 9 (TNFRSF9) 
Urokinase-type plasminogen activator (uPA) 
Vascular endothelial growth factor A (VEGF-A) 
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Dry Immersion Inclusion and Exclusion Criteria 
Inclusion criteria were as follows: 
 Healthy male volunteer  
 Aged 20 – 45, Height between 158 and 190cm  
 Not overweight nor excessively thin with a BMI (weight kg/height m2) between 20 
and 26 
 No personal or family record of acute or chronic disease or psychological 
disturbances which could have affected the physiological data and/or create a risk 
for the subject during the experiment 
 Fitness level assessment required 
 if age < 35 years: 35 ml/min./kg < VO2 max < 60ml/min./kg 
 if age > 35 years: 30 ml/min./kg < VO2 max < 60ml/min./kg 
 Active and free from any orthopaedic, musculoskeletal and cardiovascular disorders 
 Non-smokers and no alcohol or drug dependence 
 Free of any engagement during the study signed consent forms. 
 
Exclusion criteria were as follows: 
 Past record of orthostatic intolerance or cardiac rhythm disorders 
 Chronic back pain, history of hiatus hernia or gastro-oesophageal reflux 
 History of thyroid dysfunction, renal stones, diabetes, migraines, 
 Family history of thrombosis or a positive response to the thrombosis screening 
procedure (anti thrombin III, S-protein, C-protein, factor V Leiden mutation or 
mutation 20210 of the prothrombin gene) 
 Echocardiography: inappropriate thoracic acoustic window 
 History of/or active claustrophobia 
 History of genetic muscle and bone diseases, bone mineral density: T-score < -1.5 
on the hip 
 Poor tolerance to blood sampling, having given blood (more than 8ml/kg) in a week 
period of 8 weeks or less before the experiment 
 Subject who, in the judgment of the investigator, was likely to be non-compliant 
during the study, or unable to cooperate because of a language problem or poor 
mental development, 
 Subject who had received more than 4500 Euros within 12 months for being a 
research subject. 
 Subject already participating or in the exclusion period of a clinical research, 
 
 
 
 
 
 
 
 
 RR 
 
 
 
 
 
